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Abstract 
 
Toby Gareth David Capstick 
The Effectiveness of Pharmacist Interventions in Improving Asthma Control and 
Quality of Life in Patients with Difficult Asthma 
Keywords: Asthma; Pharmacist interventions; Pharmacist prescribing; Quality of 
life; Asthma control; Hospital pharmacists; Community pharmacists; Care 
transitions.  
 
Despite national guidelines, the management of difficult asthma remains 
suboptimal, and there may be opportunities for pharmacists to improve asthma 
outcomes. This six-month prospective, randomised, open study investigated the 
effects of pharmaceutical care across primary and secondary care on difficult 
asthma. 
Fifty-two patients attending a hospital difficult asthma clinic were randomised 
(1:1) to receive usual medical care (UC), or pharmacist interventions (PI) 
comprising asthma review, education, and medicines optimisation from a 
hospital advanced clinical pharmacist, plus follow-up targeted Medicines Use 
Review (t-MUR) from community pharmacists. 
Forty-seven patients completed the study. More interventions were performed in 
the PI group at baseline (total 79 vs. 34, p<0.001), but only six patients received 
a t-MUR. At six-months, PI were non-inferior to UC for all outcomes. The 
primary outcome measure was Juniper’s Asthma Control Questionnaire score 
and reduced (improved) from a median (IQ) score of 2.86 (2.25, 3.25) and 3.00 
(1.96, 3.71) in the PI and UC groups respectively to 2.57 (1.75, 3.67) and 2.29 
(1.50, 3.50).  
At baseline, 58.8%, 46.9% and 17.6% of patients had optimal inhaler technique 
using Accuhalers, Turbohalers or pMDIs; education improved technique but this 
was not maintained at six-months. Adherence rates <80% were observed in 
57.5% of patients at baseline, and was improved in the PI group at six-months 
(10/20 PI vs. 3/21 UC had adherence rates of 80-120%, p=0.020). 
This study demonstrates that the management of difficult asthma by specialist 
pharmacists is as effective as usual medical care. Future research should 
investigate whether pharmacist-led follow-up produces further improvements. 
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1 Executive Summary 
1.1 Introduction 
Asthma is a condition that is characterised by variable expiratory airflow 
obstruction resulting from chronic airway inflammation producing characteristic 
symptoms of wheeze, breathlessness, chest tightness and cough that vary over 
time and intensity (British Thoracic Society and Scottish Intercollegiate 
Guidelines Network, 2014, Global Initiative for Asthma, 2014). 
 
There are an estimated 5.4 million people with asthma in the UK (National 
Institute for Health and Care Excellence, 2013), and the majority of adults can 
be successfully treated with low to moderate inhaled corticosteroid doses at 
Steps 1 to 3 of the British Thoracic Society and Scottish Intercollegiate 
Guidelines Network (BTS/SIGN) asthma guidelines. It is estimated that about 
13.8% of patients in the UK are treated at Steps 4 and 5 of the BTS Asthma 
guidelines (Hoskins et al., 2000). Approximately half of these are thought to be 
inadequately controlled by maximal inhaled and oral therapies (Hoskins et al., 
2000), and are labelled as having ‘difficult asthma’ (British Thoracic Society and 
Scottish Intercollegiate Guidelines Network, 2014).  
 
The aim of asthma treatment is to achieve and maintain asthma control and 
normal activity levels, and to minimise the future risk of exacerbations, fixed 
airflow limitation and adverse effects (Global Initiative for Asthma, 2014, British 
Thoracic Society and Scottish Intercollegiate Guidelines Network, 2014). Whilst 
this is achievable for most patients, those with difficult asthma are more 
complex and require referral to specialist hospital services led by consultant 
physicians in order to improve patient outcomes (NHS England, 2013). The goal 
of difficult asthma management is frequently to stabilise the condition and to 
maintain the highest level of asthma control and quality of life as possible rather 
than achieving total asthma control, which may not be achievable in all patients.  
 
The Royal College of Physicians recently published a report from a national 
investigation into asthma deaths in the UK between February 2012 and January 
2013 (Royal College of Physicians, 2014). This identified a number of 
deficiencies in asthma care including lack of asthma action plans, sub-optimal 
use of preventer inhalers and over use of short-acting reliever inhalers. This 
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report identified that pharmacists can play a key role in asthma management by 
identifying patients who may underuse preventer inhalers or who overuse 
reliever inhalers, as well as assessing inhaler technique, and providing self-
management education including developing personalised asthma action plans.  
 
Previous pharmacist interventional studies have reported benefits to patients 
with asthma when provided with asthma education, asthma action plans, inhaler 
technique training, and behaviour modification. However these studies have 
focused on the management of asthma in patients with mild to moderate 
asthma symptoms, but there is minimal research in patients with difficult 
asthma.  
 
The research study presented in this thesis is the first to investigate the effects 
of a redesigned pharmaceutical pathway across the primary and secondary 
care interface in patients with difficult asthma. It is also the first to compare 
pharmaceutical management of asthma compared to usual medical care. 
 
1.2 Aims 
To determine the effects of a co-ordinated management strategy between 
primary and secondary care pharmacists on asthma control and Quality of Life 
in patients with difficult asthma. 
 
1.3 Objectives 
The primary objective of this study is to measure the impact on asthma control 
on the management of difficult asthma by a Hospital Advanced Clinical 
Pharmacist and community pharmacist. 
 
Secondary objectives are to determine the impact of the intervention on quality 
of life, exacerbations, lung function, inhaler technique and adherence.  
 
1.4 Methods 
The study was designed as a pragmatic six-month, prospective, randomised, 
open trial. Fifty-two patients attending a hospital difficult asthma clinic were 
randomised to either a usual medical care (UC) group, or pharmacist 
intervention (PI) group. The inclusion criteria included patients aged 18 to 70 
  3 
years, with a clinical diagnosis of asthma, fulfilling the criteria for difficult 
asthma, who were able to speak, read and write in English, and were eligible for 
a Medicines Use Review (MUR). Patients were excluded if they were not 
responsible for taking their own medications, or failed to provide written 
informed consent. 
 
Patients in the UC group received a ‘usual’ standard asthma review in clinic 
from a consultant, specialist registrar, or specialist respiratory nurse in line with 
standard difficult asthma clinic procedures. Patients in the PI group received an 
asthma review from an advanced clinical pharmacist in clinic, comprising 
education on asthma and medication, inhaler technique training in addition to 
the ‘usual’ standard asthma review, plus a follow-up targeted MUR (t-MUR) 
from their usual community pharmacist at four to eight weeks following the 
baseline consultation. Patients in both groups were followed up at six months. 
 
1.5 Results 
Between 25th September 2012 and 29th October 2013, 188 patients were 
screened for inclusion in the study and 52 were recruited. Twenty-six were 
randomly assigned to the PI group and 26 to the UC group. Forty-seven 
patients (24 in the PI group) were followed up for a median (interquartile range, 
IQ) of 182 (175, 203) days and were included in the intention to treat analysis. 
Only six participants (23%) in the PI group received a t-MUR at a mean of 60 
days (range 28 – 143 days) following randomisation. The most common reason 
given by community pharmacists for poor uptake of t-MURs was failure of the 
patient to attend, although this was often contradicted by patients who stated 
that their community pharmacist did not arrange a t-MUR. 
 
Participants recruited to the study had uncontrolled asthma at baseline, with a 
median (IQ) asthma control questionnaire (ACQ) score of 3.00 (2.14, 3.57) 
across both groups, despite high doses of inhaled corticosteroid (ICS) (median 
(IQ) daily equivalent beclometasone-CFC dose of 1600 (800, 2000) 
micrograms). In the 12 months prior to the study, participants had required a 
mean (SD) of 4.8 (3.22) emergency courses of oral corticosteroids per person 
and a median of 1 hospital admission or accident and emergency department 
visit per person. 
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1.5.1 Number of interventions 
At the initial consultation, participants randomised to the PI group received 
significantly more interventions in total than those in the UC group (total 79 vs. 
34 respectively, p<0.001). These interventions addressed: medication-related 
issues (54 vs. 18); allergy tests and asthma investigations (5 vs. 1); the 
management of associated medical conditions (6 vs. 4); and education or 
advice (14 vs. 11). Possession rates of asthma action plans were similar in the 
two groups and increased following the baseline consultation: from 61.5% to 
83.3% of participants in the PI group; and from 57.7 to 73.9% in the UC group.  
 
1.5.2 Asthma control 
The effect of pharmaceutical care in the PI group was found to be non-inferior 
to medical management in the UC group. At six months, the median (IQ) ACQ 
score had reduced (improved) from 2.86 (2.25, 3.25) and 3.00 (1.96, 3.71) in 
the PI and UC groups respectively to 2.57 (1.75, 3.67) and 2.29 (1.50, 3.50). 
Similarly, there was no difference between the two groups in the proportion of 
participants who had controlled asthma (defined as an ACQ <1.0 (Juniper et al., 
2006)) at either baseline or follow-up. There was no significant difference 
between the two groups in the proportion of patient’s whose asthma control 
improved, nor in the proportion of patients who achieved a clinically significant 
improvement in ACQ score (reduction of at least 0.5 units). 
 
Participants in both groups achieved reductions in exhaled nitric oxide, and 
required fewer corticosteroid rescue courses and used fewer doses of short-
acting beta2-agonist reliever inhaler each week at follow up compared to 
baseline, however there was no significant difference between the two 
treatment arms at either baseline or follow-up. 
 
1.5.3 Quality of life 
The effect of pharmaceutical care in the PI group on asthma quality of life, using 
Juniper’s standardised asthma quality of life questionnaire (AQLQ(S)) was 
found to be non-inferior to medical management in the UC group. Participants 
were very limited or had moderate limitation in their quality of life throughout the 
study; at baseline, the median (IQ) AQLQ(S) score was 4.11 (3.38, 5.21) and 
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3.77 (2.87, 5.30) in the PI and UC groups respectively, and at follow-up was 
4.12 (3.55, 5.49) and 4.22 (2.97, 5.66) respectively. There was no significant 
difference between the two groups in the proportion of patient’s whose quality of 
life improved, nor in the proportion of patients who achieved a clinically 
significant improvement in AQLQ(S) score (increase of at least 0.5 units). 
 
1.5.4 Inhaler technique 
Most patients had received previous inhaler technique training, although less 
than half of the patients had received training from healthcare professionals in 
primary care. 
 
There was wide variation in the type of inhaler device prescribed, although the 
most frequent were pMDI (67.3%), Turbohaler (61.5%) and Accuhaler (26.9%). 
The majority of patients (n=34) were prescribed at least two different inhaler 
devices. 
 
Errors in inhaler technique were common, with fewer than half of patients in 
both the PI and UC groups having optimal inhaler technique (no errors using 
inhaler device) using pMDI and Turbohaler devices at baseline. More patients 
had optimal inhaler technique using Accuhaler devices than with Turbohaler or 
pMDI devices (58.8% vs. 46.9% and 17.6%, respectively). Significantly more 
patients in the PI group compared to the UC group were assessed to have an 
unsatisfactory technique (at least one critical error that would significantly affect 
the delivered dose) using their pMDI and Turbohaler inhalers at baseline (pMDI: 
17/17 vs. 10/17; Chi-Square 8.815, p=0.012; Turbohaler: 12/17 vs. 3/15; Chi-
Square 8.977, p=0.011). 
 
After education, the proportion of patients in the PI group who had optimal 
inhaler technique after education increased from 0% to 70.6% for pMDI, 58.3% 
to 92.3% for Accuhaler, and from 29.4% to 88.2% for Turbohaler. Similarly in 
the UC group, the proportion of patients who had optimal inhaler technique after 
education increased from 35.3% to 82.4% for pMDI, 60.0% to 100.0% for 
Accuhaler, and from 66.7% to 80.0% for Turbohaler. 
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Despite education at baseline, the proportion of patients with optimal inhaler 
technique was not maintained in all patients. For the six patients in the PI group 
who had a t-MUR at 2-months, 0% and 25% still had optimal inhaler technique 
with pMDI and Turbohaler devices. At six months, optimal inhaler technique 
was found for 6.3%, 75% and 71.4% of patients using pMDI, Accuhaler and 
Turbohaler devices respectively, and was not significantly different between the 
two intervention groups. 
 
1.5.5 Adherence 
Poor adherence was admitted by four patients in the PI group and by none in 
the UC group. However retrospective analysis of prescription data for the 40 
participants where data were available for a six-month period prior to 
randomisation, median (IQ) adherence rate to ICS (defined as the percentage 
of prescribed doses issued compared to expected prescribed number of doses 
required over a six-month period) was 75.3% (35.7, 98.5). More than half of 
patients (57.5%) had adherence rates less than 80% and more than a third 
(35%) had adherence rates less than 50%. 17.5% of participants had 
adherence rates exceeding 100%, of whom 6 (15%) had adherence rates 
exceeding 120%. 
 
At six months, a significantly greater proportion of patients in the PI group were 
adherent to ICS (defined as an adherence rate of 80-120%) than in the UC 
group (10/20 vs. 3/21, p=0.020). Good or improved adherence was not 
associated with improvements in asthma outcomes. 
 
1.6 Discussion 
This study recruited patients with difficult asthma, who had experienced 
prolonged periods of poor asthma control, frequent courses of oral 
corticosteroid rescue course and high use of SABA inhalers. Both intervention 
groups were successful in stabilising asthma control over the course of the 
study as there was no significant change in asthma outcome measures, and the 
provision of pharmaceutical care from hospital-based advanced clinical 
pharmacists was non-inferior to usual medical care for all asthma control 
measures.  
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Since uptake of t-MUR was poor, it is likely that the greatest impact to patients 
in the PI group was achieved with the baseline intervention from the hospital 
advanced clinical pharmacist. There is insufficient data from this study to 
determine whether t-MUR may achieve added benefits to patients with difficult 
asthma. However since inhaler technique had deteriorated by 2-months in the 
six patients who had received a t-MUR in the PI group, this may indicate that 
patients with difficult asthma require early follow-up after initial consultations to 
support and reinforce education and training. 
 
The fact that fewer than half of participants had received inhaler technique in 
primary care may suggest that many healthcare professionals may not have 
sufficient knowledge about the importance of optimising inhaler technique or 
how to use inhaler devices. 
 
The poor rates of adherence observed in this study are typical of populations of 
patients with difficult asthma. The failure to identify poor adherence in the 
baseline consultation suggests that asking about adherence is a poor strategy, 
and should be supported using prescription data. 
 
1.7 Conclusions 
Advanced clinical pharmacists who have a specialist interest in respiratory 
medicine have the knowledge and skills to manage difficult asthma in outpatient 
clinic settings. Complex pharmacist interventions incorporating asthma 
monitoring, inhaler technique training, medicines optimisation and adherence 
counselling, education, asthma action plan provision, and healthy living advice 
are useful in stabilising difficult asthma and preventing exacerbations. Further 
research should focus on how initial consultations can be supported in 
community settings to prevent loss of knowledge and deteriorating inhaler 
technique and adherence over time. 
 
1.8 Recommendations 
Specialist pharmacists should be incorporated into multidisciplinary teams 
working in secondary care difficult asthma clinics, and this should be a 
requirement of the NHS England service specification for severe asthma 
services. 
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Pharmacists in primary and secondary care should also seek to ensure that 
their knowledge and skills are kept up to date to ensure that their knowledge 
and skills are adequate to provide asthma services to patients with difficult 
asthma. These services should include asthma reviews with clinics as well as 
identifying and prioritising patients with difficult asthma for MURs. Pharmacist-
led asthma reviews should be structured to ensure that all aspects of asthma 
management are covered including stop smoking advice, inhaler technique 
training, asthma monitoring, medicines optimisation, education and lifestyle 
advice. 
 
Education for healthcare professionals should be prioritised to ensure that there 
is widespread competence in both using and training patients how to use 
inhaler devices.  
 
1.9 Publication history 
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2 Introduction 
2.1 Asthma 
2.1.1 The impact of asthma on patients and healthcare systems 
Despite the availability of evidence-based guidelines and effective drugs to 
manage asthma, care in the UK remains suboptimal with high rates of hospital 
admissions (40,243 in 2011-12) and asthma deaths that remain higher in the 
UK than much of Europe (Royal College of Physicians, 2014), which contribute 
to estimated costs for around £1billion per year (Asthma UK, Undated).  
 
The Royal College of Physicians have recently published a report of a national 
investigation into asthma deaths in the UK between February 2012 and January 
2013 and found a significant number of areas where asthma care could have 
been improved (Royal College of Physicians, 2014). This study identified 3,544 
people who had died and had ‘asthma’ documented anywhere on the death 
certificate. After excluding cases where no further information was available, or 
where asthma was unlikely be the cause of death, a total of 276 cases were 
reviewed by the confidential enquiry multidisciplinary panel and 195 confirmed 
as deaths due to asthma. The enquiry reported deficiencies in the management 
of asthma; 43% had not had an asthma review in the past 12 months, 57% had 
not been under specialist care, only 23% had an asthma action plan, 80% had 
sub-optimal use of preventer inhalers and 39% had been issued at least 12 
short-acting reliever inhalers in the year before they died. These data clearly 
demonstrate that there is an unmet need in managing asthma in the UK, which 
could be achieved through an expanded role of clinical pharmacists. Indeed, the 
authors identified that pharmacists can play a key role in asthma management 
by identifying patients who may underuse preventer inhalers or overuse reliever 
inhalers, assessing inhaler technique, and providing self-management 
education including developing personalised asthma action plans.  
 
Whilst previous pharmacist interventional studies have reported benefits to 
patients with asthma when provided with asthma education, asthma action 
plans, inhaler technique training, and behaviour modification (see Chapter 
3.3.1), there remain a number of gaps in the evidence base. The majority of 
current research has focused on the management of asthma in community 
settings where most asthma patients, particularly those with mild to moderate 
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asthma symptoms, are routinely managed. Therefore there is minimal research 
examining whether pharmacists have the expertise to manage the minority of 
patients with severe asthma symptoms.  
 
2.1.2 Definitions and pharmacological therapies 
Asthma is a condition characterised by variable expiratory airflow obstruction 
resulting from chronic airway inflammation producing characteristic symptoms 
of wheeze, breathlessness, chest tightness and cough that vary over time and 
in intensity (British Thoracic Society and Scottish Intercollegiate Guidelines 
Network, 2014, Global Initiative for Asthma, 2014). 
 
There are an estimated 5.4 million people in the UK who are receiving treatment 
for asthma (National Institute for Health and Care Excellence, 2013), for which 
there are clear evidence-based stepwise guidelines (British Thoracic Society 
and Scottish Intercollegiate Guidelines Network, 2014). In brief, the UK 
guidelines advise the use of inhaled short-acting beta2-agonist (SABA) inhalers 
for adults with mild asthma at Step 1, adding in a low dose inhaled 
corticosteroid (ICS) at Step 2 if uncontrolled. If still uncontrolled, treatment at 
Step 3 adds a long-acting beta2-agonist (LABA) as a third drug and the ICS 
dose is then increased if necessary, up to an equivalent daily dose of 800 
micrograms of beclometasone-CFC, or if the LABA is not effective a trial of an 
alternative such as a leukotriene receptor antagonist (LKTa) or theophylline 
should be attempted. If asthma is still uncontrolled in adults, Step 4 treatment 
requires high doses of ICS (increasing from an equivalent daily dose of 800 
micrograms, up to 2000 micrograms of beclometasone-CFC) and two additional 
controller medicines used (e.g. LABA, LKTa or theophylline), whilst regular oral 
corticosteroid (OCS) should be reserved for Step 5 use only. 
 
The majority of adults with asthma can be successfully treated with low to 
moderate ICS doses at Steps 1 to 3 of the British Thoracic Society/Scottish 
Intercollegiate Guidelines Network (BTS/SIGN) asthma guidelines. This is 
because ICS have a dose-response effect in asthma, and almost 90% of the full 
therapeutic effect is achieved at approximate equivalent daily doses of 400 to 
500 micrograms of beclometasone-CFC (Holt et al., 2001, Masoli et al., 2004). 
It is estimated that approximately 13.8% of patients in the UK are treated at 
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Steps 4 and 5 of the BTS/SIGN Asthma guidelines, and about half of these are 
thought to be inadequately controlled by maximal inhaled and oral therapies 
(Hoskins et al., 2000). These patients are labelled as having ‘difficult asthma’, 
which is defined as persistent symptoms and/or frequent exacerbations despite 
treatment at step 4 or step 5 BTS/SIGN Asthma guidelines (British Thoracic 
Society and Scottish Intercollegiate Guidelines Network, 2014).  
 
Throughout this thesis, patients will be described as having difficult asthma, 
using the definition described in the BTS/SIGN asthma guidelines, rather than 
using similar alternative definitions or terminologies of severe asthma used by 
the European and American Respiratory Societies (Chung et al., 2014), or the 
World Health Organisation (WHO) (Bousquet et al., 2010). This is because 
most UK practitioners use the BTS/SIGN asthma guideline definition, and so a 
study that recruited patients who meet these criteria would allow the results to 
be interpreted within the context of UK practice.  
 
The prevalence of difficult asthma has been estimated at 5-10% of the total 
asthma population, although there is some uncertainty with this figure due to 
variations in definitions of difficult or severe asthma used (Chung et al., 2014). 
The appropriate and effective management of difficult asthma accounts for a 
relatively large proportion of resource expenditure in asthma because they are 
treated with more medicines at higher doses and often remain uncontrolled 
compared to adults with mild to moderate severity asthma (O'Neill et al., 2014). 
Furthermore the management of asthma exacerbations incurs greater costs 
than maintenance management of asthma, and tends to be more expensive in 
adults with difficult asthma (Hoskins et al., 2000, Chung et al., 2014). One five-
year pharmacoeconomic study found that the mean cost of treating patients in 
primary care at step 4 and 5 of the BTS/SIGN asthma guidelines (i.e. the steps 
at which patients with difficult asthma are treated) was 3.5 to 16 times higher 
than the mean annual cost of managing patients at steps 1 to 3 (Das Gupta and 
Guest, 2003). The main costs incurred were associated with General 
Practitioner (GP) consultations and prescription medicines, where there may be 
opportunities for pharmacists to help improve asthma management.  
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Although the severity of asthma may vary between patients, the aim of 
treatment at Steps 1 to 5 remains the same; specifically to achieve and maintain 
asthma control and normal activity levels, and minimising the future risk of 
exacerbations, fixed airflow limitations and adverse effects (Global Initiative for 
Asthma, 2014, British Thoracic Society and Scottish Intercollegiate Guidelines 
Network, 2014). This was found to be achievable in the majority of patients in 
the Gaining Optimal Asthma controL (GOAL) study, including those who were 
uncontrolled on low to moderate ICS doses at baseline (Bateman et al., 2004, 
Bateman et al., 2008, Woodcock et al., 2007). This therefore demonstrates that 
achieving asthma control should be an appropriate goal and is achievable for 
most asthma patients. 
 
However, difficult asthma is a complex multifactorial condition and patients are 
commonly referred to specialist hospital services led by consultant physicians in 
order to improve patient outcomes such as exacerbation frequency, mortality, 
lung function and quality of life (NHS England, 2013). Due to the complexity of 
difficult asthma, the goal of difficult asthma management is frequently to 
stabilise the condition and maintain as high a level of asthma control and quality 
of life as possible rather than achieving total asthma control, which may not be 
achievable in all patients.  
 
2.1.3 Non-pharmacological interventions in asthma 
Asthma is a complex multifactorial condition and it has been shown that brief or 
limited interventions may not to be as effective as more complex multi-faceted 
interventions targeting different aspects of asthma management. In one 
systematic review, isolated limited asthma education, such as aspects of the 
disease process, its causes and its treatment, did not significantly affect health 
outcomes in terms of hospitalisations, doctor visits or medication use; however 
it did improve patient’s perceptions of their symptoms (Gibson et al., 2002b). A 
second systematic review of patient education combined with providing self-
management education and action plans, combined with regular medical review 
demonstrated significant improvements in hospitalisations, emergency room 
visits, indirect costs and quality of life (Gibson et al., 2002a).  
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Current national and international asthma guidelines used in the UK 
recommend that the management of asthma requires a mixture of 
pharmacological and non-pharmacological therapies, as well as advocating 
patient education and self-management strategies (British Thoracic Society and 
Scottish Intercollegiate Guidelines Network, 2014, Global Initiative for Asthma, 
2014). Non-pharmacological management strategies include allergen and 
trigger avoidance, weight reduction and smoking cessation and have been 
demonstrated in some cases to have significant benefits on asthma control 
(British Thoracic Society and Scottish Intercollegiate Guidelines Network, 2014, 
Global Initiative for Asthma, 2014).  
 
2.1.4 Pharmacy services for asthma patients 
There is a potential role for pharmacists to perform asthma reviews, either in 
hospital clinics or as part of Medicines Use Reviews (MURs) and the New 
Medicines Service, in order to optimise asthma medicines and improve 
medicine use, as well as to identify and address non-adherence. Patients with 
difficult asthma should be targeted since they commonly experience persistent 
breakthrough asthma symptoms such as wheeze, breathlessness, chest 
tightness and cough, night-time waking and limitation of daily activities. They 
are also at risk of frequent severe exacerbations requiring rescue courses of 
OCS and associated GP attendance, Accident and Emergency (A&E) visits and 
hospital admissions and adverse reactions to prescribed medication, as well as 
being at an increased risk of death (Heaney et al., 2003, Barnes and Woolcock, 
1998, Wener and Bel, 2013, Chung et al., 2014, Bousquet et al., 2010, Royal 
College of Physicians, 2014). 
 
In recent years, many pharmacists have developed their skills to provide 
asthma management services to patients with asthma in both hospital and 
community settings (Benavides et al., 2009). The ability of pharmacists to teach 
self management skills, correct inhaler technique and identify non-adherence in 
asthma patients is recognised in asthma management guidelines as effective 
for improving asthma control (British Thoracic Society and Scottish 
Intercollegiate Guidelines Network, 2014, Global Initiative for Asthma, 2014). In 
particular, pharmacists have been shown to produce significant improvements 
in asthma outcomes in community pharmacy settings (Armour et al., 2007, Saini 
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et al., 2008), and more recently pharmacists have been performing asthma 
reviews in GP practices (Khachi and Karikari, 2013).  
 
The role of pharmacists working in secondary care difficult asthma clinics is less 
well studied despite a number of UK pharmacists working alongside consultant 
physicians, specialist nurses and physiotherapists in these settings. Published 
studies in hospital settings have generally reported the effects of asthma 
management provided by physicians and pharmacists working in collaboration. 
One such study reported the role of pharmacists supporting the interventions 
made by physicians in US hospital outpatient clinics rather than working 
independently to provide asthma reviews. The pharmacist role was to provide 
education on self-management and was reported to produce similar 
improvements in asthma quality of life and exacerbations to usual physician 
care alone over a 45 day period (Knoell et al., 1998). This demonstrated that 
pharmaceutical care could potentially assist usual medical management of 
asthma in hospital outpatient clinics. However limitations on the study design, 
such as selective patient recruitment and lack of randomised allocation, prevent 
firm conclusions to be made on the potential added benefit of asthma 
management provided by specialist hospital pharmacists on overall outcomes. 
This lack of research studies may explain why the first draft of the National 
Health Service (NHS) England service specification for severe asthma services 
fails to specify that a specialist pharmacist should be part of the severe asthma 
multidisciplinary team (NHS England, 2013).  
 
In primary care, UK Community Pharmacists, accredited by a Higher Education 
Institution, are funded to provide an MUR service to review the use of medicines 
for long-term conditions in individual patients. The underlying purpose of MUR 
services is, with the patient’s agreement, to improve the patient’s knowledge 
and use of drugs by (i) establishing the patient’s actual use, understanding and 
experience of taking drugs; (ii) identifying, discussing and assisting in the 
resolution of poor or ineffective use of drugs by the patient; (iii) identifying side 
effects and drug interactions that may affect the patient’s compliance with 
instructions given to them by a health care professional for the taking of drugs; 
and (iv) improving clinical and cost effectiveness of drugs prescribed to patients, 
thereby reducing the wastage of such drugs (Department of Health, 2013).  
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At the time of this study, the terms of service allowed for each patient to have a 
maximum of one MUR in a 12-month period (unless there were sufficient 
changes in a patient’s circumstances to justify a further MUR) and at least 50% 
of MURs had to be targeted MURs (t-MUR), specifically for patients who are: (i) 
prescribed a high risk medicine (non-steroidal anti-inflammatory drug, 
anticoagulants, antiplatelets or diuretics); (ii) recently discharged from hospital 
with changes to their regular medicines; or (iii) prescribed a respiratory drug 
(bronchodilator, corticosteroid, cromoglicate, LKTa or phosphodiesterase type-4 
inhibitor). Community pharmacists use a standard MUR form to collect data on 
each consultation, and a copy is provided for the patient and their GP with a list 
of interventions and recommendations made. Pharmacists are required to 
record all issues identified and interventions made including healthy living 
advice, non-adherence, problems taking medicines or using devices, education 
provided, adverse drug reactions, and reasons for expected improvement in 
adherence (Pharmaceutical Services Negotiating Committee, 2013). The MUR 
service in Leeds is well established, with 93.7% of the 174 community 
pharmacies in Leeds providing MUR services in 2012-13, and a total of 46,222 
MURs undertaken (Prescribing and Primary Care team, 2013). Published data 
does not report the number of t-MURs performed, so it is unclear whether 
respiratory drug t-MURs are also well established. 
 
The role of MURs to target specific patient groups such as those with asthma is 
justified as reviews have reported that there is evidence that they may improve 
outcomes (Blenkinsopp, 2010). Two studies, which will be discussed in the 
literature review (Chapter 3.3.2), have demonstrated that existing community 
pharmacy services can be successfully utilised to improve asthma management 
(Bagole et al., 2007, The Cambridge Consortium, 2012), although there is a 
lack of data specifically assessing their impact specifically in patients with 
difficult asthma.  
 
Although pharmacists have been identified as being competent to provide 
asthma services, there are no studies assessing the impact of the transition of 
asthma services between secondary and primary care pharmacists. Patients 
with difficult asthma should receive regular follow-up reviews (British Thoracic 
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Society Standards of Care Committee, 2008), and since these patients need to 
collect regular prescriptions for a number of asthma medicines, there are 
regular opportunities for community pharmacists to provide support for asthma 
management.  
 
There is an absence of published research investigating the effects of 
community pharmacists performing follow-up reviews of patients with difficult 
asthma, and this appears to be a real problem in clinical practice. A pilot study 
preceding this study demonstrated that only one third of patients attending the 
difficult asthma clinic had received a MUR within the past 12 months (Capstick 
et al., 2012). Therefore there is a need for research to investigate this 
opportunity for community pharmacists to provide follow-up reviews using the 
funded MUR service. 
 
2.1.5 NHS Outcomes strategy for Chronic Obstructive Pulmonary 
Disease (COPD) and asthma 
The NHS outcomes strategy for COPD and asthma require healthcare 
professionals to “ensure that people with asthma…are free of symptoms 
because of prompt and accurate diagnosis, shared decision making regarding 
treatment, and on-going support as they self manage their own condition and to 
reduce need for unscheduled health care and risk of death” (Department of 
Health, 2011). This is supported by the National Institute for Health and Care 
Excellence (NICE) quality standards for asthma, which describe the high priority 
areas for quality improvement in asthma care, and describe a number of areas 
where pharmacists should take an increasing role in asthma management 
(National Institute for Health and Care Excellence, 2013). NICE advise that 
people with difficult asthma are offered an assessment by a multidisciplinary 
asthma service, because they need specialist assessment to ensure an 
accurate diagnosis and exclude alternative causes, manage comorbidities, 
confirm adherence and ensure they receive the most appropriate treatment. 
However, as NICE do not specify which healthcare groups should form this 
multidisciplinary team, pharmacists may be overlooked as a key member, which 
may be to the detriment of patients with difficult asthma. 
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Pharmacists are well placed and have the appropriate training and skills to 
focus on a number of NICE quality standards, including provision of a written 
personalised action plan (statement 3), training and assessment of inhaler 
technique (statement 4), structured asthma reviews in the community 
(statement 5), and assessment of asthma control (statement 6). Since the 
optimum management of asthma relies heavily on using inhaler devices 
correctly and good adherence, which may be facilitated through good 
consultation skills, it is important to understand the theory underpinning these 
issues when designing a research study. 
 
 
2.2 The effect of inhaler technique on asthma control 
2.2.1 The science of inhaler technique 
The use of inhaled therapy has a number of advantages over systemic therapy, 
as it allows a smaller dose to be administered, with a faster onset of action and 
fewer systemic side effects (Everard, 2001, Newman, 1985). The deposition of 
the inhaled drug in the lung is dependent on particle size, inhalation technique 
and the type of inhaler device. Consequently correct inhaler technique is of 
critical importance, since errors in inhaler technique are associated with 
suboptimal delivery of the drug into the lungs and may also potentially increase 
the risk of adverse effects, particularly with ICS (Capstick and Clifton, 2012). To 
understand the importance of performing the correct steps in using inhaler 
devices in asthma, it is essential to understand the science behind inhaler 
technique. 
 
The lung deposition of inhaled drugs is dependent on three different 
mechanisms: inertial impaction, sedimentation and diffusion. However, as 
aerosol therapies require particles 1–10 μm in size in order to target central and 
peripheral airways, only inertial impaction and gravitational sedimentation are 
important. The third mechanism, Brownian motion/diffusion, is only relevant in 
aerosols of less than 1 μm in diameter (Bell, 2008, Newman, 1985), and 
therefore is unlikely to be of consequence for inhaled drugs.  
 
Inertial impaction occurs with large or high velocity particles in either the 
oropharynx or at bifurcations of main branches of the bronchial tree, particularly 
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in the large central airways, where they are unable to follow the airstream when 
it changes direction, thus impacting on the airway wall (Bell, 2008, Newman, 
1985). Gravitational sedimentation occurs for smaller particles that are able to 
follow the airstream and penetrate the more peripheral bronchioles and alveoli. 
Here the airstream flows more slowly, allowing the particles to settle on to the 
airway surfaces either during the course of slow steady breathing or during 
breath-holding (Bell, 2008, Newman, 1985). Breath-holding is important for 
smaller particle sizes owing to the increased chance of exhalation of the drug, 
because they can remain airborne for a considerable time (Usmani et al., 2005), 
with more than half of 1.5 μm particles remaining airborne for over 5 minutes 
(Biddiscombe et al., 2003).  
 
The total lung deposition of an inhaled drug from a dry powder inhaler (DPI) is 
strongly affected by the turbulent energy generated in the inhaler device during 
inhalation, which causes the powder formulation to de-aggregate and produce 
an emitted dose with a particle size distribution that will penetrate the peripheral 
airways (Azouz and Chrystyn, 2012). This turbulent energy is generated 
through a combination of inspiratory flow and the resistance of the inhaler 
device, such that DPIs require a fast and deep inhalation to create the pressure 
drop required to ‘suck up’ the drug in the inhaler device (Bell, 2008, Chrystyn, 
2003, Haughney et al., 2010). Failure to achieve this high internal force 
increases the likelihood of the dose impacting in the mouth and throat, due to 
generation of large drug particles with a high inertia.  
 
By contrast, aerosol inhalers, such as the pressurised Metered Dose Inhaler 
(pMDI), require a slow and deep inhalation, with an inspiratory flow rate (IFR) of 
less than 60 L/min. This is because aerosol inhalers generate their own aerosol, 
and so a slower inhalation rate is required to ensure that the drug deposits in 
the peripheral airways, since a fast inhalation will increase the velocity of the 
drug particles, thus increasing inertial impaction in the oropharynx (Al-Showair 
et al., 2007, Haughney et al., 2010). Alternatively, the use of extra-fine particles 
in a pMDI device results in increased lung deposition at higher IFRs, since 
inertial impaction is a function of the velocity and size of drug particles (Usmani 
et al., 2005).  
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IFR measurements through inhaler devices is of importance, since a significant 
proportion of patients with asthma have been shown to have an inspiratory flow 
too high for an pMDI, which could potentially reduce the clinical effectiveness of 
inhaled drugs (Al-Showair et al., 2007). Similarly, slow IFRs through DPIs (such 
as the Accuhaler, Easyhaler and Turbohaler) have been shown to reduce lung 
deposition of inhaled drugs (Borgström et al., 1994, Palander et al., 2000), 
which again adversely affect clinical effectiveness. 
 
The In-Check DIAL® inspiratory flow meter (Clement Clarke Ltd, UK) can be 
used to ensure that patients can inhale through their inhaler device at the 
clinically effective IFR. The device mimics the internal resistance of a range of 
inhaler devices (Accuhaler, Easi-Breathe, HandiHaler, pMDI and Turbohaler 
devices), allowing the measurement of IFR through these devices (Chrystyn, 
2003, Nsour et al., 2001), and can be used as part of inhaler technique 
assessments. There are alternative training aids available to assist inhaler tech-
nique training with specific inhaler devices such as the Turbohaler Trainer 
(AstraZeneca, Sweden), the Accuhaler training Device (Vitalograph, Ennis, 
Ireland), the 2-Tone Trainer® (Canday Medical Ltd, UK), and the Flo-Tone 
Trainer (Clement Clarke International Ltd, UK), which can be used to train 
patients to inhale at the correct IFR when using a Turbohaler, Accuhaler or 
pMDI. 
 
2.2.2 Patients’ ability to use inhaler devices 
The ability to use inhaler devices correctly is crucial to the management of 
asthma, but despite this, many patients make multiple and/or serious errors 
using their inhaler devices. This is of concern, since poor inhaler technique is 
known to result in significant reductions in the effective dose reaching the lungs 
(Newman et al., 1995, Newman, 1985), which would affect the clinical 
effectiveness of the inhaled drug. In a relatively old systematic review, the 
optimum inhaler technique (where no errors are made), was observed in 23-
43% for pMDI, 53-59% for DPIs and 55-57% for pMDI + spacer (Brocklebank et 
al., 2001). However this systematic review included patients with different 
respiratory conditions across all age groups, and included within the meta-
analysis a wide variety of DPIs (several no-longer available in the UK) including 
data from Cyclohalers, Diskhalers, Rotahalers, Spinhalers and Turbohalers, 
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making an unjustifiable assumption that inhaler technique is similar for all DPIs. 
This is clearly not the case, as there is diverse range of different DPI devices 
with different methods for orientation and priming prior to inhalation, and with 
different internal resistances requiring different inspiratory efforts. In one real-life 
study of 3,811 inhaler technique assessments performed on people with 
asthma or COPD in 575 GP practices in France, at least one error was made by 
76% of patients using a pMDI, 54% using a Turbohaler and 49% using an 
Accuhaler (Molimard et al., 2003). Furthermore, at least one critical error 
(defined as an error liable to substantially affect dose delivery to the lung) was 
observed in 28% of patients using a pMDI, 32% using a Turbohaler and 11% 
using an Accuhaler, clearly demonstrating that some inhaler devices may be 
easier to use than others. 
 
Despite increasing recognition of the importance of good inhaler technique, 
studies in GP practices, hospital outpatient clinics and community pharmacies 
continue to report high prevalence of poor inhaler technique in asthma patients. 
However the rate of good inhaler technique continues to be highly variable 
across studies, even for devices that are very commonly prescribed. In one 
study assessing the inhaler technique of 4,078 adult asthmatics using pMDI 
devices in GP practices, 71% were considered to be poor users and 33% were 
poor coordinators, based on a checklist assessment (Giraud and Roche, 2002). 
However two more recent studies, again based in GP practices, used the 
Vitalograph Aerosol Inhalation Monitor to assess pMDI inhaler technique; in one 
study of 1,291 adult asthma patients 85.6% failed to demonstrate optimum 
inhaler technique at the first attempt (Hardwell et al., 2011), but in a second 
study in 2,480 adult asthma patients only 58% failed at the first attempt (Levy et 
al., 2013). 
 
The variation in prevalence of good and poor inhaler technique reported in 
different studies is likely to be in part due to a chance finding, but also reflects 
inconsistencies in study design and inhaler technique assessments. Basheti et 
al, 2014, recently described concerns over the lack of a defined standard for 
assessing inhaler technique, in particular with regards to the number and 
content of inhaler checklists, which makes it difficult to compare and contrast 
findings from study to study, and few have been validated by supporting 
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evidence that improving inhaler technique results in improvements in asthma 
outcomes (Basheti et al., 2014). A further concern with many studies is that 
there is very rarely an objective measure on inspiratory flow through inhaler 
devices, which is known to be critical to lung deposition. The In-Check DIAL 
inspiratory flow meter is a useful tool that allows studies to objectively measure 
inspiratory flow through different inhaler devices, but is only useful for a limited 
range, and not for newer inhaler devices such as the Easyhaler, Ellipta, 
NEXThaler or Spiromax devices. 
 
2.2.3 Effect of inhaler technique on asthma 
Concerns over poor inhaler technique arise since the significant reduction in the 
dose delivered to the lungs has been demonstrated to adversely affect asthma 
control using measures such as the Asthma Control Test (ACT) (Baddar et al., 
2014, Melani et al., 2011), asthma instability scores (Giraud and Roche, 2002), 
and Juniper’s Asthma Control Questionnaire (ACQ) (Giraud et al., 2011). Poor 
technique has also been associated with increased beta2-agonist use, nocturnal 
waking, exercise-induced dyspnoea, emergency room visits, and increased 
global perception of asthma (Giraud and Roche, 2002, Melani et al., 2011). 
 
It is often considered that the most important errors to avoid in the process of 
using an inhaler device are the ‘critical’ or ‘essential’ steps, where failure to 
perform these steps would result in a substantial reduction in emitted dose, or 
even result in no dose being delivered. Examples of critical errors include failure 
to remove the inhaler cap, failure to prime or actuate device, and failure to 
inhale correctly through the device (Basheti et al., 2014, Melani et al., 2011, 
Molimard et al., 2003). Melani et al (2011) demonstrated that patients who 
make at least one critical error using an inhaler had significantly worse asthma 
control, and higher rates of OCS use and hospital admissions (Melani et al., 
2011). Despite this recognition that critical errors are likely to have the most 
serious consequence for asthma management, no studies have examined the 
impact of critical errors compared to minor errors on asthma control. 
 
2.2.4 Healthcare professionals’ ability to use inhaler devices 
Since poor inhaler technique has been demonstrated to have an adverse effect 
on asthma control, it is important that healthcare professionals are competent at 
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using inhaler devices and are able to teach correct inhaler technique to 
patients. However in one UK study across primary and secondary care, only 7% 
of healthcare professionals (including hospital doctors, hospital nurses, GPs, 
practice nurses, hospital and community pharmacy staff) were able to 
adequately perform the correct inhaler technique for a pMDI, including having 
the correct IFR. This demonstrates that poor inhaler technique is common 
across all healthcare professionals and not limited to one group of professionals 
(Baverstock et al., 2010). Similarly poor inhaler technique has been 
demonstrated by healthcare professionals using pMDIs in an Oman study 
(Baddar et al., 2001), specialist respiratory doctors and nurses, or emergency 
department staff using pMDIs in US studies (Interiano and Guntupalli, 1993, 
Jones et al., 1995), and hospital pharmacists using pMDIs, Accuhalers and 
Turbohalers in a Canadian study (Jackevicius and Chapman, 1999). 
 
This consistent finding that healthcare professionals frequently have poor 
inhaler technique highlights their need for training to improve their knowledge 
and skills, in order that they can then teach patients how to use their inhalers 
correctly. Basheti et al, 2009, demonstrated that one 3-hour evening 
educational workshop on asthma and inhaler technique training was sufficient 
for pharmacists to learn and maintain optimal inhaler technique using Accuhaler 
and Turbohaler devices. In this single-blind randomised controlled trial involving 
31 community pharmacists, those in the active education group demonstrated 
significantly better inhaler technique at 2-years than pharmacists in the control 
group who had not received inhaler technique training (Basheti et al., 2009).  
 
Individual or small-group teaching methods, which incorporate practical 
demonstrations have consistently been demonstrated to significantly improve 
the inhaler technique of healthcare professionals including pharmacists (Basheti 
et al., 2009, Cain et al., 2001, Jackevicius and Chapman, 1999) and junior 
doctors (Resnick et al., 1996). This method appears to be more effective than 
less intensive training using written materials only (Jackevicius and Chapman, 
1999), but as good as self-directed web-based training with video 
demonstration of correct inhaler technique (Toumas et al., 2009). 
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However, whilst Basheti et al demonstrated that improved technique following 
intensive small-group teaching could be maintained over prolonged periods 
(Basheti et al., 2009), this was not replicated in other studies (Jackevicius and 
Chapman, 1999, Resnick et al., 1996). These contrasting findings may be 
explained by the fact that the community pharmacists who maintained good 
inhaler technique were using these skills routinely in a structured interventional 
study designed to improve patients’ inhaler technique and asthma control 
(Basheti et al., 2009), whilst the hospital pharmacists (Jackevicius and 
Chapman, 1999) and junior doctors (Resnick et al., 1996) may not have been 
involved with regular inhaler technique education and were not involved in an 
interventional study on improving patient’s inhaler technique. The authors of 
these two latter studies concluded that one-time education for healthcare 
professionals on inhaler technique is unlikely to be effective in the long-term. 
 
The implication for practice, is that any study that aims to improve patients’ 
inhaler technique would have to ensure that the healthcare professionals or 
researchers performing the intervention are adequately trained, skilled and 
knowledgeable in the correct use of a range of inhaler devices, and may need 
this training reinforced if they do not regularly teach inhaler technique for 
prescribed inhaler devices. 
 
 
2.3 Adherence and behaviour modification 
Poor adherence to asthma medication has been consistently described in the 
medical literature and has been demonstrated to be a significant issue across 
all drug classes including ICS (Horne and Weinman, 2002, James et al., 1985), 
OCS (James et al., 1985, Glanz et al., 1984), theophyllines (James et al., 
1985), inhaled SABAs and LABAs (James et al., 1985, Kinsman et al., 1980) 
and oral beta2-agonists (James et al., 1985). Since ICS are considered to be 
the most-effective preventer drug for achieving asthma control (British Thoracic 
Society and Scottish Intercollegiate Guidelines Network, 2014), it is critical that 
adherence to this class of drug is maintained. However a systematic literature 
review in asthma reported that short-term studies (with a two to 12 week 
duration) demonstrated that patients took the recommended doses of 
medication on 20% to 73% of days, underusing their ICS on 24% to 69% of 
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days, and overusing on 2% to 23% of days (Cochrane et al., 2000). In a five-
year study, adults with asthma were reported to only adhere to their asthma 
prescriptions for around 30% to 60% of the time, based on prescription data. 
Furthermore, 25% of patients with mild to severe asthma had compliance rates 
estimated at 30% or less (Das Gupta and Guest, 2003).  
 
Factors affecting adherence are complex and are described as intentional non-
adherence (when the patient makes a conscious decision not to take their 
medication) or unintentional non-adherence (such as when the patient forgets 
to take their medication or is unable to use their prescribed inhaler devices) 
(Cochrane et al., 1999, Horne, 2006). Intentional non-adherence to ICS in 
asthma is particularly common and has been shown to be closely related to 
patients’ beliefs, particularly due to doubts about the necessity for medication, 
concerns about the potential for adverse drug reactions, and perceived 
consequences and perceptions of their illness (Horne and Weinman, 2002, 
Horne and Weinman, 1999, Menckeberg et al., 2008).  
 
It is important to identify poor adherence to ICS because it is known to result in 
poor asthma outcomes and increased mortality (Suissa and Ernst, 2001, Suissa 
et al., 2000). Confusingly, some studies have shown higher self-reported 
adherence rates in people with more severe asthma (Bolman et al., 2011, Clark 
et al., 2012), when it would be more logical to find that poor adherence resulted 
in more severe asthma symptoms. This may be explained by the fact that these 
two studies used self-reported measures of adherence rather than objective 
measures such as prescription data or dose monitoring, and so may be subject 
to over-reporting. On the other hand, it may be logical to anticipate that 
increasing severity of asthma symptoms may provide a stimulus to patients to 
adhere to their treatment regimen, but this should then result in improved 
asthma control and show an association between adherence and fewer asthma 
symptoms. This suggests, therefore, that the inter-relationship between asthma 
control and adherence are complex, and other factors may also be important. 
 
Other factors that are associated with improved adherence in asthma include 
having fewer negative perceptions of ICS, habitual use of ICS (Bolman et al., 
2011), and presence of an asthma action plan (Clark et al., 2012). Conversely, 
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factors that may be associated with poorer adherence in asthma include 
concerns about side effects, more negative perceptions of ICS (Sofianou et al., 
2013, Park et al., 2010), impulsivity (Axelsson et al., 2009), forgetfulness and 
having to take inhaled medicines more than once a day (Park et al., 2010). 
Furthermore, cohort studies have suggested that the choice of inhaler device 
may also affect adherence, with one cohort study reporting improved adherence 
using a DPI rather than a pMDI device. This may have been due to patients’ 
preference for DPI devices, being easier to use, or due to greater symptomatic 
improvement using DPIs, which tended to be an ICS/LABA combination inhaler 
whilst pMDIs contained ICS alone (Roy et al., 2011). 
 
These studies suggest that adherence may be improved by education on 
asthma management in order to address misconceptions or to allay concerns 
about taking medications, as well as ensuring that the inhaler device prescribed 
is acceptable to the patient. A literature review focussing on the effect of 
interventions aiming to improve adherence is presented in Chapter 3.3.4. 
 
2.3.1 How adherence to inhaled corticosteroids affects asthma control  
The importance of adherence to ICS in asthma has been demonstrated in a 
number of studies analysing a link between adherence and asthma control. 
 
Despite the fact that patient-reported adherence frequently over-estimates true 
adherence (Hyland et al., 2012, Ivanova et al., 2008), two studies have 
demonstrated that better patient-reported adherence shows a weak correlation 
with asthma control using the ACT (Wojtczak et al., 2012), a reduction in 
emergency room visits and improved quality of life (Takemura et al., 2010). 
However another failed to demonstrate an association between adherence 
using the Medication Adherence Report Scale (MARS) questionnaire and 
asthma control using ACT (Axelsson et al., 2009), although this may have been 
confounded by the overall sample population having a mean ACT of 21.34 
indicating a sample population with well controlled asthma, and thus having less 
scope for improving asthma control further.  
 
There are concerns over patient-reported measures of adherence, and this was 
highlighted in a cohort study that reported that whilst there was an association 
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between asthma exacerbations and adherence when measured with 
prescription records, there was not when patient self-reported adherence was 
used (Hyland et al., 2012). This disparity in association between asthma 
exacerbations and adherence measured using two different methods may be 
due to over-estimation of adherence when reliant on patients’ memories. This is 
supported by the fact that studies that measured adherence using prescription 
record data have demonstrated significant associations with asthma control 
using ACT (Baddar et al., 2014), asthma quality of life using Juniper’s Asthma 
Quality of Life Questionnaire (AQLQ) (Gamble et al., 2009), lung function using 
Forced Expiratory Volume in 1 second (FEV1) and sputum eosinophil counts 
(Murphy et al., 2012b), and exacerbations (Williams et al., 2011). In contrast, 
one study did not find a significant association between adherence and asthma 
control using ACQ (Murphy et al., 2012b).  
 
A concern with these studies lies in the variation of the cut-off for good or poor 
adherence making it hard to compare findings between studies; with a 50% 
adherence rate being used to analyse the impact on asthma symptoms and 
control in one study (Gamble et al., 2009), and 75% (Williams et al., 2011, 
Hyland et al., 2012), or 80% in others (Murphy et al., 2012b). However, the cut-
offs used to define good or poor adherence appear to be an arbitrary value, with 
no large real-life studies available to adequately determine what is the lower 
limit for good adherence that may be associated with an optimal clinical effect.  
 
Similarly real-life adherence in other long-term conditions is substantially lower 
than achieved in clinical trials, with adherence rates commonly between 33% 
and 50%, representing a personal and economic loss to patients, the healthcare 
system and society (National Institute for Health and Care Excellence, 2009). 
Adherence studies in other long-term conditions similarly appear to use arbitrary 
values to define good adherence without data to confirm that these achieve 
optimum clinical effects (Esposti et al., 2011, Slejko et al., 2014). This contrasts 
with the use of antiretrovirals in HIV (human immunodeficiency virus) infection, 
where adherence rates less than 95% have been demonstrated to increase the 
risk of treatment failure (WIlliams et al., 2012). The lack of clear information on 
the effect of adherence on treatment outcomes for many long-term conditions 
such as asthma therefore makes it difficult for healthcare professionals to 
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advise patients about definite adherence requirements, which would otherwise 
assist concordant management discussions. Other interventions are therefore 
required to improve adherence in asthma. 
 
2.3.2 Measuring adherence to inhaled corticosteroids in asthma 
Different methods of assessing adherence may under or over-estimate the true 
rate of adherence in asthma and other long-term conditions. In particular, 
indirect methods commonly used in asthma such as those based on clinical 
judgement, patient self-reporting and dose counting are often unreliable or 
subject to a high degree of under or over-estimation (Cochrane et al., 1999, 
Osterberg and Blaschke, 2005). In asthma, patient reported adherence has 
been demonstrated to over-estimate true adherence based on prescription 
collection data (Hyland et al., 2012, Ivanova et al., 2008). In one study, patient 
self-reported good adherence on the Morisky scale (a 4-item questionnaire) was 
20.7%, but only 2.7% met the definition of good adherence (defined as ≥80% 
medication possession ratio) based on prescription collection data (Ivanova et 
al., 2008). A similar observational study reported that 32% of patients reported 
regular use of ICS, 14% reported regular but suboptimal use of ICS and 54% 
reported symptom-directed use of ICS. However prescription data 
demonstrated only that only 28% regularly used their ICS (Hyland et al., 2012). 
It should be noted, however that objective measures of adherence such as 
prescription refill data may produce inaccurate data since there is no guarantee 
that patients will use their inhalers if they get them dispensed, and refill counts 
from pharmacies may under-estimate adherence if patients use multiple 
pharmacies (Cochrane et al., 1999, Osterberg and Blaschke, 2005). 
 
In an attempt to overcome disadvantages of indirect adherence assessments, 
the MARS (Horne and Weinman, 2002) was developed. This is a self-report 
questionnaire that utilises non-threatening questions in order to encourage 
patients to openly describe their medication adherence, and has been validated 
in a study comparing asthma patient’s self-reporting to pharmacy prescribing 
records (Menckeberg et al., 2008). Consequently, the MARS may be a useful 
questionnaire to use in research and clinical practice to assess adherence. 
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2.3.3 Strategies to improve medication adherence 
Common methods used in clinical practice to improve adherence in asthma 
have often focussed on simplifying treatment regimens such as through the use 
of combination ICS/LABA inhalers, rather than separate ICS and LABA 
inhalers. This is frequently justified because studies have demonstrated greater 
adherence to LABA inhalers than to ICS inhalers when given separately 
(Murphy et al., 2012b), which may be due to subjective improvements observed 
by patients receiving bronchodilators compared to ICS where long-term benefits 
may not be perceived as easily. However, there has been a significant body of 
research that has sought to determine whether adherence can be improved 
through modifying behaviours. 
 
Cognitive-based behaviour change techniques (CBCT) are becoming 
increasingly recommended for use by healthcare professionals to improve 
adherence. A recent meta-analysis across a range of medical conditions 
including asthma, tuberculosis, HIV, epilepsy, diabetes and hypertension found 
a significant improvement in medication adherence through the use of CBCT. 
Such interventions included motivational interviewing, one to one counselling 
sessions, and brief intervention to elicit beliefs and resolve barriers (Easthall et 
al., 2013). Motivational interviewing was one of the most common forms of 
CBCT employed across the studies since it is designed to address patient’s 
ambivalence to change, targeting intentional non-adherence, as well as 
reflecting on unintentional non-adherence in order to facilitate behaviour change 
and identify solutions to resolving non-adherence (Easthall et al., 2013). 
 
Further evidence that supports the benefit of combinations of behaviour 
modification interventions is asthma is provided by a systematic review, which 
investigated the efficacy of different components of the Chronic Care Model 
(CCM) to improve adherence to ICS in asthma (Moullec et al., 2012). The CCM 
incorporates interventions such as self-management, decision support (such as 
evidence-based guidelines and integrating specialist services), delivery system 
design (such as the use of multidisciplinary teams, including pharmacists) and 
clinical information system (such as clinical registries). The systematic review 
incorporated 18 studies, all but one of which was conducted in patients with 
moderate to severe asthma, and all included a self-management component, 
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including education about the condition as well as prevention and treatment 
strategies, behavioural support including monitoring and incorporating tools to 
modify behaviours, and motivational interviewing. Of the 13 studies that 
incorporated just one CCM component (12 taught self-management skills and 
one used decision support), a significant improvement in adherence was found, 
with a pooled effect size of 0.29 (95% CI 0.16-0.42), such that mean adherence 
in the intervention group was 0.29 of a standard deviation above the control 
group mean. However when two or four CCM components were used, the 
pooled effect size was greater at 0.53 (95% CI 0.40-0.66) and 0.83 (95% CI 
0.69-0.98) respectively (Moullec et al., 2012). 
 
This study therefore suggests that whilst a consultation that incorporates CBCT 
interventions such as self-management strategies is important, it still needs to 
be incorporated with other interventions. Such consultation methods have been 
employed successfully in a Belfast adherence study, which used an intervention 
based on a Compliance Therapy Model encompassing the Transtheoretical 
Model of Change, Motivational Interviewing and Cognitive Behavioural Therapy 
principles (Gamble et al., 2011). This intervention resulted in a significant 
improvement in adherence to ICS. 
 
Studies that incorporated combinations of individualised interventions seeking 
to alter behaviours have demonstrated significant improvements in asthma 
symptoms as a direct result of changes in asthma behaviours (Bailey et al., 
1990, Put et al., 2003, van Es et al., 2001). In one study, an intensive 
programme of six 1-hour sessions was used to provide psycho-education about 
each patient’s illness perceptions and what causes their symptoms, behavioural 
techniques such as self-monitoring and the control and avoidance of asthma 
triggers, and cognitive techniques designed to address erroneous views about 
asthma and its treatment (Put et al., 2003). At three months, this intervention 
was associated with a significant improvement in quality of life as measured 
using the AQLQ (increase of 0.9 vs. -0.1, p<0.0001), lung function as measured 
using peak expiratory flow and adherence after completion of the programme 
and after three months follow-up. This study therefore demonstrates the value 
of consultation styles focusing on behaviour changes in asthma as an 
intervention that can improve asthma symptoms.  
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2.4 Summary 
There may be potential for improvement of the care and health of patients with 
difficult asthma through the better use of medicines and greater input from 
pharmacists, but more research is needed. In particular, research is needed to 
determine whether a co-ordinated approach comprising complex interventions 
from hospital specialist pharmacists and community pharmacists improves 
asthma control or other asthma outcome measures. A number of areas have 
been highlighted in this chapter that demonstrate issues affecting medicines 
use that may influence asthma control. Before commencing a research study, it 
is important to understand previously published literature in order to identify 
aspects of asthma management where the evidence base is lacking in order to 
develop a research study to address these gaps. 
 
The research study presented in this thesis is the first to investigate the effects 
of a redesigned pharmaceutical pathway across the primary and secondary 
care interface in patients with difficult asthma. It is also the first to compare 
pharmaceutical management of asthma to usual medical care, since previous 
studies have focussed on comparisons of enhanced pharmaceutical 
management to usual pharmacist management (Armour et al., 2007, Barbanel 
et al., 2003, Charrois et al., 2006, Cordina et al., 2001, Garcia-Cardenas et al., 
2013, Kritikos et al., 2007, Mehuys et al., 2008, Petkova, 2008, Saini et al., 
2008). 
 
The research question being examined is whether a co-ordinated management 
strategy between a hospital Advanced Clinical Pharmacist specialising in 
respiratory medicine and community pharmacists can improve asthma control in 
patients with difficult asthma. 
 
2.5 Aim 
To determine the effects of a co-ordinated management strategy between 
primary and specialist secondary care pharmacists on asthma control and 
quality of life in patients with difficult asthma. 
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2.6 Objectives 
This primary objective of this study is to measure the impact on asthma control 
from the management of difficult asthma by a hospital advanced clinical 
pharmacist and community pharmacist. 
 
Secondary objectives are to determine the impact of the intervention on quality 
of life, exacerbations, lung function, inhaler technique and adherence.  
 
The results of this study will be used to make recommendations for the future 
delivery of services provided by pharmacists for patients with difficult asthma. 
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3 Literature Review 
3.1 Introduction 
During the planning of a research study on how pharmacists may impact on the 
management of patients with difficult asthma, it is important to critically analyse 
published literature in order to understand how the current evidence-base 
influences potential study aims and objectives. A new research study should 
build on existing research as well as seeking to investigate areas of practice 
where there are currently gaps in the literature and identify areas where 
research is lacking. This literature review will critically analyse research 
investigating the different aspects of how pharmacists may intervene in the 
management of asthma, concentrating on the role of complex interventions, 
inhaler technique, and adherence on asthma control.  
 
 
3.2 Literature review methods 
The methods used in this literature review are based on the those 
recommended by the Cochrane Collaboration for performing systematic reviews 
(Higgins and Green, 2011). Cochrane recommend that Cochrane review groups 
include a trials search co-ordinator to assist with the search for studies for 
inclusion in reviews, by designing search strategies and running these in the 
selected bibliographic databases. Where trials search co-ordinators are not 
available, Cochrane recommend that guidance is sought from a local healthcare 
librarian or information specialist with experience of conducting searches for 
systematic reviews. Since this thesis reports the conduct of a research study 
performed under supervision for award of Doctor of Pharmacy programme, the 
literature review was performed independently, without assistance from 
librarians or information specialists despite the recommendations from the 
Cochrane collaboration.  
 
A literature review was planned for three aspects of interest for the present 
research study, namely the role of complex interventions performed by 
pharmacists, inhaler technique and adherence on asthma outcomes. The aim of 
the search strategies was to obtain as many published studies as possible 
within time and funding constraints. As such, search terms used within each 
literature review were kept as broad as possible. It was decided that all 
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international published studies were potentially relevant as asthma is a global 
health problem, and its management is similar across many countries, with 
similar access to medicines, inhaler devices and healthcare resources (Global 
Initiative for Asthma, 2014). Whilst Cochrane recommend that no language 
restrictions should be placed on search strategies, this is known to substantially 
increase the costs and time taken to complete literature reviews (Higgins and 
Green, 2011). Consequently the search strategies for these literature reviews 
had to be limited to English Language as there was no funding available for 
translation services. 
 
A decision was made to perform literature searches in a variety of healthcare 
search engines to prevent selection bias in the literature review, as a systematic 
review has shown that only 30% to 80% published randomised trials may be 
identifiable from using MEDLINE alone (Higgins and Green, 2011). Whilst the 
Cochrane Central Register of Controlled Trials (CENTRAL) is considered by the 
Cochrane Collaboration to be the best single source of reports of trials for 
inclusion in Cochrane reviews, it was not available to the lead investigator and 
so was not used. Consequently the healthcare databases used were MEDLINE, 
and AMED, EMBASE, HMIC, PsycINFO, BNI, CINAHL, HEALTH BUSINESS 
ELITE because these are all freely accessible to NHS staff. Hand searching of 
references in published studies was also used to identify additional studies that 
had not already been identified. A decision was made to exclude the use of 
conference abstracts from the literature review as these often provided 
insufficient data. Other potential sources of grey literature were not searched, 
due to time and budget restraints. Web searching, such as using Google or 
Google Scholar, was avoided, because there is little empirical evidence to the 
value of using general internet search engines (Higgins and Green, 2011). 
 
3.2.1 The effects of complex pharmacist interventions on asthma control 
It is important to understand the evidence base for pharmacist-led management 
of asthma, and so a literature review was performed to identify controlled 
studies that assessed the impact of complex pharmacist interventions of any 
form in the management of asthma. The inclusion criteria for this literature 
review were quantitative randomised trials or controlled trials in which the effect 
of more than one intervention performed by a pharmacist in community or 
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hospital settings was compared to usual care of patients with asthma. All 
studies had to report relevant asthma outcome measures, although no 
restriction was placed on specific asthma outcome measures due to low 
number of studies identified. Studies were excluded if they recruited patients 
with acute exacerbations of asthma, or if they included follow-up of interventions 
instigated by other healthcare professionals. 
 
Studies were identified using the healthcare databases MEDLINE, and AMED, 
EMBASE, HMIC, PsycINFO, BNI, CINAHL, HEALTH BUSINESS ELITE. The 
searches were performed on 12th June 2012 and 3rd July 2012, and then 
updated on 4th February 2014 and again on 9th September 2014. The search 
terms used were: (exp PHARMACY AND exp ASTHMA), (exp PHARMACISTS 
AND exp ASTHMA), (exp PHARMACY SERVICE, HOSPITAL AND exp 
ASTHMA), and (exp ASTHMA AND exp HEALTH CARE COSTS). Where 
necessary, these search strategies were limited to [Humans and (Age Groups 
All Adults 19 plus years)]. These searches identified 548 articles, which were 
reduced to 89 after review of the article titles and removal of duplicates. 
Screening of the abstracts identified 40 unique articles that met the inclusion 
criteria for full text review. Further application of the inclusion criteria was 
applied to these articles to identify those that truly met the inclusion criteria. The 
selection process was recorded as a Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA) flow diagram (Liberati et al., 2009) 
(Figure 1). 
 
The risk of bias was assessed for each of the nine included studies for seven 
separate domains (random sequence generation, allocation concealment, 
blinding of participants and personnel, blinding of outcome assessment, 
incomplete outcome data, selective outcome reporting, other biases), using 
criteria outlined in the Cochrane Handbook for Systematic Reviews (Higgins 
and Green, 2011). The risk of bias was graded as high, low or unclear, with 
justifications for this judgement in the ‘Risk of bias’ table (see Appendix 1). 
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Figure 1. Study selection diagram: Literature Review on the effects of 
complex pharmacist interventions on asthma control. 
 
 
3.2.2 Effect of inhaler technique on asthma control  
Published data, outlined in the introduction (see Chapter 2.2) clearly 
demonstrates that asthma patients frequently have poor inhaler technique, 
which may impact on their asthma control. Consequently, it is important to 
determine whether inhaler technique in patients can be improved, and how this 
affects their asthma control. A literature review was performed to identify 
studies that assess the impact of interventions that were solely focused on 
improving inhaler technique in asthma, and the effectiveness of both this and 
the impact on asthma outcomes. Inclusion criteria for the literature review were 
quantitative studies investigating the effect of interventional and educational 
strategies specifically targeting only inhaler technique on (i) improvement in 
overall inhaler technique, and (ii) asthma control and health status. Due to 
limited numbers of studies that met these inclusion criteria, studies were not 
548 records 
identified through 
database searching 
95 records identified 
for screening 
89 unique records 
screened 
49 records excluded after 
screening of abstracts 
40 full-text articles 
assessed for eligibility 
31 full-text articles 
excluded, due to not 
meeting the inclusion 
criteria 
9 studies meet 
eligibility criteria for 
qualitative synthesis 
453 records excluded after 
preliminary screening of 
titles ± abstracts 
6 duplicate records 
excluded 
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restricted to randomised controlled trials. Studies were excluded where inhaler 
technique training comprised one of several interventions, since this could 
confound study outcomes. 
 
Studies were identified using the healthcare database MEDLINE, and AMED, 
EMBASE, HMIC, PsycINFO, BNI, CINAHL, HEALTH BUSINESS ELITE and 
were performed on 17th July 2012, 25th March 2014, and 9th September 2014. 
The search terms were as follows: (exp NEBULIZERS AND VAPORIZERS 
AND exp ADMINISTRATION, INHALATION AND technique.ti,ab). Where 
necessary, these search strategies were limited to [English Language and 
Humans]. 
 
These searches identified 347 articles, which were reduced to 99 after review of 
the article titles and removal of duplicates. Review of the reference lists 
identified a further 39 studies. Screening of this total of 138 abstracts identified 
45 articles that met the inclusion criteria for full text review. Further application 
of the inclusion criteria was applied to these articles to identify those that 
completely fulfilled the inclusion criteria. The selection process was recorded as 
a PRISMA (Liberati et al., 2009) flow diagram (Figure 2). 
 
The risk of bias was assessed for each of the six included studies for seven 
separate domains (random sequence generation, allocation concealment, 
blinding of participants and personnel, blinding of outcome assessment, 
incomplete outcome data, selective outcome reporting, other biases), using 
criteria outlined in the Cochrane Handbook for Systematic Reviews (Higgins 
and Green, 2011). The risk of bias was graded as high, low or unclear, with 
justifications for this judgement in the ‘Risk of bias’ table (see Appendix 2). 
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Figure 2. Study selection diagram: Literature Review on the effect of 
inhaler technique on asthma control. 
 
 
3.2.3 The effect of interventions to improve adherence to inhaled 
corticosteroids on asthma control 
Since published data, outlined in the introduction (see Chapter 2.3) clearly 
demonstrate an association between adherence to ICS and asthma control, it is 
important to determine whether interventions designed to improve adherence 
may improve asthma outcomes. A literature search was performed to examine 
this, with inclusion criteria comprising studies that investigate the effect of 
interventional and educational strategies specifically targeting adherence to ICS 
on (i) improvement in overall adherence, and (ii) asthma control or health 
347 records 
identified through 
database searching 
101 records identified 
for screening 
138 unique records 
screened 
93 records excluded after 
screening of abstracts 
45 full-text articles 
assessed for eligibility 
39 full-text articles 
excluded, due to not 
meeting the inclusion 
criteria 
6 studies meet 
eligibility criteria for 
qualitative synthesis 
246 records excluded after 
preliminary screening of 
titles ± abstracts 
2 duplicate records 
excluded 
39 records 
identified through 
hand searching 
99 unique records 
identified for screening 
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status. Studies were excluded from the literature review if they investigated 
adherence only to asthma medicines other than ICS, where no interventions 
were made, or if they only performed qualitative analysis of adherence. 
 
Studies were identified using the healthcare database MEDLINE, and searches 
were performed on 3rd July 2012 and repeated on 18th September 2012, 4th 
February 2014 and again on 9th September 2014. The search terms used were 
(exp MEDICATION ADHERENCE AND exp ASTHMA), and were limited to 
[English Language and Humans AND (Age Groups All Adults 19 plus years)]. 
This search was repeated on other healthcare databases on 4th February 2014, 
and 9th September 2014 using: AMED, EMBASE, HMIC, PsycINFO, BNI, 
CINAHL, and HEALTH BUSINESS ELITE. These searches found a total of 682 
articles, which were reduced to 115 after review of the article titles and removal 
of duplicates. Screening of the abstracts of each of these articles identified 49 
that appeared to meet the literature review inclusion criteria, and full-text was 
obtained for detailed assessment. The selection process was recorded as a 
PRISMA (Liberati et al., 2009) flow diagram (Figure 3). 
 
The risk of bias was assessed for each of the six included studies for seven 
separate domains (random sequence generation, allocation concealment, 
blinding of participants and personnel, blinding of outcome assessment, 
incomplete outcome data, selective outcome reporting, other biases), using 
criteria outlined in the Cochrane Handbook for Systematic Reviews (Higgins 
and Green, 2011). The risk of bias was graded as high, low or unclear, with 
justifications for this judgement in the ‘Risk of bias’ table (see Appendix 3). 
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Figure 3. Study selection diagram: Literature Review on the effect of 
interventions to improve adherence to inhaled corticosteroids on asthma 
control. 
 
 
3.3 Literature review and critical analysis 
3.3.1 The effects of complex pharmacist interventions on asthma control 
3.3.1.1 Results of the search 
After screening of study titles and abstracts, and removal of duplicates, 40 full-
text articles were retrieved for consideration for review, and nine were found to 
meet the eligibility criteria (see Figure 1). 
 
3.3.1.2 Included studies 
See Characteristics of included studies (Appendix 1) for details. A total of nine 
articles met the inclusion criteria for the literature review (Armour et al., 2007, 
Barbanel et al., 2003, Charrois et al., 2006, Cordina et al., 2001, Garcia-
Cardenas et al., 2013, Kritikos et al., 2007, Mehuys et al., 2008, Petkova, 2008, 
682 records 
identified through 
database searching 
281 records identified 
for screening 
115 unique records 
screened 
66 records excluded after 
screening of abstracts 
49 full-text articles 
assessed for eligibility 
43 full-text articles 
excluded, due to not 
meeting the inclusion 
criteria 
6 studies meet 
eligibility criteria for 
qualitative synthesis 
401 records excluded after 
preliminary screening of 
titles ± abstracts 
75 duplicate records 
excluded 
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Saini et al., 2008), and are summarised in Table 1. All nine studies were based 
in community pharmacies (range one to 66 pharmacies per study). No studies 
that met the inclusion criteria reported the effects of complex interventions 
performed by secondary care pharmacists, and similarly no studies were found 
that sought to exclusively recruit patients who are classed as having difficult 
asthma (British Thoracic Society and Scottish Intercollegiate Guidelines 
Network, 2014).  
 
Two studies did not report the level of asthma control or severity of symptoms of 
recruited patients (Barbanel et al., 2003, Cordina et al., 2001), two used the 
severity classification from the National Asthma Council Australia (Armour et al., 
2007, Saini et al., 2008), two used ACQ (Charrois et al., 2006, Garcia-Cardenas 
et al., 2013), one used the ACT (Mehuys et al., 2008), one used severity based 
on an unreferenced Expert Panel Report 2: Guidelines for diagnostic and 
management of asthma, 1997 (Petkova, 2008), and one used an apparently un-
validated and unreferenced measure of asthma severity (Kritikos et al., 2007). 
Four studies reported the proportion of patients with severe asthma symptoms; 
ranging from 30% of patients in one study (Petkova, 2008), to 71-88% in 
another (Armour et al., 2007). However three studies only reported the mean 
level of asthma control using different scoring systems (Charrois et al., 2006, 
Mehuys et al., 2008, Saini et al., 2008). Due to the variety of methods of 
reporting asthma severity or control, it is not possible to standardise or compare 
the extent of impact of pharmacist interventions on asthma outcomes across the 
nine studies included in the literature review. 
 
3.3.1.3 Excluded studies 
Thirty one studies did not meet the literature review inclusion criteria for a 
variety of reasons including: lack of relevant asthma outcome data (6 articles) 
(Saini et al., 2011b, Smith et al., 2007, Takemura et al., 2012, Hinchageri et al., 
2012, Rathan Shyam et al., 2013, Ovchinikova et al., 2011), study design (e.g. 
non-quantitative methodology, lack of comparative arm or control group, non-
randomised controlled study, systematic review) (9 articles) (Emmerton et al., 
2003, Mangiapane et al., 2005, Saini et al., 2011a, Saini et al., 2006, Stiegler et 
al., 2003, Watanabe et al., 1998, Adunlin and Mahdavian, 2012, Benavides et 
al., 2009, Armour et al., 2013), mixed healthcare professional interventional 
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studies (3 articles) (Knoell et al., 1998, Pauley et al., 1995, Wang et al., 2010), 
study not being fully published (3 articles) (Basheti et al., 2007, Lim et al., 2012, 
Murphy et al., 2012a), wrong age group due to recruitment of children (2 
articles) (Munzenberger and Hill, 2007, Petrie and Segal, 2010), articles that 
were not research studies (2 articles) (Kelly, 2006, Wittbrodt et al., 2006), 
intervention performed on different long term conditions or in addition to asthma 
(2 articles) (Pizzi et al., 2001, Weinberger et al., 2002), implementation of a 
single rather than a complex intervention (3 articles) (Simpson et al., 2004, 
Giraud et al., 2011, Basheti et al., 2008), lack of reporting of inclusion or 
exclusion criteria (1 article) (McLean et al., 2003), and incomplete data reporting 
(1 article) (McLean et al., 2003).  
 
3.3.1.4 Interventions 
See summary table of complex pharmacist interventions on asthma control 
(Table 1) and Characteristics of included studies (Appendix 1) for details.  
 
The complex interventions performed in these nine studies were broadly similar 
and content included patient education (eight studies (Armour et al., 2007, 
Barbanel et al., 2003, Charrois et al., 2006, Cordina et al., 2001, Kritikos et al., 
2007, Mehuys et al., 2008, Petkova, 2008, Saini et al., 2008)), medication 
review and/or inhaler technique assessment (nine studies (Armour et al., 2007, 
Barbanel et al., 2003, Charrois et al., 2006, Cordina et al., 2001, Garcia-
Cardenas et al., 2013, Kritikos et al., 2007, Mehuys et al., 2008, Petkova, 2008, 
Saini et al., 2008)), asthma review including assessment of asthma control (four 
studies (Armour et al., 2007, Cordina et al., 2001, Garcia-Cardenas et al., 2013, 
Saini et al., 2008)), adherence assessment (three studies (Armour et al., 2007, 
Garcia-Cardenas et al., 2013, Mehuys et al., 2008)), self-management 
education and provision of action plan (five studies (Armour et al., 2007, 
Barbanel et al., 2003, Charrois et al., 2006, Petkova, 2008, Saini et al., 2008)). 
 
All but one study had at least a 3-month follow-up period following the initial 
pharmacist intervention (range 12 weeks to 12 months), with a 6-month duration 
in five studies. The mean number of patients recruited to each of the studies 
was 156 (range 24 to 396), and seven studies recruited 50 or more patients. All 
nine studies ensured that community pharmacists providing the interventions 
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under investigation were adequately trained. The duration of training ranged 
from a half-day workshop to a three day multidisciplinary course, but all 
appeared to have similar content comprising aspects of education on asthma 
pathophysiology, assessment and monitoring, medications, inhaler technique, 
adherence, lifestyle modifications and patient education and self-management. 
The broad similarities shown for pharmacist training demonstrates that 
education of healthcare professionals is an important aspect in the study design 
of pharmacist interventional studies, and has been found to have a positive 
impact on the behaviour of intervention pharmacists in these studies (Saini et 
al., 2006). 
 
3.3.1.5 Primary outcomes 
See summary table of complex pharmacist interventions on asthma control 
(Table 1) and Characteristics of included studies (Appendix 1) for details. 
 
The primary outcome was a measure of asthma control or asthma severity in 
six studies: National Asthma Council Australia asthma severity (Armour et al., 
2007, Saini et al., 2008), ACQ (Charrois et al., 2006, Garcia-Cardenas et al., 
2013), ACT (Mehuys et al., 2008), or a validated North of England asthma 
symptoms scale (Barbanel et al., 2003). One study used Quality of life 
(measured using the Short Form (SF)-36 and Living with Asthma Questionnaire 
(LWAQ)) as the primary outcome (Cordina et al., 2001), one used inhaler 
technique (Kritikos et al., 2007), whilst another did not specify a primary 
outcome measure (Petkova, 2008). Common secondary outcome measures 
included quality of life measures (most frequently AQLQ), lung function, inhaler 
technique and adherence. The method of reporting inhaler technique varied, 
with some studies reporting percentage scores (Cordina et al., 2001, Mehuys et 
al., 2008, Saini et al., 2008), whilst others reported the proportion of patients 
with optimal technique (Garcia-Cardenas et al., 2013, Kritikos et al., 2007, 
Petkova, 2008, Armour et al., 2007). Similarly, adherence was measured using 
a variety of methods including prescription records (Armour et al., 2007, 
Mehuys et al., 2008), self-reporting (Cordina et al., 2001), or questionnaires 
(Armour et al., 2007, Garcia-Cardenas et al., 2013, Kritikos et al., 2007, Saini et 
al., 2008). 
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3.3.1.6 Risk of bias 
The assessment and justification of the risk of bias for each of the included 
studies is presented in the Characteristics of included studies (Appendix 1). All 
studies had at least one domain where there was assessed to be a potential 
high risk of bias, primarily because outcome assessments did not appear to 
blinded in all but one study. Four studies were at high risk of bias as there was 
no blinding of participants and personnel and there could be a high risk of 
contamination of usual care (Barbanel et al., 2003, Charrois et al., 2006, 
Mehuys et al., 2008, Petkova, 2008). 
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Table 1. Brief summary of the effect of complex pharmacist interventions on asthma control 
 
Citation, 
Country 
Purpose of study Study description Interventions Outcomes 
measures 
Key findings Comments 
(Armour et al., 
2007), Australia 
To evaluate the 
effect of the 
Australian 
Pharmacy Asthma 
Care Program on 
asthma control and 
other clinical and 
humanistic 
outcomes. 
Design: multi-site 
randomised 
intervention versus 
control study. 
N: 396. 
Duration: 6 months. 
Pharmacy Asthma 
Care Program 
protocol: assessing 
asthma control, 
targeted counselling 
and education on 
asthma, medication 
and lifestyle issues, 
review of inhaler 
technique, 
adherence, 
detection of drug-
related problems, 
goal setting and 
referral to GP as 
appropriate. 
The control group 
received usual care 
only. 
Primary: Change in 
asthma control 
Secondary: 
Adherence, SABA 
use, quality of life, 
asthma knowledge. 
The proportion of 
patients with severe 
asthma declined in 
the PI group (87.9% 
to 52.7%, p<0.001), 
but was unchanged 
in the UC group 
(71.2% to 67.9%, 
p=0.11). 
Greater 
improvement in 
AQLQ in the PI vs. 
UC group (p<0.05), 
adherence (p=0.03), 
and SABA use 
(p<0.03). 
Pharmacists in the 
intervention group 
received training 
and education on 
asthma and its 
management. 
Intervention 
performed in 
community 
pharmacies. 
  
4
8
 
Citation, 
Country 
Purpose of study Study description Interventions Outcomes 
measures 
Key findings Comments 
(Barbanel et al., 
2003), London 
To test whether 
community 
pharmacists can 
improve asthma 
control with self-
management advice 
Design: randomised 
controlled study. 
N: 24. 
Duration: 3 months. 
Patient education, 
assessment of 
inhaler technique, 
and self-
management advice 
based on peak 
expiratory flow 
measurements and 
symptoms, with 
weekly telephone 
follow-up. 
The control group 
received usual care 
only. 
Primary: asthma 
health status, 
measured using the 
North of England 
asthma symptoms 
scale. 
Significant 
improvement in 
patients in the 
intervention 
compared to the 
control group (7.0, 
p<0.001). 
Pharmacists in the 
intervention group 
received training 
and education on 
asthma and its 
management. 
Intervention 
performed in 
community 
pharmacies. 
(Charrois et al., 
2006), Canada 
To determine 
whether community 
pharmacists could 
improve asthma 
control in a rural 
setting. 
Design: randomised 
controlled study. 
N: 70. 
Duration: 6 months. 
Educational 
program on asthma, 
action plan, 
assessment of 
asthma therapy, 
and referral to a 
respiratory therapist 
and primary care 
physician as 
needed. 
The control group 
patients received an 
asthma education 
booklet and general 
advice as needed. 
Primary: change in 
ACQ. 
Secondary: use of 
ICS, change in 
FEV1, courses of 
oral steroids, 
hospital admissions. 
Mean change in 
ACQ: 0.33 and 0.43 
in the control and 
intervention groups 
(no significant 
difference between 
the 2 groups, p = 
0.66). 
No significant 
difference for any 
secondary outcome. 
All pharmacists 
received training 
and education on 
asthma and its 
management. 
Intervention 
performed in 
community 
pharmacies. 
  
4
9
 
Citation, 
Country 
Purpose of study Study description Interventions Outcomes 
measures 
Key findings Comments 
(Cordina et al., 
2001), Malta 
To examine the 
impact of a 
community 
pharmacy-based 
education and 
monitoring program 
on asthma 
outcomes. 
Design: randomised 
controlled 
prospective trial. 
N: 152. 
Duration: 12 
months. 
Comprehensive 
asthma education 
and monitoring 
program, including 
information on 
asthma pathology, 
triggers, use of 
inhaler devices and 
peak flow meters. 
The control group 
received routine 
dispensing only. 
Primary: Quality of 
life using SF-36 and 
LWAQ. 
Secondary: Peak 
expiratory flow 
(PEF), inhaler 
technique, 
compliance, 
No significant 
differences between 
the 2 groups on SF-
36 or LWAQ, 
although there was 
a significant 
improvement at 12 
months on LWAQ in 
the intervention 
group. 
PEF unchanged in 
the intervention 
group, but worse in 
the control group. 
Significant 
improvement in 
inhaler technique in 
intervention group. 
There was no 
difference in self-
reported adherence. 
Pharmacists in the 
intervention group 
received training 
and education on 
asthma and its 
management. 
Intervention 
performed in 
community 
pharmacies. 
  
5
0
 
Citation, 
Country 
Purpose of study Study description Interventions Outcomes 
measures 
Key findings Comments 
(Garcia-Cardenas et 
al., 2013), Spain 
To evaluate the 
effect of a 
pharmacist 
intervention on 
asthma control 
Design: cluster 
randomised trial. 
N: 346. 
Duration: 6 months. 
Protocol-based 
intervention 
addressing 
individual needs 
related to asthma 
control, inhaler 
technique and 
adherence. 
The control group 
received usual care 
only. 
Primary: ACQ 
Secondary: inhaler 
technique, 
adherence. 
Significant 
improvement in 
ACQ in the 
intervention group (-
0.66, p<0.001), but 
not in the control 
group (-0.15 (p 
value not reported). 
Higher proportion of 
patients with correct 
Turbohaler inhaler 
technique and 
adherence at 6 
months in the 
intervention group. 
Pharmacists in the 
intervention group 
received training 
and education on 
asthma and its 
management. 
Intervention 
performed in 
community 
pharmacies. 
  
5
1
 
Citation, 
Country 
Purpose of study Study description Interventions Outcomes 
measures 
Key findings Comments 
(Kritikos et al., 
2007), Australia 
To compare the 
effects of asthma 
education 
interventions 
provided by a 
pharmacist, a 
pharmacist 
educator, or usual 
community 
pharmacist care on 
asthma outcomes. 
Design: parallel 
group pilot study. 
N: 48. 
Duration: 12 weeks. 
Education on 
asthma, its 
management, 
asthma medication, 
inhaler use, and 
relevant written 
information. 
The control group 
received the same 
written information 
without additional 
education. 
Primary: no primary 
outcome measure 
was specified 
Secondary: inhaler 
technique, asthma 
severity, AQLQ, 
adherence. 
Significant reduction 
in percentage of 
patients with severe 
asthma / poor 
control at 12 weeks 
in the two 
pharmacist 
intervention arms 
compared to usual 
care (25% and 13% 
vs. 50%, p=0.04). 
Significant increase 
in the proportion of 
patients with optimal 
pMDI and DPI 
technique and 
improvement in 
AQLQ at 12 weeks 
in intervention 
groups. There was 
no difference in 
adherence at 12 
weeks. 
Pharmacists in the 
intervention group 
received training 
and education on 
asthma and its 
management. 
Intervention 
performed in 
community 
pharmacies. 
  
5
2
 
Citation, 
Country 
Purpose of study Study description Interventions Outcomes 
measures 
Key findings Comments 
(Mehuys et al., 
2008), Belgium 
To determine 
whether pharmacist 
Interventions would 
result in improved 
asthma control. 
Design: 
randomised, 
controlled, parallel-
group trial. 
N: 201. 
Duration: 6 months. 
Education on 
inhaler technique, 
asthma symptoms, 
triggers and warning 
signs, 
understanding 
medication, 
adherence and 
smoking cessation. 
The control group 
received usual care 
only. 
Primary: ACT 
Secondary: PEF, 
SABA use, inhaler 
technique, 
adherence. 
Mean ACT was 
unchanged in both 
groups, however in 
patients 
insufficiently 
controlled at 
baseline, a 
significant 
improvement was 
seen (mean 
difference 2.0 vs. 
control, p=0.038). 
Improvement in 
adherence and 
inhaler technique, 
and reduction in 
SABA use in the 
intervention group. 
All pharmacists 
received training 
and education on 
asthma and its 
management. 
Intervention 
performed in 
community 
pharmacies. 
(Petkova, 2008), 
Bulgaria 
To evaluate the 
effect of education 
programs provided 
by community 
pharmacists on 
quality of life. 
Design: randomised 
controlled trial. 
N: 50. 
Duration: 4 months. 
Educational 
program on asthma, 
triggers, exercise, 
self-management, 
smoking-cessation, 
treatment, inhaler 
technique, and side 
effects. 
The control group 
received usual care 
only. 
Primary: no primary 
outcome measure 
was specified 
Secondary: quality 
of life (assessed 
through an adapted 
disease-specific 
instrument Asthma 
Assessment form, 
PEF, inhaler 
technique. 
Improvement in 
quality of life in the 
intervention group 
(from 3.55 to 3.77 
on a 5-point scale, 
p<0.0001), but was 
reduced in the 
control group (from 
3.39 to 3.00, 
p=0.039). 
No effect on PEF. 
Inhaler technique 
data is inadequate 
to make 
conclusions. 
All pharmacists 
received training 
and education on 
asthma and its 
management. 
Intervention 
performed in 
community 
pharmacies. 
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Citation, 
Country 
Purpose of study Study description Interventions Outcomes 
measures 
Key findings Comments 
(Saini et al., 2008), 
Australia 
To compare the 
effect of a 
pharmacist-
delivered asthma 
service on asthma 
outcomes compared 
to standard care. 
Design: parallel 
group, controlled 
repeated measures 
study. 
N: 51. 
Duration: 6 months. 
Intensive 
pharmacist 
education 
(assessment of 
asthma severity, 
medication and 
inhaler use, 
performing 
spirometry, 
providing Action 
Plan, and 
education, and 
making appropriate 
interventions). 
The control group 
received usual care 
only. 
Primary: 
Asthma severity 
score calculated 
using the Australian 
National Asthma 
Council’s asthma 
severity 
classification. 
Secondary: inhaler 
technique, 
adherence, quality 
of life. 
Significant 
improvement in 
asthma severity 
score in the 
intervention group 
compared to usual 
care (reduction in 
score of 3.6 vs. 
0.09; p<0.001 in the 
as per protocol 
analysis). 
Significant reduction 
in the risk of non-
adherence. 
No effect on SABA 
use or quality of life. 
Improvement in 
inhaler technique 
scores for pMDI, 
Accuhaler and 
Turbohaler devices. 
Pharmacists in the 
intervention group 
received training 
and education on 
asthma and its 
management. 
Intervention 
performed in 
community 
pharmacies. 
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3.3.1.7 Effects of interventions 
See summary table of complex pharmacist interventions on asthma control 
(Table 1) and Characteristics of included studies (Appendix 1) for details. 
 
The two studies that used the Australian National Asthma Council asthma 
severity assessment table to determine the outcome of the complex pharmacist 
interventions, demonstrated statistically significant improvements in asthma 
severity after six-months follow-up (Armour et al., 2007, Saini et al., 2008). 
These two studies recruited a population with high rates of severe asthma 
symptoms; in one study 71-88% of patients had severe asthma symptoms 
(Armour et al., 2007), whilst in the other the mean asthma severity score was 
10.3 and 11.4 (on a 5- (mild) to 15-point (severe) scale) in the control and 
intervention groups respectively (Saini et al., 2008). 
 
The two six-month studies that used ACQ as a measure of asthma control failed 
to demonstrate a significant impact of complex pharmacist interventions 
compared to control in the overall population (Charrois et al., 2006, Garcia-
Cardenas et al., 2013). One study recruited patients considered to be at high 
risk, defined as those with recent admissions to hospital, attendance at the 
emergency department, or using at least 2 canisters of inhaled beta2-agonist in 
the previous 6 months. At baseline the mean ACQ was 1.45 to 1.91 but only 
69% to 77% of patients were prescribed an ICS (Charrois et al., 2006), 
suggesting either that many patients had an incorrect self-reported diagnosis, or 
had only mild symptoms. This study found no improvement in any asthma 
outcome measure, although the authors reported that this might have been due 
to poor uptake of the intervention or contamination of the usual care group. In 
the second study, 55-72% of recruited patients were uncontrolled at baseline 
(Garcia-Cardenas et al., 2013), and when the improvement in ACQ was 
measured for only those patients with uncontrolled asthma at baseline, a 
statistically significant and clinically important improvement in ACQ was found.  
A similar finding was noted in the study using ACT to measure change in 
asthma control six-months after the complex pharmacist intervention (Mehuys 
et al., 2008), where no significant improvement was observed in the overall 
patient population, but was observed in those patients with uncontrolled asthma 
at baseline. Barbanel et al (2003) used the 'North of England asthma symptoms 
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scale' as a validated instrument to measure asthma related health status, and 
found a clinically meaningful improvement in asthma symptom scores at three-
months (Barbanel et al., 2003). 
 
The only study to use quality of life as the primary endpoint failed to 
demonstrate a significant benefit in terms of general health or asthma-specific 
quality of life (Cordina et al., 2001). However two studies using AQLQ as a 
validated measure of asthma-related quality of life as a secondary outcome 
measure demonstrated significant improvements in patients randomised to 
complex pharmacist interventions compared to usual care (Armour et al., 2007, 
Kritikos et al., 2007). In contrast, a third study failed to demonstrate any 
significant effect of pharmacist interventions on AQLQ in the overall patient 
population (Mehuys et al., 2008), but may have been confounded by the 
presence of well controlled patients in the population, which would also explain 
the failure of other studies to demonstrate significant benefits using un-validated 
measures of quality of life (Petkova, 2008). 
 
A further benefit of complex pharmacist interventions, consistently 
demonstrated across randomised trials, was a significant improvement in 
inhaler technique compared to patients in control groups (Cordina et al., 2001, 
Garcia-Cardenas et al., 2013, Kritikos et al., 2007, Mehuys et al., 2008), which 
may contribute to positive asthma outcomes such as asthma control and quality 
of life (see Chapter 3.3.3). The different methods used to rate inhaler technique 
makes direct comparison between the studies difficult (Basheti et al., 2014), 
because some reported percentage of steps performed correctly, whilst others 
reported percentage of patients with optimal inhaler technique. 
 
In summary, the literature review on the effect of complex pharmacist 
interventions on asthma outcomes is limited by a number of factors, in particular 
the heterogeneity of study designs comprising a variety of different individual 
interventions and varying follow-up schedules ranging from weekly telephone 
follow-up interviews, to monthly follow-up reviews, or just two follow-up 
sessions. A further limitation of many of the studies was that there was 
assessed to be a high risk of bias introduced into the study design, through 
unclear randomisation methods and the nature of the interventional study 
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preventing any blinding into the intervention and assessment. Most studies 
were considered to have a low risk of contamination bias as most studies 
randomised patients by recruiting community pharmacists to provide only the 
interventions being studied or to provide usual care. Contamination bias can be 
a significant concern, as in one study where there was a risk of contamination 
between intervention and control patients within the same community 
pharmacy, no significant impact was observed on asthma control or quality of 
life (Mehuys et al., 2008). 
 
The short duration of some of the studies (three had a duration of less than six 
months), which also had relatively small patient populations (Barbanel et al., 
2003, Kritikos et al., 2007, Petkova, 2008), may be of concern in a literature 
review where the other studies are all of at least six months in duration. This is 
because short, small studies may not allow an adequate reflection of the 
variable nature of asthma, and consequently may not be sufficiently powered to 
allow an accurate assessment of the effects on asthma control or 
exacerbations, where these data may be skewed by the changes in clinical 
condition due to the variable nature of asthma rather than a true effect of the 
intervention, or vice versa.  
 
A limitation of the literature review was that the inclusion criteria limited studies 
to those that had a control arm, and so several pre-post intervention 
prospective studies that demonstrate significant benefits of complex pharmacist 
interventions, but without a control arm, were excluded (Armour et al., 2013, 
Emmerton et al., 2003, Mangiapane et al., 2005).  
 
The overall consensus from the studies included in the literature review is 
supportive of complex interventions performed by community pharmacists in 
managing asthma, apparently when targeted at patients with uncontrolled 
asthma who have the greatest potential to benefit. Studies that recruited a large 
proportion of people with asthma who were reasonably well controlled reported 
less favourable results, which is unsurprising considering their baseline health 
status. These findings justify recommendations from the BTS/SIGN and GINA 
guidelines, which recommend that all patients with asthma should be offered, 
what should be considered as a complex intervention comprising self-
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management education, reinforced with a written asthma action plan as this can 
reduce healthcare resource utilisation (British Thoracic Society and Scottish 
Intercollegiate Guidelines Network, 2014, Global Initiative for Asthma, 2014). 
Asthma education recommendations are consequently complex, and include 
the nature of asthma and its treatment, how to use prescribed medication, how 
to undertake self-monitoring, developing a written personalised asthma action 
plan, recognition and management of acute exacerbations and allergen or 
trigger avoidance (British Thoracic Society and Scottish Intercollegiate 
Guidelines Network, 2014, Global Initiative for Asthma, 2014). The provision of 
a personalised asthma action plan is an important component of asthma 
management, since the failure to provide an action plan may be associated with 
an increased risk of asthma deaths (Royal College of Physicians, 2014).   
 
3.3.2 Medicines use reviews 
Since 2005, UK community pharmacists have been funded to provide MURs for 
patients with long-term conditions. Asthma has been listed as one of the NHS 
national target groups for MUR services since October 2011 (Department of 
Health, 2013). All asthma patients are eligible for one t-MUR per year if they 
have received pharmaceutical services from the same pharmacy for at least 
three consecutive months (Department of Health, 2013). 
 
As there have been no large randomised controlled studies assessing the 
impact of MUR services in asthma, a thorough literature review has not been 
performed for this thesis. However it is important to summarise and understand 
the current literature in order to appreciate how and why the MUR service might 
be incorporated into the present research study.  
 
A number of audits have demonstrated that a large proportion of MURs result in 
either interventions or advice being provided, highlighting the value of this 
service to improve patients’ knowledge and use of drugs (Department of Health, 
2013). One such audit of ten MUR forms collected from each of ten pharmacies 
within Brighton and Hove Primary Care Trust, found that recommendations 
were made in 81% of MURs, and the patient was referred to the GP in 18% of 
cases (MacAdam and Sherwood, 2011); whilst a second audit of 464 MUR 
forms from 15 community pharmacies found that 24.7% had lifestyle 
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recommendations, 23.4% identified drug interactions or contra-indications, 
34.8% reported adherence problems, 32.9% advised review by the GP, and 
3.2% gave advice on synchronising repeat prescriptions (van den Berg and 
Donyai, 2010).  
 
There have been a small number of studies that have assessed the value of 
MURs in asthma patients, and have consistently demonstrated that they are a 
useful service to improve asthma management. An early prospective analysis of 
asthma MUR interventions by 47 community pharmacies in Hampshire and the 
Isle of Wight sought to describe and evaluate this service over a 6 month period 
(Portlock et al., 2009). Components of the MUR included inhaler technique and 
adherence assessments, and were performed in a total of 965 patients. 37% of 
patients demonstrated primary non-adherence (defined as less than 75% of 
prescriptions collected within the past 12 months), and all these patients also 
had secondary adherence problems (described as being due to beliefs about 
medicines, due to inhaler device issues, or due to medicines issues). Of the 607 
patients collecting more than 75% of their prescriptions, 300 reported similar 
secondary adherence issues. Overall, pharmacists made a total of 1,787 
interventions, of which 41% were device checks, 10% were GP or nurse referral 
and 49% were educational. This study also demonstrated that MURs were well 
accepted by asthma patients, but no assessment of effect on asthma control or 
symptoms was performed to determine the impact of any interventions. 
 
A second study published in abstract form, assessed the impact on asthma 
control using the ACT in 154 patients after an asthma MUR (Bagole et al., 
2007). All patients received their MUR in person with subsequent assessment 
of asthma control by telephone interview. 44% of patients completed the 
telephone interview, 15% declined to participate, whilst 41% could not be 
contacted.  The mean ACT score improved from 17.2 to 18.8 (p = 0.0048) after 
MUR. The proportion of patients with controlled asthma increased from 5% to 
9%, and reasonably controlled asthma increased from 36% to 46%, whilst those 
who were not controlled decreased from 59% to 45% (p=0.0074). The asthma 
MUR service was rated as very good by 73% of patients, and good by 21%. 
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A recent large audit across the South Central region in England reported a 40% 
increase in the proportion of patients with reasonably well-controlled asthma 
(measured using ACT) between a first and second MUR, where there was an 
extra emphasis on improving inhaler technique (The Cambridge Consortium, 
2012). However, this audit has severe limitations in that the follow-up period 
was not reported and no explanation was provided to account for why only 596 
of 4,004 patients underwent a follow-up MUR and asthma control assessment. 
It is therefore uncertain whether the data provided were an interim analysis or 
whether there was a high discontinuation rate, and how this may have affected 
the overall results. 
 
Studies in asthma patients have demonstrated that MURs are well accepted, 
and can identify and manage adherence problems and potentially may improve 
asthma control (Bagole et al., 2007, Portlock et al., 2009). 
 
3.3.3 Effect of inhaler technique training on asthma control  
3.3.3.1 Results of the search 
After screening of study titles and abstracts, and removal of duplicates, 45 full-
text articles were retrieved for consideration for review, and six were found to 
meet the eligibility criteria (see Figure 2). 
 
3.3.3.2 Included studies 
See Characteristics of included studies (Appendix 2) for details. Six studies 
met the inclusion criteria for the literature review (Al-Showair et al., 2007, 
Alamoudi, 2003, Ammari and Chrystyn, 2013, Basheti et al., 2008, Basheti et 
al., 2005, Giraud et al., 2011). 
 
The studies varied in study design, setting and duration, ranging from two 
weeks to six months. Two studies were six-week controlled trials assessing 
different methods for correcting IFRs on inhaler technique and quality of life, of 
which one was based in a hospital outpatient clinic (Al-Showair et al., 2007) and 
one based in community pharmacies (Ammari and Chrystyn, 2013). A third 
study was a two-week pilot study examining different methods of inhaler 
technique training in community pharmacy settings (Basheti et al., 2005), which 
followed on to a second larger six-month single-blind cluster randomised 
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parallel group study examining the effect of inhaler technique training in 
community pharmacies on lung function, inhaler technique and asthma control 
(Basheti et al., 2008). The final two studies were uncontrolled prospective 
studies, one of which assessed the effects of training on improving inhaler 
technique in hospital outpatients (Alamoudi, 2003), and the other examined the 
impact on asthma control over one month in community pharmacies (Giraud et 
al., 2011).  
 
3.3.3.3 Excluded studies 
Seven studies were found to provide cross-sectional data on inhaler technique 
in asthma patients (Adeyeye and Onadeko, 2008, Baddar et al., 2014, Giraud 
and Roche, 2002, Hardwell et al., 2011, Levy et al., 2013, Melani et al., 2011, 
Roy et al., 2011), and ten provided data in inhaler technique in healthcare 
professionals (Baddar et al., 2001, Basheti et al., 2009, Baverstock et al., 2010, 
Cain et al., 2001, Hanania et al., 1994, Interiano and Guntupalli, 1993, 
Jackevicius and Chapman, 1999, Jones et al., 1995, Resnick et al., 1996, 
Toumas et al., 2009).  
 
A further 22 studies were did not meet the inclusion criteria for a variety of 
reasons including: policy document (one paper (Laube et al., 2011)), review 
article (eight papers (Azouz and Chrystyn, 2012, Basheti et al., 2014, Capstick 
and Clifton, 2012, Chrystyn, 2003, Chrystyn and Price, 2009, Crompton et al., 
2006, Haughney et al., 2010, Price et al., 2013)), mixed respiratory disease (five 
papers (Chorão et al., 2014, Lavorini et al., 2008, Melani et al., 2004, Molimard 
et al., 2003, Press et al., 2012)), Editorial (one paper (Nikander, 2010)), study 
objectives did not meet literature review criteria and had incomplete outcome 
data (one paper (Goodyer et al., 2006)), no outcome data (six papers (Brennan 
et al., 2005, Campos et al., 2006, Ovchinikova et al., 2011, Press et al., 2012, 
Takemura et al., 2010, The Cambridge Consortium, 2012)). One study, 
published as an investigation on the potential impact of inhaler technique on 
asthma control, was confounded by multiple additional interventions performed 
during hospital clinic appointments and so was also excluded from the literature 
review (Harnett et al., 2014). 
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3.3.3.4 Interventions 
See summary table of the effects of inhaler technique training on asthma 
control (Table 2) and Characteristics of included studies (Appendix 2) for 
details. 
 
All six studies provided verbal instructions on correct inhaler technique, but only 
three reinforced this with demonstration by the healthcare professional 
providing the training (Alamoudi, 2003, Basheti et al., 2008, Basheti et al., 
2005). Two studies also provided written instructions (Basheti et al., 2008, 
Giraud et al., 2011) and two provided training aids in the form of a 2Tone 
Trainer whistle (Al-Showair et al., 2007, Ammari and Chrystyn, 2013).  
 
Inhaler technique education was provided by a pharmacist in three studies 
(Basheti et al., 2008, Basheti et al., 2005, Giraud et al., 2011), a nurse in one 
study (Alamoudi, 2003), the lead researcher in one study (Ammari and 
Chrystyn, 2013), but was uncertain who provided the education in the other 
study (Al-Showair et al., 2007). 
 
3.3.3.5 Primary outcomes 
See summary table of complex pharmacist interventions on asthma control 
(Table 2) and Characteristics of included studies (Appendix 2) for details. The 
primary outcome was only specified in one study (Basheti et al., 2008), which 
used peak flow variability. In terms of secondary outcomes, all but one study 
reported inhaler technique (Al-Showair et al., 2007), and only two reported 
objective measures of peak IFR (Al-Showair et al., 2007, Ammari and Chrystyn, 
2013). Two studies measured the effect of the intervention on asthma control 
(Basheti et al., 2008, Giraud et al., 2011), two measured the effect on quality of 
life (Al-Showair et al., 2007, Ammari and Chrystyn, 2013), one other study 
measured the effect on lung function (Alamoudi, 2003), and one also reported 
adherence (Giraud et al., 2011). 
 
3.3.3.6 Risk of bias 
The assessment and justification of the risk of bias for each of the included 
studies is presented in the Characteristics of included studies (Appendix 2). 
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Two studies were judged to be at high risk of bias as they were prospective 
observational studies with no control arm (Alamoudi, 2003, Giraud et al., 2011). 
Of the remaining studies, all had at least one domain where there was 
assessed to be a potential high risk of bias, primarily because outcome 
assessments did not appear to be blinded. Only one study was considered to 
be of low risk of bias (Basheti et al., 2008), although this study failed to report 
data on the primary outcome measure. 
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Table 2. Brief summary of the effect of inhaler technique training on asthma control 
Citation, 
Country 
Purpose of study Study description Interventions Outcomes 
measures 
Key findings Comments 
(Al-Showair et al., 
2007), England 
To determine 
whether a 2Tone 
Trainer [2T]; 
Canday Medical 
Ltd; Newmarket, 
UK) helps to 
maintain the correct 
inhaler technique. 
Design: randomised 
controlled trial.  
N: 108. 
Duration: 6 weeks. 
Measurement of 
peak IFR using In-
Check DIAL, and 
assessment of 
pMDI inhaler 
technique. 
Patients with fast 
peak IFR 
randomised to 
verbal training (VT) 
or verbal training 
plus provision of a 
2Tone trainer 
inhaler (2T).  
Patients with good 
inhaler technique 
(GT) received no 
intervention. 
Primary: none 
stated. 
Secondary: peak 
IFR at 6 weeks, 
AQLQ. 
 
At 6 weeks, there 
was an increase in 
the proportion of 
patients with a 
correct peak IFR 
through a pMDI in 
both the VT 
(increased from 0 to 
23/35 [66%], 
p<0.001) and 2T 
groups (increased 
from 0 to 35/36 
[97%), p<0.001). 
Improvements in 
AQLQ were 
demonstrated; 14 
VT patients had a 
change >0.5 points 
and three >1; 22 2T 
patients had a 
change >0.5 points 
and 8 >1. None of 
the GT patients 
achieved a 
significant 
improvement in 
AQLQ. 
It is unclear who 
performed the 
intervention in this 
study. 
Intervention 
performed in 
hospital outpatient 
clinics. 
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Citation, 
Country 
Purpose of study Study description Interventions Outcomes 
measures 
Key findings Comments 
(Alamoudi, 2003), 
Saudi Arabia 
To assess whether 
educational 
programs can 
improve inhaler 
technique; and 
whether this may be 
associated with PEF 
measurements. 
Design: prospective 
open study. 
N: 130. 
Duration: 6 to 8 
weeks. 
Education and 
demonstration on 
correct inhaler 
technique, for 
approximately 15-20 
minutes. 
There was no 
control group. 
Primary: none 
stated. 
Secondary: inhaler 
technique, PEF. 
 
Education resulted 
in a significant 
reduction in errors 
in inhaler technique 
from 2.8 to 1.0 
(p<0.001) for pMDI 
and from 0.76 to 
0.081 (p=0.002) for 
Turbohaler. 
Increase in mean 
PEF from 312.4 
L/min to 331.0 L/min 
(p=0.003). 
 
No control group. 
Intervention 
performed by a 
nurse in hospital 
outpatient clinics. 
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Citation, 
Country 
Purpose of study Study description Interventions Outcomes 
measures 
Key findings Comments 
(Ammari and 
Chrystyn, 2013), 
England 
To investigate if 
methods to train 
patients to use a 
slow IFR with their 
pMDI would 
improve and 
maintain good pMDI 
use. 
Design: parallel-
grouped clinical 
study. 
N: 50. 
Duration: 6 weeks. 
Measurement of 
peak inhalation flow 
(IFR) using In-
Check DIAL, and 
assessment of 
pMDI inhaler 
technique. 
Patients with a fast 
IFR (>90 L/min) 
were randomised to 
either verbal 
counselling (VC) or 
verbal counselling 
plus provision of a 
2Tone trainer 
inhaler (2T). 
The control (CT) 
group received no 
intervention. 
Primary: none 
stated. 
Secondary: peak 
IFR at 6 weeks, 
inhaler technique, 
AQLQ. 
In adults, the 
change in IFR 
between baseline 
and 6 weeks in the 
VT and 2T groups 
was a median –
143.5 (p<0.001), 
and –165.0 
(p<0.001) 
respectively, 
compared to 
+12L/min in the CT 
group. 
Significant reduction 
in the median 
number of mistakes 
using pMDI in both 
the VT (from 5.5 to 
0, p<0.01) and 2T 
groups (from 5 to 1; 
p<0.01), but no 
change in the 
control group. 
Improvements in 
quality of life were 
achieved in both 
intervention groups. 
The intervention 
was performed by 
the lead researcher. 
Intervention 
performed in 
community 
pharmacies. 
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Citation, 
Country 
Purpose of study Study description Interventions Outcomes 
measures 
Key findings Comments 
(Basheti et al., 
2005), Australia 
To compare the 
effect of three 
counselling 
methods provided at 
the community 
pharmacies on 
Turbuhaler 
technique 
Design: pilot study. 
N: 26. 
Duration: 2 weeks. 
Turbohaler inhaler 
technique training 
by one of three 
methods: verbal 
counselling using 
patient information 
leaflet vs. 
augmented 
counselling (patient 
information leaflet 
with emphasis on 
essential steps) vs. 
augmented 
counselling plus 
demonstration. 
There was no 
control group. 
Primary: none 
stated. 
Secondary: inhaler 
technique. 
 
At baseline 0/26 
had optimal 
technique. After 2 
weeks, optimal 
technique (no 
errors) achieved in 
0/7, 2/8 and 7/9 in 
the verbal 
counselling, 
augmented 
counselling and 
augmented 
counselling plus 
demonstration 
groups respectively 
(p=0.006).  
The intervention 
was performed by 
one of the study 
investigators, who is 
a qualified 
pharmacist. 
Intervention 
performed in 
community 
pharmacies. 
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Citation, 
Country 
Purpose of study Study description Interventions Outcomes 
measures 
Key findings Comments 
(Basheti et al., 
2008), Australia 
To evaluate the 
feasibility, 
acceptability and 
effectiveness of a 
brief intervention 
about inhaler 
technique, delivered 
by community 
pharmacists. 
Design: single-blind 
cluster randomised 
parallel group study. 
N: 97. 
Duration: 6 months. 
Patients in the 
active group 
received inhaler 
technique training 
using augmented 
counselling and 
demonstration, 
repeated up to three 
times until the 
patient performed 
all steps correctly. 
An inhaler 
technique label was 
stuck on the inhaler 
device outlining the 
correct steps for 
using the inhaler 
device. 
The control group 
received usual care 
only. 
Primary: peak flow 
variability 
(Min%Max). 
Secondary: inhaler 
technique, asthma 
severity. 
 
Min%Max was not 
reported. 
Mean inhaler 
technique score 
improved 
significantly from 
baseline in both 
groups, but was 
significantly greater 
in the intervention 
group (for Accuhaler 
and Turbohaler 
combined, the mean 
change in score 
was 2.8 vs. 0.9, p < 
0.001). 
Asthma severity 
was significantly 
reduced in the 
intervention group 
at 2, 3, and 6 
months compared 
to the control group. 
The intervention 
was performed by 
trained community 
pharmacists. 
Intervention 
performed in 
community 
pharmacies. 
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Citation, 
Country 
Purpose of study Study description Interventions Outcomes 
measures 
Key findings Comments 
(Giraud et al., 
2011), France 
To determine 
whether there is a 
link between inhaler 
technique (pMDI, 
Easi-Breathe or 
Autohaler), asthma 
control, and self-
reported adherence. 
Design: prospective 
observational study.  
N: 727. 
Duration: 1 month. 
Inhaler technique 
training using verbal 
instruction and 
written instructions 
in the form of a 
sticker to attach to 
the inhaler device 
(average duration 6 
minutes).  
There was no 
control group. 
Primary: none 
stated. 
Secondary: inhaler 
technique, ACQ and 
Morisky assessment 
of adherence. 
Immediately after 
community 
pharmacist training, 
optimal technique 
increased from 24% 
to 79% (p<0.001).  
At 1 month, mean 
ACQ improved from 
1.8 to 1.4 p<0.001. 
Self-reported 
adherence 
improved from 
mean 1.4 (1.3) to 
1.1, p<0.001. 
There were 
significantly greater 
improvements in 
ACQ and 
adherence n 
patients where 
inhaler technique 
improved. 
No control group. 
The intervention 
was performed by 
community 
pharmacists. 
Intervention 
performed in 
community 
pharmacies. 
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3.3.3.7 Effects of interventions 
See summary table of the effects of inhaler technique training on asthma 
control (Table 2) and Characteristics of included studies (Appendix 2) for 
details. 
 
The shortest study was a two-week pilot study aiming to determine the most 
effective method of teaching patients how to use inhaler devices (Basheti et al., 
2005). The intervention was performed by the lead researcher, a pharmacist, 
and found that verbal education strategies based on reading the patient 
information leaflet to the patient, with our without emphasis on the most critical 
steps, failed to ensure that most patients achieved optimal technique (defined 
as performing all the steps correctly) using a Turbohaler device. However when 
this was accompanied by physical demonstration of correct inhaler technique, 
high rates of optimal inhaler technique was achieved, and was significantly 
better than verbal education only. This study clearly demonstrated the 
importance for healthcare professionals to demonstrate correct inhaler 
technique when teaching patients how to use their inhaler device, as visual 
stimuli appear to be more successful than verbal education. The research group 
followed this study with a six-month single-blind cluster randomised parallel 
group study involving 31 community pharmacists, of whom 16 had received 
training on correct inhaler technique (Basheti et al., 2008). 97 patients 
prescribed a Turbohaler or Accuhaler device were randomised to receive 
intensive inhaler education with physical demonstration of correct inhaler 
technique from the trained pharmacists, at regular intervals and written 
instructions in the form of instruction stickers for inhalers, or to usual care from 
untrained pharmacists. Improvement in inhaler technique was significantly 
greater following intensive inhaler education, and was maintained over the six-
month duration of the study. This was associated with a significant reduction in 
the proportion of patients with severe asthma, based on the National Asthma 
Council Australia criteria at 2-, 3-, and 6-months, and a significant correlation 
with improvement in peak flow variability. This study is of critical importance to 
pharmacy practice as it demonstrates that if the only intervention performed by 
pharmacists is to optimise inhaler technique, a significant improvement in 
asthma control can be produced. However, whilst optimal inhaler technique was 
promoted and maintained at frequent intervals in the initial stages of the study 
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(at baseline, one month, two months and three months), there was a small 
reduction in inhaler technique scores between three and six months where 
inhaler technique education was not reinforced. This demonstrates that inhaler 
technique should be checked at regular intervals, probably more frequently than 
every three months, even in patients who have taken inhaled medicines for long 
periods and have previously demonstrated good inhaler technique. 
 
A limitation of the two studies by Basheti et al, was that there was no objective 
measure of inspiratory flow through the inhaler devices, which is known to be an 
important factor in ensuring an emitted dose with particles at the size required 
to deposit in the central and peripheral airways (Basheti et al., 2008, Basheti et 
al., 2005). This was addressed in two identical studies, one in a hospital 
outpatient department (Al-Showair et al., 2007), and one in community 
pharmacies (Ammari and Chrystyn, 2013). In these studies, patients using 
pMDI devices with an excessively fast peak IFR, which is known to significantly 
reduce lung deposition (Newman et al., 1995), were randomised to receive 
either verbal counselling alone or verbal counselling and training using a 2Tone 
Trainer whistle. Both studies included a control group of patients with correct 
inhaler technique and inspiratory flow through pMDIs. The 2Tone Trainer 
(Canday Medical Ltd, UK) is a pMDI shaped device that will whistle with a 
mono-tone when a person inhales through it at the optimal IFR, but will whistle 
with two-tones if a person inhales too fast through the device. In both studies, 
verbal counselling with or without provision of the 2Tone Trainer was associated 
with a significant reduction in peak IFR from too fast to the optimal rate for using 
pMDI, and this was associated with improvements in asthma quality of life using 
AQLQ (Al-Showair et al., 2007, Ammari and Chrystyn, 2013). There was no 
significant change in IFR or quality of life in patients in the control groups, 
demonstrating a real effect of education strategies on inspiratory flow and 
quality of life. 
 
The results of these comparative studies have been replicated in uncontrolled 
prospective studies where all patients received inhaler technique training by 
either a nurse who provided education and demonstration of correct inhaler 
technique (Alamoudi, 2003) or community pharmacist who provided verbal and 
written instructions in the form of instruction stickers for inhalers (Giraud et al., 
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2011). These larger studies have demonstrated significant improvements in 
inhaler technique associated with improvements in lung function (Alamoudi, 
2003), asthma control measured using ACQ and adherence (Giraud et al., 
2011). 
 
In summary, these studies have demonstrated that inhaler technique can be 
improved with physical demonstration of correct inhaler technique. However, 
with the exception of one 6-month study, these studies were of short duration 
and so cannot provide evidence that patients can maintain optimal inhaler 
technique. In fact, the longest study showed small reductions in inhaler 
technique score towards the end of the 6-month study period, which may reflect 
patients falling back into bad habits of forgetting correct inhaler technique. A 
major limitation that this literature review identified was that few studies with 
control arms have been published, and data on widely recognised and validated 
asthma outcome measures were lacking. A further limitation was that only two 
studies (Al-Showair et al., 2007, Basheti et al., 2008) reported sample size 
calculations to demonstrate whether they were powered to demonstrate a 
significant benefit of inhaler technique training. Consequently it is unclear 
whether the remaining four studies were powered for the outcomes being 
tested.  
 
3.3.4 The effect of interventions to improve adherence to inhaled 
corticosteroids on asthma control 
3.3.4.1 Results of the search 
After screening of study titles and abstracts, and removal of duplicates, 49 full-
text articles were retrieved for consideration for review, and six were found to 
meet the eligibility criteria (see Figure 3). 
 
3.3.4.2 Included studies 
See Characteristics of included studies (Appendix 3) for details. Six studies 
met the inclusion criteria for the literature review (Bender et al., 2010, Gamble 
et al., 2011, Garcia-Cardenas et al., 2013, Janson et al., 2009, Strandbygaard 
et al., 2010, Williams et al., 2010).  
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3.3.4.3 Excluded studies 
Of the remaining studies that were excluded from the literature review, nine 
were cross-sectional studies (Axelsson et al., 2009, Baddar et al., 2014, Bolman 
et al., 2011, Gamble et al., 2009, Hyland et al., 2012, Ivanova et al., 2008, Roy 
et al., 2011, Takemura et al., 2010, Moldrup et al., 2010), three were non-
interventional studies (Clark et al., 2012, Williams et al., 2011, Wojtczak et al., 
2012), three were uncontrolled observational studies (Giraud et al., 2011, Park 
et al., 2010, Sofianou et al., 2013), one was an audit (Murphy et al., 2012b), 
and one was a systematic review in asthma patients (Moullec et al., 2012). 
 
26 other papers were excluded for various reasons including 15 that did not 
meet literature review inclusion criteria (Apter et al., 2011, Axelsson et al., 2013, 
Axelsson et al., 2011, Clerisme-Beaty et al., 2011, Douglass et al., 2012, 
Emilsson et al., 2011, Kang et al., 2013, Krauskopf et al., 2013, Lim et al., 2010, 
Mora et al., 2011, Ponieman et al., 2009, Santos et al., 2010, Shams and 
Fineman, 2014, Vaidya et al., 2013, Patel et al., 2013), five were review articles 
(Chan et al., 2013, Donaldson et al., 2013, Heaney and Horne, 2012, Horne, 
2011, Roller and Gowan, 2013), two were study protocols (DiBello et al., 2013, 
To et al., 2013), one was a report of practice (Boise, 2014), one was a 
conference abstract (Engelkes et al., 2013), one was a letter (McNicholl and 
Heaney, 2013), and one was systematic review in a variety of long-term 
conditions (Haynes et al., 2008). 
 
3.3.4.4 Interventions 
See summary table of interventions to improve adherence to ICS on asthma 
control (Table 3) and Characteristics of included studies (Appendix 3) for 
details.  
 
All the included studies were randomised trials. The interventions ranged from 
automated telephone calls (Bender et al., 2010) or text reminders 
(Strandbygaard et al., 2010), to intensive educational or motivational strategies 
that were performed by nurses in two studies (Gamble et al., 2011, Janson et 
al., 2009), GPs in one (Williams et al., 2010), and community pharmacists in a 
final study (Garcia-Cardenas et al., 2013). Adherence measures varied between 
electronic monitors in two studies (Bender et al., 2010, Janson et al., 2009), 
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prescription records in two studies (Gamble et al., 2011, Williams et al., 2010), 
review of inhaler dose counter in another (Strandbygaard et al., 2010), and use 
of the Morisky scale in a final study (Garcia-Cardenas et al., 2013). The varied 
study design and adherence measures make comparison between individual 
studies difficult. 
 
3.3.4.5 Primary outcomes 
See summary table of complex pharmacist interventions on asthma control 
(Table 3) and Characteristics of included studies (Appendix 3) for details.  
 
Only three of the six included studies reported adherence as the primary 
outcome measure (Gamble et al., 2011, Strandbygaard et al., 2010, Williams et 
al., 2010), whilst two did not specify any primary outcome measures (Bender et 
al., 2010, Janson et al., 2009), and one reported ACQ as the primary outcome 
measure (Garcia-Cardenas et al., 2013). Asthma outcome measures 
incorporated a measure of asthma control (ACT, ACQ or perceived control of 
asthma questionnaires) in five studies (Bender et al., 2010, Gamble et al., 2011, 
Garcia-Cardenas et al., 2013, Janson et al., 2009, Strandbygaard et al., 2010), 
quality of life in four studies (Bender et al., 2010, Gamble et al., 2011, Janson et 
al., 2009, Strandbygaard et al., 2010), lung function in three studies (Gamble et 
al., 2011, Janson et al., 2009, Strandbygaard et al., 2010) and exacerbations in 
two studies (Gamble et al., 2011, Williams et al., 2010). 
 
3.3.4.6 Risk of bias 
The assessment and justification of the risk of bias for each of the included 
studies is presented in the Characteristics of included studies (Appendix 3). 
Three studies were judged to have low or unclear risk of bias for all domains 
(Bender et al., 2010, Gamble et al., 2011, Janson et al., 2009). All of the 
included studies were assessed to have low or unclear risk of selection bias, but 
two studies were judged to have high risks of bias due to performance and/or 
detection bias (Garcia-Cardenas et al., 2013, Strandbygaard et al., 2010), 
attrition bias (Williams et al., 2010), or reporting bias (Garcia-Cardenas et al., 
2013). 
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Table 3. Brief summary of the effect of interventions to improve adherence to inhaled corticosteroids on asthma control 
 
Citation, 
Country 
Purpose of study Study description Interventions Outcomes 
measures 
Key findings Comments 
(Bender et al., 
2010), USA 
To examine the 
effectiveness of an 
interactive voice 
response 
intervention on 
adherence to 
controller 
medications  
Design: randomised 
controlled trial. 
N: 50. 
Duration: 10 weeks. 
5-minute interactive 
voice response 
telephone call 
(repeated once or 
twice at 1-month 
intervals depending 
on asthma control), 
which comprised 
core educational 
messages, 
encouraged filling of 
ICS prescriptions 
and to increase 
communication with 
their physician.  
The control group 
received no 
telephone calls. 
Primary: not 
specified, but 
assumed to be 
adherence to 
controller 
medications. 
Secondary: ACT, 
AQLQ 
 
Adherence over 10 
weeks was 32% 
higher in the 
intervention arm 
than in the control 
group (mean 64.5% 
vs. 49.1%, 
p=0.003). 
No significant 
change in ACT or 
AQLQ. 
Participants 
recruited from a 
tertiary care centre. 
Adherence 
measured using 
electronic tracking 
device on pMDI or 
Accuhaler, or by 
weighing 
Turbohaler. 
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Citation, 
Country 
Purpose of study Study description Interventions Outcomes 
measures 
Key findings Comments 
(Gamble et al., 
2011), Belfast 
To determine 
whether identified 
non-adherence to 
ICS/LABA inhalers 
in difficult asthma, 
could be improved 
using (i) a simple 
concordance 
interview and (ii) a 
menu driven 
psycho-educational 
intervention 
strategy, with better 
asthma outcomes. 
Design: sequential 
2-stage study. 
Phase 1 was an 
observational study; 
Phase 2 was a 
prospective single 
blind randomised 
controlled trial. 
N: phase 1: 83; 
phase 2: 20. 
Duration: phase 1: 9 
months; phase 2: 12 
months. 
Phase 1: patient 
concordance 
consultation, 
resulting in an 
agreed treatment 
plan to address 
poor adherence. 
Phase 2: control vs. 
individualised 
psycho-educational 
nurse-led menu 
intervention to 
improve adherence 
Primary: change in 
adherence to 
ICS/LABA. 
Secondary: daily 
ICS dose, use of 
OCS rescue 
courses, SABA use, 
hospital admissions, 
lung function, ACQ, 
AQLQ. 
 
Phase 1: 31 of 83 
non-adherent 
patients (37%) 
significantly 
improved 
adherence after 
concordance 
interview (in these 
31 patients 
adherence 
increased from 
37.3% to 88.5%). 
This was associated 
with a significant 
ICS dose reduction, 
fewer OCS rescue 
courses and 
hospital admissions. 
Phase 2: Greater 
improvement in 
adherence in the 
intervention group 
(37.6% to 61.9%), 
compared to the 
control group 
(31.7% to 28.8%); 
p=0.01. 
No effect on ACQ, 
daily ICS dose, 
AQLQ, use of OCS 
rescue courses, 
SABA use, hospital 
admissions, or lung 
function. 
Intervention was 
performed in 
hospital difficult 
asthma clinic. 
Adherence as 
measured using 
prescription refill 
records. 
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Citation, 
Country 
Purpose of study Study description Interventions Outcomes 
measures 
Key findings Comments 
(Garcia-Cardenas et 
al., 2013), Spain 
To evaluate the 
effect of a 
pharmacist 
intervention on 
asthma control 
Design: cluster 
randomised trial. 
N: 346. 
Duration: 6 months. 
Protocol-based 
intervention 
addressing 
individual needs 
related to asthma 
control, inhaler 
technique and 
adherence. 
The control group 
received usual care 
only. 
Primary: ACQ 
Secondary: inhaler 
technique, 
adherence. 
Adherence 
increased in the 
intervention (from 
38.2% to 60.8%, 
p<0.001) and 
control groups (from 
39.3% to 55.3%, 
p<0.001). 
The proportion of 
patients who were 
adherent at 6 
months was 
significantly higher 
in the intervention 
group than in the 
control group 
(78.5% vs. 52.0%, p 
< 0.001).   
Significant 
improvement in 
ACQ in the 
intervention group (-
0.66, p<0.001), but 
not in the control 
group (-0.15 (p 
value not reported). 
Intervention 
performed in 
community 
pharmacies. 
Adherence was 
assessed using the 
4-item Morisky-
Green-Levine scale. 
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Citation, 
Country 
Purpose of study Study description Interventions Outcomes 
measures 
Key findings Comments 
(Janson et al., 
2009), USA 
To examine the 
effect of self-
management 
education on 
adherence to ICS 
and markers of 
asthma control. 
Design: randomised 
controlled trial. 
N: 95. 
Duration: 24 weeks. 
Individualised self-
management 
education (a 30 
minute intervention, 
comprising 
provision of asthma 
information, 
assessment, inhaler 
technique education 
and asthma action 
plan, and trigger 
avoidance), plus 
self-monitoring of 
symptoms and PEF. 
The control group 
received usual care 
of self-monitoring 
alone. 
Primary: not 
specified, but 
assumed to be 
adherence to ICS. 
Secondary: 
perceived control of 
asthma, lung 
function, quality of 
life. 
 
No significant 
different in mean 
ICS adherence 
between the 
intervention and 
usual care groups 
(82% and 80% 
respectively at 
baseline, and 77% 
and 73% at 24 
weeks). 
At 24 weeks, the 
intervention group 
maintained 3-fold 
greater odds of 
>60% adherence to 
ICS vs. control.  
Significant 
improvement in 
perceived asthma 
control in the 
intervention vs. 
control group. No 
significant 
difference in quality 
of life or lung 
function between 
the 2 groups. 
Intervention 
performed in private 
and public 
community clinics. 
Adherence was 
measured using an 
electronic 
medication monitor 
attached to pMDIs. 
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Citation, 
Country 
Purpose of study Study description Interventions Outcomes 
measures 
Key findings Comments 
(Strandbygaard et 
al., 2010), Denmark 
To examine the 
impact of daily text 
message reminders 
on adherence to 
asthma treatment 
Design: randomised 
prospective study. 
N: 26. 
Duration: 12 weeks. 
Daily SMS reminder 
(at 10am) on their 
mobile phone to 
take their asthma 
medication from 
weeks 4 to 12. 
The control group 
received no SMS 
reminders. 
Primary: mean 
adherence rate to 
ICS/LABA. 
Secondary: ACQ, 
mini-AQLQ, exhaled 
nitric oxide, lung 
function, airway 
responsiveness. 
 
Adherence 
improved in the 
intervention group 
and reduced in the 
control group; at 12 
weeks the absolute 
difference in mean 
adherence rate was 
17.8%, p=0.019. 
No difference 
between the two 
groups in ACQ, 
mini-AQLQ, exhaled 
nitric oxide, lung 
function or airway 
responsiveness. 
Participants 
recruited from 
advertisements in 
free local 
newspapers. 
Adherence 
measured using 
ICS/LABA dose 
counter on 
Accuhaler device. 
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Citation, 
Country 
Purpose of study Study description Interventions Outcomes 
measures 
Key findings Comments 
(Williams et al., 
2010), USA 
To assess the effect 
of supplying patient 
adherence 
information to 
primary care 
providers. 
Design: cluster-
randomised trial. 
N: 2698. 
Duration: 12 
months. 
Use of electronic 
prescription 
software to view 
ICS adherence, 
education for 
medical staff on 
non-confrontational 
approaches to 
discussing 
adherence, and 
include ways to 
identify barriers to 
taking medication, 
tips to help patients 
remember to take 
their medication, 
and methods to 
promote self-
efficacy. 
The control group 
had no access to 
electronic 
prescription 
software. 
Primary: ICS 
adherence over the 
last 3 months of the 
study. 
Secondary: 
emergency room 
visits, hospital 
admissions, OCS 
use. 
 
No significant 
difference in mean 
ICS adherence at 
baseline (25.6% 
and 27.7%, p=0.21) 
or at 12-months 
(21.3% and 23.3%, 
p=0.553). 
Patients with stable 
or improved 
adherence had 
lower rates of 
emergency room 
visits and required 
fewer courses of 
OCS, but there was 
no effect on hospital 
admissions. 
Intervention was 
performed in 
primary care 
practices, and 
provided by GPs. 
Adherence was 
measured using GP 
prescribing and 
pharmacy claims 
data. 
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3.3.4.7 Effects of interventions 
See summary table of interventions to improve adherence to ICS on asthma 
control (Table 3) and Characteristics of included studies (Appendix 3) for 
details.  
 
The two shortest studies of 10 - 12 weeks duration involved automated SMS 
text reminders to patients to take their ICS (Strandbygaard et al., 2010), or 
interactive voice response telephone calls to provide patient education and 
provide reminders to collect prescriptions (Bender et al., 2010). These two 
studies recruited small patient populations (26 and 50, respectively) and provide 
limited data relevant to cohorts of patients with severe asthma, due to either not 
reporting any baseline demographic data (Bender et al., 2010), or because the 
recruited sample population had a high proportion of patients who either had 
only mild (31%) or moderate (62.5%) asthma, or who were not prescribed any 
ICS at baseline (65.3%) (Strandbygaard et al., 2010). Consequently, whilst 
there was an increase in adherence associated with automated telephone calls 
or SMS text reminders, this was not associated in an improvement in asthma 
control or quality of life (Bender et al., 2010, Strandbygaard et al., 2010). It may 
be that a combination of a small population and short study duration may have 
resulted in the study being underpowered to detect any significant impact on 
important asthma outcomes associated with the improvement in adherence. 
However the fact that many patients had only mild to moderate symptoms and 
did not require regular treatment at baseline in one study (Strandbygaard et al., 
2010) may have prevented significant improvements in asthma outcomes to be 
achieved in a relatively well controlled sample population.  
 
Williams et al (2010), performed a large cluster-randomised trial that 
incorporated an educational intervention targeted to patients where poor 
adherence was identified using electronic prescription software (Williams et al., 
2010). Adherence was poor throughout the study and overall it was not 
significantly affected by the intervention, but this was thought to be due to poor 
uptake of the intervention by GPs in the intervention group. This is supported by 
the observation that where the intervention was performed, a significant 
improvement in adherence was achieved compared to patients in the control 
group or where the intervention was not performed. Furthermore, in these 
 81 
patients, the improvement in adherence was associated with reduced asthma 
exacerbations in terms of use of reduced OCS and emergency department 
visits, although not in terms of asthma-related hospitalisations. 
 
Three studies employed complex educational and motivational strategies in 
order to improve adherence, two of which were performed by nurses in primary 
(Janson et al., 2009) or secondary care (Gamble et al., 2011), and one by 
community pharmacists (Garcia-Cardenas et al., 2013). Adherence was 
significantly improved over six to 12 months in two studies when measured 
using GP prescription data (Gamble et al., 2011), or patient self-reporting using 
the Morisky scale (Garcia-Cardenas et al., 2013), but this was associated with 
an improvement in asthma control (measured using ACQ) in only the latter 
study (Garcia-Cardenas et al., 2013). It is likely that the Gamble study failed to 
demonstrate a significant impact on asthma control, despite recruiting patients 
with difficult asthma (defined as at persistent symptoms of asthma despite 
treatment at BTS/SIGN step 4/5, and an ACQ >3.0) and following them up for a 
long duration, because only 20 patients were recruited and so the study may 
have been under powered (Gamble et al., 2011). In contrast to these two 
studies, Janson et al (2009) reported that overall adherence was not improved 
compared to control, when measured using electronic monitors attached to 
inhaler devices (Janson et al., 2009). Whilst mean adherence was noted to fall 
in both groups, it was found to be more likely to be maintained in patients in the 
intervention group, and consequently significantly more patients had a greater 
than 60% adherence to ICS in the intervention, than in the control group. This 
was associated with a significant improvement in perceived asthma control, 
quality of life and reduced use of SABA. 
 
In summary, despite the varied study designs, interventions and adherence 
measures, these studies have frequently found that interventions aimed to 
improve adherence are successful and generally improve asthma outcomes. 
Studies that have not replicated these findings, have often either recruited 
inappropriate patients that have only mild asthma and/or required no asthma 
medication prior to the study, recruited only a small sample population are were 
likely to be underpowered, or the intervention was not consistently performed. 
Consequently, there is good evidence highlighting the importance of identifying 
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and addressing medication adherence concerns in patients with difficult 
asthma.  
 
 
3.4 Summary 
This literature review has examined the role of complex interventions provided 
by pharmacists in the management of asthma, and the importance of optimising 
inhaler technique and adherence in order to improve asthma control. 
 
Whilst there is some evidence that complex interventions provided by 
pharmacists may improve asthma outcomes, there remain a number of gaps in 
the literature. These studies have all been based within community pharmacies, 
and often recruited a varied cross-section of asthma patients, with some well 
controlled and some who had uncontrolled asthma. There are currently no 
published randomised controlled studies examining asthma management by 
hospital pharmacists, nor are there any published randomised controlled 
studies examining the management of difficult asthma by pharmacists. 
 
This gap in the literature confirms that the research study presented in this 
thesis is the first to investigate the effects of a redesigned pharmaceutical 
pathway across the primary and secondary care interface in patients with 
difficult asthma.  
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4 Methodology 
4.1 Reflections on different research methods 
The design of any research study should involve due consideration of a variety 
of different research methods to ensure that the most suitable approach is used 
to test the hypothesis under investigation. Research designs may be broadly 
classified as either survey, observational or experimental, and each was 
considered for this study. 
 
Survey methods are used to measure certain phenomena, such as events or 
behaviours, in the population of interest (Bowling, 2002). However cross-
sectional surveys are most commonly used to determine prevalence and to 
identify potential associations between an exposure or intervention and a 
possible outcome. These surveys are consequently descriptive and since data 
are collected at fixed points in time, they cannot test hypotheses, and further 
studies are usually required to confirm associations (Bowling, 2002, Campbell 
and Machin, 1999, Clancy, 2002, Mann, 2003). Alternatively, analytical 
longitudinal surveys may be used to analyse data at several points in time, 
which can suggest the direction of cause and effect associations, but again 
further studies would be required to confirm associations (Bowling, 2002). 
Therefore survey methods were not considered an appropriate research 
method since they would not have allowed the prospective determination of the 
extent of the impact of pharmacist interventions in a relatively small study. 
 
Observational studies, such as cohort and case-control studies are often used 
when no interventions are made, or when randomised controlled experimental 
studies cannot be used. In these studies, the intervention is not controlled by 
the investigator, but a comparison is made between people with or without the 
disease for the outcome under investigation, allowing the extent of a causal 
relationship to be determined (Clancy, 2002). 
 
The starting point for case-control studies is with the identification of cases 
comprising people with the disease or condition of interest, and then these are 
matched with controls comprising people without that disease or condition. The 
cases and controls are then compared to determine the potential relationship of 
a risk factor or past exposures on the disease or condition of interest (Campbell 
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and Machin, 1999, Clancy, 2002, Greenhalgh, 2006, Mann, 2003, Bowling, 
2002). Case-control studies have the advantage that they are relatively 
inexpensive to perform as they are often quick and allow the assessment of 
multiple exposures (Clancy, 2002, Mann, 2003). However limitations in these 
studies include difficulties in identifying controls that are suitably matched and 
identical to cases and often require large number of participants to prevent 
selection bias, recall bias where cases suffering from a disease may be more 
likely to recall exposures to risk factors than controls, and measurement bias 
from the investigator if they know the outcome (Campbell and Machin, 1999, 
Clancy, 2002, Mann, 2003, Bowling, 2002). Consequently a case-control study 
was thought not to be appropriate for this research study, which examines the 
effect of an active intervention on, rather than investigating possible causes of, 
an outcome that is only appropriate for patients with asthma. Additionally it may 
be unlikely that a retrospective case-control study would allow analysis of all 
potential data pertinent to an asthma research study since many types of 
possible outcome test, such as quality of life measures, are not investigated in 
routine management. 
 
A cohort study was considered a potentially appropriate observational research 
design as this method can be used to follow up two groups of patients 
prospectively, one of whom has experienced an exposure or an intervention, 
and determine the effect on a particular disease or outcome. This type of 
observational study most closely resembles randomised controlled experimental 
studies, except that the investigator does not control the allocation to the 
exposure or intervention (Campbell and Machin, 1999, Clancy, 2002, 
Greenhalgh, 2006, Mann, 2003, Bowling, 2002). However cohort studies are 
most commonly used to study the incidence or prognosis of disease, or to 
investigate aetiological factors (Campbell and Machin, 1999, Mann, 2003, 
Greenhalgh, 2006). Retrospective cohort study designs may be appropriate 
where it is unethical to examine the effect of an intervention or exposure in an 
experimental study, such as the exposure to an environmental toxin and are 
generally simpler to perform than experimental studies.  
 
It was considered that a prospective cohort study could have been designed for 
this research study, with one cohort undergoing usual care and a second cohort 
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undergoing the intervention from a pharmacist and the outcomes observed. 
However as the research aims and objectives were clearly indicating that the 
effects of an active intervention by pharmacists were going to be assessed, an 
experimental design was considered more appropriate than a cohort study, and 
was not thought to be ethically problematic. A retrospective cohort study was 
also considered, as this could look at the impact of pharmacist interventions in 
one cohort of patients compared to a second cohort where no pharmacist 
intervention was made. However it was thought that this study design would be 
logistically difficult to perform, as it would be unlikely that sufficient data on 
relevant outcome measures would be available to study the impact of 
pharmacist interventions, and matching the two groups of patients could be 
difficult. 
 
Experimental studies describe research methods comprising at least two 
differently treated identical groups, where the experimental group are exposed 
to an intervention under investigation, whilst a second control group is not 
exposed, and both groups are then followed up under tightly controlled and 
defined conditions (Bowling, 2002, Clancy, 2002). The randomised controlled 
trial is considered to be the gold standard experimental study design, where 
patients should be randomly allocated to either the experimental or control 
group in order to prevent bias and differences developing between the two 
groups (Greenhalgh, 2006, Kendall, 2003). Furthermore, experimental studies 
are considered to be the only research design that can yield causal results and 
allow powerful statistical manipulation of data (Bowling, 2002). However it is 
often hard to design experiments that represent the overall general patient 
population and thus produce data that are valid in the ‘real world’, and such 
studies are often expensive in terms of time and money (Bowling, 2002, 
Greenhalgh, 2006). Furthermore, it is also considered that randomised 
controlled trials may be either (i) unnecessary if the effect of an intervention is 
likely to be dramatic or where there are previous studies demonstrating a 
definite effect; (ii) impractical if it would be unethical to recruit patients to the 
study, or where large numbers of patients would be required for the study due 
to infrequent outcomes under investigation; or (iii) inappropriate where an 
alternative study design is preferred, e.g. using a cohort study to investigate the 
prognosis of the disease (Clancy, 2002, Greenhalgh, 2006). 
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Consequently it was considered that an experimental study design should be 
used to investigate the impact of pharmacist interventions of asthma control in 
patients with difficult asthma, since this would allow the prospective data to be 
collected to quantify effect of the intervention compared to a control group that 
did not receive the intervention. 
 
As the lead researcher was performing the interventions in the PI group, this 
meant that this study met the criteria for being action research, as it sought to 
generate new knowledge on the management of difficult asthma whilst 
simultaneously trying to change it (Bowling, 2002). There are concerns that 
such action research may affect the validity of the study because the researcher 
has a direct involvement with the study rather than being an objective outsider, 
and may introduce bias even subconsciously by subjectively misinterpreting 
data or making false assumptions. Conversely, action research may have 
advantages compared to independent research as the insider may be able to 
access and obtain data and information from patients more easily due to 
familiarity between the subjects of the study and the researcher (Asselin, 2003, 
Bowling, 2002). 
 
 
4.2 Reflections on experimental study design for an interventional study 
Prospective and retrospective data collection methods were considered when 
designing this study. Prospective studies have advantages over retrospective 
studies because they usually have fewer potential sources of bias and 
confounding than retrospective studies, and may be easier to ensure that all 
data are collected, particularly in this study where a number of outcomes were 
investigated, where data are not collected in routine practice. Consequently, 
this research study was designed as a prospective, randomised, open study.  
 
Quantitative and qualitative methods for data analysis were considered, but 
qualitative methods requiring interviews and focus groups were discounted as 
these tend to focus on understanding the meanings that study participants 
might attach to their social world, rather than providing a measure of the extent 
of the effects of an intervention (Bowling, 2002). In this study examining the 
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effects of pharmacist interventions in the management of patients with difficult 
asthma, there is a lack of data whether or not this intervention is beneficial in 
this subgroup of asthma patients. Consequently, it was thought that the primary 
objective of this study should be to investigate the extent of this impact of 
pharmacist interventions on objective measures of asthma control and 
symptoms, rather than subjective assessments based on interview methods. 
 
The simplest experimental studies analyse the effects of one single intervention 
compared to no intervention, and this is the format used in randomised 
controlled trials of a drug versus placebo (Craig et al., 2008). However 
interventional studies are frequently complex as the main intervention is 
frequently associated with other aspects that need to be considered. In this 
study, assessing the impact of pharmacist interventions in difficult asthma, there 
are a number of interventions that have been seen to be effective in the 
literature review (see Chapter 3.3.1), including education about asthma, 
education about medication, self-management and trigger avoidance, and 
inhaler technique training. Each of these may have an impact on overall asthma 
symptoms and asthma control, and may impact both independently and inter-
dependently, and is therefore described as a complex intervention (Craig et al., 
2008). Additionally, since it is likely that individual patients will have different 
aspects of their asthma that require addressing, it is likely that the interventions 
made will vary from patient to patient. For example, some patients may require 
the intervention to concentrate on education about asthma self-management, 
whilst others may require additional training on correct inhaler technique. 
Overall, it is likely that each patient may undergo a number of varying 
interventions, since this has previously been demonstrated to improve 
adherence and asthma symptoms, when provided by doctors or nurses (Bailey 
et al., 1990, van Es et al., 2001, Put et al., 2003, Moullec et al., 2012). Further 
complexity to the intervention was introduced following initial pilot studies, which 
found that the involvement of community pharmacists to provide follow-up 
assessment and intervention was a necessity due to clinic capacity restrictions 
(see Chapter 4.6). 
 
In the context of this study, which comprises a complex intervention, it is usually 
advisable to consider a randomised study design to prevent bias being 
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introduced into the study (Craig et al., 2008). However since an important 
outcome from the study was to understand whether the interventions have a 
positive impact on asthma control and asthma symptoms under real-life 
conditions and therefore whether a pharmacist-led asthma service should be 
provided, a pragmatic research study was designed. In contrast, clinical, 
explanatory studies rarely reflect routine practice and have very narrow patient 
selection criteria and require a very strict intervention, rather than as an 
intervention that differs from patient to patient (Roland and Torgerson, 1998). 
 
The nature of the intervention precluded the study design from being blinded as 
it would be impossible to prevent the researcher from knowing which patients 
had undergone usual care and which had undergone the pharmacist 
intervention. This is because there was no practical way for the lead researcher 
to be blinded as he was also responsible for patient recruitment, randomisation, 
providing assessment questionnaires (e.g. ACQ, AQLQ(S)) to all participants, 
performing the baseline intervention to participants in the PI group, and 
performing the follow-up inhaler technique assessments in all participants. At 
the time of the study, there were no other pharmacists working in the study 
centre who met the criteria of advanced specialist pharmacist who could have 
performed the intervention in order to separate the roles of researcher and 
pharmacist.  
 
As the interventional study had to be unblinded, it was important to institute a 
selection method to prevent patients being actively selected in a manner that 
could institute bias into the study.  This was itself difficult, since the researcher 
was principally responsible for identifying suitable patients to be invited to 
participate in the study, in collaboration with the lead consultant in the difficult 
asthma clinic. A convenience sampling method was considered as a simple way 
to identify prospective patients for the study, because the primary setting for the 
study was in the local difficult asthma clinic, and would be easier than trying to 
randomly recruit potential patients from the local population. Convenience 
sampling methods may assist recruitment, allow easier monitoring, and are 
thought to achieve good response rates with low attrition rates (Bowling, 2002). 
However, since patients with alternative diagnoses such as COPD, 
bronchiectasis, or mild to moderate asthma were often booked into this clinic, 
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purposive criteria were applied before recruitment and randomisation (Bowling, 
2002). Therefore, the investigator and clinical supervisor reviewed future clinic 
lists to ensure the suitability of individual patients for the study, as well as 
ensuring that they had a confirmed diagnosis of asthma, since significant 
numbers of patients attending difficult asthma clinics may have alternative 
diagnoses (Heaney et al., 2003, Barnes and Woolcock, 1998).   
 
An unrestricted random allocation method, performed after each patient had 
provided written, informed consent to participate in the study, was also used to 
prevent bias in intervention allocations and to attempt to minimise differences 
between patients in the two intervention groups (Bowling, 2002). It was 
identified that there was an unavoidable risk of contamination of the control 
group as patients in both the intervention and usual care group would be 
reviewed within the same clinic, as the difficult asthma clinic was located on just 
one hospital site within the Trust. Furthermore, there are relatively few hospital 
Trusts in the UK that operate similar tertiary referral difficult asthma clinics, and 
very few that incorporate advanced clinical pharmacists into the difficult asthma 
service in the UK. In 2006, there were no difficult asthma clinics that had direct 
access to pharmacists in clinic (Roberts et al., 2006), and to my knowledge 
there is currently only one in the North of England, which was the study centre. 
This therefore prevented a multi-centre study design being used, which would 
have allowed for a cluster randomisation allocation method to be used and 
reduce the risk of contamination bias. However several study centres would 
have been required to allow each site to only recruit a small number of patients 
to reduce the risk of data from one cluster site dominating the overall outcome 
effects (Craig et al., 2008, Bowling, 2002), and this would not be achievable.  
 
There were no practical or ethical reasons for discounting an unrestricted 
random allocation method in this study and patient recruitment was not 
anticipated to be a problem. Similarly it was not thought that patients might 
have strong preferences about their treatment allocation, which could affect 
patient recruitment. Consequently other experimental designs such as 
preference trials or randomised consent studies (Craig et al., 2008) were not 
considered as necessary. 
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A further potential problem with random allocation methods was due to the 
relatively small study population required to allow the study to be adequately 
powered to demonstrate a potential improvement in asthma control with 
pharmacist-led management of asthma. There was a risk that random allocation 
methods involving a small study population could result in a random imbalance 
in patient numbers in each group. Therefore, a random permuted blocks 
allocation method was used to ensure that approximately equal numbers of 
patients were assigned to each intervention arm (Campbell and Machin, 1999). 
Other allocation methods such as stratified randomisation and minimisation 
methods (Bowling, 2002) were discounted since they were not relevant to the 
study design. 
 
4.2.1 Reflections on study settings 
A number of settings for the study were considered, including being based 
within secondary care at the difficult asthma clinic at the hospital, or within 
primary care in community pharmacies or designated GP practices. 
 
A study based in primary care may be more convenient for patients to attend, 
particularly if multiple study sites are identified in community pharmacies. 
However, as the study was designed to investigate the management of patients 
with difficult asthma, which usually takes place within secondary care, it was 
considered essential that the location of the pharmacist intervention should take 
place within this same setting. This would ensure that patients were treated 
equally apart from the intervention, because locating the pharmacist 
intervention in primary care may result in a design bias (Bowling, 2002).  
 
An intervention solely delivered by pharmacists working within community 
pharmacies or GP practices could possibly result in an unintentional negative 
bias, if patients with difficult asthma think that these pharmacists may not have 
the expertise to manage their condition, which could have adversely affected 
recruitment rates, or affect patients’ adherence to the intervention. One patient 
preference study reported that the majority of patients rated asthma services in 
community pharmacies as good to excellent (Naik-Panvelkar et al., 2012), but 
the opinions of patients with difficult asthma on pharmacist-led services is 
unknown. Alternatively patients could be more likely to report improvements in 
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asthma control and symptoms, especially if they know their pharmacist who is 
performing the intervention. This is an example of acquiescence bias (Bowling, 
2002), and may be managed by using validated measures of asthma control 
and quality of life.  
 
A final risk of setting the study in GP practices or community pharmacies is that 
it would be difficult for all GP practices and community pharmacies to be 
recruited as study sites for economical and logistical reasons, despite this 
approach potentially maximising patient recruitment. Consequently this 
approach would require a cluster sample of practices or pharmacies to be used 
as study sites, but this could incorporate risk associated with the location of the 
practices or pharmacies, as different socio-economic factors might affect 
asthma control, and could result in the sample population being 
unrepresentative of the overall population. However evidence about a link 
between socio-economic status and difficult asthma is limited and is variable 
across the UK (Heaney et al., 2010). 
 
Setting the study in hospital would overcome problems associated with potential 
sampling biases as patients are referred from all GP practices in the local area 
and thus patients from all socio-economic backgrounds may be encountered. 
Patients with uncontrolled asthma in Leeds are referred to the local difficult 
asthma clinic, which allows easy identification of suitable participants for the 
study. 
 
Therefore it was decided to conduct this study in the Leeds Difficult Asthma 
Clinic at Leeds General Infirmary, Leeds, West Yorkshire.  The Leeds Teaching 
Hospitals NHS Trust serves a population of approximately 757,655 people 
(Office for National Statistics, 2013). This site was selected, as it has a difficult 
asthma clinic that reviews patients appropriate for this study, and is the 
employing organisation of the researcher and the clinical supervisor. The 
difficult asthma clinic operates on one day each week and has capacity for two 
consultants, one or two specialist registrars, one asthma nurse specialist and 
one pharmacist to review patients. 
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Setting the study in the difficult asthma clinic would allow interventions in two 
study groups to be performed in the same clinic setting, ensuring that both 
study groups would be treated equally. This would also allow for follow-up 
interventions in the pharmacist intervention group to be performed in the same 
clinic, ensuring a consistent approach to asthma management in the study. 
Similar pharmacist intervention studies, set in community pharmacies utilised 
regular follow-up interventions, such as at months 1, 3 and 6 to reinforce the 
baseline intervention (See Chapter 3.3.1) (Armour et al., 2007, Basheti et al., 
2008, Charrois et al., 2004, Mangiapane et al., 2005, Mehuys et al., 2008). 
However, due to insufficient capacity within the clinic, it was not possible to 
perform additional routine follow-up visits in addition to baseline and end of 
study visits in the difficult asthma clinic. Therefore it was decided that follow-up 
reinforcement of baseline interventions could be performed by community 
pharmacists who provide the nationally commissioned t-MUR service 
(Department of Health, 2013) (see Chapter 4.6). The involvement of community 
pharmacists providing t-MUR follow-up of participants in this study was 
supported by the Chief Executive for Leeds, Bradford & Airedale, Calderdale & 
Kirklees Local Pharmaceutical Committees (now known as Community 
Pharmacy West Yorkshire) (see Appendix 4). 
 
In order to ensure that community pharmacists had the knowledge and skills to 
undertake effective targeted asthma MURs, two evening educational sessions 
on asthma, the medical condition, its treatment and management were 
arranged with the Leeds, Bradford and Airedale Local Pharmaceutical 
Committee. Bradford and Airedale were encouraged to attend, particularly 
those working in areas with high admission rates due to asthma. Funding for 
these sessions were not available for community pharmacists outside this 
region, and so patients attending the difficult asthma clinic as a tertiary referral 
from outside this region were not recruited to the study. 
 
The format to these educational sessions were broadly similar to sessions 
arranged in other interventional studies (Charrois et al., 2004, Basheti et al., 
2008, Armour et al., 2007, Mehuys et al., 2008), comprising education of the 
pathophysiology, trigger factors and the pharmacological and non-
pharmacological treatment of asthma, followed by education on the importance 
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of and method of teaching inhaler technique. In addition community 
pharmacists working in areas of Leeds and Bradford with high admission rates 
due to asthma were also encouraged to attend follow-up intensive educational 
sessions on inhaler education. 
 
Inhaler technique training for community pharmacists at these educational 
sessions was provided by the lead investigator for this study, who has expertise 
on theoretical and practical aspects of inhaler technique (Capstick and Clifton, 
2012). Education on asthma pathophysiology, trigger factors and the 
pharmacological and non-pharmacological treatment of asthma was provided 
by one of the local consultant respiratory physicians.  
 
 
4.3 Study population 
The study population comprised adult patients, aged 18 to 70 years, with a 
clinical diagnosis of asthma, and fulfilled the criteria for difficult asthma (see 
Chapter 2.1.2). The inclusion criteria was set to be broad in order to ensure that 
the research study would be inclusive and open to as many patients as 
possible, based on the fact that there are relatively fewer people with difficult 
asthma than mild to moderate asthma. 
 
There is known to be a certain degree of diagnostic uncertainty with patients 
attending difficult asthma clinics, as many may have an alternate diagnosis 
(Barnes and Woolcock, 1998), or significant co-morbidities that contribute to 
their symptoms (Heaney et al., 2003). Therefore it was decided that all recruited 
patients must have a diagnosis of asthma confirmed by a consultant respiratory 
physician based on subjective and objective criteria, such as demonstration of 
airflow obstruction on spirometry (British Thoracic Society and Scottish 
Intercollegiate Guidelines Network, 2014). Patients with other co-morbidities 
that could contribute to their respiratory symptoms were excluded because 
other respiratory conditions such as bronchiectasis or COPD may not respond 
to an intervention focussed upon asthma education and treatment. 
 
It was considered that this research study should attempt to recruit patients of 
all severities from mild to severe asthma.  However many asthma patients will 
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remain well controlled and require limited intervention from healthcare 
professionals, and so it may be unlikely that an interventional study would 
achieve significant impact in people with well-controlled asthma. Indeed, some 
community pharmacy studies have targeted patients with mild to moderate 
asthma and have failed to demonstrate a significant impact on asthma control 
after pharmacist interventions comprising education, inhaler technique training 
and smoking cessation advice (Mehuys et al., 2008).  
 
Consequently, it was decided that it was most appropriate to target patients 
who are labelled as having ‘difficult asthma’, defined by the BTS/SIGN asthma 
guidelines as persistent symptoms and/or frequent exacerbations despite 
treatment at step 4 or step 5 (British Thoracic Society and Scottish 
Intercollegiate Guidelines Network, 2014). It was thought appropriate to include 
only patients with difficult asthma despite previous studies that have failed to 
demonstrate a significant impact after intervention from community pharmacists 
in patients at high risk of asthma exacerbations (Charrois et al., 2006). This is 
because compliance with the intervention was poor in that study, and it is 
possible that the lack of specialist training, knowledge and skills of community 
pharmacists may have adversely affected the study. 
 
A number of sampling methods to recruit patients were considered including 
selecting patients from within the difficult asthma clinic itself, during admission 
to hospital because of an exacerbation of asthma, or from GP practices. There 
is however no specific register of difficult asthma patients in primary or 
secondary care from which to identify potential suitable patients for the study. 
Additionally, advertising in the local newspaper for potential patients was not 
considered, as the cost of this was prohibitive. 
 
Since the primary setting for the study was in the local difficult asthma clinic, 
recruitment from patients referred to the difficult asthma clinic had advantages 
over the other methods, as this provided an easily accessible cohort of patients 
thought to have difficult asthma. In addition to ease of recruitment, this would 
allow ease of monitoring and follow-up, and has been shown to have generally 
good response and retention rates within single clinic settings (Bowling, 2002). 
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Hospital admissions allowed another source for identifying suitable patients, but 
would require screening of all admissions to respiratory and medical admission 
wards to identify patients who potentially met the inclusion criteria. This was 
thought to be too labour intensive to be a practical method, and suitable 
patients tended to be referred to the difficult asthma clinic anyway, and 
consequently the screening of hospital admissions could duplicate the effort to 
identify the same patients. 
 
Screening of patients registered with GP practices was considered a method 
that could potentially highlight large numbers of patients that could be invited for 
the study, but it was decided that it was impossible to screen all asthma patients 
in each of the 112 GP practices within the three Leeds Clinical Commissioning 
Groups. A cluster sampling method (Bowling, 2002) selecting specific GP 
practices would have been required to screen for suitable patients, but this 
would have risked creating sampling errors if practices were not representative 
of the general patient population. In addition, some GP practices may have 
been better at managing asthma than others, so it could be harder to 
demonstrate a positive response to the intervention in this scenario. Similarly, if 
the majority of patients are recruited from GP practices where asthma is not 
managed so well, there could be a potential for a greater impact of the 
intervention in the sample than would be expected for the whole population. 
Consequently, it was decided that the most appropriate sampling method for 
the study was to identify patients from the hospital difficult asthma clinic. 
 
4.3.1 Sample size 
On the 7-point scale of the ACQ, a change in score of 0.5 is the smallest that 
can be considered clinically important.  In the original validation study, the ACQ 
was able to detect a change in asthma control with a mean change (± standard 
deviation (SD)) of 0.73 ± 0.54 (Juniper et al., 1999b, Juniper et al., 2000). 
 
A sample size calculation can be based on the ability to detect a difference of 
0.5 in the mean ACQ score, assuming a SD of 0.54.  Therefore for a power of 
80% and a two-tailed significance level of 5%, the required study population is 
38 patients.  However, allowing for an attrition rate of 25%, observed in other 
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studies of Pharmacist intervention in asthma patients, the sample size required 
for this study is 52 patients. 
 
This is based on a Comparison of means (unpaired data) sample size 
calculation: 
   
           
   
  
 
 
Where: 
   The approximate number of patients per group 
   The standard deviation 
   The difference in mean response between the intervention and 
control groups 
           
  A function based on the study power of 80% (=7.849) 
 
Therefore: 
   
                 
    
 
 
Therefore  = 19 patients per group. 
 
 
4.4 Study method 
The study was designed as a pragmatic six-month, prospective, randomised, 
open trial in which patients were randomised to pharmacist intervention (PI), or 
usual care (UC). The study procedure is summarised in Figure 4. 
 
The inclusion criteria included patients, aged 18 to 70 years, with a clinical 
diagnosis of asthma, and fulfil the criteria for difficult asthma, who were able to 
speak, read and write in English, and were eligible for a MUR. Patients were 
excluded if they were not responsible for taking their own medications, or failed 
to provide written informed consent.  
 
Screening future clinic lists and past clinic letters at the Leeds difficult asthma 
clinic identified patients for inclusion in the study. This was performed by the 
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investigator and reviewed by the clinical supervisor to ensure that potential 
patients had a confirmed diagnosis of asthma and met the criteria for difficult 
asthma. At least 2 weeks prior to their scheduled Difficult Asthma clinic 
appointment, a letter was posted to each patient who met these criteria inviting 
him or her to participate in the study. This letter was addressed from the Lead 
Consultant, introducing and describing the study and a copy of the patient 
information sheet was included with it (see Appendix 5).  
 
On the scheduled date of each screen patient’s appointment at the difficult 
asthma clinic, their medical notes were reviewed and patient questioned to 
ensure that they met the full study inclusion criteria, and written informed 
consent (Appendix 6) was obtained if they agreed to enrol in the study. 
 
Patients were randomly allocated to one of two intervention arms. The first was 
the UC group, where patients received the ‘usual’ standard asthma review in 
clinic from a consultant, specialist registrar, or specialist respiratory nurse in line 
with the ‘usual’ standard difficult asthma clinic procedures. The second was the 
PI group, where patients received an asthma review from an advanced clinical 
pharmacist in clinic, comprising education on asthma and medication, inhaler 
technique training in addition to the ‘usual’ standard asthma review. 
 
4.4.1 Intervention group 
A protocol for independent practice was developed to guide the investigator in 
managing patients with difficult asthma (see Appendix 7).  This was based on 
observation of the methods used by senior clinicians, as well as on the content 
of other educational intervention studies identified in the literature review. 
 
The intervention provided by the advanced clinical pharmacist, an autonomous 
independent prescriber, in the difficult asthma clinic comprised: 
1. Patient education on asthma pathology and medication, and self-
management, including the use and provision of a peak flow meter and 
Asthma Action Plan where necessary. This has formed an integral 
component of most pharmacist interventional studies, as described in the 
literature review (Chapter 3.3.1), and so formed an similarly essential 
component of the intervention (Gibson et al., 2002b, British Thoracic Society 
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and Scottish Intercollegiate Guidelines Network, 2014, Global Initiative for 
Asthma, 2014, Armour et al., 2007, Charrois et al., 2006, Mangiapane et al., 
2005, Mehuys et al., 2008). 
2. Inhaler technique assessment and optimisation using a structured 
assessment, using a ‘‘show and tell’’ inhaler technique training method 
(Basheti et al., 2008), where inhaled technique is observed and assessed 
using a checklist (Appendix 8) up to a maximum of three times for each 
device. In addition, inspiratory flow for different devices was determined 
using an In-Check DIAL flow meter (Clement Clarke, UK) to ensure that 
patients used the correct inhalation speeds to use their inhaler devices 
optimally (Capstick and Clifton, 2012). 
3. Asthma assessment and review, which was based on components 
described in asthma guidelines (British Thoracic Society and Scottish 
Intercollegiate Guidelines Network, 2014, Global Initiative for Asthma, 2014) 
and SIMPLES approach for primary care physicians (Ryan et al., 2013): 
a. Assessment of asthma control 
b. Where appropriate, review of: past asthma history (e.g. exacerbation 
frequency requiring OCS use or hospital admission), associated 
medical conditions that may impact on asthma control (e.g. symptoms 
of gastro-oesophageal reflux disease, rhinitis), family history. 
c. Adherence assessment, using on non-confrontation questioning of 
the patient (Gamble et al., 2011, Gamble et al., 2009). 
d. Review of aggravating factors, such as allergies, lifestyle (e.g. weight, 
diet and nutrition, smoking status), and housing condition [e.g. 
presence of mould or damp, pets, or dust). 
e. Medication review, ensuring their prescription is in line with the 
BTS/SIGN 2012 Guidelines on the management of asthma (British 
Thoracic Society and Scottish Intercollegiate Guidelines Network, 
2014). 
 
All patients in the PI group were referred by telephone and in writing (see 
referral form, Appendix 9) for a t-MUR from their usual community pharmacist, 
to take place between weeks 4 to 8. All patients were followed up at 6 months. 
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4.4.2 Usual care group 
Patients randomised to this group had routine management comprising a 
standard review from a Consultant Physician, Specialist Registrar or Asthma 
Nurse Specialist. Standard practice is to assess asthma control, compliance, 
inhaler technique, and aggravating factors, then step up or down therapy as 
appropriate. Patients in this group were excluded from having a t-MUR during 
the study. All patients were followed up at 6 months. 
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Figure 4. Study Procedure 
Includes anticipated potential patient deviations from protocol. 
T = 0 weeks 
Assessed for eligibility 
Excluded 
 Not meeting inclusion criteria 
 Declined to participate 
 Other reasons 
T= 0 weeks 
Allocated to Usual Care Group 
Received allocated intervention 
Did not receive allocated intervention 
T= 0 weeks 
Allocated to Pharmacist Intervention Group 
Received allocated intervention 
Did not receive allocated intervention 
T= 6 months 
 Lost to follow-up 
 Discontinued intervention 
T= 6 months 
 Lost to follow-up 
 Discontinued intervention 
T = -2 weeks 
Potential patients identified from future 
Difficult Asthma Clinic lists 
Initial invitation letter and 
Information Sheet posted 
to patients 
Pharmacist review 
and assessment 
Optional case review between 
Doctor and Pharmacist 
R 
Follow-up 
Allocation 
Enrolment 
Doctor review and 
assessment 
T= 4 - 8 weeks 
Patient should not have targeted MUR 
 Did Not receive t-MUR  
 Received t-MUR (protocol deviation) 
 
T= 4 - 8 weeks 
Patient requires targeted MUR  
 Received t-MUR 
Did Not receive t-MUR (protocol deviation) 
 
Referral to Community 
Pharmacy 
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4.5 Consultation review 
Studies have demonstrated that the experience of patients’ consultations were 
more likely to be positive when their physician listened to them carefully and 
demonstrated nonverbal attention, employed an interactive conversation style, 
and tailored individualised treatment plans, and may lead to a reduction in 
healthcare use and improvements in health outcomes (Clark et al., 2008, 
Stewart, 1995). Other studies have reported favourable outcomes and more 
honest answers when questions on adherence are phrased in a non-
threatening manner (Horne and Weinman, 2002). 
 
As a consequence, GINA recommend that the key components of effective 
asthma consultations include demonstrating a congenial demeanour, showing 
empathy and reassurance, engaging in interactive dialogue, giving 
encouragement and praise, giving appropriate personalised information, 
eliciting shared goals, and ending the consultation with feedback and review 
(Global Initiative for Asthma, 2014). It was essential therefore that the 
consultation style used by the researcher followed a similar format to these 
studies and guidelines, because this interventional study is largely based on 
education and training that is provided verbally. 
 
Therefore a communication style based on the enhanced Calgary-Cambridge 
consultation model (Kurtz et al., 2003) was used. This aims to allow a rapport to 
develop between the investigator and patients and ensure that patients 
experienced a satisfactory approach to their consultation. This consultation 
model emphasises the importance of building a relationship with patients and to 
explore the patient’s own perspective of their illness including their ideas, 
beliefs, concerns and expectations. This allows healthcare professionals to 
obtain the required information to perform a medical review, and then discuss 
findings and management options with patients. 
 
Whilst the content of the consultation is discussed previously (Chapter 2.3.3), it 
was considered important that the format and consultation style had a specific 
objective to change patients’ behaviours in order to improve their own self-
management of their asthma and where necessary improve adherence to 
treatment. Traditional methods for improving adherence have focussed on 
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simplifying treatment regimens such as through the use of ICS/LABA 
combination inhalers, and ensuring that inhaler devices are prescribed that 
patients can use. However more recently, cognitive-based behaviour change 
techniques (CBCT) have been recommended for use by healthcare 
professionals to improve adherence.  
 
It was therefore important to incorporate some of the CBCTs into the 
intervention in my study. However due to the complexities of behaviour change 
interventions and the time required to use these in an identical manner to 
published studies, only brief behaviour change interventions could be 
incorporated, but focussed on self-monitoring, identification and avoidance of 
asthma triggers, addressing erroneous views about asthma and its treatment. 
These interventions assist the development of a self-management plan (British 
Thoracic Society and Scottish Intercollegiate Guidelines Network, 2014, Global 
Initiative for Asthma, 2014) and this combined with CBCT can help motivate 
patients to improve their asthma management and asthma control. 
  
 
4.6 Feasibility and piloting 
4.6.1 Feasibility of patient recruitment 
In order to ensure that sufficient patients could be recruited to the study to be 
powered to demonstrate a positive impact of pharmacy interventions, a three-
month audit using a self-reporting questionnaire design was performed to 
determine the number of patients likely to meet the inclusion criteria for MUR 
(Capstick et al., 2012). Over a 12-week period between November 2011 and 
February 2012, 237 patients were scheduled to attend the Leeds Difficult 
Asthma Clinic and 64 completed questionnaires (10 new referrals and 54 follow-
up attendees), representing a 27% response rate. 
 
50 patients reported that they used the same community pharmacist for at least 
the past 3 months, and 33 (66%) of these patients who would be eligible for a 
MUR had not received this service within the past 12 months.  At the time of the 
audit approximately 70% of community pharmacies were registered with their 
Primary Care Trust to provide an MUR service, and consequently most of these 
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patients were likely to have attended community pharmacies that provided this 
service.   
 
By assuming that the completion rates of the questionnaire would be equivalent 
to consent rates for participation in the study, it was thought possible that 36% 
of consenting patients (70% of 33/64 patients) attending the Leeds Difficult 
Asthma Clinic were likely to be eligible for a t-MUR as part of the study protocol, 
and attend a community pharmacy that provided a MUR service.  As the audit 
took place over a 12-week period, this would equate to 3 patients per week who 
may be likely to consent to inclusion in the study and be eligible for and able to 
have a t-MUR. Due to the number required, it was thus anticipated that patients 
could potentially be recruited to the study over a 9 to 12 month period. 
 
4.6.2 Pilot study 
In order to ensure that the study intervention was viable, the researcher 
reviewed patients within the difficult asthma clinic according to the intervention 
protocol, and found that it was appropriate, achievable and acceptable to 
patients. However as mentioned above (Chapter 4.2), the initial study design 
comprising reinforcement follow-up visits was found to not be possible because 
the hospital difficult asthma clinic was limited such that there was insufficient 
capacity within the clinic to allow additional repeated follow-up outpatient visits. 
The initial study design plan specified that patients would return for review and 
reinforcement of education and inhaler technique training at regular intervals 
(after 1, 3 and 6 months) as previous community pharmacy-based interventional 
studies incorporated one to three follow up visits in between the baseline and 
final visits to reinforce the intervention and assess asthma outcomes (Armour et 
al., 2007, Basheti et al., 2008, Charrois et al., 2004, Mangiapane et al., 2005, 
Mehuys et al., 2008).  As this was not possible alternative methods for providing 
reinforcement education and assessment were considered, and the role of 
community pharmacists providing the nationally commissioned t-MUR 
(Department of Health, 2013) was thought to be suitable to provide this role.  
 
Whilst previous pharmacist intervention studies had used at two or three 
reinforcement interventions, patients are only allowed one MUR every 12 
months (Department of Health, 2013). This caused concerns that interventions 
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made during the baseline consultation could not be reinforced by community 
pharmacists on a regular basis, but pragmatically it was thought that one 
reinforcement visit would more closely mimic NHS services than previous 
pharmacist intervention studies, and provide data more relevant for usual 
clinical practice. 
 
All patients reviewed in this pilot stage were excluded from the main study. 
 
 
4.7 Data Collection 
The aim of this study was to determine the effects of a co-ordinated 
management strategy between primary and secondary care pharmacists on 
asthma control and quality of life in patients with difficult asthma. Therefore, as 
this study was designed as a pragmatic interventional study in a real-world 
setting, it was important that the outcome measures investigated were relevant 
for clinical practice, using measures that are meaningful and relevant for 
assessing asthma symptoms and control in individual patients, and therefore 
allowing the results to be interpreted into routine practice.  
 
Additionally, it was also important for outcome measures to be similar to those 
employed in other pharmacist intervention studies, so that the results of this 
study could be compared to previous research. 
 
Outcome measures selected for the proposed study were based on the 
American Thoracic Society (ATS) / European Respiratory Society (ERS) 
statement on standardising endpoints for clinical asthma trials and clinical 
practice (Reddel et al., 2009). The primary endpoint in this study was the impact 
on asthma control from the management of difficult asthma by a hospital 
advanced clinical pharmacist and a community pharmacist, and so it was 
important that validated and approved measures of asthma control were 
employed. The ATS and ERS recommend composite scores to measure 
asthma control and quality of life, as well as lung function and symptom-based 
outcome measures such as the number of symptom-free days, reliever use and 
exacerbation history (Reddel et al., 2009).  
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A data collection form was designed to collect data on the outcome measures 
and where data were collected using additional questionnaires, a tick box was 
included to remind the investigator to ensure all questionnaires were completed 
and collected (see Appendix 10). 
 
Whilst most of the data were collected by the investigator, data for patients 
undergoing usual care was collected by clinic nurses and doctors who were 
reviewing the patient. Therefore, to ensure complete data collection, the form 
was designed to highlight which sections were to be completed by non-
researcher staff managing patients in the usual care group. 
 
 
4.8 Outcome Measures 
Due to limited time and staff resources, it was decided that the study design 
should be simple for both the research process and patients. There was limited 
time available during each patient’s clinic appointment to teach patients how to 
complete patient diaries that are frequently used in clinical trials to assess daily 
asthma symptoms and control. Instead it was decided to collect data at baseline 
and at six-months, and to collect indirect measures of asthma control such as 
corticosteroid use and hospital admissions, which are accepted outcome 
measures for asthma control (Reddel et al., 2009).  
 
A six-month follow-up period was chosen since this is thought to be the 
minimum duration required to identify outcomes such as unscheduled use of 
secondary health care including hospital admissions and attendance in the A&E 
department (Reddel et al., 2009). This interval was also desirable on a practical 
basis since it prevented patients having to attend the difficult asthma clinic more 
frequently than anticipated, which may have been burdensome for both the 
patient and investigator and may have negatively affected recruitment. However 
this had to be countered by the fact that a previous study demonstrating 
significant improvements on inhaler technique and asthma control over a six 
month duration required patients to attend their community pharmacy for the 
intervention to be reinforced at regular intervals (at one, two and three months) 
(Basheti et al., 2008). Consequently it was considered that this reinforcement 
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strategy might be critical to improving asthma control and was specified in an 
early draft of the study protocol.  
 
For practical reasons in this study, community pharmacists were asked to 
provide this reinforcement role for patients allocated to the intervention group, 
by using MURs to reinforce inhaler technique and identify other medication 
related issues (see Chapter 4.2.1). To improve uptake by patients who were 
likely to have busy working lives, it was decided that the MUR could be flexible 
and take place within four to eight weeks after the initial consultation in the 
difficult asthma clinic. However, since patients are only allowed one MUR every 
12 months (Department of Health, 2013), this prevented patients having more 
than one reinforcement episode during the study and meant that patients were 
ineligible for the study if they had already had an MUR that year. 
 
4.8.1 Measures of asthma control and quality of life 
Patient questionnaires should be designed to be acceptable for patients to 
complete; specifically they should be short, reliable, validated and responsive to 
change (Bowling, 2002). Therefore it was decided that any questionnaire used 
in this study should comply with these criteria. 
 
As a measure of asthma control, two questionnaires were considered: the ACT 
(Nathan et al., 2004) and ACQ (Juniper et al., 1999b), which are both 
recommended by GINA (Global Initiative for Asthma, 2014), the BTS/SIGN 
(British Thoracic Society and Scottish Intercollegiate Guidelines Network, 2014), 
and the ATS/ERS (Reddel et al., 2009).  A decision has been made to use the 
ACQ in this study, as it has been extensively validated in adults aged 17 years 
or older (Juniper et al., 1999b, Juniper et al., 2005, Juniper et al., 2006) and is 
widely recognised and used in research and clinical practice, and so was 
thought to best comply with the requirements for a valid test. Additionally, 
copyright restrictions prohibited the use of the ACT for financial reasons. 
 
The ACQ has six questions requiring patients to rate their asthma symptoms, 
use of SABA over the previous week, and one question requiring measurement 
of their lung function. It is scored on a seven-point scale from 0 (totally 
controlled) to 6 (severely uncontrolled), with a cut-off for controlled asthma 
 107 
defined as an ACQ less than 1.0 (Juniper et al., 2006), and a clinically 
significant improvement in asthma defined as a reduction in ACQ score greater 
than 0.5 units. 
 
Similarly, to determine quality of life, AQLQ was used since it has been 
validated in patients aged 16-70 years, and has excellent test-retest reliability, 
is very responsive to within-patient change over time and can discriminate 
between patients with different levels of impairment (Juniper et al., 1992, 
Juniper et al., 1993). However this questionnaire has 32 questions comprising 
four domains (symptoms, activity limitation, emotional function and 
environmental stimuli), and so may be less acceptable to patients because of its 
length. Each question is answered on a 7-point scale (where 7 = not impaired at 
all, to 1 = severely impaired). The overall AQLQ score is the mean of all 32 
responses, and a change in score of 0.5 on the 7-point scale is clinically 
significant. 
 
Additionally, since quality of life may be compared across different conditions, it 
is often useful to also use a generic measure that can be used to compare the 
impact of interventions on quality of life. The European Quality of Life-5 
Dimensions Questionnaire (EQ-5D™) (The EuroQol Group, 1990, Brooks, 
1996) is a standardised, validated tool for measuring health outcomes that is 
not specific for any medical condition, but has been used in asthma studies and 
is recognised as a validated tool in the NICE Guide to the methods of 
technology appraisals (National Institute for Health and Clinical Excellence, 
2008), and so was considered appropriate for use in this study. This 
questionnaire also includes a patient-reported self-rated health measure using 
the EQ visual analogue scale (EQ VAS), which allows patients to rate their 
health on a 20cm vertical visual analogue scale from 0 (‘the worst health you 
can imagine’) to 100 (‘the best health you can imagine’). 
 
4.8.2 Exhaled nitric oxide 
Exhaled Nitric Oxide (FENO) is a marker of eosinophilic inflammation associated 
with asthma (Berry et al., 2005, British Thoracic Society and Scottish 
Intercollegiate Guidelines Network, 2014, Global Initiative for Asthma, 2014, 
Michils et al., 2008, Shaw et al., 2007). It is a simple and reproducible test 
 108 
(Kharitonov et al., 2003) that is commonly used in difficult asthma clinics (British 
Thoracic Society and Scottish Intercollegiate Guidelines Network, 2014, Global 
Initiative for Asthma, 2014) and may be measured as a marker of asthma 
control (Michils et al., 2008). A raised FENO above 50 ppb has been 
demonstrated to be predictive of a positive response to inhaled corticosteroids 
(British Thoracic Society and Scottish Intercollegiate Guidelines Network, 2014, 
Smith et al., 2005a). Since FENO is reduced with inhaled corticosteroid 
treatment, it has been postulated that it may be used to guide reductions in 
maintenance ICS treatment without resulting in loss of asthma control (Smith et 
al., 2005b), however data on this are currently lacking (Global Initiative for 
Asthma, 2014). FENO will be measured in this study to determine whether this 
may have a value as a marker of the success of the intervention. 
 
4.8.3 Inhaler technique 
As outlined in the literature review (Chapter 3.3.3), studies investigating 
interventions to improve inhaler technique vary in study design. Furthermore, 
these studies and cross-sectional studies of inhaler technique in patients (see 
Chapter 2.2.2) and healthcare professionals (see Chapter 2.2.4) vary in the 
assessment methods and reporting of inhaler technique (Basheti et al., 2014). 
This is primarily due to the fact that there is no one approved and validated 
assessment checklist for each inhaler device (Basheti et al., 2014). This study 
therefore used bespoke inhaler checklists for each inhaler device based upon 
the manufacturer’s instructions and checklists used in previous studies (see 
Appendix 8). 
 
These checklists can be used to determine the proportion of patients with 
optimal inhaler technique (performing all the correct steps on the checklist), the 
proportion of patients with satisfactory technique (performing all the critical 
steps on the checklist, but with some minor errors), and the average inhaler 
technique score. Each of these outcomes have recently been recommended in 
one review article that has made recommendations on performing and reporting 
inhaler technique studies (Basheti et al., 2014). 
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4.8.4 Inhaler preference 
An important factor that may be frequently overlooked when prescribing inhaler 
devices is to determine each patient’s preference of inhaler device as this may 
affect their adherence to treatment (Capstick and Clifton, 2012, Dolovich et al., 
2005), and this was investigated in this study. 
 
All patients in the PI group were trained in the use of Accuhaler, Easi-Breathe, 
Easyhaler, HandiHaler, pMDI, Respimat and Turbohaler devices, and asked to 
rank each device in order of preference. Two scoring systems were used to 
evaluate overall patient preference, the first using a previously published 
method used in one independent patient preference study (Lenney et al., 2000). 
This study allocated each patient’s first choice device a score of 3 points, 
second choice was 2 points and third choice was 1 point, then the points added 
to give an overall score for each device. 
 
Since this scoring system does not allocate scores to devices consistently 
ranked outside the top 3, it may not adequately establish the rank of these 
lesser-preferred devices. The alternative preference scoring system used in the 
present study allocated 7 points to each patient’s first choice device, 6 points for 
their second choice, 5 points for their third, 4 points for their fourth, 3 points for 
their fifth, 2 points for their sixth and 1 point for their seventh choice. The total 
score was added to give an overall score for each device, and the devices 
ranked in order of highest total score. 
 
4.8.5 Adherence 
In order to measure adherence, a number of strategies were considered 
including GP records and community pharmacy patient medication records. 
This is a simple method to assess adherence (Murphy et al., 2012b), but may 
not be accurate if patients are not actually taking/using their medication. 
Consequently, an additional tool was considered necessary to measure 
adherence, and the MARS (Horne and Weinman, 2002) was used. This is a 
self-report questionnaire that utilises non-threatening questions in order to 
encourage patients to openly describe their medication adherence, and has 
been validated in a study comparing asthma patient’s self-reporting to 
pharmacy prescribing records (Menckeberg et al., 2008). It has been well 
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validated in asthma patients, and therefore increases confidence in the 
accuracy of the adherence results produced. However patients were asked to 
answer the questions in the context of their use of ICS rather than all their 
asthma medicines as a whole, so that comparisons could be made between 
patients in terms of adherence to regular preventer therapy.  There was a risk 
with the use of an additional questionnaire as it could potentially over burden 
patients with questionnaires. Furthermore, there is a risk of acquiescence 
responses (Bowling, 2002) with the MARS questionnaire if patients felt 
compelled to report good adherence for fear of disappointing the investigator. 
This could potentially have been combatted by asking patients to seal this 
questionnaire in an envelope, but this was discounted as a solution as it may 
have been useful for the asthma consultation. 
 
A final tool used in the study was the Beliefs about Medicines Questionnaire 
(BMQ), which has been validated for use in patients with asthma (Horne et al., 
1999), and has been recommended as a useful intervention to facilitate optimal 
adherence (Haughney et al., 2008). The BMQ was thought to be useful for 
identifying potential perceptual and practical barriers to adherence in individual 
patients, because it assesses each patient’s beliefs about the need for regular 
preventer therapy for controlling their asthma, and also assesses their concerns 
about potential adverse effects of treatment. 
 
4.8.6 Exacerbations of asthma  
The constraints of time and resource within the initial clinic appointments 
prevented the use of use of asthma diaries to document asthma symptoms, 
lung function, symptom-free days, side effects, and use of reliever inhaler on a 
daily basis. This also prevented patients prospectively documenting any 
exacerbations requiring OCS use, hospital admissions or attendance at the 
A&E department.  Consequently retrospective measures were used to collect 
these data, including GP records, the hospital patient database ‘Patient Centre’ 
(which collects data on admissions and outpatient clinic appointments) and 
hospital pharmacy patient medication records. 
 
Whilst diaries are thought to be more accurate to collect information on asthma 
exacerbations, because data can be recorded by patients on a prospective 
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basis, this relies on recruiting patients who would be motivated to do this 
(Reddel et al., 2009). Additionally, it was thought to be an extra burden to 
instruct patients on how to complete the diaries, and what they would need to 
record, and so the use of diaries was discounted. Instead indirect measures 
recommended by the ATS and ERS were decided upon (Reddel et al., 2009). 
 
The downside to this is that since asthma is, by the very nature of the condition, 
associated with significant variation in symptoms over time, a lot of data may be 
lost by not using a patient diary. Consequently data collected at baseline and at 
six months maybe subject to chance variation in patient’s condition and chance 
exposure to exacerbating factors in the period running up to each appointment, 
which could interfere with outcomes that measure the impact of the intervention. 
However this would be the same for patients in both the intervention and control 
groups, and so this effect may be balanced across the groups. 
 
 
4.9 Analysis plan 
It was anticipated that the primary outcome of ACQ would produce ordinal data 
that would not be normally distributed, but it was planned to confirm this by 
looking at histograms of the data, measuring p-p plots, and by using the 
Kolmogorov-Smirnov test.   
 
For the primary outcome measure, planned statistical tests included change in 
ACQ from baseline within groups using the Wilcoxon test for non-parametric 
data, whilst the difference in ACQ between the two intervention groups was 
planned to be tested using the Mann-Whitney test for non-parametric data. 
 
Similarly, it was planned to test for normality of data for the secondary 
outcomes by looking at histograms of the data, measuring p-p plots, and by 
using the Kolmogorov-Smirnov test. Planned statistical tests are outlined in 
Table 4. 
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Table 4. Planned statistical tests on secondary outcome measures. 
Measure Type of Data Data Description  Statistical Test 
(between 
groups) 
Statistical Test 
(within group) 
Standardised Asthma 
Quality of Life 
Questionnaire (AQLQ(S)) 
Ordinal Non-parametric Mann-Whitney Wilcoxon 
European Quality of Life-5 
Dimensions (EQ-5D-5L) 
Ordinal Non-parametric   
Number of steroid courses 
within the previous 6 
months 
Scale (ratio) Non-parametric 
(expected) 
Mann-Whitney Wilcoxon 
Number of A&E 
attendances and 
hospitalisations within the 
previous 6 months 
Scale (ratio) Non-parametric 
(expected) 
Mann-Whitney Wilcoxon 
Lung function (FEV1, 
FEV1/FVC) 
Scale (ratio) parametric Paired samples 
T test 
Independent 
samples T test 
Exhaled Nitric Oxide Scale (ratio) Non-parametric 
(expected) 
Mann-Whitney Wilcoxon 
Inhaler technique score Ordinal Non-parametric 
(expected) 
Mann-Whitney Wilcoxon 
Ability to use prescribed 
inhaler device before and 
after instruction 
Nominal  Chi-square Wilcoxon 
Inspiratory flow before and 
after instruction through 
prescribed inhaler device 
Scale (ratio) Non-parametric 
(expected) 
Mann-Whitney Wilcoxon 
Adherence (Patient 
reported [MARS and 
BMQ], GP reported [based 
on prescription data]. 
Ordinal Non-parametric 
(expected) 
Mann-Whitney Wilcoxon 
Interventions Nominal  Chi-square n/a 
MUR data: 
1. Interventions 
2. GP referrals 
3. Adherence 
4. Inhaler technique 
Nominal (all) 
 
  
 
 
 
Chi-square 
 
 
 
 
Wilcoxon 
 
 
4.9.1 Exploratory analysis plan 
Since this study is classed as a complex interventional study, the effects of 
different components of the intervention on asthma control and other outcomes 
will be explored. 
 
4.9.1.1 Effect of Pharmacist education 
It is anticipated that the intervention will improve all outcomes: 
1. Improvement on adherence (Patient reported [MARS and BMQ], GP 
reported [based on prescription data], Community Pharmacist 
reported [based on prescriptions dispensed]) 
2. Asthma control, measured using ACQ 
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3. Quality of life, measured using AQLQ(S) and EQ-5D-5L 
4. Number of exacerbations, defined as OCS courses and hospital or 
A&E visits 
5. Exhaled nitric oxide 
6. Lung function, measured using FEV1 and FEV1/FVC ratio 
7. Inhaler technique at 6 months 
 
4.9.1.2 Inhaler technique at 6-months 
Patients recruited to the pharmacist intervention group will have received 
intensive education and training on the correct use of inhaler devices. If 
good technique is maintained from baseline to 6-months, it is anticipated 
that this will have a positive impact on the following outcome measures: 
1. Asthma control, measured using ACQ 
2. Quality of life, measured using AQLQ(S) and EQ-5D-5L 
3. Number of exacerbations, defined as OCS courses and hospital or 
A&E visits 
4. Exhaled nitric oxide 
5. Lung function, measured using FEV1 and FEV1/FVC ratio 
 
4.9.1.3 Effect of adherence rates 
It is anticipated that patients with high levels of adherence to their preventer 
therapy (ICS or combined ICS/LABA) will be associated with improvements 
in all outcomes: 
1. Asthma control, measured using ACQ 
2. Quality of life, measured using AQLQ(S) and EQ-5D-5L 
3. Number of exacerbations, defined as OCS courses and hospital or 
A&E visits 
4. Exhaled nitric oxide 
5. Lung function, measured using FEV1 and FEV1/FVC ratio 
 
4.9.1.4 Effect of MUR 
It was anticipated that not all of the patients randomised to the intervention 
group would have their planned MUR. Therefore, a subgroup analysis study 
will be performed to determine differences in all outcome measures between 
the following subgroups: 
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1. Pharmacist Intervention with MUR 
2. Pharmacist Intervention without MUR 
 
 
4.10 Ethical considerations 
This study was reviewed and given favourable opinion by Humber Bridge 
Research Ethics Committee on 5th July 2012 (Appendix 11), and was approved 
by Research & Development at Leeds Teaching Hospitals on 27th July 2012 
(Appendix 12). 
 
A number of ethical issues were identified in the study, mainly due to the 
perceived risks associated with changing current clinical practice, in particular 
associated with patients having an asthma review from a pharmacist rather than 
a doctor, and also asking patients to refrain from having a MUR for the duration 
of the study. 
 
On the first issue, this study recruited patients to receive an asthma review from 
an advanced clinical pharmacist rather than their usual care, which could 
comprise an asthma review from a consultant physician, specialist registrar or 
asthma nurse specialist. It was considered that there was a potential risk that 
the pharmacist review may not be as comprehensive or on a comparative level 
to established members of the asthma team. Consequently, the advanced 
clinical pharmacist, who already had knowledge, skill and expertise in asthma, 
spent several weeks observing consultations and had their asthma reviews 
supervised by the lead clinician for the difficult asthma service in order to 
ensure consistent and appropriate management. Additionally the study design 
allowed for the advanced clinical pharmacist to seek advice on complex issues 
during the consultation despite independent practice, which is consistent with 
the operation of healthcare professionals in outpatient settings where advice 
and opinions may be sought on individual complex cases. 
 
On the second issue, asking patients in the usual care to not have a MUR was 
considered to be potentially ethically problematic by denying some patients a 
commissioned healthcare service. However an audit of patients attending the 
difficult asthma clinic found that only half of the patients who were eligible for a 
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MUR had been offered one (Capstick et al., 2012), and only a third of patients 
had received an MUR. This suggests that the uptake for the MUR service is 
sub-optimal in this patient group, and that asking patients to avoid having an 
MUR would affect relatively few of them. 
 
 
4.11 Study sponsorship 
This report is independent research commissioned by the Pharmaceutical Trust 
for Educational and Charitable Objects (now known as Pharmacy Research 
UK). The views expressed in this publication are those of the author and not 
necessarily those of the Pharmaceutical Trust for Educational and Charitable 
Objects. 
 
 
4.12 Dissemination of findings 
It is anticipated that the results will be published in a peer-reviewed scientific 
journal (e.g. pharmacy practice or respiratory specialist medical journals), and 
presented at local, national or international meetings. Potential areas for 
publication include: (i) the impact of pharmacist interventions on asthma control 
and quality of life; (ii) the impact of pharmacist training on inhaler technique at 
baseline and at 6 months; (iii) adherence in patients with difficult asthma. 
 
The results of this research project will be disseminated internally within the 
Leeds Teaching Hospitals NHS Trust by presenting to the pharmacy and 
respiratory medicine departments, and by writing a business case to 
demonstrate the need for on going pharmacist involvement within the Leeds 
difficult asthma clinic. 
 
It is anticipated that the results will be shared with community pharmacists in 
the form of the executive summary report via Community Pharmacy West 
Yorkshire. 
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5 Results 
5.1 Introduction 
Outcome measures used in the study were based on the ATS/ERS statement 
on standardising endpoints for clinical asthma trials and clinical practice (Reddel 
et al., 2009).  
 
The data generated in the study were analysed to determine whether there 
were any significant differences between the PI group and UC group at 
baseline, or at follow-up, and also to determine whether any significant effects 
had occurred as a result of the interventions performed. To help ensure the 
validity of statistical testing, all data collected were characterised as scale, 
ordinal or nominal. Scale data were further assessed for normality. Normality 
was tested for all data collected using histograms, P-P plots and Kolmogorov-
Smirnov tests using SPSS Statistics version 21.0.0.0 (© Copyright IBM 
Corporation). These data are presented in Appendix 13. 
 
 
5.2 Baseline demographics 
Of the 188 patients screened for inclusion in the study, a total of 52 patients 
were recruited to the study between 25th September 2012 and 29th October 
2013. Twenty-six were randomly assigned to the PI group and 26 to the UC 
group. Forty-seven patients (24 in the PI group) were followed up for a median 
(interquartiles, IQ) of 182 (175, 203) days and were included in the intention to 
treat analysis. Only six participants (23%) in the PI group received a t-MUR at a 
mean of 60 days (range 28 – 143 days) following randomisation (see Figure 5). 
All but one of the participants received their t-MUR within the four to eight week 
range stipulated in the protocol. The mean (SD) age of participants was 46.9 
(12.4) years, and there were slightly more female (63.5%) than male 
participants. Almost half of all participants had never smoked (48.1%) and only 
11.5% were current smokers. There were no significant differences in the 
demographic characteristics between participants in the PI and UC group at 
baseline (see Table 5). 
 
The median (IQ) duration of asthma instability was 3.50 (1.17, 8.75) years and 
the majority of patients were currently prescribed asthma medicines at Step 4 or 
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5 of the BTS/SIGN asthma guidelines (British Thoracic Society and Scottish 
Intercollegiate Guidelines Network, 2014), with all patients prescribed a high 
dose ICS at a median (IQ) equivalent beclometasone-CFC dose of 1600 (800, 
2000) micrograms. Most patients were prescribed a LABA in a combination 
ICS/LABA inhaler, except one who was prescribed separate ICS and LABA 
inhalers to allow ciclesonide to be prescribed (due to the oropharyngeal 
adverse effects of alternative ICS). The most common additional controller 
medicines prescribed were LKTa (65.4%), methylxanthines (30.8%), and long-
acting muscarinic antagonists (LAMA) (17.3%). Most patients in the UC group 
were prescribed a SABA reliever inhaler, except one who was prescribed the 
Symbicort® maintenance and reliever therapy regimen. Participants reported a 
mean (SD) of 4.8 (3.22) emergency courses of OCS in the past 12 months and 
a median of 1 hospital admission or A&E department visit within the past 12 
months, which is typical of patients with difficult asthma (British Thoracic 
Society and Scottish Intercollegiate Guidelines Network, 2014). 
 
Participants recruited to the study had uncontrolled asthma at baseline, with a 
median (IQ) ACQ score of 3.00 (2.14, 3.57) across both groups, a median (IQ) 
exhaled nitric oxide (FeNO) of 36.0 (15.0, 67.0) ppb, and were using were using 
a median (IQ) 49.0 (21.0, 75.75) puffs of SABA inhaler each week. As is 
characteristic of asthma, a wide variation in lung function was observed on 
spirometry testing, with a mean (SD) FEV1/FVC ratio of 69.34 (10.73) (range 
47.95 to 90.83), and a FEV1 of 71.79 (19.13) % of predicted (range 36.60% to 
123.00%). Participants in the PI group had worse asthma control at baseline 
than those in the UC group based ACQ score, SABA use, emergency courses 
of OCS in the past 12 months and duration of asthma instability, although this 
did not reach statistical significance (see Table 5). 
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Figure 5. CONsolidated Standards of Reporting Trials (CONSORT)/patient 
flow diagram.  
PI, pharmacist intervention group; UC, usual care group; t-MUR, targeted 
medicines use review. 
 
 
 
188 participants screened 
26 assigned to UC group 
 
24 completed 23 completed 
 
136 participants excluded 
54 did not attend 
23 declined 
20 alternate diagnoses 
19 ineligible for MUR 
8 did not receive letter 
4 language barrier 
4 study closed 
3 did not read letter 
3 protocol breach (prior to 
consent) 
2 pregnancy 
1 recent pharmacist review 
1 referred to immunologist 
TOTAL 142 reasons for 
screening exclusions 
2 lost to 
follow-up 
26 assigned to PI group 
3 lost to 
follow-up 
6 received t-MUR 
20 did not receive t-MUR 
(protocol deviation) 
1 received t-MUR 
(protocol deviation) 
25 did not receive t-MUR  
 
52 randomly assigned 
  
1
1
9
 
Table 5. Baseline demographic data 
 PI group UC group Statistical Test Value p value 
Number of participants 26 26    
Sex (Female; n, %) 17 (65.4%) 16 (61.5%) Fisher’s Exact Test 0.083 1.000 
Exact age at recruitment (mean years (SD)) 46.36 (12.88) 47.71 (12.14) Independent samples t-test -0.330 0.743 
Baseline Smoking Status:  
Never Smoked (n, %) 
Ex-smoker (n, %) 
Current Smoker (n, %) 
 
13 (50.0%) 
10 (38.5%) 
3 (11.5%) 
 
12 (46.2%) 
11 (42.3%) 
3 (11.5%) 
Chi-Square 0.0088 0.957 
Duration of asthma instability (median years, IQ) 5.0 (2.0, 10.0) 2.5 (1.0, 6.5) Mann-Whitney 261.500 0.161 
Steroid courses in previous 12 months (mean (SD)) 5.62 (3.62) 3.92 (2.50) Independent samples t-test 1.942 0.059 
Steroid courses in previous 3 months (median, IQ) 2.0 (1.0, 3.0) 1.0 (0.0, 2.0) Mann-Whitney 266.500 0.179 
Hospital admissions and A&E visits in previous 12 months 
(median, IQ) 
1.0 (0.0, 1.25) 1.0 (0.0, 1.25) Mann-Whitney 325.500 0.808 
Hospital admissions and A&E visits in previous 3 Months 
(median, IQ) 
0.0 (0.0, 1.0) 0.0 (0.0, 1.0) Mann-Whitney 327.000 0.819 
Number of puffs of reliever (SABA) inhaler per week 
(median, IQ) 
49.0 (33.25, 64.75) 45.5 (12.5, 90.5) Mann-Whitney 328.000 0.854 
ACQ  (median, IQ) 2.86 (2.25, 3.25) 3.00 (1.96, 3.71) Mann-Whitney 333.000 0.927 
AQLQ(S) (median, IQ) 4.11 (3.38, 5.21) 3.77 (2.87, 5.30) Mann-Whitney 310.500 0.615 
FEV1 (% predicted; mean (SD)) 72.92 (20.06) 70.57 (18.41) Independent samples t-test 0.432 0.668 
FEV1/FVC (mean (SD)) 69.46 (11.05) 69.21 (10.61) Independent samples t-test 0.079 0.937 
FeNO (median, IQ) 38.0 (19.0, 70.75) 27.0 (14.0, 67.0) Mann-Whitney 110.000 0.693 
Possession of Asthma Action Plan (n, %) 16 (61.5%) 15 (57.7%) Fisher’s Exact Test 0.080 1.000 
  
1
2
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 PI group UC group Statistical Test Value p value 
Current asthma treatment: 
ICS (n, %) 
ICS/LABA (n, %) 
LABA (n, %) 
LKTa (n, %) 
Methylxanthine (n, %) 
SABA (n, %) 
LAMA (n, %) 
Anti-IgE (n, %) 
Prednisolone (n, %) 
Methotrexate (n, %) 
 
1 (3.8%) 
25 (96.2%) 
1 (3.8%) 
18 (69.2%) 
7 (26.9%) 
26 (100%) 
4 (15.4%) 
0 (0%) 
5 (19.2%) 
0 (0%) 
 
2 (7.7%) 
26 (100%) 
0 (0%) 
16 (61.5%) 
9 (34.6%) 
25 (96.2%) 
5 (19.2%) 
0 (0%) 
3 (11.5%) 
2 (7.7%) 
 
Fisher’s Exact Test 
 
 
0.354 
1.020 
1.020 
0.340 
0.361 
1.020 
0.134 
n/a 
0.591 
2.080 
 
1.000 
1.000 
1.000 
0.771 
0.764 
1.000 
1.000 
n/a 
0.703 
0.490 
Baseline equivalent beclometasone-CFC dose (micrograms; 
median, IQ) 
1600 (800, 2000) 2000 (800, 2000) Mann-Whitney 293.000 0.394 
PI, pharmacist intervention group; UC, usual care group; SD, standard deviation; IQ, interquartiles; ACQ, Juniper’s asthma control questionnaire; AQLQ(S), 
Juniper’s standardised asthma quality of life questionnaire; FEV1, forced expiratory volume in one second; FEV1/FVC, ratio of forced expiratory volume in one 
second / forced vital capacity; FeNO, exhaled nitric oxide; ICS, inhaled corticosteroid; ICS/LABA, inhaled corticosteroid / long-acting beta2-agonist combination 
inhaler; LABA, long-acting beta2-agonist; LKTa, leukotriene receptor antagonist; SABA, short-acting beta2-agonist; LAMA, long-acting muscarinic antagonist; anti-
IgE, humanised monoclonal antibody that selectively binds to immunoglobulin E. 
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5.3 Interventions 
This study was designed as a pragmatic (real-life) complex intervention study. 
The intervention comprised a number of possible issues that could be identified 
and addressed during a routine consultation in the difficult asthma clinic. Since 
this was a real-life study, appointments were prolonged due to the assessments 
performed in addition to the verbal consultation, which meant that many 
patients spent between one and two hours in the clinic, although it was not 
practical to perform accurate time keeping. 
 
5.3.1 Number of interventions 
At the initial consultation, participants randomised to the PI group received 
significantly more interventions than those in the UC group (79 vs. 34 
respectively; Mann-Whitney U=96.5, p<0.001) (see Table 6). Each patient 
received a median (IQ) of 3 (2, 4) interventions in the PI group, compared to 1 
(0, 2) in the UC group. In contrast, those in the UC group were significantly 
more likely to receive no interventions during their consultation (7 vs. 0 patients; 
χ2 8.089, p=0.010; Fisher’s Exact Test).  
 
Participants in the PI group received more interventions within each specified 
category compared to those in the UC group (Table 6), including: medication-
related issues (54 vs. 18); allergy tests and asthma investigations (5 vs. 1); 
management of associated medical conditions (6 vs. 4); and education or 
advice (14 vs. 11). Despite the lower number of interventions performed overall, 
inhaler technique training was the only specific intervention that significantly 
more participants received in the PI group (24 vs. 4; χ2 30.952, p<0.001; 
Fisher’s Exact Test). 
 
Provision of asthma action plans as part of the intervention in both groups 
increased the proportion of patients possessing these: from 61.5% to 83.3% of 
participants in the PI group; and from 57.7 to 73.9% in the UC group. 
Possession rates were not statistically different between the two groups. 
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5.3.2 Inhaler technique at baseline 
5.3.2.1 Devices prescribed 
A total of 96 inhaler devices were prescribed for the 52 participants recruited to 
the study, with the majority using two different inhaler devices (n=34). Only 11 
patients were prescribed just one type of inhaler device, whilst five had three 
different devices. The most frequently prescribed devices were pMDI (67.3%), 
Turbohaler (61.5%) and Accuhaler (26.9%) for all patients in both groups. The 
types of inhaler devices prescribed were similar for participants in the PI and 
UC group, with no significant difference in the proportion of participants 
prescribed each device (Table 7). 
 
5.3.2.2 Previous training 
Almost all participants in the study had previously received inhaler technique 
training, most commonly from hospital nursing staff (usually in the difficult 
asthma clinic) or practice nurses in GP surgeries. Training from physicians and 
pharmacists in primary and secondary care was reported less commonly (Table 
8). 
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Table 6. Interventions made during asthma consultation 
Classification of 
intervention 
Intervention 
PI (n=26) UC (n=26) All (n=52) Chi Square 
(Fisher's 
Exact Test) 
p value 
n % n % n % 
Management of 
Associated 
Medical 
Condition 
Investigation for additional diagnosis  
(e.g. cor pulmonale, VCD, bronchiectasis), or 
psychological referral 
0 0.0% 0 0.0% 0 0.0% n/a  
Reflux 4 15.4% 2 7.7% 6 11.5% 0.754 0.668 
Rhinitis 2 7.7% 2 7.7% 4 7.7% 0.000 1.000 
Education / 
Advice 
Allergen avoidance 1 3.8% 0 0.0% 1 1.9% 1.020 1.000 
Asthma Action Plan provision / monitoring 3 11.5% 6 23.1% 9 17.3% 1.209 0.465 
Healthy Living (exercise, smoking cessation, 
weight management) 
4 15.4% 1 3.8% 5 9.6% 1.991 0.350 
Medication / Adherence 6 23.1% 4 15.4% 10 19.2% 0.495 0.726 
Medication 
Optimise dose of asthma medicines / 
maintenance OCS 
4 15.4% 4 15.4% 8 15.4% 0.000 1.000 
Addition of new asthma medication 4 15.4% 3 11.5% 7 13.5% 0.165 1.000 
Inhaler Device Switch 9 34.6% 3 11.5% 12 23.1% 3.900 0.097 
Inhaler Technique +/- provision of training aid / 
spacer 
24 92.3% 4 15.4% 28 53.8% 30.952 <0.001 
Consideration for omalizumab 1 3.8% 1 3.8% 2 3.8% 0.000 1.000 
Stop non-essential / non-effective asthma 
medicine 
3 11.5% 2 7.7% 5 9.6% 0.221 1.000 
ADR advice / management 2 7.7% 0 0.0% 2 3.8% 2.080 0.490 
Acute course OCS 3 11.5% 1 3.8% 4 7.7% 1.083 0.610 
Theophylline TDM 4 15.4% 0 0.0% 4 7.7% 4.333 0.110 
Tests Allergy testing / investigations 5 19.2% 1 3.8% 6 11.5% 3.014 0.191 
None No intervention required 0 0.0% 7 26.9% 7 13.5% 8.089 0.010 
PI, pharmacist intervention group; UC, usual care group; N, number of patients in intervention group; n, number of participants receiving 
specific intervention; VCD, vocal cord dysfunction; OCS, oral corticosteroid; TDM, therapeutic drug monitoring.
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Table 7. Inhaler devices prescribed at baseline 
 PI (n=26) UC (n=26) 
 n % n % 
Accuhaler 10 38.5% 4 15.4% 
Easi-Breathe 2 7.7% 2 7.7% 
Easyhaler 0 0% 0 0% 
HandiHaler 4 15.4% 2 7.7% 
pMDI 17 65.4% 18 69.2% 
pMDI + Spacer 2 7.7% 1 3.8% 
Respimat 0 0% 2 7.7% 
Turbohaler 17 65.4% 15 57.7% 
Total Number of Inhaler  
Devices prescribed 52  44  
PI, pharmacist intervention group; UC, usual care group; pMDI, pressurised 
metered dose inhaler. The proportion of participants in the PI and UC groups 
prescribed each device was not statistically significant (Fisher’s Exact Test). 
 
Table 8. Previous inhaler technique training. 
 PI (n=26) UC (n=26) 
Hospital Respiratory Nurse 18 18 
Practice Nurse 9 8 
Hospital Respiratory Physician 2 2 
Hospital non-Respiratory Physician 0 1 
GP 2 5 
Hospital Pharmacist 3 2 
Community Pharmacist 1 4 
Never Checked 1 3 
PI, pharmacist intervention group; UC, usual care group. 
 
5.3.2.3 Inspiratory flow 
Analysis of patients’ peak inspiratory flow rate (IFR) through different devices 
demonstrated that some data were normally distributed, whilst others were not 
normally distributed. As a consequence, non-parametric statistical tests were 
used for data analysis, specifically Mann-Whitney for two independent samples, 
and Wilcoxon for two related samples (Campbell and Machin, 1999). 
 
At baseline, participants in the PI group were assessed to have a significantly 
faster median (IQ) peak IFR than participants in the UC group through pMDI 
devices 130.0 (93.8; 153.8) L/min vs. 55.0 (43.0; 120.0) L/min; Mann-Whitney U 
32.0, p<0.001 and Accuhaler devices 75.0 (68.8; 121.3) L/min vs. 55.0 (31.3; 
67.5) L/min; Mann-Whitney U 6.5, p=0.021, but not through Turbohaler devices 
65.0 (62.5; 75.0) L/min vs. 78.0 (70.0; 85.0) L/min; Mann-Whitney U 62.5, 
p=0.013. 
 125 
 
Education on the correct IFR achieved a significant reduction in the median (IQ) 
peak IFR through pMDI devices to 57.5 (48.8; 60.0) L/min (Wilcoxon Z -3.623, 
p<0.001) in the PI group, but achieved no significant change in median peak 
IFR through other devices in the PI group, and no significant effect for any 
device in the UC group (see Figure 6). 
 
Consequently, more patients achieved the correct IFR after education in the PI 
group (Figure 7) through: pMDI (one before education compared to 15 after 
education); Accuhaler (9 before education compared to 14 after education); and 
Easi-Breathe devices (0 before education compared to 2 after education). 
There was limited effect observed in the UC group, with no increases in the 
number of patients achieving the correct IFR for any device. This was in part 
due to fewer IFR assessments being performed (4, 0 and 2 assessments for 
Accuhaler, HandiHaler and Easi-Breathe inhalers respectively). 
 
5.3.2.4 The effect of education on inhaler technique score  
Interim baseline data on the inhaler technique of the first 25 patients recruited to 
the study was presented at the 2013 European Respiratory Society Congress 
(Capstick et al., 2013). This highlighted that at least one critical error was made 
in 57% of inhaler technique assessments, whilst optimal technique was found in 
only 31% of assessments. 
 
When inhaler technique was assessed for all the recruited patients, using 
inhaler technique score calculated as a percentage of all the steps performed 
correctly, technique scored relatively highly (>80%) for the most commonly 
prescribed devices: pMDI, Accuhaler and Turbohaler. It was not significantly 
different between patients in the PI and UC group. Across both groups, the 
mean, SD inhaler technique score was highest for Turbohaler (93.75, 6.60), 
followed by Accuhaler (91.36, 15.03), then pMDI,  (80.26, 17.70). In addition, 
inhaler technique scores were higher than pMDI alone for: Easi-Breathe, 
Easyhaler, HandiHaler and pMDI with spacer. This may be an artefact due to 
the small numbers of patients prescribed these devices (ranging from one to 
five patients). 
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Since inhaler technique was not perfect for any of the devices, further training 
was provided. The improvements in mean, SD inhaler technique score for the 
three most commonly used inhaler devices are presented in Figure 8. 
Significant improvements were observed for participants in the PI group using 
pMDI (from 80.30, 7.38 to 97.33, 4.27; Wilcoxon -3.677, p<0.001), Accuhaler 
(from 94.87, 7.34 to 98.41, 5.94; Wilcoxon -2.121, p=0.034) and Turbohaler 
devices (from 91.76, 6.36 to 99.41, 2.43; Wilcoxon -3.357, p=0.001). In 
contrast, significant improvements were only observed in participants in the UC 
group using pMDI devices (from 80.21, 24.32 to 95.72, 10.22; Wilcoxon -2.527, 
p<0.001). 
 
The most common errors in inhaler technique included failure to prime the 
inhaler device correctly (e.g. priming Turbohaler in the vertical position, priming 
Accuhaler during rather than before inhalation), incorrect inspiratory flow, and 
poor coordination. 
 
5.3.2.5 Classification of inhaler technique  
Inhaler technique was assessed for patients in both the PI and UC groups using 
the same checklists (Appendix 8) and was classified as optimal (no errors 
made), satisfactory (some minor errors, but no critical errors), or as 
unsatisfactory (at least one critical error) (Basheti et al., 2005, Basheti et al., 
2014). Based on this categorising system, less than half of patients across both 
study groups had optimal inhaler technique using pMDI and Turbohaler devices 
at baseline. More patients had optimal inhaler technique using Accuhaler 
devices than with Turbohaler or pMDI devices (58.8% vs. 46.9% and 17.6%, 
respectively). 
 
Significantly more patients in the PI group compared to the UC group were 
assessed to be using their prescribed pMDI and Turbohaler inhalers with an 
unsatisfactory technique at baseline (pMDI: 17/17 vs. 10/17; Chi-Square 8.815, 
p=0.012; Turbohaler: 12/17 vs. 3/15; Chi-Square 8.977, p=0.011). There was 
no significant difference in baseline assessment of inhaler technique for other 
devices between participants in the PI group and UC group, although low use of 
alternative devices is likely to have contributed to this. 
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After education by the pharmacist within the PI group, or clinic nurse in the UC 
group, the proportion of patients who achieved optimal technique increased for 
the commonly used inhaler devices pMDI, Accuhaler and Turbohaler (Figure 
9). A statistically significant increase in the proportion of patients with optimal 
inhaler technique was observed for pMDI and Turbohaler devices in the PI 
group, but only for the pMDI device in the UC group. In the PI group, the 
proportion of patients who had optimal inhaler technique after education 
increased from 0% to 70.6% for pMDI (Fisher’s Exact Test 18.545, p<0.001), 
58.3% to 92.3% for Accuhaler (Fisher’s Exact Test 3.949, p=0.073), and from 
29.4% to 88.2% for Turbohaler (Fisher’s Exact Test 12.143, p=0.001). Similarly 
in the UC group, the proportion of patients who had optimal inhaler technique 
after education increased from 35.3% to 82.4% for pMDI (Fisher’s Exact Test 
7.771, p=0.005), 60.0% to 100.0% for Accuhaler (Fisher’s Exact Test 2.50, 
p=0.444), and from 66.7% to 80.0% for Turbohaler (Fisher’s Exact Test 0.682, 
p=0.682). 
 
Despite education, a significant proportion of patients persisted in being 
assessed as having unsatisfactory inhaler technique, including pMDI (29.4% 
and 17.6% in the PI and UC groups respectively), Accuhaler (7.7% in the PI 
group), and Turbohaler (5.9% and 6.7% in the PI and UC groups respectively). 
 
5.3.2.6 Preference 
All patients in the PI group were trained in the use of Accuhaler, Easi-Breathe, 
Easyhaler, HandiHaler, pMDI, Respimat and Turbohaler devices, and asked to 
rank each device in order of preference, and two scoring systems used to 
evaluate overall patient preference. 
 
Preference based on the method used in one independent patient preference 
study (each patient’s first choice device scores 3 points, second choice scores 2 
points and third choice scores 1 point, then the points added to give an overall 
score and ranking (Lenney et al., 2000)) demonstrated that the overall preferred 
inhaler device was the Easi-Breathe, followed by pMDI and Turbohaler (see 
Table 9). Devices that were not frequently used prior to the study such as 
Respimat, HandiHaler and Easyhaler scored poorly, despite the fact that Easi-
Breathe devices were also infrequently used. 
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The alternative preference scoring system used in this study (each patient’s first 
choice devices scores 7 points, second choice scores 6 points, third choice 
scores 5 points, fourth choice scores 4 points, fifth choice scores 3 points, sixth 
choice scores 2 points, seventh choice scores 1 point, then the points added to 
give an overall score and ranking. This method ranked inhaler devices in similar 
order of preference to the Lenney method, although Turbohaler scored slightly 
higher than pMDI (Table 10). Of the three least preferred devices, this method 
may more accurately demonstrate that HandiHaler was the least preferred 
device compared to Respimat and Easyhaler device in contrast to the Lenney 
method. 
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Figure 6. Peak inspiratory flow rate through inhaler devices before and after education at baseline.  
PI, pharmacist intervention group (bold lines); UC, usual care group (dashed lines); pMDI, pressurised metered dose inhaler (target 
inspiratory flow 25-60 L/min); Accuhaler (target inspiratory flow 30-90 L/min); Turbohaler (target inspiratory flow 30-90 L/min); HandiHaler 
(target inspiratory flow 20-60 L/min); Easi-Breathe (target inspiratory flow 20-60 L/min). *Improvement in peak IFR for pMDI PI p<0.001.
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Figure 7. Effect of education on the number of patients with correct peak inspiratory flow rate through inhaler devices at 
baseline.  
PI, pharmacist intervention group; UC, usual care group; pMDI, pressurised metered dose inhaler; Acc, Accuhaler; TH, Turbohaler; HH; 
HandiHaler; EB, Easi-Breathe. 
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Figure 8. Effect of education on inhaler technique score (% of each step performed correctly) at baseline, before and after 
education for the three most commonly used inhaler devices.  
(Data for all inhaler devices are presented in Figure 20, Appendix 14). PI, pharmacist intervention group; UC, usual care group; pMDI, 
pressurised metered dose inhaler; Acc, Accuhaler; TH, Turbohaler; HH. Improvements in inhaler technique assessed using Wilcoxon 
test.  
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Figure 9. Effect of education on the proportion of patients with optimal, satisfactory, or unsatisfactory inhaler technique at 
baseline for the three most commonly used inhaler devices.  
(Data for all inhaler devices are presented in Figure 21, Appendix 15). Optimal technique is defined as no errors using inhaler device; 
satisfactory inhaler technique is defined as making some minor but no critical errors; unsatisfactory inhaler technique is defined as 
making at least one critical error. PI, pharmacist intervention group; UC, usual care group; pMDI, pressurised metered dose inhaler; Acc, 
Accuhaler; TH, Turbohaler.  
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Table 9. Inhaler preference using previously published scoring methods 
(Lenney et al., 2000). 
 
Order of Preference 
Total Score Rank First Second Third 
Easi-Breathe 4 6 6 30 1 
pMDI 6 3 3 27 2= 
Turbohaler 5 3 6 27 2= 
Accuhaler 4 4 2 22 4 
Respimat 4 1 4 18 5 
HandiHaler 3 3 1 16 6= 
Easyhaler 0 6 4 16 6= 
 
 
Table 10. Inhaler preference using alternative preference scoring system. 
 
Order of Preference Total 
Score Rank First Second Third Fourth Fifth Sixth Seventh 
Easi-
Breathe 4 6 6 0 5 1 4 115 1 
Turbohaler 5 3 6 3 3 3 3 113 2 
pMDI 6 3 3 3 5 3 3 111 3 
Accuhaler 4 4 2 5 4 3 4 104 4 
Easyhaler 0 6 4 8 2 3 2 102 5 
Respimat 4 1 4 3 3 7 3 92 6 
HandiHaler 3 3 1 4 4 5 6 88 7 
 
5.3.3 Targeted MURs  
All 26 patients recruited to the PI group were referred to their community 
pharmacy for a t-MUR, but only six (23%) actually received one, at a mean 60 
days (range 28 – 143 days) following randomisation. In addition, one patient in 
the UC group received a MUR 178 days after randomisation, despite both the 
patient and community pharmacist being requested verbally and in writing not to 
provide one during the study.  
 
Explanations from community pharmacists and patients for the protocol 
deviation contrasted considerably. The community pharmacist admitted not 
arranging a t-MUR on four occasions, in one case because they claimed not to 
have received a written referral form. Eleven community pharmacists blamed 
the patient, either for not attending (10 occasions) or for not asking for a t-MUR 
(one occasion). Seven community pharmacists were unable to explain the 
protocol deviation. In contrast, patients blamed their community pharmacist for 
the lack of t-MUR, with 11 stating that their pharmacist did not arrange a t-MUR 
and one that the community pharmacist declined to perform a t-MUR stating 
that “that they couldn't do anything more than the pharmacist in the asthma 
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clinic”. Four patients admitted fault, explained that they had insufficient time to 
attend, forgot, were unwell, or were unsure how to request a t-MUR. Two 
patients were unable to explain the failure to have a t-MUR. 
 
The six patients in the PI group who received a t-MUR received a total of 11 
interventions, comprising reinforcement of correct inhaler technique (n=4), 
education on medication or adherence (n=3), healthy living advice (n=2), and 
management of side effects (n=2). The one patient in the UC group who had a 
t-MUR received education on their medication. 
 
 
5.4 Effect of pharmacist interventions on asthma control 
5.4.1 Asthma control questionnaire 
The primary outcome measure in the study was improvement in asthma control 
as measured using ACQ (Juniper et al., 1999b). The effect of pharmaceutical 
care in the PI group was found to be non-inferior to medical management in the 
UC group. At six months, the median (IQ) ACQ score had reduced from 2.86 
(2.25, 3.25) and 3.00 (1.96, 3.71) in the PI and UC groups respectively to 2.57 
(1.75, 3.67) and 2.29 (1.50, 3.50). This reflects a small improvement in asthma 
control (Figure 10), but this was not clinically or statistically significant in either 
the PI (Wilcoxon -0.870, p=0.931) or UC groups (Wilcoxon -1.150, p=0.250).  
 
There was no difference between the two groups in the proportion of 
participants who had controlled asthma (defined as an ACQ <1.0 (Juniper et al., 
2006)) at either baseline or follow-up. At baseline, one patient in each study 
group had controlled asthma (χ2 0.000, p=1.000; Fisher’s Exact Test), and at 
follow up, 1 participant in the PI group and 2 in the UC group had controlled 
asthma (χ2 0.517, p=0.592; Fisher’s Exact Test).  
 
ACQ data at both baseline and follow-up were available for 45 participants. 
Eight and 13 patients in the PI and UC groups respectively experienced a 
reduced ACQ (improved asthma control), whilst 13 and six patients respectively 
experienced a raised ACQ (worsening asthma control), but this was not 
statistically significant (χ2 3.786, p=0.151). Of these patients, four in each group 
achieved a clinically important improvement in asthma control (defined as a 
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reduction in ACQ >0.5 points), whilst four in the PI group and three in the UC 
group experienced a clinically important worsening in asthma control (χ2 0.077, 
p=0.962). 
 
Sub-group analysis for the six participants in the PI group who had a t-MUR 
showed that they did not have a significantly different asthma control than those 
who did not receive a t-MUR at baseline or at 6-month follow-up. 
 
5.4.2 Other markers of asthma control 
Participants in both the PI and UC groups required fewer corticosteroid rescue 
courses and used fewer doses of SABA reliever inhaler each week at follow up 
compared to baseline, however there was no significant difference between the 
two treatment arms at either baseline or follow-up (Table 11). 
 
Reductions in FeNO were observed in both groups, but values were not 
statistically significant between groups. Lung function measures were stable 
throughout the study, and hospital admissions and A&E visits remained 
uncommon (Table 11).  
 
There was no significant effect on median (IQ) equivalent beclometasone-CFC 
daily dose in either the PI (from 1600 (800, 2000) to 1800 (1150, 2000) 
micrograms) or UC groups (from 2000 (800, 2000) to 1600 (800, 2000) 
micrograms). Smoking status remained stable with three current smokers in the 
PI group at baseline and 6 months, compared to three at baseline and four at 6 
months in the UC group.  
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Figure 10. Change in median asthma control questionnaire score during study.  
PI, pharmacist intervention group; UC, usual care group. 
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Table 11. Effects of interventions on measures of asthma control. 
Outcome Measure 
Intervention 
Arm 
0 Months 
(n=52) 
Difference between PI and UC 
groups at baseline 6 Months 
(n=45) 
Difference between PI and UC 
groups at follow-up 
Mann- 
Whitney 
p value Mann- Whitney p value 
ACQ (median, IQ) 
PI 2.86 (2.25, 3.25) 
333.000 0.927 
2.57 (1.75, 3.67) 
219.000 0.452 
UC 3.00 (1.96, 3.71) 2.29 (1.50, 3.50) 
Exhaled Nitric Oxide 
(median, IQ) 
PI 38.0 (19.0, 70.75) 
110.000 0.693 
29.0 (14.0, 58.0) 
140.500 0.707 
UC 27.0 (14.0, 67.0) 19.5 (14.0, 55.25) 
% Predicted FEV1 
(mean (SD))  
PI 72.92 (20.06) 
0.432* 0.668 
69.59 (20.02) 
-0.575* 0.568 
UC 70.57 (18.41) 72.61 (15.07) 
FEV1/FVC (mean (SD))  
PI 69.46 (11.05) 
0.079* 0.937 
67.12 (13.31) 
-0.890* 0.378 
UC 69.21 (10.61) 70.19 (9.68) 
Steroid courses in 
previous 3 months 
(median, IQ) 
PI 2.0 (1.0, 3.0) 
266.500 0.179 
0.0 (0.0, 2.0) 
256.500 0.857 
UC 1.0 (0.0, 2.0) 0.0 (0.0, 2.0) 
Hospital admissions in 
previous 3 Months 
(median, IQ) 
PI 0.0 (0.0, 1.0) 
327.000 0.819 
0.0 (0.0, 0.0) 
232.500 0.194 
UC 0.0 (0.0, 1.0) 0.0 (0.0, 1.0) 
Number of puffs of 
SABA per week 
(median, IQ) 
PI 49.0 (33.25, 64.75) 
328.000 0.854 
42.0 (15.75, 56.0) 
275.000 0.983 
UC 45.5 (12.5, 90.5) 35.0 (28.0, 63.0) 
PI, pharmacist intervention group; UC, usual care group; ACQ, asthma control questionnaire score; FEV1, forced expiratory volume in 
one second; FVC, forced vital capacity; IQ, interquartiles; SD, standard deviation; *, independent Samples T test used.  
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Table 12. Effect of interventions on asthma quality of life measures. 
Outcome Measure 
Intervention 
Arm 
0 Months 
(n=52) 
Difference between PI and UC 
groups at baseline 6 Months 
(n=47) 
Difference between PI and UC 
groups at follow-up 
Mann-Whitney p value  Mann-Whitney p value  
AQLQ(S) (median, IQs) 
PI 4.11 (3.38, 5.21) 
310.500 0.615 
4.12 (3.55, 5.49) 
269.000 0.882 
UC 3.77 (2.87, 5.30) 4.22 (2.97, 5.66) 
 AQLQ-Symptoms 
(median, IQs) 
PI 3.75 (2.89, 5.73) 
322.000 0.770 
4.00 (3.42, 5.27) 
266.000 0.831 
UC 3.67 (3.06, 5.13) 4.17 (2.92, 5.58) 
 AQLQ-Activity 
Limitations (median, 
IQs) 
PI 4.41 (3.64, 5.52) 
290.000 0.379 
4.50 (3.48, 5.91) 
247.500 0.544 
UC 4.23 (2.91, 5.89) 4.47 (2.91, 6.36) 
 AQLQ-Emotional 
Function (median, 
IQs) 
PI 3.90 (2.80, 5.10) 
296.500 0.447 
3.80 (3.00, 5.10) 
242.000 0.468 
UC 4.20 (3.10, 5.50) 4.60 (3.20, 5.40) 
 AQLQ-Environmental 
Stimuli (median, IQs) 
PI 4.50 (3.69, 5.25) 
300.000 0.486 
4.63 (3.75, 5.69) 
238.500 0.424 
UC 4.25 (3.00, 6.63) 4.25 (3.00, 6.00) 
PI, pharmacist intervention group; UC, usual care group; AQLQ(S), standardised asthma quality of life questionnaire; IQ, interquartiles.  
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Figure 11. Profile of the population (%) reporting problem, using EQ-5D-5L questionnaire.  
PI, pharmacist intervention group; UC, usual care group. 
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5.5 Quality of life 
5.5.1 Asthma quality of life 
At six-months, the effect of pharmaceutical care in the PI group on asthma 
quality of life, using Juniper’s standardised asthma quality of life questionnaire 
(AQLQ(S)) (Juniper et al., 1999a), was found to be non-inferior to medical 
management in the UC group. Similarly pharmacist management was non-
inferior to usual medical care in all four individual domains of the AQLQ(S), 
including symptoms, activity limitation, emotional function and environmental 
stimuli (Table 12).  
 
On average, participants in both groups reported to be very limited or have 
moderate limitation in their quality of life and within all domains, at both baseline 
and follow-up. At baseline, the median (IQ) AQLQ(S) score was 4.11 (3.38, 
5.21) and 3.77 (2.87, 5.30) in the PI and UC groups respectively, and at follow-
up was 4.12 (3.55, 5.49) and 4.22 (2.97, 5.66) respectively, and was not 
statistically different between the two groups at either baseline (Mann-Whitney 
310.5, p=0.615) or follow-up (Mann-Whitney 269.0, p=0.882). 
 
Of the 47 participants who completed the study and had baseline and follow-up 
data available, an improvement in AQLQ(S) was found in 11 and 14 participants 
in the PI and UC group respectively, whilst a worsening was found in 12 and 8 
participants respectively. There was no significant difference between the two 
study groups (χ2 1.139, p=0.566). A clinically important improvement in quality 
of life (defined as an increase in AQLQ(S) score of >0.5 units) was found in six 
and five participants in the PI and UC groups respectively, whilst a clinically 
important worsening in quality of life (decrease in AQLQ(S) score of >0.5 units) 
was found in three participants in each group. There was no significant 
difference between the two study groups (χ2 0.070, p=0.966). 
 
Sub-group analysis of participants in the PI group who had a t-MUR did not 
demonstrate any significant effect of quality of life compared to those who did 
not have a t-MUR. 
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5.5.2 General health status  
Health status, as measured using the EQ-5D-5L questionnaire demonstrated no 
differences in the proportion of participants in the PI and UC groups reporting 
problems within each of the five dimensions of the questionnaire (mobility, self-
care, usual activities, pain/discomfort and anxiety/depression) at either baseline 
or at follow-up using Chi-Square analysis. At six months, a small decrease in 
the proportion of participants reporting problems with mobility was observed in 
both groups, but slightly more participants reported problems with pain and self-
care. In contrast, whilst there were small increases in the proportion of 
participants reporting problems with usual activities and anxiety/depression in 
the PI group, the opposite was observed in the UC group (Figure 11).  
 
The mean self-rated health status, as measured using the EQ VAS was similar 
at baseline in both study groups (Table 13), and improved similarly over 6-
months in both study groups, but was not statistically significant (mean (SD) 
increase in EQ VAS was 1.88 (19.43) and 3.89 (15.38) in the PI and UC groups 
respectively; independent samples test -0.0396, p=0.694).  
 
Table 13. EQ VAS values. 
 PI UC 
 0 Months 
(n=26) 
6 Months 
(n=24) 
0 Months 
(n=25) 
6 months 
(n=23) 
Mean 60.96 62.72 63.48 66.59 
SD 16.972 19.866 17.093 13.979 
PI pharmacist intervention group; UC, usual care group; SD, standard deviation. 
 
 
5.6 Inhaler technique 
5.6.1 Inspiratory flow 
Inhaler technique education during the baseline consultation improved the IFR 
though different devices amongst participants in the PI group, in particular for 
those using the pMDI device, and also increased the number of patients who 
achieved the correct IFR. Six-months after the intervention, there was a large 
clinically important and statistically significant increase in the median (IQ) peak 
IFR through pMDI devices of 35.0 (21.3, 85.0) L/min (Wilcoxon -3.413, p=0.001) 
in the PI group and 80.0 (20.0, 107.5) L/min (Wilcoxon -2.971, p=0.003) in the 
UC group. There was a similarly large increase in the peak IFR through Easi-
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Breathe inhalers from a median of 50 and 70 L/min to 55 and 92.5 L/min in the 
PI and UC groups respectively, but did not reach statistical significance 
(Wilcoxon -0.447,  P=0.655 and Wilcoxon -1.342, p=0.180 respectively) due to 
low numbers of participants using these devices. In addition, there was also a 
small, but statistically significant, reduction in the median peak IFR through 
Turbohaler devices -5.0 (-21.3, 0.0) L/min (Wilcoxon -2.002, p=0.045) and -7.5 
(-20.0, 1.3) L/min (Wilcoxon -2.175, p=0.030) in the PI and UC groups 
respectively. There was no significant change in the peak IFR over 6-months for 
participants in the PI group using Accuhaler or HandiHaler devices, but in the 
UC group there was a large increase in the median IFR through Accuhaler 
devices of 42.5 (5.0, 65.0) L/min (Wilcoxon -1.461, p=-0.144), which was not 
statistically significant due to low patient numbers using this device (Figure 12). 
 
These changes in IFR over the 6-month study duration was clinically important 
for pMDI devices, since was associated with a large reduction in the number of 
patients who were using this inhaler at the correct IFR (from 15 to 2 participants 
in the PI group and from 10 to 3 participants in the UC group). The observed 
increases in IFR through dry powder devices had no impact on the number of 
participants using these inhaler devices at the correct IFR (Figure 13). 
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Figure 12. Change in median peak inspiratory flow rate through inhaler devices.  
PI, pharmacist intervention group (bold lines); UC, usual care group (dashed lines); pMDI, pressurised metered dose inhaler (target 
inspiratory flow 25-60 L/min); Accuhaler (target inspiratory flow 30-90 L/min); Turbohaler (target inspiratory flow 30-90 L/min); HandiHaler 
(target inspiratory flow 20-60 L/min); Easi-Breathe (target inspiratory flow 20-60 L/min). Change in peak IFR between baseline and 6-
month follow-up; *pMDI PI p=0.001; †pMDI UC p=0.003; ‡Turbohaler PI p=0.045; **Turbohaler UC p=0.030 
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Figure 13. Effect of the intervention on the number of patients maintaining correct peak inspiratory flow rate through inhaler 
devices.  
PI, pharmacist intervention group; UC, usual care group; pMDI, pressurised metered dose inhaler; Acc, Accuhaler; TH, Turbohaler; HH; 
HandiHaler; EB, Easi-Breathe. 
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5.6.2 Inhaler technique score  
Although inhaler technique (calculated as the percentage of all steps completed 
correctly) improved with education at the baseline consultation, this was not 
maintained during the 6-month study for all inhaler devices (Figure 14). In 
particular, the mean (SD) inhaler technique score was significantly worse for 
pMDI at 6-months compared to the baseline score after education for 
participants in both the PI and UC groups (-9.09% (8.13); Wilcoxon -3.025, 
p=0.002, and -9.09% (15.68); Wilcoxon -2.032, p=0.042 respectively), and for 
Turbohaler device in UC patients (-5.71% (7.56); Wilcoxon -2.309, p=0.021). 
Inhaler technique scores at 6 months were higher for dry powder inhalers than 
for aerosol inhalers. The highest mean (SD) scores were observed in 
participants using Turbohaler devices (95.38% (7.76) and 92.86% (7.26) in the 
PI and UC groups respectively), followed by Accuhaler devices (94.02% (13.31) 
and 91.11% (12.17) in the PI and UC groups respectively). The mean (SD) 
score for pMDI devices was lower at 88.24% (6.24) and 83.77% (10.20) 
respectively (Table 14). 
 
Participants in the PI group who had a t-MUR and reinforcement of inhaler 
technique did not have a significantly different inhaler technique score from 
participants in the UC group, indicating no additive benefit from the t-MUR. 
 
5.6.3 Classification of inhaler technique 
The proportion of patients with optimal inhaler technique at baseline was poor 
for all devices prescribed to individual participants, but education during the 
initial consultation resulted in the majority achieving optimal technique. At two 
and six months, the proportion of participants with optimal inhaler technique 
was not maintained (Figure 15). This was particularly so for the three most 
commonly prescribed inhaler devices: pMDI, Accuhaler and Turbohaler. In 
these cases the initial percentage of participants with optimal inhaler technique 
increased with education at the baseline consultation from 0% to 70.6%, 58.3% 
to 92.3% and 29.4% to 88.2% respectively. At 2-months, in those patients who 
had a t-MUR, there were 0% and 25% who had optimal inhaler technique with 
pMDI and Turbohaler devices. At six months, the percentage of patients with 
optimal inhaler technique was 6.3%, 75% and 71.4% for pMDI, Accuhaler and 
Turbohaler devices (Table 15). At 6-months, there was no statistically 
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significant difference in the proportion of participants in the PI and UC group 
who had optimal inhaler technique for pMDI (χ2 0.010, p=1.000; Fisher’s Exact 
Test), Accuhaler (χ2 0.383, p=0.600; Fisher’s Exact Test) or Turbohaler (χ2 
2.333, p=0.252; Fisher’s Exact Test). 
 
Similar to the inhaler technique score, sub-group analysis did not demonstrate 
any significant effect on the proportion of participants with optimal inhaler 
technique after having a t-MUR. 
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Figure 14. Effect of education on inhaler technique score (% of each step performed correctly) throughout study, for the three 
most commonly used inhaler devices.  
(Data for all inhaler devices are presented in Figure 22, Appendix 16). PI, pharmacist intervention group; UC, usual care group; pMDI, 
pressurised metered dose inhaler; Acc, Accuhaler; TH, Turbohaler. Improvements in inhaler technique assessed using Wilcoxon test. 
Change in inhaler technique score from baseline to six-month follow-up: *pMDI PI p=0.002; †pMDI UC p=0.042; ‡TH UC p=0.021 
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Table 14. Effect of education on inhaler technique score (% of each step performed correctly) throughout study. 
Inhaler 
Device 
Intervention 
Arm 
0 Months (before 
education) 
0 Months (after education) 2 Months (t-MUR) 6 Months (Follow-up) 
n % (SD) Score n % (SD) Score n % (SD) Score n % (SD) Score 
pMDI 
PI 17 80.30 (7.38) 17 97.33 (4.27) 2 54.55 (51.43) 17 88.24 (6.24) * 
UC 17 80.21 (24.32) 17 95.72 (10.22) 0 n/a 14 83.77 (10.20) † 
Acc 
PI 13 94.87 (7.34) 14 98.41 (5.94) 0 n/a 13 94.02 (13.31) 
UC 5 82.22 (25.58) 5 100.00 (0.00) 0 n/a 5 91.11 (12.17) 
TH 
PI 17 91.76 (6.36) 17 99.41 (2.43) 4 82.50 (17.08) 13 95.38 (7.76) 
UC 15 96.00 (6.32) 15 98.67 (3.52) 0 n/a 14 92.86 (7.26) ‡ 
HH 
PI 4 94.23 (7.36) 4 96.92 (6.88) 2 76.93 (21.76) 5 98.46 (3.44) 
UC 1 84.62 1 100 0 n/a 1 92.31 
EB 
PI 2 83.34 (7.86) 2 94.45 (7.86) 1 88.89 2 94.45 (7.86) 
UC 2 94.45 (7.86) 2 94.45 (7.86) 0 n/a 2 83.34 (7.86) 
EH 
PI 1 100.00 3 93.33 (5.77) 1 90 2 90.00 (14.14) 
UC 0 n/a 0 n/a 0 n/a 0 n/a 
MDISS 
PI 2 92.86 (0.00) 2 100.00 (0.00) 1 85.71 1 100 
UC 0 n/a 0 n/a 0 n/a 0 n/a 
MDISM 
PI 1 85.71 1 100 1 92.86 2 100.00 (0.00) 
UC 1 100.00 1 100 0 n/a 1 78.57 
RSP 
PI 0 n/a 0 n/a 0 n/a 0 n/a 
UC 2 40.00 (28.28) 2 40.00 (28.28) 0 n/a 1 100 
PI, pharmacist intervention group; UC, usual care group; pMDI, pressurised metered dose inhaler; Acc, Accuhaler; TH, Turbohaler; HH; 
HandiHaler; EB, Easi-Breathe; EH, Easyhaler; MDISS, pMDI + spacer (single-breath method); MDISM, pMDI + spacer (multiple-breath 
method); RSP, Respimat. *,p=0.002 vs. 0 months (after education); †, p=0.042 vs. 0 months (after education); ‡, p=0.021 vs. 0 months 
(after education).Improvements in inhaler technique assessed using Wilcoxon test. 
 
 
 
  
1
4
9
 
 
Figure 15. The proportion of patients with optimal, satisfactory, or unsatisfactory inhaler technique throughout the 6-month 
study, for the three most commonly used inhaler devices.  
(Data for all inhaler devices are presented in Figure 23, Appendix 17). Optimal technique is defined as no errors using inhaler device; 
satisfactory inhaler technique is defined as making some minor bur no critical errors; unsatisfactory inhaler technique is defined as 
making at least one critical error. PI, pharmacist intervention group; UC, usual care group; pMDI, pressurised metered dose inhaler; Acc, 
Accuhaler; TH, Turbohaler.  
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Table 15. The number of patients with optimal, satisfactory, or unsatisfactory inhaler technique throughout the 6-month study 
Treatment 
Arm 
Device Time Number of 
Participants 
Assessed 
Unsatisfactory 
Inhaler Technique 
Satisfactory Inhaler 
Technique 
Optimal Inhaler 
Technique 
n % n % n % 
PI 
pMDI 
0 Months (Before Education) 17 17 100.0% 0 0.0% 0 0.0% 
0 Months (After education) 17 5 29.4% 0 0.0% 12 70.6% 
2 Months (t-MUR) 2 0 0.0% 2 100.0% 0 0.0% 
6 Months (Follow-Up) 16 15 93.8% 0 0.0% 1 6.3% 
Accuhaler 
0 Months (Before Education) 12 4 33.3% 1 8.3% 7 58.3% 
0 Months (After education) 13 1 7.7% 0 0.0% 12 92.3% 
2 Months (t-MUR) 0 0 n/a 0 n/a 0 n/a 
6 Months (Follow-Up) 12 3 25.0% 0 0.0% 9 75.0% 
Turbohaler 
0 Months (Before Education) 17 12 70.6% 0 0.0% 5 29.4% 
0 Months (After education) 17 1 5.9% 1 5.9% 15 88.2% 
2 Months (t-MUR) 4 0 0.0% 3 75.0% 1 25.0% 
6 Months (Follow-Up) 14 4 28.6% 0 0.0% 10 71.4% 
UC 
pMDI 
0 Months (Before Education) 17 10 58.8% 1 5.9% 6 35.3% 
0 Months (After education) 17 3 17.6% 0 0.0% 14 82.4% 
2 Months (t-MUR) 0 0 n/a 0 n/a 0 n/a 
6 Months (Follow-Up) 14 13 92.9% 0 0.0% 1 7.1% 
Accuhaler 
0 Months (Before Education) 5 2 40.0% 0 0.0% 3 60.0% 
0 Months (After education) 5 0 0.0% 0 0.0% 5 100.0% 
2 Months (t-MUR) 0 0 n/a 0 n/a 0 n/a 
6 Months (Follow-Up) 5 2 40.0% 0 0.0% 3 60.0% 
Turbohaler 
0 Months (Before Education) 15 3 20.0% 2 13.3% 10 66.7% 
0 Months (After education) 15 1 6.7% 2 13.3% 12 80.0% 
2 Months (t-MUR) 0 0 n/a 0 n/a 0 n/a 
6 Months (Follow-Up) 14 8 57.1% 0 0.0% 6 42.9% 
Optimal technique is defined as no errors using inhaler device; satisfactory inhaler technique is defined as making some minor bur no critical errors; unsatisfactory 
inhaler technique is defined as making at least one critical error. PI, pharmacist intervention group; UC, usual care group; pMDI, pressurised metered dose inhaler; 
Acc, Accuhaler; TH, Turbohaler; EB, Easi-Breathe; EH, Easyhaler; HH; HandiHaler; RSP, Respimat; MDISM, pMDI + spacer (multiple-breath method); MDISS, 
pMDI + spacer (single-breath method).
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5.7 Adherence 
5.7.1 Patient reported adherence compared to prescription data 
Four patients in the PI group self-reported poor adherence, whilst all other 
patients in the PI and UC groups reported no problems with adherence, but this 
was not supported by prescription data from GP and hospital records.  
 
Based on analysis of prescription data for 40 participants where this was 
available over a six-month period prior to randomisation, median (IQ) 
adherence rate to ICS (defined as the percentage of prescribed doses issued 
compared to expected prescribed number of doses required over a six-month 
period) was 75.30% (35.71, 98.51), and ranged from 5% to 600%. This was not 
significantly different between the two study arms. 57.5% of patients had 
adherence rates less than 80%, 35% had adherence rates less than 50%. 
17.5% of participants had adherence rates exceeding 100%, of whom 6 (15%) 
had adherence rates exceeding 120% (Figure 16). 
 
Although the proportion of patients with adherence rates 80-100% increased in 
the PI group compared to the UC group, this was not significantly different at 
either baseline (6/19 and 4/21 participants respectively; χ2 0.835, p=0.473; 
Fisher’s Exact Test), or at the 6-month follow-up visit (8/20 and 3/21 participants 
respectively; χ2 3.450, p=0.085; Fisher’s Exact Test). However specifying an 
upper limit of 100% may inappropriately suggest that some patients have been 
overusing their medicines, as some may have been proactive and obtained a 
repeat prescription early to prevent missed doses, such as to cover holidays. 
Consequently it may be appropriate to define good adherence as an adherence 
rate of 80-120% as this will include patients who may have received a 
prescription early, whilst excluding those who may be overusing their inhalers 
and have a very high adherence rate. Furthermore, previous pharmacist 
intervention studies have classified adherent patients as those taking 80-120% 
of preventer medication prescribed, although without explanation or discussion 
for this (Armour et al., 2007). When adherence rates of 80-120% were 
considered, a significantly greater proportion of participants in the PI group 
were classed as adherent at the 6-month follow-up visit compared to the UC 
group (10/20 vs. 3/21; χ2 6.034, p=0.020; Fisher’s Exact Test χ2). 
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5.7.2 Medication Adherence Report Scale (MARS) 
Self-reported adherence to ICS, measured using the MARS questionnaire 
(Horne and Weinman, 2002) demonstrated that whilst the mean MARS scores 
were high indicating self-reported good adherence (ranging from 3.88 to 4.96 
out of 5 for all questions), a relatively large percentage of patients admitted to 
some form of non-adherent behaviour (Table 16). Specifically, at baseline 
46.2% and 26.9% of PI and UC participants admitted to altering the dose of 
their ICS, 42.3% and 26.9% respectively admitted to taking more than 
instructed, and 11.5% of UC participants admitted to stopping their ICS for a 
while (Figure 17). 
 
This behaviour was not significantly different at the 6-month follow-up visit, with 
the exception that significantly more participants in the PI group admitted to 
stopping their ICS for a while (increased from a mean 0% to 12.5%; Wilcoxon -
2.264, p=0.024). 
 
5.7.3 Beliefs about Medicines Questionnaire (BMQ) 
The BMQ data (Table 17) demonstrate that the participants in the study had 
high levels of perception of the necessity for taking their asthma medications, as 
indicated by high mean (SD) scores in the BMQ-Specific Necessity sub-scale 
(mean score 20.69 (3.56) amongst all participants). Although there were some 
concerns about taking medicines (BMQ-Specific Concerns sub-scale mean 
score of 17.80 (4.84) in all patients), this was not reflected by concerns of 
overuse or harm from medicines, as indicated by a BMQ-General-overuse sub-
scale mean score 9.31 (2.64) and BMQ-General-harm sub-scale mean score of 
9.52 (2.52) in all patients. There were very few people who reported high levels 
of concerns about asthma medicines, with only four, one and two participants 
reporting high levels of concerns in the BMQ-Specific Necessity, BMQ-General-
overuse, and BMQ-General-harm sub-scales respectively at baseline. 
 
There was no significant difference in beliefs about medicines between 
participants in the two intervention arms, nor were there any differences in 
medication beliefs at follow-up. 
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Figure 16. Frequency of six-month adherence rates to inhaled corticosteroid inhalers in participants In the PI and UC groups.  
PI, pharmacist intervention group; UC, usual care group. 
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Table 16. Adherence to inhaled corticosteroid using MARS questionnaire. 
 
Type of non-adherent 
behaviour relating to 
ICS use 
Baseline Follow-up 
Mean (SD) score 
(range 1-5) 
(High scores indicates self-
reported good adherence) 
Percentage of sample 
admitting to non-adherent 
behaviour 
Mean (SD) score 
(range 1-5) 
(High scores indicates self-
reported good adherence) 
Percentage of sample 
admitting to non-adherent 
behaviour 
PI UC PI UC PI UC PI UC 
M1 I forget to take them 4.31 (0.74) 4.35 (1.04) 15.4% 19.2% 4.42 (0.72) 4.32 (1.04) 12.5% 18.2% 
M2 I alter the dose 3.92 (1.09) 4.27 (1.04) 46.2% 26.9% 4.08 (1.28) 4.14 (1.04) 25.0% 36.4% 
M3 
I stop taking them for a 
while 
4.96 (0.20) 4.65 (0.69) 0.0% 11.5% 4.54 (0.98) 4.82 (0.59) 12.5% 9.1% 
M4 
I decide to miss out a 
dose 
4.73 (0.60) 4.85 (0.46) 7.7% 3.8% 4.38 (1.25) 4.82 (0.40) 13.0% 0.0% 
M5 I take less than instructed 4.96 (0.20) 4.81 (0.49) 0.0% 3.8% 4.71 (0.62) 4.82 (0.50) 8.3% 4.5% 
M6 
I take more than 
instructed 
3.88 (1.40) 4.27 (1.04) 42.3% 26.9% 4.08 (1.21) 4.43 (0.99) 29.2% 17.4% 
PI, pharmacist intervention group; UC, usual care group; SD, standard deviation. 
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Table 17. Beliefs about medicines questionnaire (BMQ) results. 
BMQ Scale Sub-scale 
Baseline Mean (SD) score  Follow-up Mean (SD) score  
PI UC PI UC 
BMQ-Specific 
Necessity 
(range 5-25) 
20.64 (2.56) 20.73 (4.36) 21.13 (3.10) 20.64 (3.42) 
Concerns 
(range 6-30) 
18.64 (5.21) 17.00 (4.41) 18.00 (5.67) 16.78 (3.91) 
BMQ-General 
General-overuse 
(range 4-20) 
9.48 (2.35) 9.15 (2.94) 9.46 (2.38) 7.96 (2.57) 
General-harm 
(range 4-20) 
10.04 (2.74) 9.33 (2.65) 9.88 (2.19) 9.14 (2.83) 
High scores in the BMQ necessity sub-scale indicates increased perception of necessity of medicines. High scores in the BMQ concerns, 
general-overuse and general-harm subscales indicate negative perceptions of medicines. PI, pharmacist intervention group; UC, usual 
care group. 
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Figure 17. Proportion of participants admitting to non-adherent behaviours at baseline and a follow-up, using the self-
administered MARS questionnaire.  
PI, pharmacist intervention group; UC, usual care group. 
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5.8 Effect of adherence on asthma outcomes 
As adherence was so variable amongst participants in both the PI and UC 
groups, an analysis was performed to examine whether there was an 
association between adherence to ICS and either asthma control or asthma 
quality of life. Since there was no significant difference between asthma control 
or quality of life in participants randomised to either the PI or UC group, the 
results for both study groups were combined for subsequent analyses. 
Adherence data were available for 36 participants who also had ACQ data at 6-
months, and for 37 participants who also had AQLQ(S) data at 6-months. 
 
Bivariate correlation found no significant relationship between adherence and 
either asthma control (Spearman’s rho 0.188, p=0.271) or asthma quality of life 
(Spearman’s rho 0.108, p=0.537) at six-months. Scatter plot graphs of 
adherence to maintenance ICS during the six-month study demonstrate clearly 
this lack of correlation with either asthma control, measured using ACQ (Figure 
18), or quality of life, measured using AQLQ(S) (Figure 19) at 6-months, with 
the R Square statistic demonstrating that adherence may explain only 5.1% and 
1.3% of the variability in ACQ and AQLQ(S) respectively. 
 
There was no significant difference between the proportions of participants who 
had good adherence (defined as taking 80-120% of ICS doses) to those who 
were non-adherent to ICS who achieved improvements in asthma control (5/13 
and 13/23 respectively; χ2 1.926, p=0.382), or asthma quality of life (7/13 and 
13/23 respectively; χ2 0.581, p=0.748). 
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Figure 18. Scatter plot of adherence to ICS during the study and effect on asthma control, measured using ACQ at the end of 
the study.  
ACQ, asthma control questionnaire; ICS, inhaled corticosteroid. 
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Figure 19. Scatter plot of adherence to ICS during the study and effect on asthma quality of life, measured using AQLQ(S) at the 
end of the study.  
AQLQ(S), standardised asthma quality of life questionnaire; ICS, inhaled corticosteroid. 
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6 Discussion 
6.1 Discussion of results 
As outlined in the introduction, there is a lack of research investigating the role 
of pharmacists in managing the care of patients with difficult asthma, and this is 
the first study to investigate the effects of a redesigned pharmaceutical pathway 
across the primary and secondary care interface in patients with difficult 
asthma. 
 
The results of this study demonstrates that the management of patients with 
difficult asthma through the provision of pharmaceutical care from hospital-
based advanced clinical pharmacists is non-inferior to usual medical care in all 
asthma outcomes measured, including asthma control, quality of life, inhaler 
technique and overall adherence. Both the PI and UC groups were successful 
in stabilising asthma control and quality of life, with low rates of exacerbations 
and hospital admissions. Although overall adherence rates were similar in the 
PI and UC groups, there was a significantly greater increase in the proportion of 
patients in the PI group who had adherence rates 80-120% than in the UC 
group over the course of the study. 
 
These outcomes were achieved despite most participants in the PI arm failing to 
receive the full protocol intervention, with only six of 26 participants having a t-
MUR. Consequently few of the participants received any follow-up interventions 
as part of an MUR from community pharmacists to support and reinforce 
interventions performed during the initial baseline consultation performed by the 
hospital advanced clinical pharmacist. It is possible that study patients in both 
groups may have received additional interventions from their community 
pharmacist when collecting their dispensed prescription as part of routine 
practice. Data on this were not collected and so the extent to which this may 
have occurred is not known, nor whether this may have impacted on asthma 
control. However as MUR uptake was low, it is unlikely that a different service 
would have been provided to patients in the two groups and so the effects of 
any interventions performed would be unlikely to significantly affect the outcome 
measures in this study. 
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Potential explanations for the results of the study are discussed in this chapter, 
in order to understand how they may impact on clinical practice and to identify 
future areas for research. 
 
6.1.1 Asthma control measures  
The intention to treat results of the study demonstrate that the provision of 
pharmaceutical care from a hospital-based advanced clinical pharmacist was 
non-inferior to usual medical care for all asthma control measures including 
ACQ, exhaled nitric oxide, lung function, exacerbations and hospital 
admissions.  
 
As expected for patients with difficult asthma attending the hospital clinic, all 
participants met the criteria for uncontrolled difficult asthma, having a median 
duration of instability of 3.5 years, a high median ACQ of 2.86 in the PI group 
and 3.00 in the UC group (where an ACQ score ≥1.0 on a 0-6 scale indicates 
uncontrolled asthma). This was despite treatment at Step 4 or 5 of the 
BTS/SIGN asthma guidelines (British Thoracic Society and Scottish 
Intercollegiate Guidelines Network, 2014), and consequently patients required 
frequent OCS rescue courses (5.6 and 3.92 courses within the past 12 months 
respectively) and high use of SABA (49.0 and 45.5 puffs per week, 
respectively). Although participants randomised to the PI group had worse 
asthma control at baseline than those in the UC group, this difference was not 
statistically significant, and is unlikely to be clinically important. The study 
population was similar in all baseline characteristics to other difficult asthma 
populations reported in a UK multicentre registry of refractory asthma (Heaney 
et al., 2010), and so can be considered to be a representative sample, and thus 
the reported outcomes are relevant to UK practice.  
 
There was no significant change in asthma outcome measures at 6-months 
compared to baseline levels, reflecting that asthma control did not deteriorate in 
either study arm over the course of the study. Participants in the PI group also 
achieved a significant reduction in corticosteroid rescue courses and SABA 
usage over a 3-month period immediately preceding consultations at follow-up 
compared to baseline, but this was not significantly different from participants in 
the UC group. Similarly the FENO level was not significantly different between 
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study groups at baseline or at 6-months, and so this study does not provide 
further data on the value of FENO for monitoring difficult asthma. However it 
remains uncertain why no difference in FENO values were observed, but may 
have been due to recruitment of patients with specific asthma phenotypes that 
are less responsive to ICS therapies, or may be due to a lack of effect on ICS 
adherence resulting in patients not taking effective doses of ICS.  
 
Difficult asthma is a complex condition to manage because patients experience 
persistent symptoms and frequent exacerbations that may not be responsive to 
conventional asthma therapies, and there are many factors that may contribute 
to asthma-like symptoms (Barnes and Woolcock, 1998, British Thoracic Society 
and Scottish Intercollegiate Guidelines Network, 2014, Heaney et al., 2010). 
Consequently, the stabilisation of asthma control in both study groups, whilst 
reducing healthcare resource use in terms of rescue OCS courses and hospital 
admissions, can be regarded as a successful outcome (Sweeney et al., 2012, 
Heaney et al., 2010). 
 
Most patients in the PI group only received interventions from the hospital-
based advanced clinical pharmacist at the baseline consultation, as even for the 
six patients who received a t-MUR, very few new interventions were performed 
during these follow-up consultations. Therefore the majority of the impact from 
pharmacist interventions observed in this study may have been achieved only 
from the baseline consultation from the hospital-based advanced clinical 
pharmacist. This lack of follow-up interventions may have affected the asthma 
outcome results, although it is not clear whether these may have achieved 
additional benefit above the initial baseline consultation. The per protocol 
subgroup analysis of the six patients who received t-MUR failed to demonstrate 
any significant improvement in asthma outcomes compared to participants in 
the UC group, but this is likely to be because there were insufficient participants 
to ensure that this subgroup analysis was adequately powered to demonstrate 
any significant change in ACQ. Consequently although the current study adds 
new evidence on the effects of pharmaceutical care provided by a hospital 
specialist pharmacist it did not determine the effects of combined 
pharmaceutical care provided by primary and secondary care pharmacists. 
However the study does provide valuable learning about the challenges of 
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‘joining up’ pharmaceutical care, which can support the development of future 
study designs. 
 
The results of this study mirror those reported in the BREATHE study, which 
was a community pharmacy based interventional study that recruited a similar 
uncontrolled asthma patient population to the present study (Charrois et al., 
2006). In the BREATHE study, there was no detectable difference in asthma 
outcomes between the intervention and usual care group, despite being 
adequately powered to detect a significant difference in ACQ score between the 
two groups (Charrois et al., 2004). The authors believed this lack of 
demonstrated effect was due to an imbalance between the study groups, 
contamination of usual care and poor implementation of the intervention. The 
present study differs from the BREATHE study in that participants in the two 
arms were well balanced at baseline and more interventions were performed in 
the PI than in the UC group. Participants in the PI group received individualised 
interventions addressing their medication, inhaler technique, educational needs, 
associated medical conditions depending on their identified needs, whilst seven 
in the UC group received no intervention at all. A possible criticism of the 
interventions performed at baseline is that there was no consistency in the type 
of interventions performed for all participants, and so it is not possible to 
determine whether any specific intervention may result in more favourable 
outcomes. For example, retrospective data from this study suggests that the 
provision of asthma action plans and interventions seeking to improve 
adherence should have been performed more consistently, because not all 
patients received an action plan and poor adherence appears common place. 
 
In contrast, the findings of this study differ from complex interventional studies 
in community pharmacy settings, which have demonstrated statistically 
significant improvements in asthma severity based on the Australian National 
Asthma Council asthma severity assessment table, although these studies 
recruited a more mixed population of asthma severity (Armour et al., 2007, Saini 
et al., 2008). Both of these studies compared enhanced pharmaceutical care to 
usual pharmaceutical care and supported the initial intervention with repeated 
follow-up consultations. Participants were recruited to these studies if medical 
care was difficult to access, which may explain the poor response in the usual 
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care arm. In addition, a certain degree of caution is necessary when comparing 
to this study as the criteria used to define asthma severity were different and the 
study populations included patients with both mild and severe asthma. 
Furthermore, both studies were successful in ensuring that all patients received 
regular follow-up to reinforce the educational interventions provided to patients, 
which may have contributed to the positive outcomes that were demonstrated. 
 
In these studies, 85% (Saini et al., 2008) and 94% (Armour et al., 2007) of 
patients who completed the study attended the first follow-up visit, four-weeks 
after the initial consultation, allowing pharmacists to reinforce the education 
interventions from the baseline consultation, and this may have contributed to 
the positive outcomes reported. In one study, the authors commented that this 
high retention rate might be due to patients valuing the service provided by their 
pharmacist at the baseline consultation, which persuaded them to return (Saini 
et al., 2008). In the present study, patients were aware that the follow-up 
consultations were to be provided by a different pharmacist outside of the 
specialist difficult asthma clinic, and this might have contributed to the poor 
uptake of the t-MUR service, whether or not they valued the service provided by 
the hospital advanced clinical pharmacist. However as no service evaluation 
data were collected, it is not possible to determine actual patient’s opinions of 
the value of consultations provided by the pharmacists in either the difficult 
asthma clinic, nor in community pharmacies. 
 
Comparing the results of the present study with other studies is difficult due to 
variations in the interventions performed and asthma outcomes reported. 
However, when comparing to the above three studies (Armour et al., 2007, 
Charrois et al., 2006, Saini et al., 2008), a number of implications for routine 
practice are highlighted. Firstly, interventions such as assessing adherence and 
providing asthma action plans should be performed more consistently, and 
secondly, initial baseline interventions should be supported with follow-up 
consultations. 
 
6.1.2 Quality of life 
The intention to treat results of the study demonstrate that the provision of 
pharmaceutical care from a hospital-based advanced clinical pharmacist was 
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non inferior to usual medical care for both quality of life measures used, with 
quality of life remaining stable in both groups throughout the six-month study. 
 
Participants in both study groups in this study were moderately to very limited in 
their asthma quality of life as demonstrated by mid-range scores in the 
AQLQ(S), and this was consistent across all four domains in the questionnaire 
(symptoms, activity limitation, emotional function and environmental stimuli). 
Similarly at least half of the participants in both groups reported general 
problems on the EQ-5D-5L with mobility, usual activities, anxiety or depression 
and pain or discomfort – all conceivably, but not necessarily, due to asthma. 
This establishes that participants had a poor quality of life at baseline and 
follow-up, which is unsurprising considering that long-term persistent asthma 
symptoms and frequent exacerbations place people with difficult asthma under 
a very substantial burden, which is known to adversely affect health related 
quality of life measures (Lloyd et al., 2007).  It has previously been shown that 
poor or worsening asthma control and exacerbations can affect day-to-day life 
and worsen quality of life (Juniper et al., 1999a, Lloyd et al., 2007). This may 
explain why both study groups were successful in preventing quality of life 
measures deteriorating, as asthma control was stabilised in both groups and 
few patients experienced any exacerbations. 
 
Previous studies have similarly failed to demonstrate any discernible changes in 
either asthma-related quality of life or general health status following complex 
pharmacy interventions, although this could be due to the inclusion of patients 
with well controlled asthma (Mehuys et al., 2008) or use of un-validated 
measures of quality of life (Petkova, 2008). However some pharmacist 
interventional studies have demonstrated improvements in asthma-related 
quality of life (Armour et al., 2007, Kritikos et al., 2007, Cordina et al., 2001), 
and whilst two of these studies included repeated follow-up to reinforce the 
interventions, which may have helped achieve significant improvements in 
quality of life (Armour et al., 2007, Cordina et al., 2001), the third was of short 
duration only, and did not measure long-term improvements in asthma 
outcomes (Kritikos et al., 2007).  
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Consequently, to achieve a significant improvement in quality of life in people 
with uncontrolled asthma, repeated reinforcement of interventions such as 
asthma education, inhaler technique training and adherence counselling may 
be a necessity. 
 
6.1.3 Inhaler technique 
The study protocol recognised that inhaler technique was of key importance in 
the study because there is increasing evidence demonstrating that uncontrolled 
asthma is associated with poor inhaler technique (Baddar et al., 2014, Giraud et 
al., 2011, Giraud and Roche, 2002, Melani et al., 2011), and may be particularly 
so where patients perform critical errors (Basheti et al., 2014, Melani et al., 
2011, Molimard et al., 2003). Despite this, inhaler technique training by 
pharmacists as part of routine practice in the current study was found to be 
poor, with only five who had previously received inhaler technique training from 
a community pharmacist and only four from a hospital pharmacist. Furthermore, 
fewer than half had received training from their practice nurse or GP, which is 
likely to account for the poor inhaler technique observed in both the PI and UC 
group at baseline. 
 
The results of the baseline intervention demonstrate significant improvements in 
inhaler technique measured using inhaler technique score for pMDI, Accuhaler 
and Turbohaler devices in the PI group, but only the pMDI device in the UC 
group. This confirms the findings of previous studies that have reported the 
benefits of using In Check DIAL inspiratory flow meters to improve IFR 
(Alamoudi, 2003), and pharmacists’ ability to correct inhaler technique (Basheti 
et al., 2008, Basheti et al., 2005). Despite initial improvements in inhaler 
technique at baseline in the present study, the proportion of participants with 
optimal inhaler technique was significantly lower at 6 months, indicating that the 
benefit of the baseline intervention dissipated over time. In the PI group, this 
was likely to have resulted from a lack of reinforcement of correct inhaler 
technique and follow-up interventions because most participants did not receive 
a t-MUR. Since maintaining correct inhaler technique over long periods of time 
has been shown to improve asthma outcomes through the use of regular and 
repeated education (Basheti et al., 2008), lack of the follow-up t-MUR is likely to 
have been an important factor in the failure to demonstrate significant effects on 
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asthma outcomes at 6-months in this study. However in the present study, a 
deterioration in inhaler technique was also observed in the six patients who 
received a t-MUR at a mean 60 days (range 28 – 143 days) following the 
baseline consultation, which suggests that inhaler technique training should be 
repeated sooner than two months after initial training. It is also likely that inhaler 
technique should be repeated regularly after t-MURs. An alternative explanation 
for the deterioration in inhaler technique may be that the education method was 
not effective to achieve long-term improvements. One similar previous study 
that assessed inhaler technique training used a similar method that included 
checklists, verbal and physical demonstration to train patients, and achieved 
and maintained improvements in inhaler technique over 6 months (Basheti et 
al., 2008). In contrast to the present study, reinforcement training was provided 
at one, two and three months, and all patients were provided with sticky labels 
attached to their inhaler devices to outline correct inhaler technique. 
Consequently, these sticky labels may be critical to maintaining correct inhaler 
technique, although further studies would be required to confirm this. 
 
Ensuring optimal inhaler technique is recommended in the management of 
respiratory conditions such as asthma (British Thoracic Society and Scottish 
Intercollegiate Guidelines Network, 2014, Global Initiative for Asthma, 2014), 
but is complicated by the diversity of inhaler device currently available in the UK 
market. This is highlighted by the fact that the 52 participants used eight 
different types of inhaler devices, and participants were often prescribed two or 
three different devices at the same time.  
 
The need to use different devices may create an additional burden for patients 
because of the need not only to remember several different types of action but 
also to correctly apply them to the appropriate device. Consequently some 
guidelines recommend that the same inhaler device should be prescribed when 
more than one inhaled drug is required (Dolovich et al., 2005), as this would 
make inhaler technique training quicker and easier because patients would only 
need to learn one technique. However this is not always possible as the some 
devices are only available in a limited range of drugs, and consequently two or 
more inhaler devices are commonly required. 
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It has been well established that knowledge of correct inhaler technique 
amongst healthcare professionals is poor (Baddar et al., 2001, Baverstock et 
al., 2010, Interiano and Guntupalli, 1993, Jackevicius and Chapman, 1999, 
Jones et al., 1995), and the wide variety of inhaler devices available for asthma 
treatment is likely to make it harder for healthcare professionals to achieve 
competence with all devices. It is unsurprising that inhaler technique was poor 
at baseline despite all patients receiving training in the past, specifically 
participants frequently had an IFR that was too fast for low resistance aerosol 
inhalers such as the pDMI and Easi-Breathe devices, and consequently the 
majority of pMDI users in particular had unsatisfactory inhaler technique. It is 
disappointing that poor inhaler technique continues to be reported as a major 
problem in this and other studies (see Chapter 2.2.2), despite being critical to 
asthma treatment. The poor inhaler technique at baseline may be a 
consequence of poor training from healthcare professionals who may be 
unfamiliar with these devices, or due to participants forgetting the correct 
technique since they were last instructed. This suggests that regularly repeated 
education is necessary for both patients and healthcare professionals; to 
ensure that inhaler devices are used correctly in order to achieve the maximum 
clinical effect from inhaled drugs and improve asthma outcomes. 
 
Analysis of the number of interventions made during baseline consultations 
demonstrate that pharmacists were significantly more likely to document 
interventions addressing inhaler technique (24 vs. 4) than physicians providing 
usual care, suggesting that pharmacists may be better at assessing and/or 
identifying poor inhaler technique. However since there was no independent 
evaluation of the quality of the inhaler technique assessments performed in 
either study group, it is not possible to confirm this assertion. 
 
6.1.3.1 Evaluation of inhaler technique assessments 
6.1.3.1.1 Inhaler technique checklists 
This study was designed as a real-life interventional study, and as such there 
was no restriction on the medicines used to treat each participant’s asthma. As 
a consequence, there was a wide range of inhaler devices used by patients and 
the majority of patients used at least two different types of inhaler device. This 
introduces a further limitation into the study, since it makes it difficult to compare 
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ability to use inhalers between different inhaler devices because each requires 
a different technique to load and prime, inhale through and close after using. 
This is evident by having separate checklists for each device (Appendix 8), 
with different total numbers of steps and a different number of potential critical 
errors per device (Haughney et al., 2010). As a consequence, inhaler technique 
score had to be standardised by calculating the percentage of correct steps 
performed, but should be interpreted with caution as some inhaler devices are 
easier to use and less complicated than others (Lenney et al., 2000).  
 
Although a checklist was used to determine each participants inhaler technique 
there are a number of issues that should be considered when using these, 
primarily that there is no standard checklist available, with one review identifying 
24 checklists for Accuhaler devices and 16 for Turbohalers (Basheti et al., 
2014), with substantial variation. This makes comparison between different 
studies difficult, even though the checklist used in this study is almost identical 
to those recommended in the review article (Basheti et al., 2014), which 
increases the confidence that the checklists used were valid. Differences in the 
present study compared to recommended checklists (Basheti et al., 2014) 
include having a step to ensure that the Turbohaler cap is replaced after use, 
and that exhaling away from the inhaler mouthpiece before use was classed as 
a critical step because exhalation through the mouthpiece can blow dry powder 
away. 
 
6.1.3.1.2 Inhaler technique assessment 
Inhaler technique score is commonly used in studies, but does not necessarily 
indicate how much of the dose each participant would receive because one 
error would still give a high score, but if it was a critical error the patient could 
potentially receive none of the dose. Consequently a greater emphasis on 
critical errors in inhaler technique is becoming more recognised (Molimard et 
al., 2003, Basheti et al., 2008, Basheti et al., 2014, Basheti et al., 2011, Basheti 
et al., 2005, Haughney et al., 2010). As participants used a wide variety of 
inhaler devices, a pragmatic decision was made to perform statistical analyses 
by assuming that inhaler technique scores were equivalent for all devices, 
despite the limitations of this. A second analysis was performed to report the 
proportion of patients with optimal technique (all steps in the checklist 
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performed correctly) and the proportion with satisfactory technique (all critical 
steps identified in each checklist correct), since the latter measures may be 
more likely to identify the proportion of patients likely to receive an effective 
dose and may therefore impact on clinical outcomes (Basheti et al., 2014).  
 
Even this approach will still have some limitations due to the variety of inhaler 
devices used by the study participants and this may have affected the data 
analysis. An alternative study methodology would have been to only recruit 
patients using one specified inhaler device since inhaler technique scores and 
the proportion with optimal and satisfactory inhaler technique could more 
precisely be studied. However, this would have restricted the potential number 
of patients in the difficult asthma clinic who could be suitable for this study, and 
may not have allowed an adequate study sample size to be recruited within the 
study timeframes. Furthermore, this would not have reflected usual clinical 
practice because there is no one inhaler device that is appropriate for every 
patient, and so would have prevented a real-life pragmatic study being 
performed.   
 
Whilst there was no significant difference in the proportion of participants with 
optimal inhaler technique at baseline and follow-up, it should be noted that this 
study was not adequately powered to determine this outcome, since there were 
not enough participants using each inhaler device to provide an adequate 
sample size for these analyses. This is demonstrated using a sample size 
calculation for comparison of proportions: 
 
            
  {                    }    
  
Where: 
    The approximate number of patients per group 
   = The proportion of participants in the UC group with optimal 
inhaler technique  
   =  The proportion of participants in the PI group with optimal 
inhaler technique 
δ = The difference in proportions between the PI and UC groups 
        
  = A function based on Study Power of 80% (=7.849) 
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Consequently, based on the study results where optimal technique at follow-up 
was observed in 6.1% and 7.3% of participants using pMDI, 75% and 61% 
using Accuhalers and 71.4% and 42.9% using Turbohalers, the total number of 
patients required in a study would be 30,658, 299 and 87 respectively. 
However, if the as per protocol intervention had been completed with all PI 
participants receiving t-MURs, it is possible that more patients would have had 
optimal inhaler technique at follow-up in the PI group, as other studies have 
demonstrated that improved inhaler technique for prolonged periods can be 
achieved with regular follow-up (Basheti et al., 2008). Consequently the 
required sample size is likely to have been smaller than this estimate, as the 
difference in proportion of patients achieving optimal inhaler technique may be 
greater with repeated follow-up than with the one-off intervention provided to 
patients in the current study. 
 
The overall results on inhaler technique have major implications for practice, as 
they demonstrate the vital importance of ensuring that every patient with 
asthma has their inhaler technique checked and corrected more frequently than 
current practice, in order to maintain optimal inhaler technique. It is possible that 
this should be done at every contact with healthcare professionals, whether 
during primary or secondary care consultations and when collecting 
prescriptions from community pharmacies. It should never be assumed that 
inhaler technique has been checked before, or by someone else, nor can it be 
expected to be as good as it was when previously checked. 
 
6.1.4 Inhaler preference 
A frequently overlooked issue in the management of asthma concerns patients’ 
preference for different inhaler devices, as this may affect adherence (Capstick 
and Clifton, 2012, Dolovich et al., 2005). However there are few published 
independent patient preference studies, and a review of evidence found that the 
majority of studies are sponsored by the pharmaceutical industry and the 
majority also report that patients prefer the device manufactured by the 
sponsoring company (Anderson, 2005). Assessment of both patient preference 
and linkage to data on adherence (prescriptions issued) were therefore included 
in the study design. Two different methods were used to assess patient 
preference of seven different inhaler devices in this study, Both scoring systems 
 172 
were consistent in the resulting rankings, showing that the Easi-Breathe device 
was most preferred, confirming findings from previous independent studies 
(Lenney et al., 2000), and indicating that the results from the current study may 
be generalisable to the overall asthma population.  
 
These results suggest that prescribing inhaled drugs in an Easi-Breathe device 
would be well accepted by most patients probably due to the ease and 
simplicity of use of this device, and may consequently improve adherence. 
However the Easi-Breathe device is only available for two drugs: 
beclometasone (Qvar®) and salbutamol, of which beclometasone without a 
LABA is only appropriate for treating patients with mild asthma at step 2 of the 
BTS/SIGN asthma guidelines (British Thoracic Society and Scottish 
Intercollegiate Guidelines Network, 2014). The Easi-Breathe inhaler is therefore 
not suitable for participants in a difficult asthma study, and consequently 
alternative inhaler devices are required.  
 
As the Easi-Breathe inhaler was found to be the preferred device in this and a 
previous study (Lenney et al., 2000), this suggests that there is a need for other 
classes of drug in this device. Alternatively, manufacturers should develop other 
inhaler devices that have a similarly easy method for use: open cap, inhale, 
close cap. Since this study commenced, a number of novel inhaler devices 
have been launched in the UK, including the Ellipta® (GlaxoSmithKline), 
Spiromax® (Teva) and NEXThaler® (Chiesi), with a similar three-step method for 
use to the Easi-Breathe device. Each of these three new devices are available 
as ICS/LABA combinations for the treatment of asthma, and may be easier to 
use than other existing inhaler devices (Svedsater et al., 2013, Voshaar et al., 
2013). Consequently the data from this preference analysis may already be out 
of date in the context of the increasing range of inhaler devices available to 
patients. 
 
Alternative devices that were well liked (rank 2 to 4) by patients, and potentially 
suitable for most patients with difficult asthma were Turbohaler, pMDI and 
Accuhaler using both ranking systems.  
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Whilst the least preferred inhaler devices in this study were the Easyhaler, 
HandiHaler and Respimat devices, it should be recognised that these devices 
were not commonly prescribed. Prior to the study, no patients in the PI group 
were prescribed an Easyhaler or Respimat, and four were prescribed a 
HandiHaler. In contrast more than half of the patients were prescribed a pMDI 
(19) or Turbohaler (17), and 10 were prescribed an Accuhaler. One recent 
patient preference study was reported that previous experiences with inhaler 
devices impacts on individual patients’ rankings even when asked to rate them 
only based on physical and functional aspects of the devices (Chorão et al., 
2014). Although not assessed in the current study, the results of the preference 
analysis may also have been influenced by current and previous use of inhaler 
devices, despite the fact that no patients had previously used the top ranking 
Easi-Breathe device. 
 
There are important implications for practice from preference analyses because 
there may be contrasting opinions between patients and healthcare 
professional’s about which device is most appropriate, when views on patient’s 
preference are balanced with their ability to use an inhaler device. Although 
there appeared to be no link between patient preference and inhaler technique 
guiding prescribing decisions on asthma outcomes, it is important that patient 
preference and inhaler technique assessments are considered equally during a 
concordant consultation in order to agree the best and most appropriate device 
to be used. 
 
6.1.5 Adherence  
The baseline consultations were clearly not effective or accurate methods to 
identify non-adherence as only 6 and 4 participants in the PI and UC groups 
were identified as needing adherence counselling, compared to retrospective 
prescription data, which demonstrated that the majority of participants in both 
groups were non-adherent. This is unsurprising as asthma patients are known 
to overestimate their true adherence (Axelsson et al., 2009). 
 
Prescription data in this study found that 57.5% of participants had adherence 
rates less than 80%, 35% had adherence rates less than 50% and 17.5% had 
adherence rates exceeding 100% over the previous six months. This is 
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consistent with previous research on adherence in asthma; one systematic 
review found that 24-69% of asthma patients underused and 30-60% overused 
their ICS (Cochrane et al., 2000), whilst in difficult asthma populations, one 
study reported that 35% collect fewer than half their ICS prescriptions and 21% 
filled more than 100% of their prescriptions (Gamble et al., 2009).  
 
This study found that the increase in proportion of patients with adherence rates 
80-120% was significantly greater in the PI than the UC group over the course 
of the study, and demonstrates that pharmacist care had a greater impact on 
adherence than physicians. This study was adequately powered to detect this 
effect, since using the sample size calculation for comparison of proportions on 
Page 170, a sample size of 15 patients per group is required for this analysis. 
However the precise reasons for improved adherence in the PI group are a 
matter for conjecture as they were not studied, but could be due to 
improvements in inhaler technique achieving greater symptomatic benefits 
reinforcing adherence through greater perceived benefit, or education of the 
role of medication reinforcing adherence. Classification of adherence in the 
range 80-120% is justified as it has been used in previous pharmacist 
intervention studies (Armour et al., 2007), which also demonstrated 
improvements in adherence in PI patients. 
 
Prescription records are considered a more accurate measure of adherence, 
than patient self-report, but caution is still advised as prescription data cannot 
show whether the patient collected their prescription from the pharmacy or 
whether they actually used their inhalers (Cochrane et al., 1999, Osterberg and 
Blaschke, 2005), and will not take in to account whether patients have 
previously received an oversupply, so non-collection of a prescription may be 
appropriate. This study tried to make the use of prescription data more robust 
by identifying all issues from each patients GP and hospital Trust over a six-
month period, as a longer duration of data could reduce the impact of 
inaccuracies in adherence rate calculations caused by one-off mitigating factors 
such as excess stock. However, the method used to collect prescription data 
could still have missed some issues, such as any that may have been received 
from hospitals outside the local area, although since hospital admissions were 
low, it is unlikely to have significantly affected the overall adherence data. 
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The MARS was used as a corroborating measure of adherence in this study, 
and it is interesting to note that the MARS questionnaire was more successful in 
identifying non-adherence than patient self-reporting during consultations, but 
still underestimated adherence compared to measurements using prescription 
data. The MARS may be more accurate than asking patients about adherence 
during consultations, because patients may be afraid of admitting to their 
physician about not taking their medicines, feeling less threatened by a 
questionnaire, or due to the non-confrontational questions used in the MARs 
(Haughney et al., 2008).  
 
The MARS has been validated in a number of studies (Horne and Weinman, 
2002) and has been shown to correlate well with other measures of adherence 
such as pharmacy prescribing records (Menckeberg et al., 2008). This study 
provides further data that the MARS questionnaire is a useful tool to determine 
adherence, and also provides useful insight into how patients use their inhalers, 
as significant proportions of participants in this study admitted to altering their 
ICS dose, taking more than instructed, or even stopping their ICS for periods of 
time. Over the course of the 6-month study, the only non-adherent behaviour 
that was found to have significantly changed was the proportion of participants 
in the PI group that admitted to stopping their ICS for periods of time. This 
contrasts with prescription records for adherence, which suggested that 
participants in the PI group were more adherent at 6-months than at baseline. 
Consequently it is likely that both prescription records and MARs data should be 
interpreted with caution in the absence of clear objective adherence 
assessments. 
 
The BMQ (Horne et al., 1999) is recommended as a useful tool to facilitate 
optimal adherence (Haughney et al., 2008), as it can be used to identify 
potential perceptual and practical barriers to adherence in individual patients 
with asthma because it assesses each patient’s beliefs about the need for 
regular preventer therapy for controlling their asthma, and their concerns about 
potential adverse effects of treatment.  
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This study found that patients rated that they had a general awareness of the 
necessity to take their medicines to manage their asthma using the BMQ. 
However on average, participants in both groups neither agreed nor disagreed 
about whether they had concerns about having to take medicines or their 
potential harm, nor whether healthcare professionals overuse them. These data 
contrast with previous research that has found that patients with controlled and 
uncontrolled asthma have a number of concerns about their medicines, with 
many having doubts about the necessity for their medicines, have concerns 
over the side effects and consequences of medicines, and perceptions over 
their illness (Axelsson et al., 2009, Bolman et al., 2011, Clark et al., 2012, 
Horne and Weinman, 1999, Horne and Weinman, 2002, Menckeberg et al., 
2008, Park et al., 2010, Sofianou et al., 2013). This suggests that participants 
recruited to this study may have been more informed about their medication that 
participants in other studies, or that the perceived need for medicines to treat 
their difficult asthma outweighed any concerns they may have had. 
Consequently the BMQ data should infer that the study population would have 
had good adherence, which was not the case when prescription data was used 
to quantify actual adherence. 
 
Whilst this study found that poor adherence was widespread, it did not confirm 
an association with asthma control. However due to the study design and 
practicalities over recruitment to the study, it was not possible to collect 
prescription data on adherence in time for the first consultation, as many GP 
practices took up to two weeks to provide the data and would provide it only 
with patient consent. Therefore during the baseline consultation, an assumption 
had to be made that patients were adherent to treatment if they stated they 
were during consultations. In addition the BMQ and MARS questionnaire 
responses were not reviewed in either the PI or UC group due to concerns that 
interpreting both questionnaires would unduly prolong each participants 
attendance in the clinic. Furthermore, there were concerns that if participants 
knew their answers were going to be read prior to the consultation, they would 
modify their answers and feel compelled to report good adherence. 
 
The data on adherence in the difficult asthma population in this study suggests 
that a greater emphasis should be placed on adherence in difficult asthma. GPs 
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or primary care pharmacists should review prescription records to determine 
adherence rates in patients with uncontrolled asthma prior to referral to 
secondary care clinics. In addition, when GPs refer patients to difficult asthma 
clinics for specialist review and assessment, they should be asked to provide 
prescription data to enable an adherence assessment to be performed. 
Alternatively, a patient record that is shared across primary and secondary care 
sectors could allow all healthcare professionals to review adherence data when 
needed. In addition, the MARS questionnaire also appears to be a useful tool to 
identify non-adherence and should be used routinely, whilst the BMQ did not 
appear to add value in this patient group. 
 
It is interesting that bivariate correlation found no significant relationship 
between adherence to ICS treatment and either asthma control or asthma 
quality of life, as it was anticipated that patients who used their ICS inhalers on 
a regular basis would have more effectively treated asthma and improved 
asthma outcomes. The failure to find such an association again suggests that 
prescription data may not be an accurate reflection of true adherence, or that 
other unidentified factors have significant effects on asthma control.   
 
6.1.6 Asthma reviews and complex interventions 
Asthma reviews were performed in the PI group using consultation styles based 
on those discussed in the methodology (see Chapter 4.5). This was important 
because the nature of the study required the pharmacist, who performed the 
baseline interventions to participants in the PI group to develop a collaborative 
partnership in order to encourage participants to discuss their asthma 
symptoms, triggers and treatments (Kurtz et al., 2003). The collaborative 
partnership approach would then allow the pharmacist and patient to discuss 
the advantages and disadvantages of different treatment options and how they 
may affect the lifestyle and asthma control, which allowed different interventions 
to be agreed. No data were collected on the consultation style used in the UC 
group. 
 
This study did not seek to investigate the opinions of participants about how 
their asthma consultations were performed in either study group. However 
participants in the PI group generally appeared to value them, as some 
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provided positive feedback at the end of the consultation about receiving new 
information about their asthma and treatments. In contrast, one patient in the PI 
group was less positive about the consultation, explaining that it was too long 
as a consequence of completing so many questionnaires and due to the 
number of interventions required. On reflection, patient evaluation of the 
baseline consultations would have been a valuable method to assess 
consultation style and performance as the pharmacist researcher, which would 
have allowed me to understand how I could improve my practice, or to 
determine how the consultation style may have affected the study outcomes 
(Bowling, 2002). 
 
This study was designed as a complex interventional study on the basis that 
previous studies have demonstrated that single interventional studies in asthma 
are not as effective as complex interventions (Gibson et al., 2002a, Gibson et 
al., 2002b). As this was a pharmacist interventional study, the interventions 
considered appropriate in this study were typically related to medication, in 
particular inhaler technique, education, and provision of asthma action plans. 
These are all well recognised to be effective in asthma management (British 
Thoracic Society and Scottish Intercollegiate Guidelines Network, 2014, Global 
Initiative for Asthma, 2014), and are similar to those used successfully in other 
pharmacist complex interventional studies (Armour et al., 2007, Barbanel et al., 
2003, Charrois et al., 2006, Cordina et al., 2001, Garcia-Cardenas et al., 2013, 
Kritikos et al., 2007, Mehuys et al., 2008, Petkova, 2008, Saini et al., 2008).  
 
Since pharmacists are recognised as medicines experts, it is not surprising that 
there were significantly more medicines-related interventions performed in this 
study in the PI rather than the UC group. The fact that so many interventions 
were identified and performed compared to the UC group, suggests that 
pharmacists have a different skill set to physicians and are able to identify 
otherwise unidentified medicines-related issues where there are opportunities to 
improving asthma management.  
 
A potential drawback with performing so many interventions during initial 
consultations is that the increasing number and complexity could cause 
confusion or provide too much information that patients may then struggle to 
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retain. It was for this reason that follow-up reinforcement interventions through t-
MURs were included in this study design. This was thought particularly 
important since previous studies have demonstrated that patients who received 
interventions focusing on improving inhaler technique began to lose their skills 
towards the end of a six-month study even with repeated follow-up (Basheti et 
al., 2008). It is uncertain whether patients with difficult asthma would benefit 
more from receiving fewer interventions at each consultation, or from receiving 
greater number of interventions supported by regular and repeated 
reinforcement from community pharmacists. Future research should be directed 
to examining the role of follow-up support and management from community 
pharmacists to determine the optimum or practicable and cost-effective number 
and frequency of consultations to improve and maintain asthma control in such 
complex cases. 
 
Analysis of the interventions performed suggests that there were certain 
interventions that were poorly performed in both the PI and UC groups. Asthma 
action plans were only provided to 11.5% and 23.1% of participants in the PI 
and UC groups respectively, despite less than two thirds having action plans at 
baseline. The rationale for not providing action plans was not collected, 
although there may have been legitimate reasons for this. For example, some 
patients in the current study were not thought able to monitor their asthma and 
use an action plan appropriately to adjust their medication and so were advised 
to stick to the same regular dose at all times, whilst other studies have reported 
that not all patients will take ownership of their asthma management and use an 
Action Plan (Armour et al., 2007). 
 
6.1.7 The role of MURs to provide follow-up consultations 
Regular follow-up has been incorporated into most other pharmacist complex 
intervention studies in asthma because the impact of interventions could 
similarly decline over time (Armour et al., 2007, Barbanel et al., 2003, Basheti et 
al., 2008, Charrois et al., 2006, Cordina et al., 2001, Garcia-Cardenas et al., 
2013, Kritikos et al., 2007, Mehuys et al., 2008, Petkova, 2008, Saini et al., 
2008). This follow-up may be of importance as previous pharmacist 
interventional studies have demonstrated that improvements in inhaler 
technique following education and training may begin to decline during long 
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follow-up periods (Basheti et al., 2008). In the present study, the initial 
improvement in inhaler technique was not maintained over the course of the 
study, which highlights the potential importance that follow-up consultations 
may have in reinforcing education provided during initial consultations.  
 
To allow for follow-up consultations for participants in the PI group, community 
pharmacists were identified as being well placed to perform t-MURs, reinforce 
baseline interventions, and to perform any new interventions identified as 
necessary. Previous studies have demonstrated that asthma MURs are well 
accepted by patients and effective in improving asthma control (Bagole et al., 
2007, Portlock et al., 2009, MacAdam and Sherwood, 2011, The Cambridge 
Consortium, 2012), so there was a high degree of confidence that they would 
be utilised by patients in this study. 
 
It was disappointing that a major limitation of this study was that very few 
participants in the PI group actually received a t-MUR, despite each 
participant’s community pharmacist being contacted verbally and in writing by 
the lead researcher. Furthermore, this study had been publicised during a 
series of educational sessions on asthma and inhaler technique preceding the 
study, as well as in a newsletter from the Leeds, Bradford & Airedale, 
Calderdale & Kirklees Local Pharmaceutical Committees (now Community 
Pharmacy West Yorkshire). This failure to provide follow-up interventions and 
reinforce education and advice may have contributed to inhaler technique being 
significantly worse at 6-months compared to baseline and also the failure to 
demonstrate improvements in asthma outcomes. It was concerning that the 
most common reason reported by community pharmacists for not performing a 
t-MUR was the patient’s failure to attend, whilst the most common reason given 
by participants was that the community pharmacist did not arrange one. This 
suggests that there was either a communication mismatch between community 
pharmacists and patients, or perhaps that the explanations provided were not 
always truthful. It was also concerning that one pharmacist did not perform a t-
MUR because they did not feel confident that performing a t-MUR would 
provide any benefit to the patient compared to healthcare professionals working 
in a difficult asthma clinic. Since the rationale for the t-MUR was to reinforce 
interventions already performed, check and optimise inhaler technique and 
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perform a standard MUR, every community pharmacist should be competent to 
perform this role. This suggests that some pharmacists do not yet understand 
the valuable contribution to asthma control that their MUR could make, despite 
other studies reporting that pharmacists have noticed a positive impact on 
health after performing MURs with patients (Waterfield and Dhir, 2011). 
 
A potential reason for the poor completion rates of t-MURs could be the 
relatively limited communication between secondary and primary care, although 
brief, written referrals for t-MURs were provided for all patients. This theory is 
supported by a systematic review that reported that poor communication and 
information transfer to primary care at discharge following hospital admissions 
was frequent and thought to adversely affect patient care (Kripalani et al., 
2007), whilst lack of access to medical notes has been raised as a concern over 
MUR provision by GPs (Celino et al., 2007). It is conceivable that community 
pharmacists may have had similar concerns in this study and whilst there were 
no reports of problems with the referral forms, a greater uptake of t-MURs may 
have been achieved by providing each community pharmacist with a copy of 
the clinic letter from the initial baseline consultation in the difficult asthma clinic. 
Consideration should also be made to making patient medical records available 
to community pharmacists providing advanced pharmacy services such as 
MURs, as well as rolling out access to summary care records to community 
pharmacists that is planned from October 2014 as a proof of concept project 
(Health and Social Care Information Centre, 2014). 
 
Potential strategies to improve the uptake of t-MURs could have included 
telephone reminders to participants and community pharmacists, and even 
personal visits from the lead researcher to review the study protocol prior to the 
t-MUR being performed and provide any ad hoc education felt necessary by 
either the researcher or the community pharmacist. However this was not 
feasible within a research study that was funded to provide one day per week of 
research time. 
 
An alternative strategy to ensure follow-up interventions in the PI group would 
have been to ask each participant to attend the difficult asthma clinic at regular 
intervals following the baseline consultation. However, although this was initially 
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considered, it was ruled out because it was thought that providing additional 
intervention consultations closer to the patient’s home in their community 
pharmacy would be more likely to achieve good attendance than asking 
patients to re-attend the hospital outpatient clinic. Secondly, the difficult asthma 
clinic had limited capacity to allow extra visits and is also not funded by local 
Clinical Commissioning Groups to provide additional follow-up visits compared 
to routine practice. Similarly, research funding did not request funding to allow 
hospital follow-up interventions as the funding submission was requested 
anticipating that participants would receive t-MURs. 
 
 
6.2 Critical appraisal of this study 
6.2.1 Aims and objectives 
This study aimed to examine the effects of a co-ordinated management strategy 
between primary and secondary care pharmacists on asthma control and 
quality of life in patients with difficult asthma. The primary objective was to 
measure asthma control using ACQ, and secondary objectives measuring other 
important outcomes including quality of life, exacerbations, lung function, 
inhaler technique and adherence. Whilst the study design was largely 
successful in collecting these data at baseline and at six months follow-up, 
there were a number of strengths and limitations in the study that will now be 
discussed. 
 
6.2.2 Literature review 
As discussed in Chapter 3.2, the literature review used to inform the study 
design was based on methods recommended by the Cochrane Collaboration 
for performing systematic reviews (Higgins and Green, 2011). This review was 
done independently since it formed the basis of a research study performed 
under supervision for award of Doctor of Pharmacy programme. However 
Cochrane advise that literature searches should be undertaken by a person 
who has expertise in designing search strategies for use in bibliographic 
databases in order to identify all relevant published articles (Higgins and Green, 
2011). This person may be a trials search co-ordinator, a local healthcare 
librarian or information specialist. Similarly, two reviewers are recommended to 
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ensure that articles included for the literature review meet the inclusion criteria 
and that those that don’t are excluded (Higgins and Green, 2011). 
 
The implications of the independent approach to performing the literature 
review should be considered, since there is a risk that suitable studies for 
inclusion in the review were not identified, particularly as the search strategies 
used identified a large number of articles. A weakness of the search strategy is 
that a ‘Cochrane Highly Sensitive Search Strategy for identifying randomised 
trials in MEDLINE’ was not incorporated into the search strategies, as this 
would have reduced the number of identified articles to more manageable 
levels (Higgins and Green, 2011), and reduce the risk of accidentally 
overlooking relevant articles. 
 
On reflection, it would have been prudent to review planned search strategies 
with someone with expertise in designing search strategies to ensure that it was 
focused and ensure that relevant articles were not missed. The search 
strategies were discussed retrospectively with a colleague who is a medicines 
information specialist, who considered the search strategy to be adequate to 
meet the requirements of the set inclusion criteria, although it could have been 
focused to a greater extent to prevent it yielding large numbers of irrelevant 
articles. 
 
6.2.3 Study design 
6.2.3.1 Methodology 
As the study was designed as a pragmatic (real-life) complex intervention in a 
real-life setting, a prospective un-blinded randomised study design was chosen, 
as described in Chapter 4.2. A prospective study was required, since it would 
have been impossible to collect data retrospectively, because the majority of 
outcomes being tested were not routinely recorded in the difficult asthma clinic, 
including objective inhaler technique assessment or asthma outcome measures 
such as Juniper’s ACQ and AQLQ(S). The lack of missing data for these 
outcome measures justifies that the prospective study design was appropriate. 
 
The study setting in a hospital difficult asthma clinic could be noted as a factor 
that contributed to the low uptake of t-MURs by participants in the PI group, 
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because this required them to receive follow-up consultations from a different 
pharmacist at a separate location. A previous study reported that patients may 
return for follow-up consultations provided by pharmacists after having a 
positive experience during the first visit (Saini et al., 2008). In the current study, 
it was not possible to provide follow-up visits at the same hospital difficult-
asthma clinic, and so patients were referred to their usual community 
pharmacist for a t-MUR. Whilst they may have a good relationship with their 
regular pharmacist when collecting their prescription, this does not necessarily 
indicate trust to manage a complex condition such as difficult asthma when a 
specialist consultant physician usually manages them. Although none of the 
patients in the study reported lack of trust in their community pharmacist, this as 
well as other reported reasons for poor uptake of t-MURs such as 
communication difficulties, should be considered for future research studies 
investigating joined up care between primary and secondary care pharmacists. 
 
As there were risks associated with the role of the lead investigator as an 
insider researcher, it was important to mitigate against the potential for bias 
being introduced into the study. This was complicated by the fact that funding 
was not available to allow for independent data collection and analysis and so 
there is a potential for performance and detection bias to have inadvertently 
being introduced into the study (Higgins and Green, 2011). In order to reduce 
this risk of this occurring, the study design incorporated as many objective 
and/or patient-completed outcome measures as possible. Such measures 
included the primary outcome measure ACQ, as well as secondary outcome 
measures including AQLQ(S), EQ-5D-5L, MARS and BMQ. Whilst checklists 
are valid measurement tools for assessing inhaler technique (Basheti et al., 
2014), they may potentially still be open to subjective interpretation. A potential 
criticism of this study is that no independent assessment was used to measure 
the ability of the lead investigator in the PI group and clinic nursing staff in the 
UC group to assess inhaler technique in a consistent manner, despite the use 
of the same checklists. However the lead investigator had a thorough 
understanding on correct inhaler technique (Capstick and Clifton, 2012), and 
was responsible for training clinic nursing staff on inhaler technique training. 
Consequently it was considered likely that all inhaler technique assessors were 
competent in performing this task. 
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6.2.3.2 Population 
The study was adequately powered based on the assumption that an 
improvement in the ACQ score of >0.5 units could be achieved with the 
intervention, where a change of 0.5 units describes a clinically important 
difference in asthma control. This required 38 patients to be followed up for 6-
months and assuming a 25% attrition rate, a sample size of 52 patients was 
required. Indeed 52 patients were recruited, and only five patients were lost to 
follow-up, which is a particular strength of this study. 
 
This study demonstrated that on average, the ACQ score in patients in the PI 
and UC groups did not change by more than 0.5 units, and so failed to meet the 
assumption that the pharmacist interventions would demonstrate a clinically 
significant change compared to usual medical care. A more conservative 
estimate of difference of change in ACQ score would have required a larger 
study, which would not have been achievable within one hospital clinic setting in 
the time available, since this clinic only managed to recruit 52 patients over a 
57-week period. 
 
6.2.3.2.1 Patient selection  
Potential participants to be screened for the study were selected through 
purposive sampling from lists of patients due to attend the difficult asthma clinic. 
Whilst this may be criticised as it meant that some patients were excluded from 
being screened for the study, it was also necessary to ensure that patients were 
not screened who obviously did not meet the study inclusion criteria, including 
those with other respiratory conditions. This sampling method also reduced the 
number of patients being screened at each clinic to manageable levels within 
the time constraints of the clinic. There is a risk that this meant that some 
patients who were potentially suitable for the study were not invited, but this risk 
is thought to be minimal since the clinic lists were screened by two people: the 
lead researcher and clinical supervisor. 
 
A criticism of the study was that asthma was not well defined, and patients were 
required only to have a clinical diagnosis of asthma and fulfil the criteria for 
difficult asthma, rather than meeting defined strict objective criteria for asthma 
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that are used in large high quality randomised clinical trials of drug therapy in 
asthma. For example in the GOAL study, which used strict criteria for assessing 
asthma control following drug therapy, the inclusion criteria required ‘at least a 
6-month history of asthma, a demonstrated improvement in FEV1 of 15% or 
more (and > 200ml) after inhalation of a SABA documented within the previous 
6 months or as assessed during run-in’ (Bateman et al., 2004). These strict 
criteria ensured that patients were recruited with a diagnosis of asthma and did 
not have other irreversible causes of obstructive lung disease such as COPD. 
This present study could not incorporate the same well-defined diagnostic 
criteria because very few patients attending the local difficult asthma clinic had 
recent lung function testing with reversibility data available, and it would not 
have been possible to request this and provide another appointment to attend 
the clinic at a later date. The broad diagnostic criteria consequently kept 
participant eligibility wide and aided recruitment to the interventional study. 
However the risks of participants being recruited to the study having alternative 
respiratory conditions was considered to be low as all patients had a clinical 
diagnosis of asthma from a consultant respiratory physician either in the difficult 
asthma clinic or during a previous hospital admission. 
 
6.2.3.2.2 Asthma phenotypes 
It is often considered that patients who are described as having difficult asthma 
(British Thoracic Society and Scottish Intercollegiate Guidelines Network, 2014) 
or severe asthma (Chung et al., 2014), are likely to persist with uncontrolled 
asthma and remain symptomatic despite maximal therapy, however this may 
not be true in all cases. The WHO consider that there are three subtypes of 
severe asthma: (i) untreated severe asthma (due to lack of available or 
affordable controller treatment), (ii) difficult-to-treat severe asthma, and (iii) 
treatment-resistant severe asthma (Bousquet et al., 2010). A distinction is made 
between these three subtypes since patients with difficult-to-treat severe 
asthma are likely to be less responsive to conventional asthma therapies since 
they frequently have other factors contributing to their symptoms, including non-
adherence, poor inhaler technique, persisting trigger factors or other medical 
conditions. Those with treatment-resistant severe asthma are unlikely to 
respond to conventional therapies no matter what interventions are made, and 
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are only identified by failure to respond to the highest recommended doses of 
recommended asthma treatments. 
 
Therefore it would be expected that some participants recruited to any difficult 
asthma study may have treatment-resistant severe asthma and would not 
respond to interventions that seek to optimise conventional asthma therapies. 
Consequently responders in studies of difficult asthma would be limited to 
patients with difficult-to-treat severe asthma and untreated severe asthma. It 
would therefore be preferable to identify and exclude patients with treatment-
resistant severe asthma prior to inclusion in an interventional study, but this 
would be difficult. This is because treatment-resistant severe asthma can only 
be identified after optimising therapy and ensuring adherence, which would 
require a baseline intervention to identify these patients, and thus would mask 
the impact of any subsequent study interventions. Furthermore, it would not be 
appropriate to exclude people with treatment-resistant severe asthma from a 
pragmatic study because these patients would not be excluded from real-life 
routine treatment. 
 
Diagnostic difficulties are one of the most challenging and complex issues in the 
management of difficult asthma today, as there is increasing research 
supporting the concept that difficult asthma has a number of different 
phenotypes, with different mechanisms driving symptoms, which could respond 
differently to different classes of medicines (NHS England, 2013). Asthma is 
often regarded as an allergic airway inflammatory condition mediated by 
eosinophils and TH2 immune pathways, which is responsive to corticosteroids. 
More recently alternative asthma phenotypes based on clinical characteristics, 
inflammatory processes and triggers have been proposed, such as obesity-
associated, smoking-associated, and neutrophilic asthma, which are less 
responsive to conventional asthma medicines such as ICS (Wenzel, 2012, 
Bousquet et al., 2010). Whilst current understanding of asthma phenotyping 
and effective therapies is insufficient to allow individualised treatment in 
present-day practice, this principle is likely to become increasingly important in 
the future management of difficult asthma. 
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It is perhaps understandable that interventional studies in patients with severe 
or difficult asthma have struggled to demonstrate large benefits in asthma-
related outcomes. This study did not seek to, and could not, identify potential 
asthma phenotypes or the proportion with treatment-resistant severe asthma, it 
is not known if or how many participants fit into these asthma phenotypes. 
Whilst asthma control was maintained during this study, these factors may 
contribute to understanding the reasons why this study did not demonstrate 
significant improvements in asthma outcomes in either the PI or UC group 
 
6.2.3.2.3 Randomisation methods 
This study was designed as a randomised interventional study to ensure that 
the characteristics of the participants in each group were identical, and a 
random permuted blocks allocation method was used to prevent imbalance in 
patient numbers and reduce potential selection bias. The blocks were designed 
to be small to prevent each group being allocated too many participants at each 
clinic, because there was only time for two or three patients to be reviewed in 
each clinic session. Consequently this could have introduced bias into the 
study, since this meant that permuted blocks of two were used, knowing the 
next allocation could have affected decisions to recruit patients to the study. 
However I am confident that this issue did not affect recruitment to the study, 
because when patients met the inclusion criteria, the decision to enter the study 
was their own and they were not aware of their allocated study group until after 
informed consent was obtained. 
 
6.2.3.3 Contamination bias 
6.2.3.3.1 Inhaler technique training 
Although a checklist was used to determine each study participant’s inhaler 
technique (Appendix 8), it should be noted that there was no validation that 
each clinician assessor could use all inhaler devices correctly. All community 
pharmacists performing t-MURs had been invited to an asthma education 
workshop and had received training on correct inhaler technique from the lead 
researcher, but no assessment or validation had taken place during these 
sessions. Similarly, nursing staff and physicians who assessed inhaler 
technique in the UC group had received similar training, but again, there is 
currently no validated assessment for healthcare professionals to ensure 
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competence. Therefore there is a risk that even with a checklist, there would still 
be a certain degree of subjective interpretation of each participant’s inhaler 
technique. This is an issue for most studies assessing inhaler technique since 
there are currently no widely recognised and validated inhaler technique 
training programmes for healthcare professionals (Basheti et al., 2014). 
 
This study could have been improved by the design of a formal training 
package for inhaler technique training and performing a formal assessment of 
each healthcare professional’s competence. This was not feasible as there is 
currently no validated formal assessment, this would have had to have been 
produced prior to the study. Furthermore, since data collection took greater than 
12 months, to ensure that each community pharmacist was competent, an 
assessment would have had to be performed prior to each t-MUR visit and 
funding would have been required to perform this. 
 
Consequently, there is a risk that inhaler technique scores and assessment of 
optimal, satisfactory and unsatisfactory technique were not consistent between 
the hospital specialist pharmacist performing baseline assessments in the PI 
group and follow-up assessments in both groups, or different community 
pharmacists during t-MURs, or different nursing staff performing baseline 
assessments in the UC group. 
 
6.2.3.3.2 Case discussion between pharmacist and physicians 
One of the ethical requirements of the study protocol was to allow for case 
discussion between the hospital specialist pharmacist performing interventions 
in the PI group following their consultations, to ensure that patients were not at 
a disadvantage from not being reviewed by a physician. Although no data were 
collected on the content of these case discussions, no concerns were raised. It 
is possible that these may have led to contamination between the two groups, 
with physicians providing usual care incorporating interventions described by 
the pharmacist into their practice, and vice versa. 
 
Contamination of the intervention could have been prevented by the use of two 
study sites; one providing the pharmacist intervention and one providing usual 
care. However this was not considered because this would have required a 
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study operating at two separate hospital Trusts, introducing a number of other 
variables into the study such as different patient characteristics arising from 
geographical differences in socioeconomic status or in differences in asthma 
management strategies and asthma drug formularies. This clearly could have 
introduced more variability into baseline characteristics than actually occurred in 
this study. 
 
6.2.3.4 Complex interventions 
As discussed in the methodology (Chapter 4.2), interventional studies are 
usually complex in their design, comprising multiple interventions that produce 
interrelating effects on study outcomes. In the early stages of planning and 
literature review for this study, it was recognised that studies investigating 
asthma management provided by pharmacists reported that patients benefited 
from multiple interventions that included education, medicines optimisation, 
inhaler technique training, trigger avoidance advice and self-management 
strategies. Consequently the study design built upon guidance provided by the 
Medical Research Council on developing and evaluating complex interventions 
(Craig et al., 2008). Specifically, this study was designed following a thorough 
literature review of published research that demonstrated how the management 
of asthma by pharmacists could improve asthma outcomes. This allowed gaps 
in the literature to be identified, and justify where further research was needed 
on the management of difficult asthma by pharmacists. 
 
The feasibility of this study and the planned range of interventions to be 
performed were confirmed as achievable through piloting of the protocol in 
patients who were subsequently not recruited to the study (Craig et al., 2008). 
On reflection, it may have been useful to assess the outcome of the intervention 
at subsequent routine follow-up appointments as a service evaluation of clinical 
practice, in order to determine the likely impact in these patients. This may have 
allowed more accurate assumptions to be made of the most practicable 
interventions to be made within the allocated clinic time slots. 
 
Furthermore, this study may have benefited from external monitoring during the 
study to ensure that specific interventions were being performed and evaluated 
correctly (Craig et al., 2008). For example, there was no external validation of 
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the competence of the pharmacist investigator or healthcare professionals’ 
ability to assess and correct inhaler technique, which would have increased the 
assurance that the resulting data are valid.  
 
This study was designed as a complex interventional study on the basis that 
previous studies have demonstrated that single interventional studies in asthma 
are not as effective as complex interventions (Gibson et al., 2002a, Gibson et 
al., 2002b), nevertheless some participants raised concerns that the 
consultations lasted a long time. The precise duration of the clinic appointment 
was often longer than 90 minutes, but could not be recorded accurately due to 
the practical difficulties achieving this because the investigator was solely 
responsible for recruiting and consenting patients, issuing questionnaires to 
provide baseline and follow-up data, and for performing the consultations in the 
PI group. There is a risk that the time taken to provide multiple interventions 
could have disengaged some participants, or that some information could have 
been forgotten after the consultation. This could have contributed to the lack of 
effect of the interventions at 6-months, and why inhaler technique was 
significantly worse at 6-months after being improved during the baseline 
consultation.  
 
With hindsight, these issues could have been addressed by informing patients 
of the expected duration of the consultation in the patient information sheet that 
was posted to them two weeks prior to their appointment, or by greater 
provision of written patient information following their consultations. This could 
have been anticipated prior to the study and a range of patient information 
collated for use within the study. On reflection it should have been anticipated 
that many participants, who received several interventions might not remember 
all the information given, especially when some of these such as inhaler 
technique and education may not be the easiest information to retain in the 
long-term. Suitable patient information leaflets are available from organisations 
such as Asthma UK and British Lung Foundation and should have been offered 
to each patient, or bespoke information could have been written for patients in 
the study.  
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There are implications for future practice as reflection on the study procedures 
may suggest that a range of patient information on asthma, its treatment and 
inhaler technique guides are made available for patients attending difficult 
asthma clinics. 
 
A strength of the study design was that there were no mandated interventions, 
other than checking inhaler technique, which allowed the interventions in the PI 
group to be tailored to the identified needs of each individual patient as part of a 
concordant consultation. This could therefore improve the effectiveness of the 
consultation and avoid the need to provide unnecessary or unwanted 
interventions. In contrast this lack of structure to the complex interventions 
might also be considered as a possible failing in the study design, as this may 
have resulted in inconsistencies in the type of interventions performed; for 
example not all patients were provided with an asthma action plan. This could 
have been improved by use of a template designed to ensure a structured 
consultation that incorporates all the interventions required to form an asthma 
review. A suitable structure could have been based on the SIMPLE asthma 
review strategy (Murphy, 2014, Murphy et al., 2012b). This acronym seeks to 
ensure that all relevant components of a review are discussed including Stop 
smoking advice, Inhaler technique training, asthma Monitoring, 
Pharmacotherapy and Medicines optimisation, Lifestyle advice and Education. 
 
6.2.3.5 Data collection  
As stated earlier, the outcome measures used in the study were based on the 
ATS/ERS statement on standardising endpoints for clinical asthma trials and 
clinical practice (Reddel et al., 2009). Thus the outcome data were appropriate 
to examine the potential impact of the interventions in routine clinical practice 
and to compare to other published studies in difficult asthma, although there are 
some concerns of a lack of consistency in outcome measures used in 
pharmacist intervention studies. 
 
For the pragmatic reasons discussed in Chapter 4.8, data were collected at 
baseline and six months due to limited time and staff resources. This meant that 
information on daily lung function using PEF, number of symptom-free days, 
side effects and daily use of SABA inhaler could not be collected. This could 
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have provided further information on the patient experience and given greater 
detail on asthma control to complement the use of ACQ as a measure of 
asthma control. 
 
It was a potential weakness of the study that asthma control measures such as 
ACQ were only collected at baseline and six-months, and so were dependent 
on how participants asthma control was in the fortnight preceding the clinic 
appointments. This fails to take into account how controlled their asthma was in 
the weeks and months before this time, and thus demonstrates further how the 
inability to record asthma symptoms on a daily basis could have adversely 
affected the study outcomes. In retrospect, it would have been useful to collect 
data at regular intervals, and the easiest way would have been to be able to 
incorporate regular follow-up visits. An alternative strategy would have been to 
ask patients to complete their study questionnaires such as the ACQ, AQLQ(S) 
and EQ5D-5L at regular intervals, and provided them with stamped addressed 
envelopes to send back to the lead researcher. However this could have 
resulted in missing data from participants who may mislay or forget to post back 
their questionnaires, and the administrative burden for patients could affect 
recruitment rates. 
 
 
6.3 Implications for practice 
As discussed in the introduction (Chapter 2.1.5), the NHS outcomes strategy 
for COPD and asthma (Department of Health, 2011) and NICE quality 
standards for asthma (National Institute for Health and Care Excellence, 2013) 
outline the priority issues in asthma where healthcare professionals should seek 
to improve the overall management of asthma. The interventions performed and 
results of this study support both of these national documents and it also 
addresses gaps in the current understanding of the potential role of 
pharmacists. 
 
This study has established that the management of patients with difficult asthma 
through the provision of pharmaceutical care from hospital-based advanced 
clinical pharmacists is non-inferior to usual medical care in difficult asthma 
clinics. The increased number of interventions focusing on medicines 
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optimisation, achieving improvements in adherence and stabilising asthma 
control in complex cases of difficult asthma demonstrates that pharmacists have 
a different skill set to doctors, which may be of additional value in difficult 
asthma clinics. For example, the increase in number of interventions addressing 
inhaler technique suggests that pharmacists may have greater understanding of 
the criteria for optimal inhaler technique and may be better at identifying steps 
in inhaler technique that are performed incorrectly.  
 
Pharmacists are well placed and have the appropriate skills to focus on a 
number of NICE quality standards (National Institute for Health and Care 
Excellence, 2013), including providing written personalised action plans 
(statement 3), training and assessing of inhaler technique (statement 4), 
performing structured asthma reviews in the community (statement 5), and 
assessing asthma control (statement 6). This is justified by the fact that these 
are all areas that pharmacists have addressed in this and other studies, 
resulting in improved asthma outcomes or non-inferiority to usual medical care. 
 
It is important that commissioners are aware of the beneficial role of 
pharmacists in difficult asthma services and that specialist pharmacists are 
encouraged to support difficult asthma services focusing on interventions 
outlined in the NICE quality standards. The challenge for the pharmacy 
profession will be to provide commissioners with information on the service 
specifications for pharmacist-provided care and data on the cost likely to be 
incurred compared to usual medical care to achieve benefits for patients, 
although further research may be required to provide this. 
 
Since this study demonstrates that pharmacists can be effective in managing 
difficult asthma, all pharmacists providing asthma services in primary and 
secondary care settings should be reassured and encouraged to take a more 
active role in leading on asthma management. It should be noted that the 
majority of pharmacist interventions in this study were performed by a hospital-
based advanced clinical pharmacist with specialist knowledge and training in 
respiratory medicine, and so the results may only be applicable to specialist 
respiratory pharmacists rather than also to non-specialist or community 
pharmacists.  
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Overall, the results of this study demonstrate that there are a number of priority 
areas that should be addressed to improve the management of difficult asthma. 
These include education of healthcare professionals, incorporation of specialist 
pharmacists into multidisciplinary difficult asthma clinics, improving the structure 
and performance of asthma reviews, patient education, medicines optimisation 
and improving adherence, improving inhaler technique education, and 
increased uptake of MURs. 
 
6.3.1 Education of healthcare professionals 
In order to ensure that pharmacists can implement and support the NICE quality 
standards for asthma (National Institute for Health and Care Excellence, 2013), 
education should be prioritised. Standardised and validated healthcare training 
courses should be developed to facilitate the training of pharmacists and other 
healthcare professionals in the correct use of inhaler devices. 
 
This is necessary to ensure that pharmacists providing asthma services in 
secondary care or as part of the MUR service become asthma experts and 
have the confidence to improve patient care, as the poor uptake of MURs in this 
study might suggest that some community pharmacists do not feel confident in 
managing complex cases of difficult asthma. 
 
The lack of validated training packages or courses on inhaler technique is a 
failing of UK healthcare practice because it is well recognised that the majority 
of healthcare professionals have poor knowledge on the correct use of different 
devices (see Chapter 2.2.4). Whilst there are inhaler technique guides 
available, such as from Asthma UK and GINA, and courses for healthcare 
professionals, such as from The Centre for Pharmacy Postgraduate Education 
and Simple Steps Education (http://www.simplestepseducation.co.uk), these 
have not been validated and vary in content. 
 
6.3.2 The role of pharmacists in difficult asthma clinics 
Specialist pharmacists should be incorporated into multidisciplinary teams 
working in secondary care difficult asthma clinics, and this should be a 
 196 
requirement of the NHS England service specification for severe asthma 
services (NHS England, 2013). 
 
The 2010 White paper, Equity and excellence, recognised that “pharmacists, 
working with doctors and other health professionals, have an important and 
expanding role in optimising the use of medicines and in supporting better 
health“ (Department of Health, 2010). This assertion is supported by the 
findings of this study, which has established that the provision of 
pharmaceutical care from hospital-based advanced clinical pharmacists to 
patients with difficult asthma is non-inferior to usual medical care.  
 
Pharmacist-led services may be cheaper than consultant physician-led services 
in terms of staff costs, and could free up consultant physician time for other 
complex tasks that others could not perform within the NHS England service 
specification for severe asthma services (NHS England, 2013). 
 
6.3.3 Format of asthma reviews 
This study did use a protocol to aid asthma reviews in the PI group (Appendix 
7), and may provide advantages in clinical practice by ensuring that all 
recommended components of an asthma review are addressed. An alternative, 
but similar method previously recommended to aid pharmacists about how to 
manage asthma is to use the acronym SIMPLE as an aid to remembering the 
main components of asthma reviews during clinic consultations or MURs 
(Murphy, 2014, Murphy et al., 2012b). Variants of this have been recommended 
to GPs (Ryan et al., 2013). SIMPLE stands for Stop smoking, Inhaler technique, 
Monitoring, Pharmacotherapy, Lifestyle and Education. 
 
Monitoring of asthma control should be performed regularly by pharmacists as 
part of asthma reviews in primary and secondary care, or to identify patients 
who may require a t-MUR. Assessing asthma control is a quick and simple task 
to perform, and can be achieved through a variety of quick and validated tools 
such as ACQ or the ACT (British Thoracic Society and Scottish Intercollegiate 
Guidelines Network, 2014). These are often given to patients to complete 
before hospital clinic appointments as a review assessment, but can also be 
given by community pharmacists to patients whilst they wait for their 
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prescription to be dispensed as this may assist in identifying which patients to 
target for asthma MURs. 
 
Healthcare professionals may benefit from training on consultation styles such 
as CBCT and motivational interviewing techniques, since these have been 
demonstrated to improve adherence in patient populations with both difficult 
asthma (Gamble et al., 2011) and other long term conditions (Easthall et al., 
2013). However these consultation styles are time and labour intensive, with 
one study in difficult asthma requiring up to eight individual intervention visits 
over a 12-week period (Gamble et al., 2011), whilst other studies described in 
one systematic review ranged from a one-off 30 minute session up to four hours 
divided over multiple visits (Easthall et al., 2013). In the current study, none of 
the healthcare professionals in either group had received prior training on these 
counselling techniques, and there was insufficient time within the clinic 
appointments to dedicate to these techniques. 
 
6.3.4 Patient education 
All patients should be provided with self-management education and offered an 
asthma action plan, such as those available from Asthma UK or the Primary 
Care Respiratory Society, as this improves health outcomes (British Thoracic 
Society and Scottish Intercollegiate Guidelines Network, 2014). In addition, 
patients should be provided with written information on asthma, such as patient 
information leaflets provided by Asthma UK and the British Lung Foundation, or 
from the NHS Choices website. These may be useful to reinforce education 
provided to patients during asthma consultations 
 
Although smoking cessation support was an uncommon intervention in this 
study as only 3 patients in each study group were current smokers, all asthma 
patients who are currently smoking should be offered nicotine replacement 
therapy or other drug therapy and referral to local stop smoking services. This is 
an important healthy living intervention and should be foremost in all patient 
contacts as smoking has been associated with worsening asthma control, 
increased exacerbations and increased risk of mortality (Ryan et al., 2013). 
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Similarly, the lifestyle of asthma patients should form part of asthma reviews 
and MURs, with particular regards to identifying and avoiding triggers for 
worsening asthma control, as well as providing healthy living advice including 
diet, exercise, weight management and alcohol since each of these can 
adversely affect asthma control (British Thoracic Society and Scottish 
Intercollegiate Guidelines Network, 2014, Ryan et al., 2013).  
 
6.3.5 Medicines optimisation 
Pharmacists should use their skills routinely to ensure that medicines are 
prescribed used correctly, by optimising treatment regimens, stepping up or 
stepping down treatment as necessary, and assessing adherence.  
 
6.3.6 Adherence 
Adherence to ICS is well recognised to be highly variable amongst asthma 
patients, and this study found that more than half of participants had adherence 
rates less than 80% and a more than a third had adherence rates less than 
50%, and nearly one in five had adherence rates exceeding 100%. Community 
pharmacists are well placed to monitor adherence using prescription refill rates, 
and should use these data proactively to identify potential non-adherent 
patients and target these for MURs, since this may improve asthma control and 
allow a reduction in prescribed ICS dose if taken regularly (Khachi and Karikari, 
2013). 
 
There is a clear need for primary care healthcare professionals, including GPs, 
practice nurses and primary care pharmacists to review adherence data as part 
of annual asthma reviews, especially in patients with uncontrolled asthma. 
Furthermore there should be easy access to GP prescribing data in difficult 
asthma clinics at hospitals.  
 
6.3.7 Inhaler technique 
Pharmacists, and other healthcare professionals in all sectors should check and 
optimise inhaler technique regularly at every patient contact, whether during 
hospital admissions, clinic appointments, asthma reviews, MURs, or when 
collecting prescriptions.  
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Inhaler technique in this study was poor amongst participants in both groups for 
all devices, with many making critical errors that would be expected to 
substantially reduce the effective dose received, and thus reducing the clinical 
efficacy of ICS. Whilst inhaler technique was improved during the baseline 
consultations, this was not maintained by six-months, and indeed was not 
maintained by two months in the six participants who had a t-MUR. This 
highlights the importance of rechecking inhaler technique soon after it has been 
optimised, and regularly thereafter. 
 
Since inhaler technique was poor throughout the study, this again highlights an 
urgent need for standardised and validated inhaler technique checklists to be 
developed to aid the assessment and optimisation of patients’ inhaler 
technique. 
 
6.3.8 MURs 
This study was designed to provide co-ordinated pharmaceutical care between 
primary and secondary care pharmacists to ensure that all participants in the PI 
group received follow-up consultations with new and reinforced interventions in 
attempt to optimise medical management of difficult asthma. A pilot study 
preceding this study had found that there were further opportunities for 
community pharmacists to provide support for asthma patients since two thirds 
of patients attending the difficult asthma clinic, who were eligible, had not been 
offered a MUR (Capstick et al., 2012). Therefore the MUR service was chosen 
as an opportunity to provide this co-ordinated pharmaceutical care because the 
community pharmacy MUR service is well established (Blenkinsopp et al., 2007, 
Blenkinsopp et al., 2008, The Cambridge Consortium, 2012). However this 
study experienced difficulties achieving shared care between secondary and 
primary care pharmacists due to poor uptake of t-MURs partly resulting from an 
apparent miscommunication between community pharmacists and patients.  
 
Community pharmacists should aim to increase the number of MURs offered to 
patients with difficult asthma, which may be achieved by identifying patients 
prescribed high ICS doses, frequent prescriptions for SABAs and using ACQ or 
ACT questionnaires. Improved education of community pharmacists may 
increase their knowledge, skills and confidence in providing MURs to patients 
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with difficult asthma, where their condition and treatment appears to be very 
complex. 
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7 Conclusions and recommendations for future work 
7.1 Conclusions  
The aim of this research study was to investigate the effects of a co-ordinated 
management strategy between primary and specialist secondary care 
pharmacists on asthma control and quality of life in patients with difficult 
asthma. This study is the first to investigate the effects of a redesigned 
pharmaceutical pathway across the primary and secondary care interface in 
patients with difficult asthma, and the first to compare pharmaceutical 
management of asthma to usual medical care. 
 
Three literature searches were performed to evaluate published studies 
examining the effects of (i) complex pharmacist interventions, (ii) inhaler 
technique, and (iii) interventions to improve adherence, on asthma control, and 
a review of research study design was undertaken. This facilitated the decision 
to design a pragmatic six-month, prospective, randomised, open trial to 
compare the management of patients with difficult asthma by a hospital-based 
specialist advanced clinical pharmacist with follow-up t-MUR from community 
pharmacists, to usual medical care. A sample size calculation required 52 
patients to be recruited to demonstrate a clinical and statistically significant 
difference in ACQ score between the two study groups assuming a 25% attrition 
rate. This study was successful in recruiting 52 patients, of whom 47 were 
followed up for six-months, and consequently this study was adequately 
powered for the primary outcome measure of ACQ score. 
 
This study recruited a representative sample of patients with difficult asthma 
who were uncontrolled, requiring frequent emergency courses of OCS to treat 
asthma exacerbations, and were high users of SABA inhalers. The interventions 
provided to participants randomised to the PI group were individualised 
according to their identified needs, and were based on current published 
evidence to ensure that they were likely to have benefits to each patient. The 
outcome measures used in this study were appropriate for use in this study, as 
they are relevant to routine clinical practice and are recommended endpoints for 
clinical asthma trials (Reddel et al., 2009).  
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In contrast, a major limitation of the study was that only six of the 26 participants 
in the PI group received a t-MUR from their usual community pharmacist, 
despite receiving a written and verbal referral. Consequently few participants in 
the PI group received the full protocol interventions or received reinforcement of 
the interventions provided in the initial baseline consultation.  
 
Participants in the PI group received significantly more interventions at the 
baseline consultation in the hospital difficult asthma clinic than participants in 
the UC group, reflecting the ability of pharmacists to identify unmet health 
needs in patients with difficult asthma. 
 
At six-months, the provision of pharmaceutical care from hospital-based 
advanced clinical pharmacists to patients with difficult asthma was non-inferior 
to usual medical care for the primary outcome measure of ACQ, and also for all 
other asthma outcomes measured, including quality of life, inhaler technique 
and overall adherence. Asthma control and quality of life was stabilised in both 
study groups, with low rates of exacerbations and hospital admissions, which 
can be regarded as a positive outcome in a study of patients with difficult 
asthma who generally 
 
Inhaler technique at baseline was poor in all participants, which was likely due 
to the fact that fewer than half of participants had previously received inhaler 
technique training by primary care healthcare professionals. Inhaler technique 
was improved with education at baseline in both study groups, but this was not 
maintained in either group. It is likely that patients should receive regular and 
repeated reinforcement of correct inhaler technique to ensure they maintain 
correct inhaler technique in the long-term. 
 
Adherence to ICS treatment was poor in both study groups and patient self-
reported adherence under-estimates adherence according to prescription data. 
Just over half of participants had sub-optimal ICS adherence (defined as 
adherence rates less than 80%), and approximately one-third of participants 
collected less than half of their ICS prescriptions. In this study, there was a 
greater increase in the proportion of patients with adherence rates 80-120% in 
the PI than the UC group over the six-month study period, demonstrating that 
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the pharmacist had a greater impact on adherence than physicians. As poor 
ICS adherence should adversely affect asthma control, there is a need for 
primary care healthcare professionals including GPs, practice nurses and 
pharmacists to review adherence data, especially in participants with poor 
asthma control.  
 
This study has provided proof of concept that the management of patients with 
difficult asthma can be adequately provided by an advanced clinical pharmacist 
with a specialist interest in respiratory medicine, as an alternative to usual 
medical management. Complex interventions provided by a pharmacist that 
incorporates asthma monitoring, inhaler technique training, medicines 
optimisation and adherence counselling, education, asthma action plan 
provision, and healthy living advice are useful in stabilising difficult asthma and 
preventing exacerbations.  
 
 
7.2 Recommendations for future research 
The main unanswered questions arising from this study stem from the fact that 
the majority of participants in the PI group did not have a t-MUR and so did not 
receive any follow-up interventions. Consequently it is not known whether 
following up baseline consultations in hospital difficult asthma clinics with t-
MURs would achieve additive benefits on asthma outcomes, inhaler technique 
or adherence. It is recommended that future research should examine whether 
t-MURs can achieve additional benefits in difficult asthma following the initial 
pharmacist consultations in order to support and build on improvements in 
medicines use. If t-MURs are not well used or effective in supporting the initial 
hospital consultation for patients with difficult asthma, research could 
investigate support provided by GPs, practice nurses or primary care practice-
based pharmacists. 
 
Research should be undertaken to determine the optimum frequency of follow-
up consultations that are required to maintain optimal inhaler technique and 
adherence.  
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Since adherence was poor for many patients, strategies to enhance the 
identification of poor adherence in primary care and secondary care difficult 
asthma clinics should be studied. The effect of increased reviews of adherence 
data in difficult asthma should be investigated to determine whether this 
improves overall adherence and asthma outcomes. 
 
There are a number of novel inhaler devices, which may be easier to use than 
existing devices that have been launched for use in asthma in 2104 including 
Ellipta, Nexthaler and Spiromax. Research should be undertaken to investigate 
patients’ preference for these devices over existing alternatives in an 
independent study, and whether these devices will improve adherence and 
inhaler technique, and how this might impact on asthma control. 
 
 
 
 
 
  205 
8 Appendices 
Appendix 1. Characteristics of included studies: Effect of complex 
pharmacist interventions on asthma control 
Criteria for judging bias is based on the Cochrane handbook for systematic 
reviews (Higgins and Green, 2011). 
 
Armour et al., 2007 
Methods Six-month, multi-site, randomised intervention versus control 
repeated measures study, in Australia. 
Participants Population: 50 community pharmacies recruited 396 patients 
(Pharmacist Intervention [PI]: 191; Usual Care [UC]: 205). 
Baseline characteristics: In the PI group, mean age 47.5 
years, FEV1 79.3% predicted. 88.0% have severe asthma 
symptoms, 9.4% have moderate symptoms. 87.2% were 
taking a preventer + reliever ± LABA, 12.8% were taking a 
reliever only. In the UC group, mean age 50.4 years, FEV1 
75.4% predicted. 70.8% have severe asthma symptoms, 
27.7% have moderate symptoms. 84.3% were taking a 
preventer + reliever ± LABA, 15.7% were taking a reliever only. 
Inclusion criteria (Pharmacies): Community pharmacies had 
to have Quality Care Pharmacy Program accreditation in 
Australia, compatible computer system to use spirometer 
software, have a minimum of two pharmacists on duty at all 
times who must have attended a study training session.  
Inclusion criteria (Patients): Adults aged 18-75 years, with a 
previous diagnosis of asthma, and fulfil 1 or more of the 
revised Jones' Morbidity Index subcriteria demonstrating 
uncontrolled asthma (within the past 4 weeks: use of reliever 
inhaler >3 times a week, nocturnal or early morning symptoms, 
time off work/study because of asthma, and no visits to a 
doctor because of asthma within the past 6 months. 
Exclusion criteria (Pharmacies): Community pharmacies 
were excluded if they were currently involved with any other 
research project. 
Exclusion criteria (Patients): Terminal illness, current 
enrolment within another clinical trial, do not self-administer 
inhalers, do not speak English well enough to complete 
questionnaires or communicate with pharmacists. 
Interventions 1. Pharmacists in the PI group were given an asthma 
education manual and were trained on risk assessment, 
pathophysiology of asthma, asthma medications, National 
Asthma Council six-step asthma management plan, patient 
education, goal setting, adherence assessment, spirometry 
(by qualified respiratory scientists), during a 2-day 
workshop delivered by the research team. The intervention 
provided to patients was the Pharmacy Asthma Care 
Program protocol, specifically assessing asthma control, 
targeted counselling and education on asthma, medication 
and lifestyle issues, review of inhaler technique, 
adherence, detection of drug-related problems, goal 
setting and referral to GP as appropriate. This was 
reinforced at 1-month, and again at 3-months if necessary. 
2. Pharmacists in the UC group were trained on risk 
assessment, spirometry and the control protocol only. 
Patients in the UC group received no intervention, except 
from the pharmacist’s usual care. 
Outcomes The primary outcome measure was change in overall asthma 
severity/control, as assessed using the Australian National 
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Asthma Council asthma severity assessment table. At 6-
months, the proportion of patients who were classified as 
having severe asthma declined significantly in the PI group 
(87.9% to 52.7%, p<0.001), whilst that of the UC group 
remained unchanged (71.2% to 67.9%, p=0.11), associated 
with an odds ratio for reduced proportion of patients with 
severe asthma in the PI group of 2.68, 95% CI 1.64 to 4.37; 
p<0.001). 
There was a greater improvement in health status in PI vs. UC 
group, with a mean difference in improvement in AQLQ of 
0.23, p<0.05. 
Risk of bias 
Bias Author’s judgement Support for judgement 
Random sequence generation 
(selection bias) 
Unclear risk Pharmacists providing PI or 
UC were randomly assigned 
to either group, but sequence 
generation was not described. 
Allocation concealment 
(selection bias) 
Unclear risk Allocation of community 
pharmacists to PI or UC group 
was not described. 
Blinding of participants and 
personnel (performance bias) 
All outcomes 
Low risk No blinding performed, but 
cluster randomisation method 
likely to minimise cross-
contamination. 
Blinding of outcome 
assessment (detection bias) 
All outcomes 
High risk Risk of detection bias due to 
unblinded assessments. 
Incomplete outcome data 
(attrition bias) 
All outcomes 
Low risk Power calculation reported, 
and attrition rate (PI:13.6%, 
UC 9.3%) was within 
acceptable limits (25%). 
Selective reporting (reporting 
bias) 
Low risk The study protocol is not 
available, but all data reported 
for patients in both groups. 
Other bias Low risk The study appears to be free 
if other sources of bias. 
 
 
 
Barbanel et al., 2003 
Methods Three-month, randomised controlled study, in London, 
England. 
 
Participants Population: 24 adults (Intervention group: 12; Control group: 
12). 
Baseline characteristics: Mean (SD) age 45 (17) in the 
intervention group and 47 (17) in the control group.  
Inclusion criteria: Age 18-65 years with a GP diagnosis of 
asthma, who were using ICS. 
Exclusion criteria: Recent attendance at secondary care 
hospital with acute asthma, change in asthma treatment within 
6 weeks, acute respiratory infection. 
 
Interventions The community pharmacist attended a 3-day multidisciplinary 
course on asthma care.  
Patients in the intervention group received education, 
assessment of inhaler technique, and self-management advice 
based on PEF measurements and symptoms, with weekly 
telephone follow-up. Patients in the control group received no 
input from the pharmacist. 
 
Outcomes Outcome measure used the 'North of England asthma 
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symptoms scale' - a validated instrument measuring asthma 
related health status, where a 6-point reduction in score 
indicates a significant improvement in asthma.  
 
In the intervention group, a significant improvement in 
symptom scores was observed (26.3 to 20.3, mean 
improvement = 6 [clinically meaningful improvement]). 
In the control group, there was a worsening of symptom scores 
(27.8 to 28.1).  
Overall, there was a significant improvement in patients in the 
intervention compared to the control group (difference adjusted 
for baseline scores = 7.0 [95% CI 4.4 to 9.5] p<0.001). 
 
Risk of bias 
Bias Author’s judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low risk Patients were randomised 
using sealed envelopes. 
 
Allocation concealment 
(selection bias) 
Unclear risk Patients were randomised 
using sealed envelopes, but 
method of allocation / 
selection of envelopes was 
not described. 
Blinding of participants and 
personnel (performance bias) 
All outcomes 
High risk No description of blinding, 
except that Control group 
received no input from the 
pharmacist. 
Blinding of outcome 
assessment (detection bias) 
All outcomes 
Low risk All patients completed 
questionnaires with no input 
from the pharmacist. 
Incomplete outcome data 
(attrition bias) 
All outcomes 
Unclear risk One control patient lost to 
follow-up. No power 
calculation performed. 
Selective reporting (reporting 
bias) 
Low risk Low risk. Data reported for 
patients in both groups. 
 
Other bias Low risk The study appears to be free 
if other sources of bias. 
 
 
 
Charrois et al., 2006 
Methods Six month, prospective, randomised controlled study, in rural 
Alberta, Canada. 
 
Participants Population: Five trained community pharmacies recruited 70 
patients (36 in the intervention group, 34 in the usual care 
group). 9 patients (2 in the intervention group) did not complete 
the 6-month study. 
Baseline characteristics: Mean ± SD age was 35.7 ± 10.2 
years in the intervention group and 38.7 ± 10.7 years in the 
usual care group. Significantly fewer patients were assessed 
as having adequate inhaler technique in the intervention group 
(66.7% vs. 88.2%, p<0.05). Patients in the intervention and 
control groups had similar baseline asthma control (Mean ± 
SE) ACQ 1.45 (0.19) vs. 1.91 (0.18) respectively, and a similar 
proportion were prescribed ICS (69.4% vs. 76.5%). 
Inclusion criteria: Adults aged 17-54 years with a self-
reported diagnosis of asthma, and considered at high risk 
(defined as an emergency department visit or hospital 
admission due to asthma in the previous 12 months or use of 
>2 canisters of inhaled beta2-agonist in the previous 6 months. 
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Exclusion criteria: Inability to understand English, patients 
who do not administer their own medicines, were not available 
for 6-month follow-up, or did not provide consent. 
 
Interventions Patients in the intervention group were received an educational 
program on asthma, action plan, assessment of asthma 
therapy, and referral to a respiratory therapist and primary care 
physician as needed.  Patients were followed up at followed up 
at 0, 0.5, 1, 2, 4 and 6 months. 
Patients in the usual care group received an asthma education 
booklet and general advice as needed. Patients were followed 
up at 0, 2, and 6 months. 
 
Outcomes The primary objective was change in ACQ. The mean change 
in ACQ at 6 
months was 0.33 for the control group (standard error [SE] 
0.17) and 0.43 in the intervention group (SE 0.15) (p = 0.66). 
There was no significant difference in change in ACQ between 
the two groups. There was no significant difference between 
the two groups for any of the secondary outcomes: emergency 
department visits, hospital admissions, use of inhaled or OCS 
or lung function using FEV1. 
 
Compliance with intervention was poor: only 75% of the 
intervention group received an action plan, fewer than half had 
education at each visit, more than half had no 
recommendations made to improve asthma control. 
 
Risk of bias 
Bias Author’s judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low risk Internet randomisation service 
provided by the Epidemiology 
Coordinating and Research 
(EPICORE) Centre and the 
Centre for Community 
Pharmacy Research and 
Interdisciplinary Strategies 
(COMPRIS) at the University 
of Alberta. 
Allocation concealment 
(selection bias) 
Low risk Central allocation methods 
were used.  
 
Blinding of participants and 
personnel (performance bias) 
All outcomes 
High risk No blinding. 
 
Blinding of outcome 
assessment (detection bias) 
All outcomes 
High risk Unblinded assessments. 
 
Incomplete outcome data 
(attrition bias) 
All outcomes 
Low risk Power calculation reported (in 
a prior publication), and 
attrition rate (13%) was within 
acceptable limits (29%). 
Selective reporting (reporting 
bias) 
Low risk All data reported. 
 
 
Other bias Low risk The study appears to be free 
if other sources of bias. 
 
 
 
Cordina et al., 2001 
Methods 12-month randomised controlled longitudinal, prospective trial, 
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in Malta. 
 
Participants Population: 22 community pharmacists (11 trained to provide 
the intervention, and 11 untrained for the control group). 152 
patients were recruited (86 in the intervention group, and 66 in 
the control group. 
Baseline characteristics: Mean age 41.3 ± 18.35 years in the 
intervention group and 45.88 ± 18.11 years in the control 
group. The mean PEF was 374.93 ± 134.08 L/min in the 
intervention group and (390.12 ± 137.91 L/min in the control 
group. 
Inclusion criteria: Adults and adolescents aged 14 years and 
older, who were registered at an asthma clinic. 
Exclusion criteria: Other significant pulmonary disease or 
condition that would hinder PFT performance or completion of 
questionnaires. 
 
Interventions Patients in the intervention group received a comprehensive 
asthma education and monitoring program, including 
information on asthma pathology, triggers, use of inhaler 
devices and peak flow meters using verbal counselling, 
educational video, information leaflet, and subsequent 
monitoring and reinforcement. Follow-up occurred at monthly 
intervals. 
Patients in the control group received routine dispensing only. 
 
Outcomes At 12 months, there was no difference in health-related quality 
of life using SF-36 between the two groups (data not reported), 
however using the LWAQ, patients in the intervention group 
reported better quality of life than patients in the control group 
at 12 months (0.96 ± 0.38 vs. 1.03 ± 0.036 at baseline, 
p=0.044), but this was not significantly different from the 
control group using repeated-measures ANOVA using age and 
gender as covariates.  
At 12 months, the mean PEF was significantly lower than at 
baseline in patients within the control group (for 55 patients 
where data were available, from 377 ± 131 L/min to 340 ± 115 
L/min, p=0.009), but was unchanged in the intervention group 
(data not reported). 
There was no significant difference in the number of GP visits 
or number of days of work or school lost. 
Significantly more patients in the intervention group improved 
their inhaler technique over the 12-month study duration than 
in the control group (40/64 vs. 24/55, p<0.001).  
 
Risk of bias 
Bias Author’s judgement Support for judgement 
Random sequence generation 
(selection bias) 
Unclear risk Pharmacists providing PI or 
UC were randomly assigned 
to either group, but sequence 
generation was not described. 
Allocation concealment 
(selection bias) 
Unclear risk Allocation of community 
pharmacists to PI or UC group 
was not described. 
Blinding of participants and 
personnel (performance bias) 
All outcomes 
Low risk No blinding performed, but 
cluster randomisation method 
likely to minimise cross-
contamination. 
Blinding of outcome 
assessment (detection bias) 
All outcomes 
High risk Unblinded assessments. 
 
Incomplete outcome data Unclear risk Sample Size calculation not 
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(attrition bias) 
All outcomes 
specified. 119 (of 152 [78%] 
patients completed study. 
Selective reporting (reporting 
bias) 
High risk Complete data on the first 
outcome measure SF-36 was 
not reported. 
Other bias Low risk The study appears to be free 
if other sources of bias. 
 
 
 
Garcia-Cardenas et al., 2013 
Methods 6 month cluster randomised controlled trial, in Spain. 
 
Participants Population: 33 community pharmacies were trained to provide 
the intervention (29 took part in study) and 32 untrained 
community pharmacies were recruited for the control group (22 
took part in the study). 373 patients enrolled, 346 patients 
completed, but one pharmacy data excluded from analysis due 
to lack of reliable data, therefore 336 patients were available 
for analysis (186 in the intervention group, 150 in the control 
group). 
Baseline characteristics: Mean (SD) age was 55.8 (19.1) 
years. Mean (SD) ACQ was 1.4 (1.1) and 1.3 (1.2) in the 
intervention and control groups respectively, however 
significantly fewer patients in the intervention group had 
controlled asthma (28% vs. 42.7%, p=0.005). 
Inclusion criteria: Adults aged 18 years or older with a 
physician diagnosis of asthma. 
Exclusion criteria: Participation in other asthma education 
programs, pregnancy, communication difficulties, suffering 
from seasonal asthma, or other pathologies such as COPD, 
lung cancer, RTIs or terminal illness. 
 
Interventions Patients recruited to the intervention group received a protocol-
based intervention addressing individual needs related to 
asthma control, inhaler technique and adherence. Patients 
also received     education using verbal and written 
instructions, and physical demonstration of Turbohaler use. 
Patients recruited to the control group received no intervention 
other than their pharmacist’s usual care (usually the safe 
supply of medicine use and advice about taking medicines). 
All patients in the intervention and control groups had three 
scheduled visits to the pharmacy, although intervention 
patients could have up to six visits if needed. 
 
Outcomes At six months, there was a clinical and statistically significant 
improvement in asthma control in the intervention group (ACQ 
-0.66, p<0.001), but not in the control group (-0.15 (p value not 
reported)).  
The mean difference between the groups in adjusted mean 
changes for ACQ from baseline to final visit was -0.18 (IC95% 
-0.37 to 0.02), p=0.079 in patients who had controlled asthma 
at baseline, and -0.62 (IC95% -0.80 to -0.43), p<0.001 in 
patients who had uncontrolled asthma at baseline.  
Turbohaler inhaler technique improved in the intervention and 
control groups from baseline to 3-month intermediate visits, but 
only from Intermediate to final 6-month visit in the intervention 
group. The proportion of patients with correct inhaler technique 
at 6 months was significantly higher in the intervention group 
compared to the control group (75.8% vs. 50.0%, p < 0.001).   
The proportion of patients who were found to be adherent to 
treatment at 6 months was significantly higher in the 
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intervention than in the control group (78.5% vs. 52.0%, p < 
0.001). 
 
Risk of bias 
Bias Author’s judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low risk Pharmacists /Pharmacies 
providing intervention or 
control were randomly 
assigned to either group, 
using a computer-generated 
list of random numbers with a 
1:1 ratio of pharmacies. 
Allocation concealment 
(selection bias) 
Low risk Allocation of pharmacies to 
intervention or control group 
performed by computer 
randomisation. 
Blinding of participants and 
personnel (performance bias) 
All outcomes 
Low risk No blinding performed, but 
cluster randomisation method 
likely to minimise cross-
contamination. 
Blinding of outcome 
assessment (detection bias) 
All outcomes 
High risk Unblinded assessments. 
 
Incomplete outcome data 
(attrition bias) 
All outcomes 
Low risk Study required 342 patients 
assuming a 20% attrition rate. 
336 completed the study, 
which was therefore within 
acceptable limits. 
Selective reporting (reporting 
bias) 
High risk 10 patients in the control 
group from one pharmacy 
were excluded from analysis 
due to lack of reliable data. 
Other bias Low risk The study appears to be free 
if other sources of bias. 
 
 
 
Kritkos et al., 2007 
Methods 12-week parallel group pilot study, with repeated measures 
design, in Sydney, Australia. 
 
Participants Population: Five trained community pharmacists providing the 
intervention, one trained pharmacist researcher, and two 
untrained community pharmacists providing usual care. 48 
patients were recruited (16 to the intervention provided by 
community pharmacist group (Group A), 16 to the intervention 
provided by pharmacist researcher group (Group B), 16 to the 
usual care provided by community pharmacist (Group C).  
Baseline characteristics: Mean ± SD age was 49.5 ± 20.6 
years, 56.9 ± 19.4 years and 46.4 ± 20.6 years in Groups A, B, 
and C respectively. The percentage of patients with severe 
asthma symptoms at baseline was 56%, 44% and 50% in 
Groups A, B and C respectively. There were no significant 
differences in medication use between Groups A, B, and C 
regarding ICS use (25%, 25%, and 19%), or combination 
therapy (75%, 75%, and 81%), respectively. 
Inclusion criteria: Age over 16 years, with a previous self-
reported diagnosis of asthma, assessed as uncontrolled using 
the Revised Jones Morbidity Index for asthma assessment, 
who could use a preventer medication, and could read and 
understand English 
Exclusion criteria: Self-reported diagnosis of COPD, unable 
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to use inhaler, or under on-going GP review within a 3+ Visit 
plan. 
 
Interventions The intervention provided by trained community pharmacists 
and the pharmacist researcher comprised education on 
asthma, its management, asthma medication, inhaler use, and 
relevant written information.  
Patients provided with usual care from their community 
pharmacists received the same written information, but had no 
additional education. Follow up was provided at 6 and 12 
weeks. 
 
Outcomes No primary outcome measure was specified. 
There was an improvement in inhaler technique; for the pMDI: 
the proportion of patients in groups A and B with optimal pMDI 
technique improved from 9% and 14%, respectively, at 
baseline to 82% and 93% respectively, at 12 weeks (n = 11, p 
=0.02; n = 14, p < 0.001). For the DPI: the proportion of 
patients in Groups A and B with optimal DPI technique 
improved from 9% and 14% respectively at baseline to 82% 
and 93% respectively at 12 weeks (n = 11, p =0.02; n = 14, p < 
0.001). There was no significant improvement in pMDI or DPI 
technique in control group.  
At baseline the proportion of patients with severe asthma/poor 
control was 56%, 44% and 50% in Groups A, B and C 
respectively; at 12 weeks there were significantly fewer 
patients in Groups A and B with severe asthma/poor control 
(25% and 13%) than in Group C (50%), p=0.04).  
There were also significant improvements in quality of life 
(measured as change in AQLQ) in Group A (change in mean 
score 1.1; p=0.03) and Group B (change in mean score 1.8; 
p=0.003) over 12 weeks, but not in Group C (change in mean 
score 0.0).  
There were also small, but significant improvements in 
adherence using the MARS in Groups A and B, although 
adherence was reported to be high at baseline. 
There was a significant increase in asthma knowledge post-
education and at 6 and 12 weeks in Groups A (p<0.001) and B 
(p<0.001), but there was no significant change in Group C. 
 
Risk of bias 
Bias Author’s judgement Support for judgement 
Random sequence generation 
(selection bias) 
Unclear risk Randomisation of Pharmacies 
to Group A, B or C not 
described. 
Allocation concealment 
(selection bias) 
Unclear risk Allocation of community 
pharmacists to each group 
was not described.  
Blinding of participants and 
personnel (performance bias) 
All outcomes 
Low risk No blinding performed, but 
cluster randomisation method 
likely to minimise cross-
contamination. 
Blinding of outcome 
assessment (detection bias) 
All outcomes 
High risk Unblinded assessments. 
 
Incomplete outcome data 
(attrition bias) 
All outcomes 
Low risk 100% retention rate. 
 
Selective reporting (reporting 
bias) 
Low risk All data reported. 
 
Other bias Low risk The study appears to be free 
if other sources of bias. 
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Mehuys et al., 2008 
Methods Six-month randomised, controlled, parallel-group trial, in 
Belgium 
 
Participants Population: 66 trained community pharmacists recruited 201 
patients (107 in the intervention group and 94 in the control 
group. 
Baseline characteristics: Mean age 35.2 years and 36.3 
years in the intervention and control groups respectively. 
Baseline morning PEF was 409.7 L/min and 390.7 L/min 
respectively. Mean ACT score at baseline was 19.7 and 19.3 
in the intervention and control groups respectively. 89.5% of 
intervention patients, and 93.9% of control group patients were 
taking either a ICS/LABA or ICS only inhaler at baseline. 
Inclusion criteria: Age 18-50yrs, treated for asthma at least 
12 months, using controller medication, and regular visitor to 
community pharmacy. 
Exclusion criteria: Smoking history >10pk years, other severe 
disease or ACT <15 or =25 
 
Interventions Patients in the intervention group received education on 
inhaler technique, asthma symptoms, triggers and warning 
signs, understanding medication, adherence and smoking 
cessation, with follow-up advice at 1- and 3-months if ACT still 
sub-optimal. 
Patients in the usual care group received usual pharmacist 
care. 
 
Outcomes 150 patients (75%) completed the study.  
Mean ACT was unchanged in both groups (However, in 
patients with insufficiently controlled asthma at baseline, the 
mean change from baseline was +2.3 and +0.3 in the 
intervention and control groups respectively, mean difference 
2.0 [95% CI 0.1-3.9] p=0.038)). There was no significant 
difference in the AQLQ. 
There was a significant decrease in rescue medicine use at 3 
and 6 months in the intervention vs. control group (at 6 months 
-0.57 vs. -0.43 inhalations per day, p=0.012).  
Adherence by prescription refill rates was higher in the 
intervention vs. control group (90.3% vs. 74.6%, p=0.016).  
Significantly more patients had optimal (100%) inhalation 
technique at 6 months in the intervention group (increase of 
40% to 64.3%, vs. a 20% increase to 36.5% in the control 
group. 
 
Risk of bias 
Bias Author’s judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low risk Sequence allocation 
predetermined by the 
investigators based on a 
randomisation table. 
Allocation concealment 
(selection bias) 
Low risk Serially numbered, closed 
envelopes were made for 
each participating pharmacy. 
Blinding of participants and 
personnel (performance bias) 
All outcomes 
High risk Each community pharmacy 
could have intervention and 
control patients. Intervention 
known 
Blinding of outcome High risk Unblinded assessments. 
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assessment (detection bias) 
All outcomes 
 
Incomplete outcome data 
(attrition bias) 
All outcomes 
Low risk Power calculation reported, 
and attrition rate (25%) was 
within acceptable limits (30%). 
Selective reporting (reporting 
bias) 
Low risk All data reported. 
 
 
Other bias Low risk The study appears to be free 
if other sources of bias. 
 
 
Petkova, 2008 
Methods Four-month, prospective, randomised controlled trial, in 
Bulgaria. 
 
Participants Population: 10 trained community pharmacies. 50 adults (22 
in the intervention group, 28 in the control group). 
Baseline characteristics: Mean age was 35.14 years and 
40.82 years in the intervention and control groups respectively. 
Three of the 22 patients in the intervention group had 
moderate to severe persistent asthma (according to Expert 
Panel Report 2: Guidelines for diagnostic and management of 
asthma, 1997) at baseline, compared to 12 of 28 in the control 
group. 
Inclusion criteria: Age >14 years with a diagnosis of bronchial 
asthma and understanding of spoken and written Bulgarian. 
Exclusion criteria: Presence of other significant pulmonary 
disease (e.g. carcinoma), presence of any condition that would 
hinder completion of questionnaires (e.g. poor eyesight or 
literacy). 
 
Interventions The intervention comprised a community pharmacy-based 
educational program on asthma, triggers, exercise, self-
management, smoking-cessation, treatment, inhaler technique, 
and side effects. Patients were followed-up on three 
occasions. 
The control group received usual care from their pharmacy, 
with no additional information provided. 
 
Outcomes No primary outcome measure was specified. 
At 4-months, quality of life (measured using patients’ 
subjective opinions assessed using an Asthma Assessment 
Form: 1 = interference all of the time, to 5 = interference none 
of the time) was increased in the intervention group (from 3.55 
± 1.355 to 3.77 ± 1.020, p<0.0001), but was reduced in the 
control group (from 3.39 ± 0.685 to 3.00 ± 0.903; p=0.039). 
There was no significant effect on lung function using PEF 
rate. 
Inhaler technique data is not presented in a manner to make 
conclusions on the clinical impact of good or poor inhaler 
technique. 
Risk of bias 
Bias Author’s judgement Support for judgement 
Random sequence generation 
(selection bias) 
High risk Random sequence generation 
not specified. However 'the 
separation is based on patient 
willingness to take part in the 
education program.' This may 
bias the recruitment process. 
Allocation concealment 
(selection bias) 
Low risk Random numbers used. 
 
  215 
 
Blinding of participants and 
personnel (performance bias) 
All outcomes 
High risk Likely no blinding. Unclear if 
any blinding occurred in any 
form - unclear if each 
pharmacy had intervention 
and control patients. 
Blinding of outcome 
assessment (detection bias) 
All outcomes 
High risk Unblinded assessments 
 
Incomplete outcome data 
(attrition bias) 
All outcomes 
Unclear risk All patients appear to have 
completed the 4-month study, 
but no Power calculation. 
Selective reporting (reporting 
bias) 
Low risk All data reported. 
 
Other bias High risk Inhaler technique assessment 
does not specify inhaler 
devices, and scoring method 
does not adequately indicate 
clinical impact of poor 
technique. 
 
 
Saini et al., 2008 
Methods Six-month, parallel group, controlled repeated measures 
research design study in New South Wales, Australia 
 
Participants Population: 12 community pharmacists trained to provide 
asthma intervention to 51 patients, and 8 untrained 
pharmacists to provide usual care to 39 patients. 90 patients in 
total (83 patients completed the study: 46 in the intervention 
group and 37 in the control group. 
Baseline characteristics: Mean age ± SD was 50.8 ± 15.3 
years in the intervention group and 50.4 ± 18.4 in the control 
group. Asthma severity score (using the National Asthma 
Council’s asthma severity classification; range 5-15 [5=mild; 
5=severe]) was 11.4 ± 2.8 and 10.3 ± 3.2 respectively. 
Inclusion criteria: Asthma patients who use their 
bronchodilator more than three times a week, frequent 
exacerbations, or patients who expressed general concerns 
over their asthma. 
Exclusion criteria: Age under 12 years, other major disease 
or terminal illness. 
 
Interventions The intervention comprised intensive pharmacist education 
(assess asthma severity, medication and inhaler use, perform 
spirometry, provide Action Plan, and education, and make 
appropriate interventions). Patients were followed up at 1-, 4- 
and 6-months. 
The control group comprised standard practice in community 
pharmacies. Patients were followed up at 6-months. 
 
Outcomes At 6 months: Asthma severity Score (range 5-15 [5=mild; 
5=severe]) showed a significant decrease (improvement) in 
intervention group compared to the control group (3.6 vs. 0.09; 
p<0.001 in the as per protocol results. This remained 
statistically significant in the intention to treat analysis 
(p<0.001). 
There was a significant reduction in the risk of non-adherence 
(-1.8 vs. -0.6 in the intervention vs. control groups, p=0.01 on a 
Brief Medication Questionnaire scale 1-11 [1=low risk of non-
adherence, 11 = high risk}, although baseline score was 3.0.  
There was no significant difference in change in quality of life 
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scores or salbutamol use in the intervention and control 
groups. 
 
Risk of bias 
Bias Author’s judgement Support for judgement 
Random sequence generation 
(selection bias) 
Unclear risk Pharmacists providing PI or 
UC were randomly assigned 
to either group, but sequence 
generation was not described. 
Allocation concealment 
(selection bias) 
Unclear risk Allocation of community 
pharmacists to PI or UC group 
was not described. 
Blinding of participants and 
personnel (performance bias) 
All outcomes 
Low risk No blinding performed, but 
cluster randomisation method 
likely to minimise cross-
contamination. 
Blinding of outcome 
assessment (detection bias) 
All outcomes 
High risk Unblinded assessments. 
 
Incomplete outcome data 
(attrition bias) 
All outcomes 
Low risk Power calculation took into 
account potential attrition rate 
and clustering effect from 
Pharmacies 
Selective reporting (reporting 
bias) 
Low risk All data reported. 
 
 
Other bias Low risk The study appears to be free 
if other sources of bias. 
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Appendix 2. Characteristics of included studies: Effect of inhaler 
technique training on asthma control 
Criteria for judging bias is based on the Cochrane handbook for systematic 
reviews (Higgins and Green, 2011). 
 
Al-Showair, 2007 
Methods Six-week, randomised controlled trial, in English hospitals. 
 
Participants Population: 108 adult asthma patients (107 completed). 36 
patients recruited to the Good Technique [GT] control arm 
(good peak IFR on baseline testing, after extended screening 
following the completion of recruitment to the intervention arm); 
36 received Verbal Training [VT] (1 drop out) and 36 received 
verbal training plus 2Tone trainer Inhaler [2T]. 
Baseline characteristics: Mean age 52.6 to 60.4 years, mean 
FEV1 62.2 to 76.9% predicted. Mini-AQLQ 3.7 to 3.9. 
Inclusion criteria: Patients with asthma attending an 
outpatient clinic, treated with ICS via a pMDI without a spacer. 
Exclusion criteria: Asthma exacerbation within the past four 
weeks, deafness, or inability to distinguish between the one 
and two tones of the 2Tone trainer inhaler, poor co-ordination 
using a pMDI. 
 
Interventions It is unclear who performed the intervention in this study. 
Measurement of peak IFR using In-Check DIAL, and 
assessment of pMDI inhaler technique. 
Patients with good inhaler technique (good co-ordination and 
slow peak IFR (<90 L/min) were placed in the good technique 
(GT) control group. Patients with a fast peak IFR (>90 L/min) 
were randomised to either verbal training (VT) or verbal 
training plus provision of a 2Tone trainer inhaler (2T). 
Follow up at 6 weeks. 
 
Outcomes All 36 GT patients had peak IFR <90L/min at baseline and at 
six-weeks. 
At six weeks, there was a significant increase in the proportion 
of patients who had an appropriately slow (<90 L/min) 
inspiratory flow rate through a pMDI in both the VT (increased 
from 0 to 23/35 [66%], p<0.001) and 2T groups (increased 
from 0 to 35/36 [97%), p<0.001).  
Mean peak IFR at week 6 was 70.0, 80.0 and 50.0 for the GT, 
VT and 2T groups respectively. Mean change in peak IFR 
could not be calculated as the In Check was calibrated only up 
to 120L/min and many of the VT and 2T patients had peak 
IFRs >120L/min at Baseline.  
 
At week 6, no GT patients had a change in AQLQ >0.5; 14 VT 
patients had a change >0.5 and 3 >1; 22 2T patients had a 
change >0.5 and 8 >1. Only patients in the 2T group perceived 
an improvement in asthma control based on a 5-point Likert 
scale (an un-validated assessment). 
 
Risk of bias 
Bias Author’s judgement Support for judgement 
Random sequence generation 
(selection bias) 
Unclear Risk. Patients with fast peak IFR 
randomly allocated, but 
method of randomisation was 
not described. 
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Allocation concealment 
(selection bias) 
High Risk. Allocation method not 
described. 
 
Blinding of participants and 
personnel (performance bias) 
All outcomes 
High Risk. No blinding. 
 
Blinding of outcome 
assessment (detection bias) 
All outcomes 
High Risk. Unblinded assessments. 
 
Incomplete outcome data 
(attrition bias) 
All outcomes 
Low Risk. Power calculation required 30 
patients (+20%) in each 
group. 36 were recruited to 
each group with only 1 lost to 
follow-up. 
Selective reporting (reporting 
bias) 
Low Risk. All data reported. 
 
 
Other bias Low risk The study appears to be free 
if other sources of bias. 
 
 
 
Alamoudi, 2003 
Methods Six- to eight-week prospective open study, in hospital 
outpatient clinics in Saudi Arabia 
 
Participants Population: 130 patients with chronic stable asthma. (24 were 
excluded - 15 lost to follow-up, 9 developed exacerbation and 
changed dose of medication). 
Baseline characteristics: Mean age 40.2 years, with a mean 
duration of asthma of 11.2 years. 
Inclusion criteria: Fulfil the American Thoracic Society (1987) 
definition and diagnosis of asthma, chronic stable asthma, 
regular use of inhaled devices (pMDI or Turbohaler), incorrect 
inhalation technique, age >13 years. 
Exclusion criteria: Correct inhalation technique, smokers, 
development of an exacerbation requiring changes in doses 
during the 6-8 week study period, chronic obstructive airway 
disease.  
 
Interventions Checklist used to assess inhaler technique (1-11 points for 
pMDI, 1-7 points for Tubohaler). The intervention was 
performed by a nurse with an interest in asthma education, 
who provided education and demonstration on correct inhaler 
technique, for approximately 15-20 minutes. Review at 6-8 
weeks. 
 
Outcomes 106 patients completed the study. After education, the mean 
number of errors (pitfalls) reduced from 2.8±2.0 to 1.0±1.29 
(p<0.001) for pMDI and from 0.76±1.34 to 0.081±0.28 
(p=0.002) for Turbohaler.  
The improvement in inhaler technique was associated with an 
increase in mean PEF from 312.4±109.9 L/min to 331.0±105.8 
L/min (p=0.003) at 6-8 weeks. 
 
Risk of bias 
Bias Author’s judgement Support for judgement 
Random sequence generation 
(selection bias) 
n/a Pre-post test analysis, with no 
control group 
 
Allocation concealment 
(selection bias) 
n/a None. 
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Blinding of participants and 
personnel (performance bias) 
All outcomes 
High Risk. All patients had the 
intervention. 
 
Blinding of outcome 
assessment (detection bias) 
All outcomes 
High Risk. Unblinded assessments. 
 
Incomplete outcome data 
(attrition bias) 
All outcomes 
High Risk. No sample size calculations 
performed. 
 
Selective reporting (reporting 
bias) 
Low Risk All data reported. 
 
 
Other bias Low risk The study appears to be free 
if other sources of bias. 
 
 
 
Ammari, 2013 
Methods Six-week parallel-grouped clinical study in English community 
pharmacies 
 
Participants Population: 39 adults and 17 children. 50 completed (34 
adults, 16 children). 
Baseline characteristics: Mean age in adults was 40.7 years, 
and in children was 10.2 years. Mean FEV1 was 93.1% 
predicted in adults and 93.0% predicted in children. Based on 
GINA 2008 guidelines, 2/39 adults had severe asthma, 6 had 
moderate asthma and 31 had mild asthma; 1/15 child had 
severe asthma, 1 had moderate asthma and 13 had mild 
asthma (2 could not be assessed due to lack of spirometry 
results). 
Inclusion criteria: Asthma, age 4 to 55 years, prescribed at 
least one pMDI without a spacer device. 
Exclusion criteria: Acute exacerbation of asthma or received 
oral prednisolone within the previous four weeks, people with 
other illnesses adversely affecting the respiratory system, 
hearing problems, or inability to distinguish between the one 
and two tones of the 2Tone trainer inhaler.  
Interventions The intervention was performed by the lead researcher. 
Measurement of peak inhalation flow (IFR) using In-Check 
DIAL, and assessment of pMDI inhaler technique. 
Patients with good inhaler technique (good co-ordination and 
slow IFR (<90 L/min) were placed in the control (CT) group. 
Patients with a fast IFR (>90 L/min) were randomised to either 
verbal counselling (VC) or verbal counselling plus provision of 
a 2Tone trainer inhaler (2T). 
Follow up at 6 weeks. 
 
Mini-AQLQ for adults measured at baseline and 6 weeks 
 
Outcomes In adults - CT, VT, 2T: Baseline Median IFR 68, 200 and 240 
L/min; at 6 weeks: 88, 48.5 (p<0.001), 65 (p<0.001) L/min.  
Change in IFR between baseline and 6 weeks in the CT, VT 
and 2T groups was a median (quartiles) 12.0 L/min (–6.0, 
41.0), –143.5 L/min (–176.2, –50.0; p<0.001), and –165.0 
L/min (–225.0, –80.0; p<0.001) respectively.  
 
AT six-weeks, there was a significant reduction in the median 
(quartiles) number of incorrect steps made on an 11-point 
scale in both the VT (from 5.5 (5; 7) to 0 (0; 1), p<0.01) and 2T 
groups (from 5 (3; 6) to 1 (0; 2), p<0.01). No significant 
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improvement in inhaler technique was observed in the CT 
group (median (quartiles) number of errors changed from 3 (1; 
3.5) to 2 (1; 2.5). 
 
The mean (95% CI) change in mini-AQLQ was 0.053 (–0.41; 
0.52), -0.748 (–1.37; –0.12; p<0.05), and -0.409 (–0.91; 0.09) 
for the CT, VT and 2T groups respectively.  
 
There was no change in lung function using FEV1 in adults in 
either of the three groups, and the absence of clinically 
important change in quality of life may be likely to be due to the 
short duration of the study. 
 
Risk of bias 
Bias Author’s judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low risk. Randomisation based on a 
randomisation table. 
 
Allocation concealment 
(selection bias) 
Unclear risk. It is not specified whether this 
was an open randomisation 
table. 
Blinding of participants and 
personnel (performance bias) 
All outcomes 
Unclear risk. Allocation method unclear 
whether randomisation was by 
community pharmacy or within 
each pharmacy. 
Blinding of outcome 
assessment (detection bias) 
All outcomes 
High Risk. No blinding. 
 
Incomplete outcome data 
(attrition bias) 
All outcomes 
Unclear Risk No sample size calculations, 
but all patients accounted for. 
 
Selective reporting (reporting 
bias) 
Low Risk. All data reported. 
 
 
Other bias Low risk The study appears to be free 
if other sources of bias. 
 
 
 
Basheti, 2005 
Methods Two week pilot Study, in community pharmacies in Sydney, 
Australia. 
 
Participants Population: 26 adult asthma patients, 24 completed the study 
(one dropped out due to moving house, and one was unable to 
attend due to a leg injury) 
Baseline characteristics: Mean age 42 years. Six patients 
(23%) had severe asthma (based on categorisation in Asthma 
Management Handbook 2002, National Asthma Council 
Australia), 16 (62%) had moderate asthma, and 4 (15%) had 
mild asthma. 
Inclusion criteria: Diagnosis of asthma, dispensed a 
Turbohaler, aged 10 years and older. 
Exclusion criteria: patients who did not self-administer their 
Turbohaler, did not speak or understand English, if this was 
their first Turbohaler prescription.  
Interventions The intervention was performed by one of the study 
investigators, who is a qualified pharmacist. 
Turbohaler inhaler technique training by one of three methods: 
verbal counselling using patient information leaflet vs. 
augmented counselling (patient information leaflet with 
emphasis on essential steps) vs. augmented counselling plus 
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demonstration. Review at 2 weeks. 
 
Outcomes At baseline 0/26 had optimal technique. After 2 weeks, optimal 
technique (no minor or essential errors) achieved in 0/7, 2/8 
and 7/9 in the verbal counselling, augmented counselling and 
augmented counselling plus demonstration groups respectively 
(Fisher's Exact Test for verbal counselling vs. augmented 
counselling plus demonstration p=0.006).  
The number of patients with satisfactory (some minor, but no 
essential errors) or optimal technique improved from 3/8 to 4/7 
in the verbal counselling group, from 2/9 to 5/8 in the 
augmented counselling group, and from 1/9 to 9/9 in the 
augmented counselling plus demonstration group (verbal 
counselling vs. augmented counselling plus demonstration 
p=0.1). 
 
Risk of bias 
Bias Author’s judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low Risk. Computer generated list. 
 
Allocation concealment 
(selection bias) 
Unclear Risk. It is not clear whether the 
computer generated list was 
sealed to conceal future 
allocations. 
Blinding of participants and 
personnel (performance bias) 
All outcomes 
High Risk. No blinding. 
 
Blinding of outcome 
assessment (detection bias) 
All outcomes 
High Risk. Unblinded assessments. 
 
Incomplete outcome data 
(attrition bias) 
All outcomes 
High Risk. This was a pilot study, and so 
sample size calculations were 
not performed. 
Selective reporting (reporting 
bias) 
Low Risk. All data reported. 
 
 
Other bias Low risk The study appears to be free 
if other sources of bias. 
 
 
 
Basheti, 2008 
Methods Six month single-blind cluster randomised parallel group study, 
in in community pharmacies in Sydney, Australia 
Participants Population: 31 community pharmacists, all trained on asthma 
inhaled medication and PEF technique, but only the active 
group (16) received education on inhaler technique and use of 
inhaler technique labels. 97 patients recruited (53 active, 40 
control). 
Baseline characteristics: Baseline demographic data not 
reported. Asthma severity was classified as mild in 10%, 
moderate in 34% and severe in 56% of patients (using National 
Asthma Council Australia guidelines). 
Inclusion criteria: Age ≥14 years, with physician-diagnosed 
asthma, use of ICS with or without a LABA given via a 
Turbohaler or Accuhaler, no change in asthma medication or 
dose within the previous one month. 
Exclusion criteria: Patients who do not self-administer their 
own medicines, do not speak or understand English, were 
already involved in another study, or unable to complete the 
study follow-up. 
Interventions The intervention was performed by trained community 
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pharmacists, who had attended one of three evening 
workshops. 
Inhaler technique was assessed using a 9-point checklist by a 
community pharmacist in the active group and a study 
researcher (a qualified pharmacist) in the control group. 
Patients in the active group received inhaler technique training 
using augmented counselling and demonstration, repeated up 
to three times until all steps were performed correctly by the 
patient. An inhaler technique label was stuck on the inhaler 
device outlining the correct steps for using the inhaler device, 
with incorrect steps highlighted as a reminder to the patient to 
remember to use their inhaler device correctly. Inhaler 
technique was reinforced at 1, 2, 3 and 6 months 
Patients in the control group received no inhaler technique 
education. 
All patients were instructed how to use a peak flow meter.  
Outcomes The primary outcome variable for the study was peak flow 
variability expressed as Min%Max (lowest morning PEF as a 
percentage of the highest PEF over a 2-week period), however 
the results of this outcome measure were not reported. 
 
At 6 months, the mean inhaler technique score improved 
significantly from baseline in both groups, but was significantly 
greater for patients in the active than in the control group (for 
both Accuhaler and Turbohaler combined, the mean (± SD) 
change in score was 2.8 (±1.6) vs. 0.9 (±1.4), p < 0.001). 
In the Active group, asthma severity was significantly reduced 
at 2 months ( p = 0.001), 3 months ( p < 0.001) and 6 months ( 
p = 0.015) compared with the Control group. By 3 months, only 
8% of Active group patients were classified as having severe 
asthma compared with 22% of Control group patients (p = 
0.037). 
 
A post hoc analysis demonstrated a significant correlation 
between improvement in inhaler technique score and 
improvement in peak flow variability (r = 0.31, p=0.008) and 
asthma-related quality of life (r = -0.37, p=0.001). 
 
Risk of bias 
Bias Author’s judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low risk. Randomisation schedule 
generated using computer-
generated list. 
Allocation concealment 
(selection bias) 
Unclear risk. Allocation of pharmacies to 
provide either the intervention 
or usual care is not described, 
so there is an unknown 
selection bias. 
Blinding of participants and 
personnel (performance bias) 
All outcomes 
Low Risk. Community pharmacists were 
blinded to the actual 
intervention under 
investigation. Pharmacists in 
the Active and Control groups 
were taught how to educate 
patients on correct peak flow 
meter technique, to provide a 
plausible ‘sham; intervention, 
but only the Active group 
pharmacists were taught how 
to educate patients on correct 
inhaler technique. 
Blinding of outcome Low risk. One researcher independently 
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assessment (detection bias) 
All outcomes 
assessed inhaler technique of 
control patients, and checked 
for active patients 
Incomplete outcome data 
(attrition bias) 
All outcomes 
Low risk. Power calculation took into 
account potential attrition rate 
and clustering effect from 
Pharmacies 
Selective reporting (reporting 
bias) 
High risk. Data on the primary outcome 
variable of peak flow 
variability (Min%Max) was not 
reported. 
Other bias Low risk The study appears to be free 
if other sources of bias. 
 
 
 
Giraud, 2011 
Methods One month prospective observational study, in France 
 
Participants Population: 727 asthma patients at 123 community 
pharmacies 
Baseline characteristics: Mean age was 52 years. 61% were 
prescribed a pMDI, 34.5% an Autohaler and 4.5% an Easi-
Breathe. 
Inclusion criteria: Up to the first 10 adult (age ≥18 years) 
patients at each community pharmacy, with asthma who 
received a prescription for an ICS in either a pDMI, Autohaler 
or Easi-Breathe device. 
Exclusion criteria: None specified 
Interventions The intervention was performed by community pharmacists, 
who had received training in the form of a 2-hour session on 
basic asthma treatment, inhaler technique and developing 
individualised instructions for each patient. 
All patients received the intervention of community pharmacist 
Inhaler technique training using verbal instruction and written 
instructions in the form of a sticker to attach to the inhaler 
device (average duration 6 minutes).  
Patients completed ACQ and Morsiky assessment of 
adherence at baseline (0 [very good adherence] to 4 [very poor 
adherence]), and were given a questionnaire to complete 
follow-up assessments (include adherence and asthma 
control) at 1 month and post back (completed by 503 patients 
(69.2%)). 
Outcomes 67% of patients had previously received inhaler technique 
education by a healthcare professional, most commonly a 
respiratory physician, GP, or pharmacist. 
 
Prior to community pharmacist training, 24.1% of patients had 
optimal (no errors) inhaler technique, and 30% did not make 
any critical errors that would substantially affect dose delivery 
to the lungs. Immediately after community pharmacist training, 
optimal technique increased from 24% to 79% (p<0.001).  
 
Poor baseline inhaler technique was associated with worse 
asthma control and poor adherence (mean (SD) ACQ: 1.9 
(1.2) vs. 1.4 (1.1), p<0.001, and mean (SD) Morisky score 1.4 
(1.3) vs. 1.1 (1.2) p<0.01, respectively for patients with sub-
optimal vs. optimal inhaler technique respectively).   
 
At 1 month, mean (SD) ACQ improved from 1.8 (1.2) to 1.4 
(1.1) p<0.001 (n=437). There were significantly greater 
improvements in ACQ in patients where inhaler technique 
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improved: -0.4 (0.8), compared to -0.2 (0.8) and -0.2 (0.9) in 
patients whose inhaler technique remained sub-optimal or 
remained optimal respectively, p<0.01. 
 
Self-reported adherence improved from mean (SD) 1.4 (1.3) to 
1.1 (1.3), p<0.001, n=436). Similarly, there were greater 
improvements in adherence when inhaler technique improved 
(-0.4 (1.1), compared to -0.3 (1.1) and -0.1 (1.1) in patients 
whose inhaler technique remained sub-optimal or remained 
optimal respectively, p<0.001). 
Risk of bias 
Bias Author’s judgement Support for judgement 
Random sequence generation 
(selection bias) 
n/a 
 
There was no control group, 
and all patients received the 
intervention. 
 
Allocation concealment 
(selection bias) 
n/a 
 
All patients received the 
intervention 
Blinding of participants and 
personnel (performance bias) 
All outcomes 
n/a 
 
All patients received the 
intervention 
Blinding of outcome 
assessment (detection bias) 
All outcomes 
n/a 
 
All patients received the 
intervention 
Incomplete outcome data 
(attrition bias) 
All outcomes 
High Risk. No sample size calculations, 
and only 69.2% completed 1-
month questionnaire.  
Selective reporting (reporting 
bias) 
High Risk. Only 69.2% completed 1-
month questionnaire. 
Furthermore ACQ and 
Morisky data not available for 
all these responding patients. 
Other bias Low risk The study appears to be free 
if other sources of bias. 
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Appendix 3. Characteristics of included studies: The effect of 
interventions to improve adherence to inhaled corticosteroids on asthma 
control 
Criteria for judging bias is based on the Cochrane handbook for systematic 
reviews (Higgins and Green, 2011). 
 
Bender, 2010 
Methods Ten-week, randomised, controlled trial, in USA. 
Participants Population: 50 adults; 25 in the treatment group and 25 in the 
control group. 
Baseline characteristics: Mean age 39.6 years in the 
treatment group and 43.5 years in the control group. Baseline 
asthma control and adherence was not reported. 
Inclusion criteria: Physician-diagnosed asthma aged 18-65 
years, who were prescribed ICS. 
Exclusion criteria: Other significant medical or psychiatric 
disorder, or current participation in any other asthma-related 
clinical trial. 
Interventions Patients were randomised to either a treatment group or 
control group. 
The intervention consisted of a 5-minute interactive voice 
response telephone call (repeated once or twice at 1-month 
intervals depending on asthma control), which comprised core 
educational messages, encouraged filling of ICS prescriptions 
and to increase communication with their physician. The 
control group received no telephone calls. 
 
Adherence was measured using electronic tracking device on 
pMDI or Accuhaler, or by weighing Turbohaler.  
 
Beliefs about medicines were measured using the BMQ - 
comprising 5 questions about negative medicines beliefs, and 
5 questions on positive medicines beliefs (on a 1 [strongly 
agree] to 5 [strongly disagree]). BMQ scores from baseline and 
10-week visits were calculated by subtracting the negative 
index total from the positive index total, so that a score >0 
indicated more positive beliefs and scores <0 indicated more 
negative beliefs. 
Outcomes Adherence over 10 weeks was 32% higher in the intervention 
arm than in the control group (mean (SD): 64.5% (17.2) vs. 
49.1% (16.8), p=0.003), with a favourable shift in perception of 
ICS on BMQ scores (+ 0.248 (1.07) vs. -0.508 (0.913), 
p=0.003), which correlated with degree of adherence change 
(r=0.342, p=0.0152).  
 
There was no significant difference in the change in asthma 
control between the treatment and control groups at 10 weeks 
(using ACT -1.120 (3.9) vs. -1.840 (4.14) respectively; p=0.53) 
or quality of life (using AQLQ -0.152 (0.92) vs. -0.381 (1.06) 
respectively; p=0.419). 
Risk of bias 
Bias Author’s judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low Risk. Randomisation table 
generated before study 
initiation. 
 
Allocation concealment 
(selection bias) 
Low Risk. Patients allocated by order of 
entry into study, but 
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investigators remained 
blinded. 
Blinding of participants and 
personnel (performance bias) 
All outcomes 
Low Risk. Investigators remained blind 
to treatment until the final data 
set was completed. 
Blinding of outcome 
assessment (detection bias) 
All outcomes 
Low Risk. Low Risk. Investigators 
remained blind to treatment 
until the final data set was 
completed. 
Incomplete outcome data 
(attrition bias) 
All outcomes 
Unclear Risk Study did not describe if all 
patients completed study. 
Selective reporting (reporting 
bias) 
Low Risk. All outcome measures 
reported. 
 
 
Other bias Low Risk The study appears to be free 
if other sources of bias. 
 
 
 
Gamble, 2011 
Methods Sequential 2 phase study, in Northern Ireland:  
Phase 1 was a median 9-month (range 6-12 months) 
observational study; Phase 2 was a 12-month prospective 
single blind randomised controlled trial. 
Participants Population (Phase 1): 239 patients. No patient had non-
adherence suspected at referral to the difficult asthma clinic, 
however prescription analysis showed 83 were non-adherent 
and 156 were adherent.  
Baseline characteristics (Phase 1): Mean age of the 83 non-
adherent patients was 45 years. No other information provided. 
Inclusion criteria (Phase 1): Patients referred to the regional 
difficult asthma service (defined at persistent symptoms of 
asthma despite treatment at BTS/SIGN step 4/5). 
Exclusion criteria (Phase 1): None specified. 
 
Population (Phase 2): 20 non-adherent patients randomised 
to intervention (11) or control (9). 
Baseline characteristics (Phase 2): In the intervention and 
control groups, mean age was 50 years and 45.2 years 
respectively, mean ACQ score was 3.7 and 4.0 respectively, 
and FEV1 was 77.1% predicted and 78,7% predicted 
respectively. 
Inclusion criteria (Phase 2): Age >18 years, ACQ score >3, 
remaining non-adherent despite participating in Phase 1 of the 
study. 
Exclusion criteria (Phase 2): Current tobacco smoking, other 
significant co-morbidities contributing to respiratory disease. 
Interventions Phase 1: patients filling ≤50% of prescriptions were defined as 
non-adherent, and underwent a patient concordance 
consultation, resulting in an agreed treatment plan to address 
poor adherence.  
 
Phase 2: patients were randomised to a control group with no 
further intervention; or to an intervention group with an 
individualised psycho-educational nurse-led menu intervention 
to improve adherence to medication, repeated up to 8 times 
within a 12-week period. The Compliance Therapy Model was 
used to perform the intervention, encompassing the 
Transtheoretical Model of Change, Motivational Interviewing 
and Cognitive Behavioural Therapy principles. 
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Outcomes Phase 1 observational study: 31 of 83 patients (37%) who 
were initially non-adherent significantly improved adherence 
after concordance interview (in these 31 patients adherence 
increased from 37.3% ± 14.0 to 88.5% ± 15.7 at median 9 
month follow-up). This allowed a reduced ICS dose 
(1616.1mcg ± 490.0 vs. 1280.7mcg ± 557.6 at the 12-18 
month follow-up; p<0.001), fewer rescue prednisolone courses 
(2.2±1.5 vs. 0.7±1.0; p<0.001) and fewer hospital admissions 
(p<0.006).  
 
Phase 2 study: With menu-driven intervention, adherence, in 
terms of percentage of prescriptions filled also improved 
(intervention: 37.6% to 61.9% vs. control: 31.7% to 28.8%; 
p=0.01). There was no significant impact on Juniper's Asthma 
Control Score (intervention improved from 3.7±0.7 at baseline 
to 2.9±1.4 at 12 months, compared to control 4.0±0.9 at 
baseline to 3.1±1.6 at 12 months, p=0.74). Similarly there was 
a lack of effect on daily ICS dose, hospital admissions, lung 
function, rescue course of OCS or quality of life measured 
using AQLQ. The lack of effect on asthma control is likely to be 
due to small patients numbers. 
Risk of bias 
Bias Author’s judgement Support for judgement 
Random sequence generation 
(selection bias) 
Unclear Risk. Phase 2 Random sequence 
generation method was not 
described. 
Allocation concealment 
(selection bias) 
Unclear Risk. Phase 2 allocation 
concealment was not 
described. 
Blinding of participants and 
personnel (performance bias) 
All outcomes 
Unclear Risk. Phase 2 study described as 
single blind, but doe not 
provide further details. 
Blinding of outcome 
assessment (detection bias) 
All outcomes 
Unclear Risk. Phase 2 study was not 
described. 
 
Incomplete outcome data 
(attrition bias) 
All outcomes 
Unclear Risk. Phase 2 study had no details 
of power calculation provided. 
 
Selective reporting (reporting 
bias) 
Low Risk. No selective reporting 
apparent. 
 
Other bias Low Risk. The study appears to be free 
if other sources of bias. 
 
 
 
Garcia-Cardenas, 2013 
Methods 6-month cluster randomised controlled trial, in Spain. 
Participants Population: 33 community pharmacies were trained to provide 
the intervention (29 took part in study) and 32 untrained 
community pharmacies were recruited for the control group (22 
took part in the study). 373 patients enrolled, 346 patients 
completed, but one pharmacy data excluded from analysis due 
to lack of reliable data, therefore 336 patients were available 
for analysis (186 in the intervention group, 150 in the control 
group). 
Baseline characteristics: Mean (SD) age was 55.8 (19.1) 
years. Mean (SD) ACQ was 1.4 (1.1) and 1.3 (1.2) in the 
intervention and control groups respectively, however 
significantly fewer patients in the intervention group had 
controlled asthma (28% vs. 42.7%, p=0.005). 
Inclusion criteria: Adults aged 18 years or older with a 
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physician diagnosis of asthma. 
Exclusion criteria: Participation in other asthma education 
programs, pregnancy, communication difficulties, suffering 
from seasonal asthma, or other pathologies such as COPD, 
lung cancer, RTIs or terminal illness. 
Interventions Patients recruited to the intervention group received a protocol-
based intervention addressing individual needs related to 
asthma control, inhaler technique and adherence. Patients 
also received     education using verbal and written 
instructions, and physical demonstration of Turbohaler use. 
Patients recruited to the control group received no intervention 
other than their pharmacist’s usual care (usually the safe 
supply of medicine use and advice about taking medicines). 
All patients in the intervention and control groups had three 
scheduled visits to the pharmacy, although intervention 
patients could have up to six visits if needed. 
Adherence was assessed using the 4-item Morisky-Green-
Levine scale, allowing each patient to be rated as adherent or 
non-adherent. 
Outcomes The proportion of patients adherent to asthma treatment 
increased in the intervention (from 38.2% at baseline to 60.8%, 
p<0.001) and control groups (from 39.3% at baseline to 55.3%, 
p<0.001), however the proportion of patients who were found 
to be adherent to treatment at 6 months was significantly 
higher in the intervention group than in the control group 
(78.5% vs. 52.0%, p < 0.001).   
 
At six months, there was a clinical and statistically significant 
improvement in asthma control in the intervention group (ACQ 
-0.66 in the intervention group (p<0.001, but not in the control 
group (-0.15 (p value not reported)).  
The mean difference between the groups in adjusted mean 
changes for ACQ from baseline to final visit was -0.18 (IC95% 
-0.37 to 0.02), p=0.079 in patients who had controlled asthma 
at baseline, and -0.62 (IC95% -0.80 to -0.43), p<0.001 in 
patients who had uncontrolled asthma at baseline.  
 
Inhaler technique improved in the intervention and control 
groups from baseline to 3-month intermediate visits, but only 
from Intermediate to final 6-month visit in the intervention 
group. The proportion of patients with correct inhaler technique 
at 6 months was significantly higher in the intervention group 
compared to the control group (75.8% vs. 50.0%, p < 0.001).   
Risk of bias 
Bias Author’s judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low risk Pharmacists /Pharmacies 
providing intervention or 
control were randomly 
assigned to either group, 
using a computer-generated 
list of random numbers with a 
1:1 ratio of pharmacies. 
Allocation concealment 
(selection bias) 
Low risk Allocation of pharmacies to 
intervention or control group 
performed by computer 
randomisation. 
Blinding of participants and 
personnel (performance bias) 
All outcomes 
Low risk No blinding performed, but 
cluster randomisation method 
likely to minimise cross-
contamination. 
Blinding of outcome 
assessment (detection bias) 
High risk Unblinded assessments. 
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All outcomes 
Incomplete outcome data 
(attrition bias) 
All outcomes 
Low risk Study required 342 patients 
assuming a 20% attrition rate. 
336 completed the study, 
which was therefore was 
within acceptable limits. 
Selective reporting (reporting 
bias) 
High risk 10 patients excluded from 
analysis due to lack of reliable 
data. 
Other bias Low risk The study appears to be free 
if other sources of bias. 
 
 
 
Janson, 2009 
Methods 24-week prospective randomised controlled trial, in USA. 
Participants Population: 95 adults, of whom 84 completed the run-in 
phase and were randomised in the study; 45 in the intervention 
group and 39 in the control group. 
Baseline characteristics: In the intervention and control 
groups, mean age was 36.8 years and 39.7 years respectively, 
measured with the validated 11-item Perceived Control of 
Asthma Questionnaire (PCAQ) was 16.0 and 15.8 respectively 
(on an 11-55 Likert scale, with low scores indicating poor 
perceived ability to deal with asthma and exacerbations in an 
effective manner). 
Inclusion criteria: Diagnosis of moderate-to-severe persistent 
asthma (FEV1<80% predicted, daily symptoms, ≥1 night-time 
awakening per week), spirometric evidence of reversible 
airflow obstruction or bronchial reactivity to inhaled 
methacholine, and current non-smoker with ≤5 pack-years 
smoking history. 
Exclusion criteria: Use of systemic steroids within 4 weeks, 
upper respiratory tract infection within 6 weeks, pregnancy, 
other chronic disease, or prior participation in a formal asthma 
education program. 
Interventions All patients had a 4-week run-in phase, with bi-weekly visits, to 
stabilise fluticasone dose, then were randomised to 
intervention or self-monitoring.  
The intervention period lasted 4 weeks and comprised bi-
weekly visits, followed by 14 weeks of observation, with visits 
held at 4-week intervals.  11 Patients withdrew during the run-
in phase for reasons unspecified. 
84 patients were randomised to usual care of self-monitoring 
alone; or to the intervention group consisting of individualised 
self-management education (a 30 minute intervention, 
comprising provision of asthma information, assessment, 
inhaler technique education and asthma action plan, and 
trigger avoidance), plus self-monitoring of symptoms and PEF, 
and reinforced at 2 week intervals.  The intervention was 
performed by a practice nurse who was a certified asthma 
educator. 
No specific information about medication adherence was 
included in the intervention, and adherence was monitored 
using an electronic medication monitor attached to each 
patients ICS inhaler.  
Outcomes Mean ± SD adherence for the intervention and control groups 
was 82% vs. 80% at the end of the run-in phase, 82% vs. 77% 
at the end of the 4-week intervention phase, and 77% vs. 73% 
at the end of the study (no significant difference between 
groups).  
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Mean change in adherence reduced in both groups over time, 
but was more likely to be maintained in the intervention group. 
The odds of maintaining a >60% adherence to ICS over the 4-
week intervention period increased 9-fold in the intervention 
group, but was unchanged in the control group (OR 9.2 vs. 0.4, 
p=0.02).  
 
At the end of the 24-week study, the intervention group 
maintained 3-fold greater odds of >60% adherence to ICS vs. 
control.  
 
Over the whole study, perceived asthma control improved 
significantly greater in the intervention group compared to the 
control group (2.87 vs. 0.68, p=0.006). Quality of Life 
increased significantly in the intervention group (-3.82, 
p<0.0005), but was not significantly different in the control 
group (-0.80, p=0.49), and was not significantly different 
between the two groups (p=0.06). During the 4-week 
intervention period, there was a significant reduction in SABA 
use (incidence rate ratio 0.56, p=0.01), but this difference was 
maintained to the end of the study. 
Risk of bias 
Bias Author’s judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low Risk. Computer generated 
allocation. 
 
 
Allocation concealment 
(selection bias) 
Unclear Risk. Allocation concealment was 
not described. 
 
Blinding of participants and 
personnel (performance bias) 
All outcomes 
Low Risk. Investigators remained blind 
to group assignment. 
 
Blinding of outcome 
assessment (detection bias) 
All outcomes 
Low Risk. Investigators remained blind 
to group assignment. 
 
Incomplete outcome data 
(attrition bias) 
All outcomes 
Low Risk. Study required 80 patients to 
provide 80% power to detect 
a 10% change in adherence 
and an alpha value of 0.05. 84 
patients were randomised, 
and ITT included all 
participants randomised, 78 
with complete data and 6 with 
incomplete data. 
Selective reporting (reporting 
bias) 
Low Risk. No selective reporting 
apparent. 
 
 
Other bias Low Risk. The study appears to be free 
if other sources of bias. 
 
 
 
Strandbygaard, 2010  
Methods 12-week randomised prospective study, in Denmark. 
Participants Population: 26 patients; 12 in the intervention group and 14 in 
the control group. 
Baseline characteristics: Eight patients had mild persistent 
asthma (GINA 2), 16 had moderate persistent asthma (GINA 
3) and two had severe persistent asthma (GINA 4). Nine 
patients were prescribed SABA alone, nine used an ICS with 
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or without a LABA, and eight had not used any treatment within 
the past three months. 
Inclusion criteria: Diagnosis of asthma based on clinical 
history and daily symptoms, age 18-45 years, positive 
methacholine challenge test. 
Exclusion criteria: Other medical comorbidities, smoking 
history >10 pack-years. 
Interventions All patients were commenced on a Seretide Accuhaler at week 
0. 
At week 4, patients randomised to receive, or to not receive, a 
daily SMS reminder (at 10am) on their mobile phone to take 
their asthma medication from weeks 4 to 12. 
Adherence was measured using the dose counter on the 
Accuhaler device. 
Outcomes At 12 weeks, the absolute difference in mean adherence rate 
was 17.8% (95% CI 3.2 - 32.3%), p=0.019. In the intervention 
group, adherence increased from 77.9% to 81.5% (mean 
change 3.6%, p=0.52), but decreased in the control group from 
84.2% to 70.1% (mean change -14.2%, p=0.01).  
 
There was no significant difference between the two groups in 
terms of ACQ (mean change -0.87 [95% CI -1.4 to -0.34]; 
p=0.005 vs. -0.62 [95% CI -1.01 to -0.23]; p=0.005 in the 
intervention and control groups respectively), mini-AQLQ, 
exhaled nitric oxide, lung function or airway responsiveness. 
Risk of bias 
Bias Author’s judgement Support for judgement 
Random sequence generation 
(selection bias) 
Low Risk. Randomisation schedule 
performed by automatic 
computer generation of 
randomisation numbers. 
Allocation concealment 
(selection bias) 
Low Risk. Allocation concealment was 
not described. 
 
Blinding of participants and 
personnel (performance bias) 
All outcomes 
High Risk. The authors did not report 
whether the study was open 
or blinded. 
Blinding of outcome 
assessment (detection bias) 
All outcomes 
High Risk. The authors did not report 
whether the study was open 
or blinded. 
Incomplete outcome data 
(attrition bias) 
All outcomes 
Unclear Risk. No power calculation was 
performed. 
 
Selective reporting (reporting 
bias) 
Low Risk. All relevant outcomes 
reported. 
 
 
Other bias Low Risk. The study appears to be free 
if other sources of bias. 
 
 
 
Williams, 2010 
Methods 12-month, cluster-randomised trial, in USA 
Participants Population: 193 GP practices (88 intervention, 105 control) 
recruited 2698 patients (1335 in the intervention group and 
1363 in the control group). 
Baseline characteristics: In the intervention and control 
groups, mean age was 26.8 years and 28.8 years respectively, 
mean adherence to ICS was 25.6% and 27.7% in the three-
months preceding the study. 
Inclusion criteria: Previous prescription for an ICS within the 
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previous two years, age 5-56 years, continuous enrolment with 
GP practice for at least one year, no diagnosis of COPD or 
congestive heart failure. 
Exclusion criteria: If ICS was sopped before the study. 
Interventions Patients were randomised by practice, such that individual 
practices were clustered as either intervention or control group 
practices. 
 
In the intervention group, clinicians could view updated ICS 
adherence information on patients via electronic prescription 
software. Education for medical staff on non-confrontational 
approaches to discussing adherence, and include ways to 
identify barriers to taking medication, tips to help patients 
remember to take their medication, and methods to promote 
self-efficacy. 
 
In the Control group, information on asthma on the electronic 
prescribing software was not available. 
Outcomes Mean adherence over the preceding 3-months to ICS was 
similar at baseline in the intervention and control groups 
respectively (25.6% and 27.7%, p=0.21). At the end of the 
study mean adherence over the preceding 3-months was not 
statistically different (21.3% and 23.3%, p=0.553).  
 
However the intervention was not routinely performed, and 
adherence was significantly higher where the clinician actually 
viewed adherence data (35.7%) compared where the clinician 
did not view adherence data (12.3%, p=0.002), and in the 
control group (23.3%, p=0.026).  
 
All patients who had stable or improved adherence throughout 
study, whether in the intervention or control group, had lower 
rates of asthma related emergency department visits than 
those patients with worse adherence (aRR, 0.73 [95% CI, 
0.55-0.98]; p=0.039) and there was also a lower use of OCS 
use (aRR, 0.77 [95% CI, 0.63-0.93]; p=0.007). However there 
was no significant reduction in asthma-related hospitalisations 
(aRR 0.77 [95% CI, 0.34-1.76]; p=0.540). 
Risk of bias 
Bias Author’s judgement Support for judgement 
Random sequence generation 
(selection bias) 
Unclear Risk. GP practices were randomly 
assigned as intervention or 
control group, but the 
sequence generation method 
was not described. 
 
Allocation concealment 
(selection bias) 
Unclear Risk. Allocation of GP practices to 
intervention or control group 
was not described. 
Blinding of participants and 
personnel (performance bias) 
All outcomes 
Low risk No blinding performed, but 
cluster randomisation method 
likely to minimise cross-
contamination. 
Blinding of outcome 
assessment (detection bias) 
All outcomes 
Low Risk. Outcomes ascertained by staff 
without knowledge of the 
treatment assignment. 
Incomplete outcome data 
(attrition bias) 
All outcomes 
High Risk. Greater than planned attrition 
rate. Study required a total of 
2598 patients from 34 
practices (i.e., 17 per arm) to 
have >80% power to detect a 
9% absolute difference in 
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adherence between study 
arms assuming a 2-sided a 
value of 0.05. 2698 patients 
recruited, however only 2074 
patients completed the study. 
Selective reporting (reporting 
bias) 
Low Risk. All relevant outcomes 
reported. 
 
 
Other bias Low Risk. The study appears to be free 
if other sources of bias. 
 
 
 
  234 
Appendix 4. Letter of support from Leeds, Bradford & Airedale, Calderdale 
& Kirklees Local Pharmaceutical Committees 
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Appendix 5. Patient invitation letter and Patient Information Sheet 
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Appendix 6. Patient Consent Forms 
(PI and UC groups) 
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Appendix 7. Asthma Clinic Format – PI Group  
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Appendix 8. Inhaler Technique Assessment Checklists 
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Appendix 9. Targeted Medicines Use Review Referral Form 
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Appendix 10. Patient Case Record Form 
I. Patient Case Record Form 
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II. Patient Feedback from t-MUR 
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III. Asthma Control Questionnaire (ACQ) 
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IV. Standardised Asthma Quality of Life Questionnaire (AQLQ(S)) 
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  272 
  273 
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V. European Quality of Life-5 Dimensions Questionnaire (EQ-5D-5L) 
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VI. Medication Adherence Report Scale (MARS) 
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VII. Beliefs about Medicines Questionnaire (BMQ) 
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Appendix 11. Confirmation of Ethical Opinion 
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Appendix 12. NHS Permission for Research 
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Appendix 13. Data Description 
 
Variable 
Type of 
Data 
Kolmogorov
-Smirnov 
Asymp. Sig. 
(2-tailed) (P) 
Shape of 
histogram 
P-P 
Plot 
Is the 
data 
normal? 
Demographic Data 
Age at recruitment Scale 0.718 
Slight 
Negative 
skew? 
Normal? Normal 
Sex Nominal n/a n/a n/a n/a 
Duration of asthma instability Scale 0.001 
Positive 
skewed 
Not 
normal 
Not 
Normal 
Steroid courses in previous 12 
months 
Scale 0.488 
Slight 
Positive 
skew? 
Normal? Normal 
Hospital admissions and A&E 
visits in previous 12 months 
Scale 0.000 
Positive 
skewed 
Not 
normal 
Not 
Normal 
Prescribed medication Nominal n/a n/a n/a n/a 
Steroid courses in previous 3 
months at baseline 
Scale 0.068 
Positive 
skewed 
Not 
normal? 
Not 
Normal 
Steroid courses in previous 3 
Months at follow up 
Scale 0.002 
Positive 
skewed 
Not 
normal 
Not 
Normal 
Hospital admissions in previous 
3 Months at baseline 
Scale 0.000 
Positive 
skewed 
Not 
normal? 
Not 
Normal 
Hospital admissions in previous 
3 Months at follow up 
Scale 0.000 
Positive 
skewed 
Not 
normal? 
Not 
Normal 
FEV1 at baseline Scale 0.981 Normal Normal Normal 
FEV1 at follow up Scale 0.948 Normal Normal Normal 
FEV1/FVC at baseline Scale 0.909 Normal Normal Normal 
FEV1/FVC at follow up Scale 0.710 Normal Normal Normal 
FeNO at baseline Scale 0.178 
Positive 
skewed 
Not 
normal 
Not 
Normal 
FeNO at follow up Scale 0.137 
Positive 
skewed 
Not 
normal 
Not 
Normal 
Smoking status Nominal n/a n/a n/a n/a 
Possession of asthma action 
plan 
Nominal n/a n/a n/a n/a 
Beclometasone-CFC dose at 
baseline 
Scale 0.002 
Positive 
skewed 
Positive 
skewed 
Not 
Normal 
Beclometasone-CFC dose at 
follow up 
Scale 0.001 
Positive 
skewed 
Positive 
skewed 
Not 
Normal 
SABA use per week at baseline Scale 0.041 
Positive 
skewed 
Positive 
skewed 
Not 
Normal 
SABA use per week at follow up Scale 0.013 
Positive 
skewed 
Positive 
skewed 
Not 
Normal 
Asthma control and quality of life data 
ACQ Ordinal n/a n/a n/a n/a 
AQLQ(S) Ordinal n/a n/a n/a n/a 
ED-5Q-5L Ordinal n/a n/a n/a n/a 
ED-5Q-5L-vas at baseline Scale 0.609 
Negatively 
skewed? 
Normal Normal 
ED-5Q-5L-vas at follow up Scale 0.589 Normal Normal Normal 
MARs data 
MARs questions Ordinal n/a n/a n/a n/a 
BMQ data 
BMQ questions Ordinal n/a n/a n/a n/a 
Inhaler technique – Inspiratory Flow 
pMDI technique at baseline 
before education 
Scale 0.650 Normal Normal Normal 
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Variable 
Type of 
Data 
Kolmogorov
-Smirnov 
Asymp. Sig. 
(2-tailed) (P) 
Shape of 
histogram 
P-P 
Plot 
Is the 
data 
normal? 
pMDI technique at baseline after 
education 
Scale 0.135 Normal 
Not 
normal? 
Normal 
Accuhaler technique at baseline 
before education 
Scale 0.418 Bimodal? 
Not 
normal 
Not 
Normal 
Accuhaler technique at baseline 
after education 
Scale 0.742 Normal 
Not 
normal? 
Normal 
Turbohaler technique at 
baseline before education 
Scale 0.355 
Positive 
skewed? 
Normal Normal 
Turbohaler technique at 
baseline after education 
Scale 0.541 Normal Normal Normal 
HandiHaler technique at 
baseline before education 
Scale 0.101 
Positive 
skewed? 
Not 
normal 
Not 
Normal 
HandiHaler technique at 
baseline after education 
Scale no data no data no data n/a 
Easi-Breathe technique at 
baseline before education 
Scale 0.787 
Positive 
skewed? 
no data n/a 
Easi-Breathe technique at 
baseline after education 
Scale 0.107 
Positive 
skewed? 
no data n/a 
pMDI technique at follow up 
before education 
Scale 0.493 
Positive 
skewed? 
Normal? 
Not 
Normal 
pMDI technique at follow up 
after education 
Scale 0.011 
Positive 
skewed? 
Not 
normal 
Not 
Normal 
Accuhaler technique at follow up 
before education 
Scale 0.970 Normal Normal Normal 
Accuhaler technique at follow up 
after education 
Scale 0.500 Bimodal 
Not 
normal? 
Not 
Normal 
Turbohaler technique at follow 
up before education 
Scale 0.324 
Negative 
skewed? 
Not 
normal? 
Not 
Normal 
Turbohaler technique at follow 
up after education 
Scale 1.000 
Insufficient 
data 
Normal Normal 
HandiHaler technique at follow 
up before education 
Scale 0.826 
Insufficient 
data 
Normal Normal 
HandiHaler technique at follow 
up after education 
Scale no data Normal no data n/a 
Easi-Breathe technique at follow 
up before education 
Scale 0.573 
Positive 
skewed? 
Normal Normal 
Easi-Breathe technique at follow 
up after education 
Scale 0.923 Normal Normal Normal 
Inhaler Technique Training and Patient Preference 
Type of healthcare professional 
who has previous provided 
inhaler technique training 
Nominal n/a n/a n/a n/a 
Inhaler device preference Nominal n/a n/a n/a n/a 
Inhaler technique training  - inhaler technique scores 
Inhaler technique score, by 
device at baseline, at t-MUR, 
and at follow up 
Ordinal n/a n/a n/a n/a 
Inhaler technique training  - total number of errors in technique (baseline data presented 
only) 
pMDI total errors at baseline 
before education 
Scale 0.022 
Positive 
skewed? 
Normal? 
Not 
Normal 
pMDI total errors at baseline 
after education 
Scale 0.000 
Positive 
skewed 
Not 
normal? 
Not 
Normal 
Accuhaler total errors at 
baseline before education 
Scale 0.010 
Positive 
skewed 
Not 
normal 
Not 
Normal 
Accuhaler total errors at 
baseline after education 
Scale 0.000 
Positive 
skewed 
Not 
normal 
Not 
Normal 
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Variable 
Type of 
Data 
Kolmogorov
-Smirnov 
Asymp. Sig. 
(2-tailed) (P) 
Shape of 
histogram 
P-P 
Plot 
Is the 
data 
normal? 
Turbohaler total errors at 
baseline before education 
Scale 0.007 
Positive 
skewed 
unclear 
Not 
Normal 
Turbohaler total errors at 
baseline after education 
Scale 0.000 
Positive 
skewed 
unclear 
Not 
Normal 
Easi-Breathe total errors at 
baseline before education 
Scale 0.580 
Negative 
Skewed 
unclear 
Not 
Normal 
Easi-Breathe total errors at 
baseline after education 
Scale 0.000 
Positive 
skewed 
unclear 
Not 
Normal 
Easyhaler total errors at 
baseline before education 
Scale 0.491 
Positive 
skewed 
Not 
normal 
Not 
Normal 
Easyhaler total errors at 
baseline after education 
Scale 0.001 
Positive 
skewed 
unclear 
Not 
Normal 
HandiHaler total errors at 
baseline before education 
Scale 0.510 Normal? Normal Normal 
HandiHaler total errors at 
baseline after education 
Scale 0.000 
Positive 
skewed 
Not 
normal 
Not 
Normal 
Respimat total errors at baseline 
before education 
Scale 0.972 
Positive 
skewed 
Not 
normal 
Not 
Normal 
Respimat total errors at baseline 
after education 
Scale 0.088 
Positive 
skewed 
Not 
normal 
Not 
Normal 
Spacer (Multiple Inhalation 
Technique) total errors at 
baseline before education 
Scale 0.953 
Negative 
skewed? 
unclear 
Insufficient 
data 
Spacer (Multiple Inhalation 
Technique) total errors at 
baseline after education 
Scale 0.110 
Positive 
skewed 
unclear 
Insufficient 
data 
Spacer (Single Inhalation 
Technique) total errors at 
baseline before education 
Scale 0.218 
Positive 
skewed 
Not 
normal 
Insufficient 
data 
Spacer (Single Inhalation 
Technique) total errors at 
baseline after education 
Scale no data Normal? unclear 
Insufficient 
data 
Inhaler technique training  - number of critical errors in technique (baseline data presented 
only) 
pMDI critical errors at baseline 
before education 
Scale 0.008 
Negative 
Skewed 
unclear 
Not 
Normal 
pMDI critical errors at baseline 
after education 
Scale 0.000 
Positive 
skewed 
unclear 
Not 
Normal 
Accuhaler critical errors at 
baseline before education 
Scale 0.001 
Positive 
skewed 
unclear 
Not 
Normal 
Accuhaler critical errors at 
baseline after education 
Scale 0.000 
Positive 
skewed 
unclear 
Not 
Normal 
Turbohaler critical errors at 
baseline before education 
Scale 0.001 
Positive 
skewed 
unclear 
Not 
Normal 
Turbohaler critical errors at 
baseline after education 
Scale 0.000 
Positive 
skewed 
unclear 
Not 
Normal 
Easi-Breathe critical errors at 
baseline before education 
Scale 0.000 
Negative 
Skewed 
unclear 
Not 
Normal 
Easi-Breathe critical errors at 
baseline after education 
Scale 0.000 
Positive 
skewed 
unclear 
Not 
Normal 
Easyhaler critical errors at 
baseline before education 
Scale 0.682 
Positive 
skewed 
unclear 
Insufficient 
data 
Easyhaler critical errors at 
baseline after education 
Scale 0.000 
Positive 
skewed 
unclear 
Not 
Normal 
HandiHaler critical errors at 
baseline before education 
Scale 0.170 
Positive 
skewed / 
Bimodal 
unclear 
Not 
Normal 
HandiHaler critical errors at Scale 0.000 Positive unclear Not 
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Variable 
Type of 
Data 
Kolmogorov
-Smirnov 
Asymp. Sig. 
(2-tailed) (P) 
Shape of 
histogram 
P-P 
Plot 
Is the 
data 
normal? 
baseline after education skewed Normal 
Respimat critical errors at 
baseline before education 
Scale 0.941 Normal? unclear Normal 
Respimat Baseline critical errors 
at baseline after education 
Scale 0.016 
Positive 
skewed 
unclear 
Not 
Normal 
Spacer (Multiple Inhalation 
Technique) critical errors at 
baseline before education 
Scale 0.933 Bimodal unclear 
Not 
Normal 
Spacer (Multiple Inhalation 
Technique) critical errors at 
baseline after education 
Scale 0.272 
Positive 
skewed 
unclear 
Insufficient 
data 
Spacer (Single Inhalation 
Technique) critical errors at 
baseline before education 
Scale 0.057 
Positive 
skewed 
unclear 
Not 
Normal 
Spacer (Single Inhalation 
Technique) critical errors at 
baseline after education 
Scale no data Normal? unclear 
Insufficient 
data 
Adherence data – GP data 
Number of rescue courses at 
baseline 
Scale 0.025 
Positive 
skewed 
Not 
normal 
Not 
Normal 
Number of rescue courses at 
follow up 
Scale 0.002 
Positive 
skewed 
Not 
normal 
Not 
Normal 
Adherence to ICS at baseline Scale 0.002 
Positive 
skewed 
Not 
normal 
Not 
Normal 
Adherence to ICS at follow up Scale 0.003 
Positive 
skewed 
Not 
normal 
Not 
Normal 
Use of inhaler devices at baseline 
Device(s) prescribed at baseline Nominal n/a    
Total number of devices 
prescribed 
Scale 0.000 
Positive 
skewed 
Not 
normal 
Not 
Normal 
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Appendix 14. Effect of education on inhaler technique score (% of each step performed correctly) at baseline, before and after 
education for all inhaler devices used. 
 
Figure 20. Effect of education on inhaler technique score (% of each step performed correctly) at baseline, before and after 
education for all inhaler devices used (complete data).  
PI, pharmacist intervention group; UC, usual care group; pMDI, pressurised metered dose inhaler; Acc, Accuhaler; TH, Turbohaler; HH; 
HandiHaler; EB, Easi-Breathe; EH, Easyhaler; MDISS, pMDI + spacer (single-breath method); MDISM, pMDI + spacer (multiple-breath 
method); RSP, Respimat. Improvements in inhaler technique assessed using Wilcoxon test. Difference in inhaler technique score before 
and after education: *p<0.001; †p=0.034; ‡p=0.001; **p=0.012.
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Appendix 15. Effect of education on the proportion of patients with optimal, satisfactory, or unsatisfactory inhaler technique at 
baseline, for all inhaler devices used. 
 
Figure 21. Effect of education on the proportion of patients with optimal, satisfactory, or unsatisfactory inhaler technique at 
baseline, for all inhaler devices used (complete data).  
Optimal technique is defined as no errors using inhaler device; satisfactory inhaler technique is defined as making some minor bur no 
critical errors; unsatisfactory inhaler technique is defined as making at least one critical error. PI, pharmacist intervention group; UC, 
usual care group; pMDI, pressurised metered dose inhaler; Acc, Accuhaler; TH, Turbohaler; EB, Easi-Breathe; EH, Easyhaler; HH; 
HandiHaler; RSP, Respimat; MDISM, pMDI + spacer (multiple-breath method); MDISS, pMDI + spacer (single-breath method).  
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Appendix 16. Effect of education on inhaler technique score (% of each step performed correctly) throughout study, for all 
inhaler devices used. 
 
Figure 22. Effect of education on inhaler technique score (% of each step performed correctly) throughout study, for all inhaler 
devices used (complete data).  
PI, pharmacist intervention group; UC, usual care group; pMDI, pressurised metered dose inhaler; Acc, Accuhaler; TH, Turbohaler; HH; 
HandiHaler; EB, Easi-Breathe; EH, Easyhaler; MDISS, pMDI + spacer (single-breath method); MDISM, pMDI + spacer (multiple-breath 
method); RSP, Respimat. Improvements in inhaler technique assessed using Wilcoxon test.  
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Appendix 17. The proportion of patients with optimal, satisfactory, or unsatisfactory inhaler technique throughout the 6-month 
study, for all inhaler devices used.  
 
Figure 23. The proportion of patients with optimal, satisfactory, or unsatisfactory inhaler technique throughout the 6-month 
study, for all inhaler devices used (complete data).  
Optimal technique is defined as no errors using inhaler device; satisfactory inhaler technique is defined as making some minor bur no 
critical errors; unsatisfactory inhaler technique is defined as making at least one critical error. PI, pharmacist intervention group; UC, 
usual care group; pMDI, pressurised metered dose inhaler; Acc, Accuhaler; TH, Turbohaler; EB, Easi-Breathe; EH, Easyhaler; HH; 
HandiHaler; RSP, Respimat; MDISM, pMDI + spacer (multiple-breath method); MDISS, pMDI + spacer (single-breath method). 
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